{"schema_version": "1.0", "videos": [{"content_id": "VID_4042011", "editorial": {"original_title": "Does luspatercept improve red cell transfusion independence in lower-risk MDS with ring sideroblasts?", "public_title": "Does luspatercept improve red cell transfusion independence in lower-risk MDS with ring sideroblasts?", "slug": "luspatercept-lower-risk-myelodysplastic-syndromes-ring-sideroblasts", "legacy_canonical_url": "https://5minutehematology.com/programs/luspatercept-lower-risk-myelodysplastic-syndromes-ring-sideroblasts", "description": "Summary of the MEDALIST double-blind, placebo-controlled phase 3 randomized trial in The New England Journal of Medicine (2020) evaluating luspatercept vs placebo for transfusion independence in lower-risk MDS with ring sideroblasts after ESA failure", "scientific_summary": "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (NEJM 2020, Fenaux et al.)", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does luspatercept improve red cell transfusion independence in lower-risk MDS with ring sideroblasts?", "language": null, "original_publication_date": "2026-02-10T13:24:53.918Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4042011/horizontal/small_170dc142-8bd1-49fb-9ef2-e0e62b290f7a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["luspatercept", "myelodysplastic syndromes", "lower-risk MDS", "ring sideroblasts", "anemia", "RBC transfusion dependence", "transfusion independence", "ESA failure", "MEDALIST trial", "phase 3 randomized trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4042011", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_31914241", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["MEDALIST"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MDS_LOWER_RISK_ANEMIA"}], "evidence_relations": [{"target_id": "EV_PMID_31914241", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MDS_LOWER_RISK_ANEMIA", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060423", "editorial": {"original_title": "Should asciminib be used as frontline therapy in newly diagnosed chronic-phase CML?", "public_title": "Should asciminib be used as frontline therapy in newly diagnosed chronic-phase CML?", "slug": "asciminib-frontline-newly-diagnosed-chronic-phase-cml-asc4first", "legacy_canonical_url": "https://5minutehematology.com/programs/asciminib-frontline-newly-diagnosed-chronic-phase-cml-asc4first", "description": "Review of the ASC4FIRST randomized controlled trial in The New England Journal of Medicine (2024) comparing asciminib vs investigator-selected TKIs and imatinib in newly diagnosed chronic-phase CML.", "scientific_summary": "ASC4FIRST randomized controlled trial comparing asciminib vs investigator-selected TKIs and imatinib in newly diagnosed chronic-phase CML.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should asciminib be used as frontline therapy in newly diagnosed chronic-phase CML?", "language": null, "original_publication_date": "2026-02-21T22:41:47.351Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060423/horizontal/small_e0aa5d44-2b65-4d52-ace0-3aba3a771b15.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["asciminib", "chronic myeloid leukemia", "CML", "chronic phase frontline therapy", "BCR-ABL1 ABL", "myristoyl pocket tyrosine kinase inhibitors", "imatinib", "ASC4FIRST", "randomized controlled trial", "NEJM"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060423", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_FRONTLINE_TKI"}], "evidence_relations": [{"target_id": "EV_PMID_28273028", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_38820078", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_ASCIMINIB", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_CML_FRONTLINE_TKI", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_ASCIMINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ASCIMINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_IMATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IMATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060462", "editorial": {"original_title": "Does adding SQ daratumumab to VRd improve PFS in transplant-eligible newly diagnosed myeloma", "public_title": "Does adding SQ daratumumab to VRd improve PFS in transplant-eligible newly diagnosed myeloma", "slug": "daratumumab-vrd-transplant-eligible-ndmm-perseus", "legacy_canonical_url": "https://5minutehematology.com/programs/daratumumab-vrd-transplant-eligible-ndmm-perseus", "description": "Phase 3 randomized trial (NEJM 2024) in transplant-eligible newly diagnosed multiple myeloma comparing D-VRd vs VRd with consolidation and lenalidomide maintenance; reviews PFS, CR/MRD, and safety.", "scientific_summary": "Phase 3 randomized trial (NEJM 2024) in transplant-eligible newly diagnosed multiple myeloma comparing D-VRd vs VRd.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-02-21T23:06:50.567Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060462/horizontal/small_82b23b2b-4ab1-4225-a434-caff5b3600f5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "transplant eligible", "newly diagnosed", "daratumumab subcutaneous", "daratumumab", "VRd", "bortezomib", "lenalidomide", "dexamethasone", "PERSEUS", "phase 3 trial", "randomized trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060462", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38084760", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["PERSEUS"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_37708911", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_38084760", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_DARAVRD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE", "via_therapy_id": "TX_MM_DARAVRD", "graph_edge_ids": ["EDGE_MM_DARAVRD_HAS_OPTION", "EDGE_MM_DARAVRD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Dara-VRd (PERSEUS, transplant eligible) resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/myeloma/dara_vrd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060467", "editorial": {"original_title": "Does adding daratumumab to VRd improve response in transplant-ineligible or deferred NDMM?", "public_title": "Does adding daratumumab to VRd improve response in transplant-ineligible or deferred NDMM?", "slug": "daratumumab-vrd-mrd-negativity-pfs-transplant-ineligible-deferred-ndmm-cepheus", "legacy_canonical_url": "https://5minutehematology.com/programs/daratumumab-vrd-mrd-negativity-pfs-transplant-ineligible-deferred-ndmm-cepheus", "description": "Randomized phase 3 CEPHEUS trial (Nature Medicine, 2025) in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma comparing D-VRd vs VRd induction followed by maintenance, assessing MRD negativity (10^-5) and PFS.", "scientific_summary": "Randomized phase 3 CEPHEUS trial in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding daratumumab to VRd improve response in transplant-ineligible or deferred NDMM?", "language": null, "original_publication_date": "2026-02-21T23:12:12.724Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060467/horizontal/small_1930ab5b-dfe2-461f-ba38-cf1ef560fff6.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed transplant ineligible", "transplant deferred", "daratumumab", "bortezomib", "lenalidomide", "dexamethasone", "VRd", "D-VRd", "D-Rd", "MRD negativity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060467", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [{"target_id": "EV_PMID_37708911", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_DARAVRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "D-VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060796", "editorial": {"original_title": "Does subcutaneous daratumumab delay progression in high-risk smoldering myeloma?", "public_title": "Does subcutaneous daratumumab delay progression in high-risk smoldering myeloma?", "slug": "daratumumab-active-monitoring-high-risk-smoldering-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/daratumumab-active-monitoring-high-risk-smoldering-multiple-myeloma", "description": "Review of the AQUILA randomized controlled trial in the New England Journal of Medicine (2025) comparing subcutaneous daratumumab monotherapy vs active monitoring in high-risk smoldering multiple myeloma.", "scientific_summary": "Review of the AQUILA comparing subcutaneous daratumumab daratumumab monotherapy vs active monitoring in high-risk smoldering myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does subcutaneous daratumumab delay progression in high-risk smoldering myeloma?", "language": null, "original_publication_date": "2026-02-22T11:33:38.494Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060796/horizontal/small_4f013fe0-4f5c-4744-be05-741bb324e89a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["daratumumab", "CD38", "high-risk smoldering multiple myeloma", "active monitoring", "subcutaneous therapy", "progression to multiple myeloma", "overall survival", "AQUILA trial", "randomized controlled trial", "NEJM"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060796", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060820", "editorial": {"original_title": "Does 7-day venetoclax with azacitidine match standard HMA-venetoclax outcomes in AML?", "public_title": "Does 7-day venetoclax with azacitidine match standard HMA-venetoclax outcomes in AML?", "slug": "reduced-venetoclax-exposure-7-days-standard-hypomethylating-agents-aml", "legacy_canonical_url": "https://5minutehematology.com/programs/reduced-venetoclax-exposure-7-days-standard-hypomethylating-agents-aml", "description": "Retrospective cohort comparison in Blood Cancer Journal (2025) evaluating azacitidine x 7 days plus venetoclax x 7 days vs standard HMA plus venetoclax in newly diagnosed AML unfit for intensive therapy.", "scientific_summary": "Retrospective cohort comparison evaluating azacitidine x 7 days plus venetoclax x 7 days vs standard HMA plus venetoclax in AML.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does 7-day venetoclax with azacitidine match standard HMA-venetoclax outcomes in AML?", "language": null, "original_publication_date": "2026-02-22T11:41:17.306Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060820/horizontal/small_542a81f6-1521-46be-b663-0b5e40323622.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "venetoclax", "azacitidine", "hypomethylating agent", "HMA", "7+7 regimen", "treatment duration", "response rate", "overall survival", "early mortality", "transfusion"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060820", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40246832", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_38343151", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_AML_AZAVEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_AZAVEN", "graph_edge_ids": ["EDGE_AML_AZAVEN_HAS_OPTION", "EDGE_AML_AZAVEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Azacitidine + Venetoclax resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/azacitidine_venetoclax.json"}]}, {"target_id": "PROT_AML_DEC10VEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_DEC10VEN", "graph_edge_ids": ["EDGE_AML_DEC10VEN_HAS_OPTION", "EDGE_AML_DEC10VEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved DEC10-VEN resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/decitabine_venetoclax_10d.json"}]}, {"target_id": "PROT_AML_DEC5VEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_DEC5VEN", "graph_edge_ids": ["EDGE_AML_DEC5VEN_HAS_OPTION", "EDGE_AML_DEC5VEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved DEC5-VEN resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/decitabine_venetoclax_5d.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060825", "editorial": {"original_title": "Should nivolumab + AVD replace Bv + AVD in newly diagnosed stage III-IV classic Hodgkin lymphoma?", "public_title": "Should nivolumab + AVD replace Bv + AVD in newly diagnosed stage III-IV classic Hodgkin lymphoma?", "slug": "nivolumab-avd-advanced-stage-classic-hodgkin-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/nivolumab-avd-advanced-stage-classic-hodgkin-lymphoma", "description": "Phase 3 multicenter open-label randomized trial in NEJM 2024 comparing nivolumab+AVD vs brentuximab vedotin+AVD for newly diagnosed stage III-IV classic Hodgkin lymphoma.", "scientific_summary": "Phase 3 multicenter trial comparing nivolumab+AVD vs brentuximab vedotin+AVD for newly diagnosed stage III-IV classic Hodgkin lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should nivolumab + AVD replace Bv + AVD in newly diagnosed stage III-IV classic Hodgkin lymphoma?", "language": null, "original_publication_date": "2026-02-22T11:59:44.919Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060825/horizontal/small_912e1c75-ea74-4ed2-9270-111d702383c2.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["classic Hodgkin lymphoma", "advanced stage", "stage III", "stage IV", "nivolumab", "AVD", "brentuximab vedotin", "BV-AVD", "PD-1 blockade", "progression-free survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060825", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_35830649", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_39413375", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_NIVOLUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "nivolumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_HL_BRECADD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_BRECADD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_BRECADD", "EDGE_HL_BRECADD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/brecadd.json"}]}, {"target_id": "PROT_HL_ABVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_ABVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_HL_ABVD", "EDGE_HL_ABVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md", "note": "Physician-reviewed link to the approved ABVD resource; HAS_OPTION does not by itself encode preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/abvd.json"}]}, {"target_id": "PROT_HL_NIVOAVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_NIVOAVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_NIVOAVD", "EDGE_HL_NIVOAVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/nivo_avd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060828", "editorial": {"original_title": "Does adding ivosidenib to azacitidine improve outcomes in newly diagnosed IDH1-mutated AML?", "public_title": "Does adding ivosidenib to azacitidine improve outcomes in newly diagnosed IDH1-mutated AML?", "slug": "ivosidenib-azacitidine-idh1-mutated-acute-myeloid-leukemia-phase-3", "legacy_canonical_url": "https://5minutehematology.com/programs/ivosidenib-azacitidine-idh1-mutated-acute-myeloid-leukemia-phase-3", "description": "Review of a phase 3 randomized, placebo-controlled trial in newly diagnosed IDH1-mutated AML ineligible for intensive induction (NEJM 2022) comparing ivosidenib plus azacitidine vs placebo plus azacitidine.", "scientific_summary": "Review of a phase 3 trial in newly diagnosed IDH1-mutated AML comparing ivosidenib plus azacitidine vs placebo plus azacitidine.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding ivosidenib to azacitidine improve outcomes in newly diagnosed IDH1-mutated AML?", "language": null, "original_publication_date": "2026-02-22T12:07:54.034Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060828/horizontal/small_4d3e7d17-c497-4cc5-a59e-f8e829c8feb1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ivosidenib", "azacitidine", "IDH1 mutation", "acute myeloid leukemia", "newly diagnosed AML", "unfit AML", "phase 3 trial", "event-free survival", "overall survival", "differentiation syndrome"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060828", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_40706052", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_AML_AZAVEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_AZAVEN", "graph_edge_ids": ["EDGE_AML_AZAVEN_HAS_OPTION", "EDGE_AML_AZAVEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Azacitidine + Venetoclax resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/azacitidine_venetoclax.json"}]}, {"target_id": "PROT_AML_DEC10VEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_DEC10VEN", "graph_edge_ids": ["EDGE_AML_DEC10VEN_HAS_OPTION", "EDGE_AML_DEC10VEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved DEC10-VEN resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/decitabine_venetoclax_10d.json"}]}, {"target_id": "PROT_AML_DEC5VEN_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AML_NON_INTENSIVE_FRONTLINE", "via_therapy_id": "TX_AML_DEC5VEN", "graph_edge_ids": ["EDGE_AML_DEC5VEN_HAS_OPTION", "EDGE_AML_DEC5VEN_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AML_V1_REVIEW.md", "note": "Physician-reviewed link to the approved DEC5-VEN resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/aml/decitabine_venetoclax_5d.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4060838", "editorial": {"original_title": "Can a single cilta-cel infusion produce 5-year remission in relapsed/refractory multiple myeloma?", "public_title": "Can a single cilta-cel infusion produce 5-year remission in relapsed/refractory multiple myeloma?", "slug": "cilta-cel-5-year-remission-survival-cartitude-1-rrmm", "legacy_canonical_url": "https://5minutehematology.com/programs/cilta-cel-5-year-remission-survival-cartitude-1-rrmm", "description": "Post hoc long-term follow-up analysis of the phase 1b/2 CARTITUDE-1 trial reported >=5-year remission and OS after ciltacabtagene autoleucel in RRMM (J Clin Oncol, 2025).", "scientific_summary": "Long-term follow-up analysis of the phase 1b/2 CARTITUDE-1 trial.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Plasma Cell & Myeloma", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can a single cilta-cel infusion produce 5-year remission in relapsed/refractory multiple myeloma?", "language": null, "original_publication_date": "2026-02-22T12:38:50.468Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4060838/horizontal/small_33a69566-fbcc-455f-a086-f16b1f0a20b4.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ciltacabtagene autoleucel", "cilta-cel", "CARTITUDE-1", "BCMA", "CAR T", "relapsed refractory multiple myeloma", "overall survival", "progression-free survival", "5-year remission", "MRD", "PET-CT", "biomarkers", "safety"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4060838", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40459151", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Long-Term 5-Year Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART"}], "evidence_relations": [{"target_id": "EV_PMID_37272512", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CILTACABTAGENE_AUTOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "cilta-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_CILTACEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_MM_CILTACEL", "graph_edge_ids": ["EDGE_MM_CILTACEL_HAS_OPTION", "EDGE_MM_CILTACEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Ciltacabtagene autoleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/cilta_cel.json"}]}, {"target_id": "PROT_CART_IDECEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_CART_IDECEL", "graph_edge_ids": ["EDGE_MM_IDECEL_HAS_OPTION", "EDGE_MM_IDECEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Idecabtagene vicleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/ide_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4062934", "editorial": {"original_title": "Frontline CLL: Acalabrutinib With or Without Obinutuzumab Compared with Chlorambucil-Obinutuzumab", "public_title": "Frontline CLL: Acalabrutinib With or Without Obinutuzumab Compared with Chlorambucil-Obinutuzumab", "slug": "acalabrutinib-obinutuzumab-vs-chlorambucil-obinutuzumab-treatment-naive-cll-elev", "legacy_canonical_url": null, "description": "Review of ELEVATE-TN, a global randomized controlled phase 3 open-label trial in The Lancet (year not reported) comparing acalabrutinib +/- obinutuzumab vs chlorambucil-obinutuzumab in treatment-naive CLL.", "scientific_summary": "ELEVATE-TN phase 3 RCT: acalabrutinib +/- obinutuzumab vs chlorambucil-obinutuzumab in treatment-naive CLL, PFS and safety results.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4062934/horizontal/small_38a01353-9301-4e62-b683-f9fd35b57c36.jpg", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL treatment-naive", "obinutuzumab chlorambucil", "BTK inhibitor", "ELEVATE-TN", "acalabrutinib", "phase 3 trial", "progression-free survival", "neutropenia", "infusion reactions"], "publication_status": "unpublished", "effective_visibility": "not_listed_as_published"}, "collection": null, "analytics": {"video_id": "VID_4062934", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ACALABRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ACALABRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4064854", "editorial": {"original_title": "Overview of the HELIOS Phase III randomized trial.", "public_title": "Overview of the HELIOS Phase III randomized trial.", "slug": "helios-trial-protocol-phase-iii-ibrutinib-bendamustine-rituximab-rr-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/helios-trial-protocol-phase-iii-ibrutinib-bendamustine-rituximab-rr-cll", "description": "Physician-focused overview of the HELIOS Phase III randomized, placebo-controlled trial protocol (Future Oncology, 2015) evaluating ibrutinib plus bendamustine-rituximab vs BR alone in relapsed/refractory CLL/SLL.", "scientific_summary": "Overview of the HELIOS Phase III randomized, placebo-controlled trial protocol evaluating ibrutinib plus BR vs BR alone in R/R CLL/SLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-02-23T18:26:25.886Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4064854/horizontal/small_4d3e7e82-6d2d-45e8-a523-6fa78f109b4b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["HELIOS trial", "ibrutinib", "bendamustine", "rituximab", "BR regimen", "relapsed CLL", "refractory CLL", "SLL", "Phase III randomized", "placebo-controlled", "progression-free survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4064854", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4065063", "editorial": {"original_title": "Is zanubrutinib superior to ibrutinib for relapsed or refractory CLL/SLL?", "public_title": "Is zanubrutinib superior to ibrutinib for relapsed or refractory CLL/SLL?", "slug": "zanubrutinib-ibrutinib-relapsed-refractory-cll-sll", "legacy_canonical_url": "https://5minutehematology.com/programs/zanubrutinib-ibrutinib-relapsed-refractory-cll-sll", "description": "Review of a multinational phase 3 head-to-head randomized trial comparing zanubrutinib vs ibrutinib in relapsed/refractory CLL/SLL (NEJM, 2023), including final PFS results.", "scientific_summary": "Review of a multinational phase 3 head-to-head randomized trial comparing zanubrutinib vs ibrutinib in relapsed/refractory CLL/SLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is zanubrutinib superior to ibrutinib for relapsed or refractory CLL/SLL?", "language": null, "original_publication_date": "2026-02-23T18:40:36.014Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4065063/horizontal/small_1976ded4-6a98-4a8f-81a5-7f35bed40b67.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "SLL", "zanubrutinib", "ibrutinib", "BTK inhibitor", "relapsed", "refractory", "phase 3 trial", "progression-free survival", "overall response rate"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4065063", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_36511784", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4065176", "editorial": {"original_title": "In relapsed or refractory CLL, does acalabrutinib improve PFS versus IR or BR?", "public_title": "In relapsed or refractory CLL, does acalabrutinib improve PFS versus IR or BR?", "slug": "ascend-phase-iii-trial-acalabrutinib-versus-ir-or-br", "legacy_canonical_url": "https://5minutehematology.com/programs/ascend-phase-iii-trial-acalabrutinib-versus-ir-or-br", "description": "Summary of ASCEND, a global multicenter randomized open-label phase III trial in the Journal of Clinical Oncology (2020) comparing acalabrutinib vs investigator's choice I-R or B-R in R/R CLL with IRC-assessed PFS.", "scientific_summary": "Summary of ASCEND, comparing acalabrutinib vs investigator's choice I-R or B-R in R/R CLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In relapsed or refractory CLL, does acalabrutinib improve PFS versus IR or BR?", "language": null, "original_publication_date": "2026-02-23T18:50:26.997Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4065176/horizontal/small_5eed21ca-76e4-43df-a70a-cd840868596f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "relapsed", "refractory", "acalabrutinib", "BTK inhibitor", "idelalisib", "rituximab", "bendamustine", "ASCEND trial", "phase III", "progression-free survival", "randomized", "open-label"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4065176", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ACALABRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ACALABRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4065199", "editorial": {"original_title": "How do you diagnose and treat copper deficiency anemia?", "public_title": "How do you diagnose and treat copper deficiency anemia?", "slug": "copper-deficiency-anemia-review", "legacy_canonical_url": "https://5minutehematology.com/programs/copper-deficiency-anemia-review", "description": "Physician-focused review of copper deficiency anemia pathophysiology, diagnostic labs (serum copper, ceruloplasmin, urine copper), and repletion strategies, based on a narrative review article (Annals of Hematology, 2018).", "scientific_summary": "Physician-focused review of copper deficiency anemia pathophysiology, diagnostic labs and repletion strategies.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How do you diagnose and treat copper deficiency anemia?", "language": null, "original_publication_date": "2026-02-23T18:58:45.245Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4065199/horizontal/small_94b20096-60c2-4a12-a198-8f89bf777b7c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["copper deficiency", "copper deficiency anemia", "ceruloplasmin", "serum copper", "urine copper", "myeloneuropathy", "zinc excess", "ATP7A", "Ctr1", "copper supplementation", "copper gluconate"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4065199", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4065223", "editorial": {"original_title": "Should pirtobrutinib replace bendamustine-rituximab as first-line therapy for CLL/SLL without del(17p)?", "public_title": "Should pirtobrutinib replace bendamustine-rituximab as first-line therapy for CLL/SLL without del(17p)?", "slug": "bruin-cll-313-pirtobrutinib-versus-bendamustine-rituximab-untreated-cll-sll", "legacy_canonical_url": "https://5minutehematology.com/programs/bruin-cll-313-pirtobrutinib-versus-bendamustine-rituximab-untreated-cll-sll", "description": "Randomized, open-label, global phase III trial (BRUIN CLL-313) in Journal of Clinical Oncology (2025) comparing pirtobrutinib vs bendamustine plus rituximab in untreated CLL/SLL without del(17p).", "scientific_summary": "Randomized phase III trial (BRUIN CLL-313) comparing pirtobrutinib vs bendamustine plus rituximab in untreated CLL/SLL without del(17p).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should pirtobrutinib replace bendamustine-rituximab as first-line therapy for CLL/SLL without del(17p)?", "language": null, "original_publication_date": "2026-02-23T19:26:58.141Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4065223/horizontal/small_2842299a-992a-4238-b498-60143a3d3670.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "SLL", "pirtobrutinib", "bendamustine", "rituximab", "BTK inhibitor", "noncovalent BTKi", "frontline therapy", "progression-free survival", "overall survival", "randomized phase III"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4065223", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4065238", "editorial": {"original_title": "Is bendamustine rituximab non-inferior to FCR for first-line treatment of fit patients with advanced CLL without del17p?", "public_title": "Is bendamustine rituximab non-inferior to FCR for first-line treatment of fit patients with advanced CLL without del17p?", "slug": "cll10-br-vs-fcr-firstline-advanced-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/cll10-br-vs-fcr-firstline-advanced-cll", "description": "International open-label randomized phase 3 non-inferiority trial (CLL10) comparing BR vs FCR in treatment-naive fit advanced CLL without del(17p) (The Lancet Oncology, 2016).", "scientific_summary": "Open-label randomized phase 3 non-inferiority trial (CLL10) comparing BR vs FCR in treatment-naive fit advanced CLL without del(17p).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is bendamustine rituximab non-inferior to FCR for first-line treatment of fit patients with advanced CLL without del17p?", "language": null, "original_publication_date": "2026-02-23T19:33:17.940Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4065238/horizontal/small_603e1314-957a-4579-a404-f6b9ee69aaec.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL10", "chronic lymphocytic leukemia", "first-line chemoimmunotherapy", "bendamustine", "rituximab", "BR", "fludarabine", "cyclophosphamide", "FCR", "progression-free survival", "non-inferiority"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4065238", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic lymphocytic leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_BR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BR", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_FLUDARABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "fludarabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4082790", "editorial": {"original_title": "In late-line CML-CP, does asciminib improve MMR and tolerability versus bosutinib?", "public_title": "In late-line CML-CP, does asciminib improve MMR and tolerability versus bosutinib?", "slug": "asciminib-superior-bosutinib-late-line-cml-cp-ascembl-4-year-follow-up", "legacy_canonical_url": "https://5minutehematology.com/programs/asciminib-superior-bosutinib-late-line-cml-cp-ascembl-4-year-follow-up", "description": "Phase 3 randomized ASCEMBL trial update with nearly 4 years follow-up, comparing asciminib vs bosutinib in CML-CP after >=2 prior TKIs (Blood Advances, 2025).", "scientific_summary": "Phase 3 randomized ASCEMBL trial update with nearly 4 years follow-up, comparing asciminib vs bosutinib in CML-CP after >=2 prior TKIs.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Free Hematology Videos", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In late-line CML-CP, does asciminib improve MMR and tolerability versus bosutinib?", "language": null, "original_publication_date": "2026-03-07T01:06:11.847Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4082790/horizontal/small_7f00365f-ef45-4292-87b7-6e3274759f35.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["asciminib", "bosutinib", "CML-CP", "ASCEMBL", "major molecular response", "MMR", "tyrosine kinase inhibitor", "safety", "tolerability", "treatment discontinuation", "adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4082790", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40334072", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["ASCEMBL nearly 4-year"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_TFR"}], "evidence_relations": [{"target_id": "EV_PMID_29735299", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_40334072", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_ASCIMINIB", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_CML_TFR", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_ASCIMINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ASCIMINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_BOSUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BOSUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083259", "editorial": {"original_title": "Does momelotinib improve overall survival in myelofibrosis versus ruxolitinib or best available therapy?", "public_title": "Does momelotinib improve overall survival in myelofibrosis versus ruxolitinib or best available therapy?", "slug": "momelotinib-overall-survival-simplify-1-simplify-2-myelofibrosis", "legacy_canonical_url": "https://5minutehematology.com/programs/momelotinib-overall-survival-simplify-1-simplify-2-myelofibrosis", "description": "Phase 3 SIMPLIFY-1 and SIMPLIFY-2 randomized trial OS and LFS analysis of momelotinib in myelofibrosis (Leukemia, 2022), including TI associations.", "scientific_summary": "Phase 3 SIMPLIFY-1 and SIMPLIFY-2 randomized trial OS and LFS analysis of momelotinib in myelofibrosis.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does momelotinib improve overall survival in myelofibrosis versus ruxolitinib or best available therapy?", "language": null, "original_publication_date": "2026-03-07T17:48:53.928Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083259/horizontal/small_88a9afb5-3185-4aae-8f84-2176d4bdb16b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["momelotinib", "myelofibrosis", "SIMPLIFY-1", "SIMPLIFY-2", "phase 3 trial", "overall survival", "leukemia-free survival", "transfusion independence", "ruxolitinib", "best available therapy", "JAK inhibitor", "ACVR1", "ALK2"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083259", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_35869266", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083285", "editorial": {"original_title": "How effective is momelotinib for anemic myelofibrosis in real-world practice?", "public_title": "How effective is momelotinib for anemic myelofibrosis in real-world practice?", "slug": "real-world-outcomes-momelotinib-myelofibrosis-anemia-momgemfin-study", "legacy_canonical_url": "https://5minutehematology.com/programs/real-world-outcomes-momelotinib-myelofibrosis-anemia-momgemfin-study", "description": "Physician-focused review of the MOMGEMFIN real-world observational study assessing outcomes of momelotinib in myelofibrosis patients with anemia (Blood Cancer Journal, 2025).", "scientific_summary": "Review of the MOMGEMFIN real-world observational study assessing outcomes of momelotinib in myelofibrosis patients with anemia.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Commentary", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective is momelotinib for anemic myelofibrosis in real-world practice?", "language": null, "original_publication_date": "2026-03-07T18:24:09.809Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083285/horizontal/small_f54b0c55-5ce8-4d9c-8c3c-32814ba014d7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["momelotinib", "myelofibrosis", "anemia", "real-world evidence", "observational study", "MOMGEMFIN", "JAK inhibitor", "outcomes"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083285", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40246837", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083289", "editorial": {"original_title": "When can a patient with CML safely discontinue TKI therapy to attempt treatment-free remission?", "public_title": "When can a patient with CML safely discontinue TKI therapy to attempt treatment-free remission?", "slug": "cml-treatment-free-remission-tki-discontinuation-lalnet-recommendations", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-treatment-free-remission-tki-discontinuation-lalnet-recommendations", "description": "Consensus guideline recommendations from the LALNET Latin American expert panel (Blood Advances, 2021) on criteria, monitoring, and restarting rules for CML treatment-free remission after TKI discontinuation outside clinical trials.", "scientific_summary": "Consensus guideline recommendations from the LALNET on criteria, monitoring, and restarting rules for CML TFR TKI discontinuation.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "When can a patient with CML safely discontinue TKI therapy to attempt treatment-free remission?", "language": null, "original_publication_date": "2026-03-07T18:42:29.630Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083289/horizontal/small_f314d2dc-5a85-4d52-9df7-a5d20c271523.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["chronic myeloid leukemia", "CML treatment-free remission", "TFR", "tyrosine kinase inhibitor", "TKI discontinuation", "deep molecular response", "MR4.5", "BCR-ABL", "qPCR monitoring", "major molecular response", "MMR loss"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083289", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_34438444", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_TFR"}], "evidence_relations": [{"target_id": "EV_PMID_29735299", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_TFR", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [{"target_id": "PHASE_CML_TREATMENT_FREE_REMISSION", "type": "ClinicalPhase", "relation": "explicit_original_editorial_subject", "source_value": "CML treatment-free remission", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083426", "editorial": {"original_title": "What are the long-term safety and survival outcomes with momelotinib in myelofibrosis?", "public_title": "What are the long-term safety and survival outcomes with momelotinib in myelofibrosis?", "slug": "momelotinib-long-term-safety-survival-myelofibrosis-phase-3-rcts", "legacy_canonical_url": "https://5minutehematology.com/programs/momelotinib-long-term-safety-survival-myelofibrosis-phase-3-rcts", "description": "Integrated pooled analysis of three phase 3 randomized controlled trials (MOMENTUM, SIMPLIFY-1, SIMPLIFY-2) assessing long-term safety, exposure, and survival with momelotinib in myelofibrosis (Blood Advances, 2023).", "scientific_summary": "Integrated pooled analysis of three phase 3 randomized controlled trials (MOMENTUM, SIMPLIFY-1, SIMPLIFY-2).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the long-term safety and survival outcomes with momelotinib in myelofibrosis?", "language": null, "original_publication_date": "2026-03-07T22:34:11.887Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083426/horizontal/small_d26b99de-b732-498f-93fe-b9bddf751f53.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["momelotinib", "myelofibrosis", "JAK1", "JAK2", "ACVR1", "phase 3", "randomized controlled trial", "MOMENTUM", "SIMPLIFY-1", "SIMPLIFY-2", "long-term safety", "adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083426", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37042865", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MPN_MYELOFIBROSIS_MF_ANEMIA"}], "evidence_relations": [{"target_id": "EV_PMID_36709073", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MPN_MYELOFIBROSIS_MF_ANEMIA", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083442", "editorial": {"original_title": "How should adult CML be managed per the 2025 European LeukemiaNet recommendations?", "public_title": "How should adult CML be managed per the 2025 European LeukemiaNet recommendations?", "slug": "eln-2025-cml-management-recommendations", "legacy_canonical_url": "https://5minutehematology.com/programs/eln-2025-cml-management-recommendations", "description": "Physician-focused summary of an expert consensus guideline/recommendations update (Leukemia, 2025) covering ELN changes in adult CML management, including TKI selection, milestones, toxicity strategies, TFR, pregnancy/parenting, and HSCT.", "scientific_summary": "ELN changes in adult CML management, including TKI selection, milestones, toxicity strategies, TFR, pregnancy/parenting, and HSCT.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should adult CML be managed per the 2025 European LeukemiaNet recommendations?", "language": null, "original_publication_date": "2026-03-07T23:14:32.278Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083442/horizontal/small_5bdd460f-9009-42e8-9dca-7146e6adcb60.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["chronic myeloid leukemia", "CML", "European LeukemiaNet", "ELN guideline", "tyrosine kinase inhibitor", "TKI", "molecular milestones", "dose reduction", "treatment sequencing", "treatment-free remission"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083442", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_TFR"}], "evidence_relations": [{"target_id": "EV_PMID_29735299", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_TFR", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083449", "editorial": {"original_title": "How should CML be diagnosed, treated, and monitored in 2025?", "public_title": "How should CML be diagnosed, treated, and monitored in 2025?", "slug": "cml-diagnosis-therapy-monitoring-tki-transplant", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-diagnosis-therapy-monitoring-tki-transplant", "description": "Physician education based on a narrative review/update in American Journal of Hematology (2024) summarizing CML diagnosis, TKI selection, monitoring, and transplant indications.", "scientific_summary": "Review/update in American Journal of Hematology (2024) summarizing CML diagnosis, TKI selection, monitoring, and HSCT indications.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should CML be diagnosed, treated, and monitored in 2025?", "language": null, "original_publication_date": "2026-03-07T23:21:37.338Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083449/horizontal/small_f7c682d6-798f-4046-8862-c202e2f65a55.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["chronic myeloid leukemia", "CML", "BCR-ABL1", "Philadelphia chromosome", "tyrosine kinase inhibitors", "imatinib", "dasatinib", "nilotinib", "bosutinib", "ponatinib", "asciminib", "T315I mutation"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083449", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_39093014", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_FRONTLINE_TKI"}], "evidence_relations": [{"target_id": "EV_PMID_28273028", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_40334072", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_ASCIMINIB", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_CML_FRONTLINE_TKI", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_IMATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IMATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_DASATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "dasatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DASATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dasatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_NILOTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_NILOTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_BOSUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BOSUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_PONATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_PONATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_ASCIMINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ASCIMINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083477", "editorial": {"original_title": "Does andexanet alfa achieve effective hemostasis in major bleeding on factor Xa inhibitors?", "public_title": "Does andexanet alfa achieve effective hemostasis in major bleeding on factor Xa inhibitors?", "slug": "andexanet-alfa-major-bleeding-factor-xa-inhibitors-annexa4-final-report", "legacy_canonical_url": "https://5minutehematology.com/programs/andexanet-alfa-major-bleeding-factor-xa-inhibitors-annexa4-final-report", "description": "Review of ANNEXA-4 final analysis, a multicenter prospective phase 3b/4 single-group cohort study of andexanet alfa for acute major bleeding on FXa inhibitors (Circulation, 2023).", "scientific_summary": "Review of ANNEXA-4 final analysis, a cohort study of andexanet alfa for acute major bleeding on FXa inhibitors (Circulation, 2023).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Original Studies", "Non-Malignant Hematology"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Non-Malignant Hematology"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does andexanet alfa achieve effective hemostasis in major bleeding on factor Xa inhibitors?", "language": null, "original_publication_date": "2026-03-08T00:03:51.733Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083477/horizontal/small_5e72f5c2-51bb-4743-a797-c63a988b09dd.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["andexanet", "ANNEXA-4", "factor Xa inhibitors", "apixaban", "rivaroxaban", "edoxaban", "enoxaparin", "major bleeding", "intracranial hemorrhage", "gastrointestinal bleeding", "anti-FXa activity", "hemostatic efficacy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083477", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_36802876", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083490", "editorial": {"original_title": "Can etranacogene dezaparvovec reduce bleeding compared with factor IX prophylaxis in hemophilia B?", "public_title": "Can etranacogene dezaparvovec reduce bleeding compared with factor IX prophylaxis in hemophilia B?", "slug": "gene-therapy-etranacogene-dezaparvovec-hemophilia-b", "legacy_canonical_url": "https://5minutehematology.com/programs/gene-therapy-etranacogene-dezaparvovec-hemophilia-b", "description": "Open-label phase 3 trial (HOPE-B) in NEJM 2023: single-infusion AAV5-Padua FIX gene therapy vs lead-in FIX prophylaxis; noninferiority/superiority on annualized bleeding rate.", "scientific_summary": "Open-label phase 3 trial: single-infusion AAV5-Padua FIX gene therapy vs lead-in FIX prophylaxis.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can etranacogene dezaparvovec reduce bleeding compared with factor IX prophylaxis in hemophilia B?", "language": null, "original_publication_date": "2026-03-08T00:29:37.029Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083490/horizontal/small_eb296447-f25f-45c5-88f4-b58781e08b0a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["hemophilia B", "etranacogene dezaparvovec", "AAV5", "factor IX Padua", "gene therapy", "annualized bleeding rate", "factor IX activity", "HOPE-B", "phase 3 trial", "FIX prophylaxis"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083490", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_36812434", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HEMOPHILIA_B", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "hemophilia B", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4083845", "editorial": {"original_title": "Does frontline nilotinib improve 10-year molecular response and TFR eligibility versus imatinib in newly diagnosed CML?", "public_title": "Does frontline nilotinib improve 10-year molecular response and TFR eligibility versus imatinib in newly diagnosed CML?", "slug": "frontline-nilotinib-versus-imatinib-10-year-enestnd-cp-cml", "legacy_canonical_url": "https://5minutehematology.com/programs/frontline-nilotinib-versus-imatinib-10-year-enestnd-cp-cml", "description": "Review of the ENESTnd randomized controlled trial 10-year analysis in newly diagnosed chronic-phase CML (Leukemia, 2021), comparing frontline nilotinib vs imatinib for deep molecular response, progression, TFR eligibility, and cardiovascular toxicity.", "scientific_summary": "Review of the ENESTnd randomized controlled trial 10-year analysis in newly diagnosed chronic-phase CML.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does frontline nilotinib improve 10-year molecular response and TFR eligibility versus imatinib in newly diagnosed CML?", "language": null, "original_publication_date": "2026-03-08T17:03:51.917Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4083845/horizontal/small_f95f7092-247c-47c4-8018-2a07402a3464.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CML", "chronic phase", "ENESTnd", "nilotinib", "imatinib", "frontline therapy", "MMR", "MR4.5", "treatment-free remission", "cardiovascular events", "TKI"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4083845", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4337637", "relation": "same_documented_source", "shared_reference_ids": ["PMID_33414482"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_33414482", "role": "reviewed_original_source", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "DIRECT", "source_field": "existing_physician_review", "source_value": "EV_PMID_33414482", "provenance": "data/content_mapping/evidence_content_review.csv + corrections"}], "clinical_trial_names": ["ENESTnd 10-year"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_FRONTLINE_TKI"}], "evidence_relations": [{"target_id": "EV_PMID_28273028", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_33414482", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_FRONTLINE_TKI", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_NILOTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_NILOTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_IMATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IMATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4084477", "editorial": {"original_title": "Does zanubrutinib plus obinutuzumab improve outcomes versus obinutuzumab alone in relapsed or refractory follicular lymphoma?", "public_title": "Does zanubrutinib plus obinutuzumab improve outcomes versus obinutuzumab alone in relapsed or refractory follicular lymphoma?", "slug": "rosewood-zanubrutinib-obinutuzumab-versus-obinutuzumab-rr-follicular", "legacy_canonical_url": "https://5minutehematology.com/programs/rosewood-zanubrutinib-obinutuzumab-versus-obinutuzumab-rr-follicular", "description": "Phase II randomized ROSEWOOD trial comparing zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy in relapsed/refractory follicular lymphoma (J Clin Oncol, 2023).", "scientific_summary": "Phase II randomized ROSEWOOD trial comparing zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy in relapsed/refractory FL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does zanubrutinib plus obinutuzumab improve outcomes versus obinutuzumab alone in relapsed or refractory follicular lymphoma?", "language": null, "original_publication_date": "2026-03-08T20:20:47.670Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4084477/horizontal/small_31de41d8-47ab-4196-9f0e-eb4524bf10ee.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "zanubrutinib", "obinutuzumab", "BTK inhibitor", "anti-CD20", "phase II randomized trial", "overall response rate", "progression-free survival safety"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4084477", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4084501", "editorial": {"original_title": "Does progression within 2 years after first-line R-CHOP predict mortality in follicular lymphoma?", "public_title": "Does progression within 2 years after first-line R-CHOP predict mortality in follicular lymphoma?", "slug": "early-progression-2-years-r-chop-follicular-lymphoma-mortality", "legacy_canonical_url": "https://5minutehematology.com/programs/early-progression-2-years-r-chop-follicular-lymphoma-mortality", "description": "Retrospective cohort analysis from the National LymphoCare Study (Journal of Clinical Oncology, 2015) evaluating POD within 2 years after first-line R-CHOP in follicular lymphoma, with independent validation.", "scientific_summary": "Retrospective cohort analysis from the National LymphoCare Study evaluating POD within 2 years first-line R-CHOP in follicular lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does progression within 2 years after first-line R-CHOP predict mortality in follicular lymphoma?", "language": null, "original_publication_date": "2026-03-08T20:33:47.247Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4084501/horizontal/small_c358dc22-64f5-4f5f-9687-08a62012bc23.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "R-CHOP", "rituximab", "early progression", "POD24", "overall survival", "FLIPI", "National LymphoCare Study", "risk stratification", "chemoimmunotherapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4084501", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "CALC_FLIPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "FLIPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "PROT_LYM_BR_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_BR", "graph_edge_ids": ["EDGE_FL_BR_FRONTLINE_HAS_OPTION", "EDGE_FL_BR_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved bendamustine + rituximab resource in the frontline-treatment decision. The source explicitly includes selected indolent B-cell lymphomas; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/bendamustine_rituximab.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_FL_RCHOP21_FRONTLINE_HAS_OPTION", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved generic R-CHOP-21 resource in the follicular-lymphoma frontline-treatment decision. The edge does not infer preferred use, cycle count, maintenance, or transformed-disease management."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4084516", "editorial": {"original_title": "Is bendamustine-rituximab noninferior to R-CHOP or R-CVP for first-line advanced indolent NHL or MCL?", "public_title": "Is bendamustine-rituximab noninferior to R-CHOP or R-CVP for first-line advanced indolent NHL or MCL?", "slug": "bendamustine-rituximab-noninferior-rchop-rcvp-firstline-indolent-nhl-mcl", "legacy_canonical_url": "https://5minutehematology.com/programs/bendamustine-rituximab-noninferior-rchop-rcvp-firstline-indolent-nhl-mcl", "description": "Global open-label randomized phase 3 noninferiority trial (BRIGHT) in Blood (2014) comparing bendamustine-rituximab vs investigator-selected R-CHOP/R-CVP in treatment-naive advanced indolent NHL or mantle cell lymphoma.", "scientific_summary": "Global open-label randomized phase 3 noninferiority trial (BRIGHT)comparing BR vs. R-CHOP/R-CVP in treatment-naive indolent NHL or MCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is bendamustine-rituximab noninferior to R-CHOP or R-CVP for first-line advanced indolent NHL or MCL?", "language": null, "original_publication_date": "2026-03-08T20:49:44.115Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4084516/horizontal/small_e936e393-4d2d-4666-a6a6-910248bc2e28.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["BRIGHT", "bendamustine", "rituximab", "BR", "R-CHOP", "R-CVP", "indolent non-Hodgkin lymphoma", "mantle cell lymphoma", "first-line therapy", "phase 3 trial", "noninferiority", "complete response rate"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4084516", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_BR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BR", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_BR_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE", "via_therapy_id": "TX_LYM_BR", "graph_edge_ids": ["EDGE_MCL_BR_HAS_OPTION", "EDGE_FL_BR_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MCL_V1_REVIEW.md", "note": "Physician-reviewed link to the approved bendamustine + rituximab resource in the older/transplant-ineligible frontline decision. The stored protocol explicitly includes mantle-cell lymphoma context; HAS_OPTION does not encode preference, BTKi combination, maintenance, or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/bendamustine_rituximab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4084676", "editorial": {"original_title": "Does 2-year rituximab maintenance improve outcomes after first-line immunochemotherapy in follicular lymphoma?", "public_title": "Does 2-year rituximab maintenance improve outcomes after first-line immunochemotherapy in follicular lymphoma?", "slug": "rituximab-maintenance-2-years-high-tumor-burden-follicular-lymphoma-prima", "legacy_canonical_url": "https://5minutehematology.com/programs/rituximab-maintenance-2-years-high-tumor-burden-follicular-lymphoma-prima", "description": "Phase 3 randomized open-label PRIMA trial (The Lancet, 2010) testing 2 years of rituximab maintenance vs observation after response to first-line rituximab-chemotherapy in high tumor burden follicular lymphoma.", "scientific_summary": "PRIMA trial testing 2 years of rituximab maintenance vs observation after first-line rituximab-chemotherapy in follicular lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does 2-year rituximab maintenance improve outcomes after first-line immunochemotherapy in follicular lymphoma?", "language": null, "original_publication_date": "2026-03-09T00:27:40.534Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4084676/horizontal/small_951603de-f15a-48ab-af79-b7f07bda4b0a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "high tumor burden", "rituximab maintenance", "PRIMA trial", "immunochemotherapy", "progression-free survival", "randomized controlled trial", "infections grade 3-4", "adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4084676", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_21176949", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_BR_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_BR", "graph_edge_ids": ["EDGE_FL_BR_FRONTLINE_HAS_OPTION", "EDGE_FL_BR_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved bendamustine + rituximab resource in the frontline-treatment decision. The source explicitly includes selected indolent B-cell lymphomas; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/bendamustine_rituximab.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_FL_RCHOP21_FRONTLINE_HAS_OPTION", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved generic R-CHOP-21 resource in the follicular-lymphoma frontline-treatment decision. The edge does not infer preferred use, cycle count, maintenance, or transformed-disease management."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4084682", "editorial": {"original_title": "Should rituximab plus lenalidomide replace rituximab-chemotherapy for first-line advanced follicular lymphoma?", "public_title": "Should rituximab plus lenalidomide replace rituximab-chemotherapy for first-line advanced follicular lymphoma?", "slug": "rituximab-lenalidomide-advanced-untreated-follicular-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/rituximab-lenalidomide-advanced-untreated-follicular-lymphoma", "description": "Multicenter international phase 3 superiority RCT (NEJM 2018) comparing rituximab-lenalidomide vs rituximab-chemotherapy, both followed by rituximab maintenance, in untreated advanced follicular lymphoma.", "scientific_summary": "Multicenter phase 3 superiority comparing rituximab-lenalidomide vs rituximab-chemotherapy in untreated advanced follicular lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should rituximab plus lenalidomide replace rituximab-chemotherapy for first-line advanced follicular lymphoma?", "language": null, "original_publication_date": "2026-03-09T00:39:12.617Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4084682/horizontal/small_56636f29-11ca-4f41-ae36-5435e8366ab0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "advanced stage", "first-line therapy", "rituximab", "lenalidomide", "R2 regimen", "rituximab-chemotherapy", "phase 3 trial", "progression-free survival", "complete response", "toxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4084682", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30184451", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_41915772", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_41990300", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_BR_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_BR", "graph_edge_ids": ["EDGE_FL_BR_FRONTLINE_HAS_OPTION", "EDGE_FL_BR_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved bendamustine + rituximab resource in the frontline-treatment decision. The source explicitly includes selected indolent B-cell lymphomas; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/bendamustine_rituximab.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_FL_RCHOP21_FRONTLINE_HAS_OPTION", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_FOLLICULAR_V1_REVIEW.md", "note": "Physician-reviewed link to the approved generic R-CHOP-21 resource in the follicular-lymphoma frontline-treatment decision. The edge does not infer preferred use, cycle count, maintenance, or transformed-disease management."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4086103", "editorial": {"original_title": "Does obinutuzumab improve outcomes versus rituximab in relapsed indolent CD20+ NHL?", "public_title": "Does obinutuzumab improve outcomes versus rituximab in relapsed indolent CD20+ NHL?", "slug": "gauss-obinutuzumab-versus-rituximab-relapsed-cd20-indolent-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/gauss-obinutuzumab-versus-rituximab-relapsed-cd20-indolent-lymphoma", "description": "Final analysis of the randomized phase II GAUSS trial in relapsed CD20+ indolent B-cell NHL comparing obinutuzumab vs rituximab (Journal of Clinical Oncology, 2015).", "scientific_summary": "Final analysis of the randomized phase II GAUSS trial in relapsed CD20+ indolent B-cell NHL comparing obinutuzumab vs rituximab.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does obinutuzumab improve outcomes versus rituximab in relapsed indolent CD20+ NHL?", "language": null, "original_publication_date": "2026-03-10T01:09:55.114Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4086103/horizontal/small_2ff9bb14-714a-4646-a19e-a9a86c62f858.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["obinutuzumab", "rituximab", "GAUSS", "phase II trial", "randomized trial", "relapsed indolent lymphoma", "CD20 positive", "follicular lymphoma", "overall response rate", "progression-free survival", "infusion reactions"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4086103", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_26282650", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4087563", "editorial": {"original_title": "How effective and safe is ciltacabtagene autoleucel in relapsed or refractory multiple myeloma?", "public_title": "How effective and safe is ciltacabtagene autoleucel in relapsed or refractory multiple myeloma?", "slug": "ciltacabtagene-autoleucel-bcma-car-t-rr-multiple-myeloma-cartitude-1-phase-1b-2", "legacy_canonical_url": "https://5minutehematology.com/programs/ciltacabtagene-autoleucel-bcma-car-t-rr-multiple-myeloma-cartitude-1-phase-1b-2", "description": "Summary of CARTITUDE-1, a single-arm open-label phase 1b/2 study in Lancet (2021) evaluating BCMA-directed CAR T therapy (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma.", "scientific_summary": "CARTITUDE-1, a single-arm open-label phase 1b/2 study evaluating BCMA-directed CAR T therapy (cilta-cel) in heavily pretreated r/r myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective and safe is ciltacabtagene autoleucel in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-11T01:19:52.442Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4087563/horizontal/small_ca17e64d-81c7-4feb-9c74-d061d7883cc8.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ciltacabtagene autoleucel", "cilta-cel", "BCMA", "CAR T-cell therapy", "multiple myeloma", "CARTITUDE-1", "phase 1b/2", "open-label single-arm"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4087563", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [{"target_id": "EV_PMID_37272512", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CILTACABTAGENE_AUTOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "cilta-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4087575", "editorial": {"original_title": "Can the CAR-HEMATOTOX score predict toxicity and outcomes after BCMA CAR-T in relapsed or refractory multiple myeloma?", "public_title": "Can the CAR-HEMATOTOX score predict toxicity and outcomes after BCMA CAR-T in relapsed or refractory multiple myeloma?", "slug": "car-hematotox-score-prognostic-toxicity-response-bcma-car-t-relapsed-refractory", "legacy_canonical_url": "https://5minutehematology.com/programs/car-hematotox-score-prognostic-toxicity-response-bcma-car-t-relapsed-refractory", "description": "Retrospective multicenter cohort study in Journal of Hematology & Oncology (2023) evaluating CAR-HEMATOTOX for predicting cytopenias, infections, ICANS, response, and survival after BCMA CAR-T in r/r myeloma.", "scientific_summary": "Retrospective multicenter cohort study evaluating CAR-HEMATOTOX after BCMA CAR-T in r/r myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can the CAR-HEMATOTOX score predict toxicity and outcomes after BCMA CAR-T in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-11T01:37:41.279Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4087575/horizontal/small_5ce04400-d532-43f6-8938-b4ade9fa5288.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CAR-HEMATOTOX", "BCMA", "CAR-T", "multiple myeloma", "idecabtagene vicleucel", "ciltacabtagene autoleucel", "cytopenias", "severe neutropenia", "infections", "ICANS", "risk stratification", "progression-free survival", "overall survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4087575", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37525244", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART"}], "evidence_relations": [{"target_id": "EV_PMID_36762851", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_IDECEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IDECABTAGENE_VICLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CILTACABTAGENE_AUTOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "CALC_CAR_HEMATOTOX", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "CAR-HEMATOTOX", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "PROT_MM_CILTACEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_MM_CILTACEL", "graph_edge_ids": ["EDGE_MM_CILTACEL_HAS_OPTION", "EDGE_MM_CILTACEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Ciltacabtagene autoleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/cilta_cel.json"}]}, {"target_id": "PROT_CART_IDECEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_CART_IDECEL", "graph_edge_ids": ["EDGE_MM_IDECEL_HAS_OPTION", "EDGE_MM_IDECEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Idecabtagene vicleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/ide_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4087585", "editorial": {"original_title": "How should cytokine release syndrome be graded after tisagenlecleucel CAR T therapy?", "public_title": "How should cytokine release syndrome be graded after tisagenlecleucel CAR T therapy?", "slug": "grading-cytokine-release-syndrome-tisagenlecleucel-car-t", "legacy_canonical_url": "https://5minutehematology.com/programs/grading-cytokine-release-syndrome-tisagenlecleucel-car-t", "description": "Review of the Penn CRS grading scale developed from University of Pennsylvania clinical experience and applied to pediatric ALL and CLL cohorts in J Hematol Oncol (2018).", "scientific_summary": "Review of the Penn CRS grading scale developed from University of Pennsylvania clinical experience and applied to pediatric ALL and CLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should cytokine release syndrome be graded after tisagenlecleucel CAR T therapy?", "language": null, "original_publication_date": "2026-03-11T01:48:35.021Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4087585/horizontal/small_0d62a51f-a37e-44ad-b8a5-b8dc91b1d89b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["cytokine release syndrome", "CRS grading", "Penn grading scale", "CAR T therapy", "tisagenlecleucel", "anti-CD19 cell therapy", "toxicity", "acute lymphoblastic leukemia", "chronic lymphocytic leukemia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4087585", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_29499750", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_CAR_T"}, {"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic lymphocytic leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [{"target_id": "EV_PMID_40108332", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_ALL_CAR_T", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_TISACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TISAGENLECLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4087591", "editorial": {"original_title": "Does glofitamab induce durable complete responses in relapsed or refractory DLBCL after at least two prior therapies?", "public_title": "Does glofitamab induce durable complete responses in relapsed or refractory DLBCL after at least two prior therapies?", "slug": "glofitamab-relapsed-refractory-dlbcl-phase-2", "legacy_canonical_url": "https://5minutehematology.com/programs/glofitamab-relapsed-refractory-dlbcl-phase-2", "description": "Phase 2 portion of a phase 1-2 study (NEJM, 2022) evaluating fixed-duration glofitamab with obinutuzumab pretreatment in heavily pretreated relapsed/refractory DLBCL, including post-CAR T patients.", "scientific_summary": "Phase 2 portion evaluating fixed-duration glofitamab with obinutuzumab pretreatment in heavily pretreated R/R DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does glofitamab induce durable complete responses in relapsed or refractory DLBCL after at least two prior therapies?", "language": null, "original_publication_date": "2026-03-11T02:01:12.084Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4087591/horizontal/small_ab93c26f-bc48-44bd-b6eb-9c0f784b8185.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["glofitamab", "DLBCL", "relapsed refractory lymphoma", "bispecific antibody", "CD20xCD3 T-cell engager", "obinutuzumab pretreatment", "cytokine release syndrome", "complete response", "post-CAR T"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4087591", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_36507690", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_GLOFITAMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_GLOFITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4090101", "editorial": {"original_title": "How effective is ide-cel for relapsed or refractory multiple myeloma?", "public_title": "How effective is ide-cel for relapsed or refractory multiple myeloma?", "slug": "ide-cel-in-relapsed-and-refractory-multiple-myeloma-nejm-2023", "legacy_canonical_url": "https://5minutehematology.com/programs/ide-cel-in-relapsed-and-refractory-multiple-myeloma-nejm-2023", "description": "Physician-focused review of a 2023 NEJM clinical trial evaluating ide-cel in patients with relapsed or refractory multiple myeloma, highlighting efficacy and safety outcomes.", "scientific_summary": "Physician-focused review of a 2023 NEJM clinical trial evaluating ide-cel in patients with relapsed or refractory multiple myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective is ide-cel for relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-12T00:56:15.893Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4090101/horizontal/small_81fc51f7-22f9-4f0c-a10a-7a0ffa7696ad.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ide-cel", "idecabtagene vicleucel", "BCMA CAR-T", "relapsed refractory multiple myeloma", "CAR T-cell therapy", "NEJM", "clinical trial", "response rate", "cytokine release syndrome", "neurotoxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4090101", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART"}], "evidence_relations": [{"target_id": "EV_PMID_36762851", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_IDECEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ide-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_IDECEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IDECABTAGENE_VICLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_CILTACEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_MM_CILTACEL", "graph_edge_ids": ["EDGE_MM_CILTACEL_HAS_OPTION", "EDGE_MM_CILTACEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Ciltacabtagene autoleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/cilta_cel.json"}]}, {"target_id": "PROT_CART_IDECEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_CART_IDECEL", "graph_edge_ids": ["EDGE_MM_IDECEL_HAS_OPTION", "EDGE_MM_IDECEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Idecabtagene vicleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/ide_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4090122", "editorial": {"original_title": "Is second-line tisagenlecleucel superior to salvage chemotherapy and autologous HSCT in aggressive B-cell lymphoma?", "public_title": "Is second-line tisagenlecleucel superior to salvage chemotherapy and autologous HSCT in aggressive B-cell lymphoma?", "slug": "second-line-tisagenlecleucel-standard-care-aggressive-b-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/second-line-tisagenlecleucel-standard-care-aggressive-b-cell-lymphoma", "description": "International phase 3 randomized trial (NEJM, 2022) comparing second-line tisagenlecleucel (with optional bridging) vs salvage chemo plus autologous HSCT in early refractory/relapsed aggressive B-cell lymphoma.", "scientific_summary": "Phase 3 randomized trial comparing second-line tisagenlecleucel vs salvage chemo plus autologous HSCT in early refractory/relapsed LBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is second-line tisagenlecleucel superior to salvage chemotherapy and autologous HSCT in aggressive B-cell lymphoma?", "language": null, "original_publication_date": "2026-03-12T01:18:54.956Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4090122/horizontal/small_5c7e6644-b1cf-4c62-851e-da0ced31348c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["tisagenlecleucel", "CAR T", "CD19", "aggressive B-cell lymphoma", "DLBCL", "second-line", "salvage chemotherapy", "autologous HSCT", "BELINDA", "event-free survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4090122", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_34904798", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_EARLY_RELAPSE_SECOND_LINE"}, {"target_id": "DIS_TRANSPLANT_CELLULAR_THERAPY", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HSCT_CELLULAR_AUTO_HSCT_PLATFORM"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_EARLY_RELAPSE_SECOND_LINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_HSCT_CELLULAR_AUTO_HSCT_PLATFORM", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_TISACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TISAGENLECLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4091429", "editorial": {"original_title": "In lenalidomide-refractory multiple myeloma after 1-3 prior lines, does cilta-cel improve PFS?", "public_title": "In lenalidomide-refractory multiple myeloma after 1-3 prior lines, does cilta-cel improve PFS?", "slug": "cilta-cel-standard-care-lenalidomide-refractory-multiple-myeloma-cartitude-4", "legacy_canonical_url": "https://5minutehematology.com/programs/cilta-cel-standard-care-lenalidomide-refractory-multiple-myeloma-cartitude-4", "description": "Phase 3 randomized open-label CARTITUDE-4 trial (NEJM 2023) comparing BCMA CAR-T cilta-cel vs physician's choice standard care in lenalidomide-refractory multiple myeloma after 1-3 prior lines.", "scientific_summary": "Phase 3 randomized CARTITUDE-4 trial comparing BCMA CAR-T cilta-cel vs physician's choice standard care in lenalidomide-refractory myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In lenalidomide-refractory multiple myeloma after 1-3 prior lines, does cilta-cel improve PFS?", "language": null, "original_publication_date": "2026-03-12T21:52:07.084Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4091429/horizontal/small_df2d05db-84b7-4fde-964d-54548c50381a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ciltacabtagene autoleucel", "cilta-cel", "BCMA", "CAR-T", "multiple myeloma", "lenalidomide-refractory", "CARTITUDE-4", "progression-free survival", "minimal residual disease", "cytokine release syndrome", "ICANS"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4091429", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37272512", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["CARTITUDE-4"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART"}], "evidence_relations": [{"target_id": "EV_PMID_37272512", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CILTACABTAGENE_AUTOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "cilta-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_CILTACEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_MM_CILTACEL", "graph_edge_ids": ["EDGE_MM_CILTACEL_HAS_OPTION", "EDGE_MM_CILTACEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Ciltacabtagene autoleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/cilta_cel.json"}]}, {"target_id": "PROT_CART_IDECEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_CART_IDECEL", "graph_edge_ids": ["EDGE_MM_IDECEL_HAS_OPTION", "EDGE_MM_IDECEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Idecabtagene vicleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/ide_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4091451", "editorial": {"original_title": "Can KTE-X19 anti-CD19 CAR T cells improve outcomes in relapsed or refractory MCL after BTK inhibitor failure?", "public_title": "Can KTE-X19 anti-CD19 CAR T cells improve outcomes in relapsed or refractory MCL after BTK inhibitor failure?", "slug": "kte-x19-car-t-relapsed-refractory-mantle-cell-lymphoma-btk-failure", "legacy_canonical_url": "https://5minutehematology.com/programs/kte-x19-car-t-relapsed-refractory-mantle-cell-lymphoma-btk-failure", "description": "Overview of a 2020 New England Journal of Medicine multicenter phase 2 trial evaluating KTE-X19 anti-CD19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma after BTK inhibitor failure.", "scientific_summary": "Overview of the multicenter phase 2 trial evaluating KTE-X19 anti-CD19 CAR T-cell therapy in R/R MCL after BTK inhibitor failure.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can KTE-X19 anti-CD19 CAR T cells improve outcomes in relapsed or refractory MCL after BTK inhibitor failure?", "language": null, "original_publication_date": "2026-03-12T22:10:15.771Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4091451/horizontal/small_8693fee0-fcc2-4348-9327-91e1a9ade917.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["KTE-X19", "CAR T-cell therapy", "anti-CD19", "mantle-cell lymphoma", "relapsed refractory", "BTK inhibitor failure", "cell therapy", "NEJM 2020", "phase 2 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4091451", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_32242358", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_CAR_T"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MANTLE_CELL_LYMPHOMA_CAR_T", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "PROT_CART_BREXUCEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_CAR_T", "via_therapy_id": "TX_CART_BREXUCEL", "graph_edge_ids": ["EDGE_MCL_BREXUCEL_HAS_OPTION", "EDGE_MCL_BREXUCEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MCL_V1_REVIEW.md", "note": "Physician-reviewed link to the approved brexucabtagene autoleucel resource. The stored protocol is explicitly the adult relapsed/refractory mantle-cell lymphoma product context."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/brexu_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4091473", "editorial": {"original_title": "What are the 5-year efficacy and safety outcomes of axi-cel in relapsed/refractory indolent NHL?", "public_title": "What are the 5-year efficacy and safety outcomes of axi-cel in relapsed/refractory indolent NHL?", "slug": "five-year-follow-up-zuma-5-axicabtagene-ciloleucel-relapsed-refractory-indolent", "legacy_canonical_url": "https://5minutehematology.com/programs/five-year-follow-up-zuma-5-axicabtagene-ciloleucel-relapsed-refractory-indolent", "description": "Phase 2 multicenter ZUMA-5 trial long-term follow-up in the Journal of Clinical Oncology (2025) reporting 5-year outcomes with axi-cel in R/R indolent NHL (FL and MZL).", "scientific_summary": "Phase 2 multicenter ZUMA-5 trial long-term follow-up (2025) reporting 5-year outcomes with axi-cel in R/R indolent NHL (FL and MZL).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Free Hematology Videos", "Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the 5-year efficacy and safety outcomes of axi-cel in relapsed/refractory indolent NHL?", "language": null, "original_publication_date": "2026-03-12T22:28:40.938Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4091473/horizontal/small_1907aa63-2194-4974-a10c-f02706ea50ed.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["axi-cel", "axicabtagene ciloleucel", "CAR T-cell therapy", "ZUMA-5", "relapsed/refractory", "indolent non-Hodgkin lymphoma", "follicular lymphoma", "marginal zone lymphoma", "overall response rate", "complete response", "progression-free survival", "duration of response"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4091473", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41100801", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["ZUMA-5 5-year"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_CAR_T"}], "evidence_relations": [{"target_id": "EV_PMID_41100801", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_CAR_T", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_AXICEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "axi-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_AXICEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "axicabtagene ciloleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_AXICABTAGENE_CILOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "axicabtagene ciloleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4091500", "editorial": {"original_title": "Does denosumab improve progression-free survival versus zoledronic acid in newly diagnosed multiple myeloma?", "public_title": "Does denosumab improve progression-free survival versus zoledronic acid in newly diagnosed multiple myeloma?", "slug": "denosumab-zoledronic-acid-pfs-multiple-myeloma-phase-3-exploratory", "legacy_canonical_url": "https://5minutehematology.com/programs/denosumab-zoledronic-acid-pfs-multiple-myeloma-phase-3-exploratory", "description": "Exploratory, post hoc subgroup analyses from an international phase 3 trial in newly diagnosed multiple myeloma (Blood Advances, 2021) comparing denosumab vs zoledronic acid for PFS, focusing on ASCT intent and PI-based induction.", "scientific_summary": "Phase 3 trial in newly diagnosed multiple myeloma comparing denosumab vs zoledronic acid focus on ASCT intent and PI-based induction.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does denosumab improve progression-free survival versus zoledronic acid in newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-03-12T23:01:59.149Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4091500/horizontal/small_9b566519-53a8-4e5d-973e-e088e6b1984d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["denosumab", "zoledronic acid", "multiple myeloma", "progression-free survival", "ASCT intent", "autologous stem cell transplant", "proteasome inhibitor", "triplet induction", "bortezomib", "renal function", "creatinine clearance"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4091500", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4091516", "editorial": {"original_title": "How effective and safe is elranatamab in relapsed or refractory multiple myeloma?", "public_title": "How effective and safe is elranatamab in relapsed or refractory multiple myeloma?", "slug": "elranatamab-relapsed-refractory-multiple-myeloma-magnetismm-3-phase-2", "legacy_canonical_url": "https://5minutehematology.com/programs/elranatamab-relapsed-refractory-multiple-myeloma-magnetismm-3-phase-2", "description": "Phase 2 MagnetisMM-3 clinical trial results of elranatamab for relapsed or refractory multiple myeloma, published in Nature Medicine (2023).", "scientific_summary": "Phase 2 MagnetisMM-3 clinical trial results of elranatamab for relapsed or refractory multiple myeloma, published in Nature Medicine (2023).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective and safe is elranatamab in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-12T23:11:56.958Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4091516/horizontal/small_95c18b9f-20c6-4a1d-8485-461c32a722a1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["elranatamab", "multiple myeloma", "relapsed", "refractory", "BCMA", "bispecific antibody", "MagnetisMM-3", "phase 2 trial", "Nature Medicine"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4091516", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37582952", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_ELRA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ELRANATAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093009", "editorial": {"original_title": "Should BPd replace PVd at first relapse in lenalidomide-exposed multiple myeloma?", "public_title": "Should BPd replace PVd at first relapse in lenalidomide-exposed multiple myeloma?", "slug": "belantamab-mafodotin-pomalidomide-dexamethasone-relapsed-refractory-myeloma-dreamm8", "legacy_canonical_url": "https://5minutehematology.com/programs/belantamab-mafodotin-pomalidomide-dexamethasone-relapsed-refractory-myeloma-dreamm8", "description": "Phase 3 randomized open-label trial (NEJM, 2024) comparing belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide-exposed relapsed/refractory multiple myeloma.", "scientific_summary": "Phase 3 randomized comparing BPd vs PVd in lenalidomide-exposed relapsed/refractory multiple myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should BPd replace PVd at first relapse in lenalidomide-exposed multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T00:35:50.017Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093009/horizontal/small_80e4a4c0-cb97-4729-8c3e-1431a6d37506.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["belantamab mafodotin", "pomalidomide", "dexamethasone", "bortezomib", "BPd", "PVd", "multiple myeloma", "relapsed refractory", "lenalidomide exposed", "DREAMM-8", "phase 3 trial", "progression-free survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093009", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS"}], "evidence_relations": [{"target_id": "EV_PMID_38828933", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_41986580", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BELANTAMAB_MAFODOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "belantamab mafodotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POMALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "pomalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_BPD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BPd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_BPD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "DREAMM-8", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_BVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS", "via_therapy_id": "TX_MM_BVD", "graph_edge_ids": ["EDGE_MM_BVD_HAS_OPTION", "EDGE_MM_BVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Belantamab Mafodotin + Vd resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/myeloma/bvd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093014", "editorial": {"original_title": "What outcomes are seen with real-world SOC regimens in triple-class exposed R/R multiple myeloma?", "public_title": "What outcomes are seen with real-world SOC regimens in triple-class exposed R/R multiple myeloma?", "slug": "locommotion-prospective-noninterventional-multinational-realworld-soc", "legacy_canonical_url": "https://5minutehematology.com/programs/locommotion-prospective-noninterventional-multinational-realworld-soc", "description": "Prospective, non-interventional, multinational real-world study (Leukemia, 2022) evaluating current standards of care and outcomes in triple-class exposed RRMM patients.", "scientific_summary": "Prospective, non-interventional, real-world study evaluating current standards of care and outcomes in triple-class exposed RRMM patients.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What outcomes are seen with real-world SOC regimens in triple-class exposed R/R multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T00:46:39.427Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093014/horizontal/small_260188f3-5df7-4de1-a810-69ab192ed8d3.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "relapsed refractory", "triple-class exposed", "real-world evidence", "prospective observational", "standard of care", "overall response rate", "progression-free survival", "overall survival", "treatment-emergent adverse events", "LocoMMotion"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093014", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093019", "editorial": {"original_title": "In relapsed or refractory multiple myeloma, does BVd improve overall survival versus DVd?", "public_title": "In relapsed or refractory multiple myeloma, does BVd improve overall survival versus DVd?", "slug": "belantamab-mafodotin-bortezomib-dexamethasone-relapsed-refractory-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/belantamab-mafodotin-bortezomib-dexamethasone-relapsed-refractory-multiple-myeloma", "description": "Updated overall survival results from DREAMM-7, a global randomized open-label phase 3 trial in RRMM comparing belantamab mafodotin plus bortezomib/dexamethasone (BVd) vs daratumumab-Vd (DVd) (The Lancet Oncology, 2025).", "scientific_summary": "Updated overall survival results from DREAMM-7, a global randomized open-label phase 3 trial in RRMM.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In relapsed or refractory multiple myeloma, does BVd improve overall survival versus DVd?", "language": null, "original_publication_date": "2026-03-14T00:56:14.579Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093019/horizontal/small_11c9500f-18e1-4988-a95f-bd06970169ec.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["belantamab mafodotin", "bortezomib", "dexamethasone", "daratumumab", "multiple myeloma", "relapsed refractory", "DREAMM-7", "overall survival", "phase 3 trial", "MRD negativity", "thrombocytopenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093019", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS"}], "evidence_relations": [{"target_id": "EV_PMID_38828933", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_41986580", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BELANTAMAB_MAFODOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "belantamab mafodotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_BVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "DREAMM-7", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_BVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS", "via_therapy_id": "TX_MM_BVD", "graph_edge_ids": ["EDGE_MM_BVD_HAS_OPTION", "EDGE_MM_BVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Belantamab Mafodotin + Vd resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/myeloma/bvd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093049", "editorial": {"original_title": "What are the efficacy and key toxicities of subcutaneous teclistamab in triple-class-exposed R/R multiple myeloma?", "public_title": "What are the efficacy and key toxicities of subcutaneous teclistamab in triple-class-exposed R/R multiple myeloma?", "slug": "teclistamab-relapsed-refractory-multiple-myeloma-majestec-1", "legacy_canonical_url": "https://5minutehematology.com/programs/teclistamab-relapsed-refractory-multiple-myeloma-majestec-1", "description": "Phase 1-2 MajesTEC-1 study (NEJM 2022) evaluating weekly subcutaneous teclistamab after step-up dosing in heavily pretreated relapsed/refractory multiple myeloma, focusing on response depth, MRD, and safety.", "scientific_summary": "Phase 1-2 MajesTEC-1 study evaluating weekly subcutaneous teclistamab after step-up dosing in heavily pretreated R/R MM.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the efficacy and key toxicities of subcutaneous teclistamab in triple-class-exposed R/R multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T02:11:52.177Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093049/horizontal/small_73ac9271-e27a-471a-a688-5a05a615920b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["teclistamab", "bispecific antibody", "BCMA", "CD3", "multiple myeloma", "relapsed refractory", "MajesTEC-1", "phase 1-2", "overall response rate", "MRD negativity", "cytokine release syndrome", "ICANS"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093049", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS"}], "evidence_relations": [{"target_id": "EV_PMID_42212933", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_TECDARA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "via_therapy_id": "TX_MM_TECDARA", "graph_edge_ids": ["EDGE_MM_TECDARA_HAS_OPTION", "EDGE_MM_TECDARA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Teclistamab + Daratumumab resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/targeted/teclistamab_daratumumab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093056", "editorial": {"original_title": "How should infections be monitored, prevented, and treated during bispecific antibody therapy for multiple myeloma?", "public_title": "How should infections be monitored, prevented, and treated during bispecific antibody therapy for multiple myeloma?", "slug": "mm-bispecific-antibody-therapy-infection-monitoring-prophylaxis-treatment-consensus", "legacy_canonical_url": "https://5minutehematology.com/programs/mm-bispecific-antibody-therapy-infection-monitoring-prophylaxis-treatment-consensus", "description": "Expert panel consensus review and graded recommendations (Blood Cancer Journal, 2023) on infection monitoring, prophylaxis, and treatment in MM patients receiving bispecific antibodies.", "scientific_summary": "Expert panel review and graded recommendations on infection monitoring, prophylaxis, and treatment in MM patients receiving BsAbs.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Free Hematology Videos", "Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should infections be monitored, prevented, and treated during bispecific antibody therapy for multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T02:23:20.222Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093056/horizontal/small_376bb4b9-994b-4a68-867e-9b6b9b54e9d3.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "bispecific antibodies", "infection prophylaxis", "infection monitoring", "HSV prophylaxis", "VZV prophylaxis", "HBV screening", "IVIG", "neutropenia", "G-CSF", "PJP", "prophylaxis", "hypogammaglobulinemia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093056", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37528088", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093393", "editorial": {"original_title": "How should clonal plasma cell disorders be risk stratified and staged in 2025?", "public_title": "How should clonal plasma cell disorders be risk stratified and staged in 2025?", "slug": "risk-stratification-staging-multiple-myeloma-clonal-plasma-cell-disorders", "legacy_canonical_url": "https://5minutehematology.com/programs/risk-stratification-staging-multiple-myeloma-clonal-plasma-cell-disorders", "description": "Guideline-style narrative review summarizing current risk stratification and staging across clonal plasma cell disorders (Leukemia, 2025).", "scientific_summary": "Guideline-style narrative review summarizing current risk stratification and staging across clonal plasma cell disorders (Leukemia, 2025).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should clonal plasma cell disorders be risk stratified and staged in 2025?", "language": null, "original_publication_date": "2026-03-14T12:36:19.768Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093393/horizontal/small_1885a8ae-ba07-4132-88bc-5ea1bd67a248.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "MGUS", "smoldering myeloma", "Waldenstrom macroglobulinemia", "AL amyloidosis", "risk stratification", "staging", "cytogenetics", "bone marrow microenvironment", "tumor burden"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093393", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40702148", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_WALDENSTROM_MACROGLOBULINEMIA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "Waldenstrom macroglobulinemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_AL_AMYLOIDOSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AL amyloidosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4093399", "editorial": {"original_title": "Does talquetamab plus teclistamab induce responses in true extramedullary, drug-resistant multiple myeloma?", "public_title": "Does talquetamab plus teclistamab induce responses in true extramedullary, drug-resistant multiple myeloma?", "slug": "dual-targeting-extramedullary-myeloma-talquetamab-teclistamab", "legacy_canonical_url": "https://5minutehematology.com/programs/dual-targeting-extramedullary-myeloma-talquetamab-teclistamab", "description": "Summary of RedirecTT-1 (NCT04586426), a clinical trial reported in The New England Journal of Medicine (2026), evaluating talquetamab plus teclistamab in true extramedullary, drug-resistant myeloma, including efficacy and grade >=3 toxicity.", "scientific_summary": "Summary of RedirecTT-1 evaluating talquetamab plus teclistamab in true extramedullary, drug-resistant myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does talquetamab plus teclistamab induce responses in true extramedullary, drug-resistant multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T12:48:05.744Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4093399/horizontal/small_5eb965ab-c29d-452b-9404-c9317edd9692.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["extramedullary myeloma", "multiple myeloma", "talquetamab", "teclistamab", "bispecific antibodies", "GPRC5D", "BCMA", "RedirecTT-1", "NCT04586426", "NEJM 2026", "toxicity", "grade 3 adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4093399", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41358582", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": ["NCT04586426"], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_TALQUE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TALQUETAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094008", "editorial": {"original_title": "Does adding ixazomib to lenalidomide-dexamethasone improve overall survival in relapsed or refractory multiple myeloma?", "public_title": "Does adding ixazomib to lenalidomide-dexamethasone improve overall survival in relapsed or refractory multiple myeloma?", "slug": "tourmaline-mm1-final-overall-survival-ixazomib-lenalidomide-dexamethasone", "legacy_canonical_url": "https://5minutehematology.com/programs/tourmaline-mm1-final-overall-survival-ixazomib-lenalidomide-dexamethasone", "description": "Final overall survival results from the double-blind, placebo-controlled phase III TOURMALINE-MM1 randomized trial (Journal of Clinical Oncology, 2021) in relapsed/refractory multiple myeloma comparing ixazomib-Rd vs placebo-Rd.", "scientific_summary": "Final overall survival results from TOURMALINE-MM1 in relapsed/refractory multiple myeloma comparing ixazomib-Rd vs placebo-Rd.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding ixazomib to lenalidomide-dexamethasone improve overall survival in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-14T19:23:59.143Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094008/horizontal/small_a7eb239d-dcf9-4227-8371-e745f8847369.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "relapsed refractory", "ixazomib", "lenalidomide", "dexamethasone", "TOURMALINE-MM1", "overall survival", "phase III trial", "randomized", "placebo-controlled", "double-blind", "Rd triplet"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094008", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094032", "editorial": {"original_title": "Should upfront autologous stem cell transplantation be used in untreated peripheral T-cell lymphoma?", "public_title": "Should upfront autologous stem cell transplantation be used in untreated peripheral T-cell lymphoma?", "slug": "upfront-autologous-stem-cell-transplantation-peripheral-t-cell-lymphoma-nlg-t-01", "legacy_canonical_url": "https://5minutehematology.com/programs/upfront-autologous-stem-cell-transplantation-peripheral-t-cell-lymphoma-nlg-t-01", "description": "Final report of the Nordic Lymphoma Group NLG-T-01 prospective phase II study (Journal of Clinical Oncology, 2012) evaluating dose-dense CHOEP induction followed by HDT/ASCT in transplant-eligible, treatment-naive systemic PTCL.", "scientific_summary": "Final report evaluating dose-dense CHOEP induction followed by HDT/ASCT in transplant-eligible, treatment-naive systemic PTCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Transplantation", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Transplantation"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should upfront autologous stem cell transplantation be used in untreated peripheral T-cell lymphoma?", "language": null, "original_publication_date": "2026-03-14T19:45:58.333Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094032/horizontal/small_1df82116-6aa3-47f9-a859-05d4fbd8f3ad.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["peripheral T-cell lymphoma", "PTCL", "autologous stem cell transplantation", "ASCT", "high-dose chemotherapy", "HDT", "CHOEP", "dose-dense induction", "phase II trial", "Nordic Lymphoma Group", "NLG-T-01", "ALK-negative ALCL"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094032", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_22851556", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094048", "editorial": {"original_title": "Should fit patients with refractory or early relapsed DLBCL who respond to salvage chemo undergo ASCT?", "public_title": "Should fit patients with refractory or early relapsed DLBCL who respond to salvage chemo undergo ASCT?", "slug": "autologous-stem-cell-transplant-fit-refractory-early-relapsed-dlbcl", "legacy_canonical_url": "https://5minutehematology.com/programs/autologous-stem-cell-transplant-fit-refractory-early-relapsed-dlbcl", "description": "Physician-focused review of a 2024 Haematologica clinical study evaluating autologous stem cell transplant in fit patients with refractory or early relapsed DLBCL responding to salvage chemotherapy.", "scientific_summary": "Clinical study evaluating ASCT in fit patients with refractory or early relapsed DLBCL responding to salvage chemotherapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Transplantation", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Transplantation"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should fit patients with refractory or early relapsed DLBCL who respond to salvage chemo undergo ASCT?", "language": null, "original_publication_date": "2026-03-14T20:02:23.438Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094048/horizontal/small_31d62915-e484-4a41-92ab-3171c20094a8.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "autologous stem cell transplant", "ASCT", "salvage chemotherapy", "refractory lymphoma", "early relapse", "transplant", "Haematologica"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094048", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38235513", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_EARLY_RELAPSE_SECOND_LINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094059", "editorial": {"original_title": "What are outcomes in refractory diffuse large B-cell lymphoma?", "public_title": "What are outcomes in refractory diffuse large B-cell lymphoma?", "slug": "outcomes-refractory-diffuse-large-b-cell-lymphoma-scholar-1-study", "legacy_canonical_url": "https://5minutehematology.com/programs/outcomes-refractory-diffuse-large-b-cell-lymphoma-scholar-1-study", "description": "Review of the international SCHOLAR-1 patient-level pooled analysis (Blood, 2017) combining two randomized trials and two academic databases to define outcomes in refractory DLBCL.", "scientific_summary": "Review of the international SCHOLAR-1 to define outcomes in refractory DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are outcomes in refractory diffuse large B-cell lymphoma?", "language": null, "original_publication_date": "2026-03-14T20:12:06.463Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094059/horizontal/small_acfcd006-1960-4382-80aa-47b12c387444.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["refractory DLBCL", "diffuse large B-cell lymphoma", "SCHOLAR-1", "pooled analysis", "randomized trials", "real-world databases", "treatment outcomes", "salvage therapy", "lymphoid malignancy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094059", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_28774879", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094237", "editorial": {"original_title": "Does adding tafasitamab to lenalidomide and rituximab improve progression-free survival in relapsed or refractory follicular lymphoma?", "public_title": "Does adding tafasitamab to lenalidomide and rituximab improve progression-free survival in relapsed or refractory follicular lymphoma?", "slug": "tafasitamab-lenalidomide-rituximab-relapsed-refractory-follicular-lymphoma-inmind", "legacy_canonical_url": "https://5minutehematology.com/programs/tafasitamab-lenalidomide-rituximab-relapsed-refractory-follicular-lymphoma-inmind", "description": "Review of the inMIND global phase 3 double-blind randomized placebo-controlled trial in relapsed/refractory follicular lymphoma (Lancet, 2026) evaluating tafasitamab plus lenalidomide and rituximab vs placebo plus lenalidomide and rituximab.", "scientific_summary": "Review of the inMIND global phase 3 double-blind randomized placebo-controlled trial in relapsed/refractory follicular lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding tafasitamab to lenalidomide and rituximab improve progression-free survival in relapsed or refractory follicular lymphoma?", "language": null, "original_publication_date": "2026-03-15T00:18:23.309Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094237/horizontal/small_c017bc23-0b9b-46ec-b45b-a412a134e719.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "relapsed refractory", "tafasitamab", "lenalidomide", "rituximab", "CD19", "phase 3 trial", "randomized controlled trial", "progression-free survival", "inMIND"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094237", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_RELAPSED_CHEMO_FREE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_RELAPSED_CHEMO_FREE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_TAFASITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tafasitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094526", "editorial": {"original_title": "What are the long-term efficacy and safety outcomes of loncastuximab tesirine in relapsed/refractory DLBCL?", "public_title": "What are the long-term efficacy and safety outcomes of loncastuximab tesirine in relapsed/refractory DLBCL?", "slug": "loncastuximab-tesirine-relapsed-refractory-dlbcl-long-term-efficacy-safety-lotis", "legacy_canonical_url": "https://5minutehematology.com/programs/loncastuximab-tesirine-relapsed-refractory-dlbcl-long-term-efficacy-safety-lotis", "description": "Phase II single-arm LOTIS-2 trial update in Haematologica (2023) reporting long-term efficacy and safety of loncastuximab tesirine in heavily pretreated R/R DLBCL, including durable CR subsets.", "scientific_summary": "Phase II single-arm LOTIS-2 trial reporting long-term efficacy and safety of loncastuximab tesirine in heavily pretreated R/R DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the long-term efficacy and safety outcomes of loncastuximab tesirine in relapsed/refractory DLBCL?", "language": null, "original_publication_date": "2026-03-15T14:10:28.397Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094526/horizontal/small_0849e0aa-c3ba-4268-9cb9-dd492f23573a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["loncastuximab tesirine", "R/R DLBCL", "diffuse large B-cell lymphoma", "anti-CD19", "ADC", "LOTIS-2", "phase II trial", "complete response", "overall response rate", "progression-free survival", "overall survival", "safety", "tolerability"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094526", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4167312", "relation": "same_documented_source", "shared_reference_ids": ["PMID_37646659"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_37646659", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_LONCASTUXIMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "loncastuximab tesirine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LONCASTUXIMAB_TESIRINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "loncastuximab tesirine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094551", "editorial": {"original_title": "Does Pola-R-CHP improve 1-year PFS versus R-CHOP in untreated DLBCL?", "public_title": "Does Pola-R-CHP improve 1-year PFS versus R-CHOP in untreated DLBCL?", "slug": "pola-r-chp-versus-r-chop-untreated-dlbcl-efficacy-relapse-profiles", "legacy_canonical_url": "https://5minutehematology.com/programs/pola-r-chp-versus-r-chop-untreated-dlbcl-efficacy-relapse-profiles", "description": "Retrospective multicentre real-world propensity score matched cohort study (British Journal of Haematology, 2026) comparing Pola-R-CHP vs R-CHOP for first-line DLBCL.", "scientific_summary": "Retrospective real-world propensity score matched cohort study comparing Pola-R-CHP vs R-CHOP for first-line DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does Pola-R-CHP improve 1-year PFS versus R-CHOP in untreated DLBCL?", "language": null, "original_publication_date": "2026-03-15T14:22:59.872Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094551/horizontal/small_a77900e4-7047-44f9-bd32-45307ce65f4f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "polatuzumab vedotin", "Pola-R-CHP", "R-CHOP", "propensity score matching", "real-world study", "progression-free survival", "overall survival", "CNS relapse", "CNS-IPI", "nodal relapse", "extranodal relapse"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094551", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41451861", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: a multicentre real-world study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_POLARCHP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "Pola-R-CHP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "CALC_CNS_IPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "CNS-IPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "PROT_LYM_POLARCHP_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_POLARCHP", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_POLARCHP", "EDGE_POLARCHP_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved Pola-R-CHP resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/pola_r_chp.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_LIMITED_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094569", "editorial": {"original_title": "What are survival outcomes after CD38 monoclonal antibody refractory multiple myeloma?", "public_title": "What are survival outcomes after CD38 monoclonal antibody refractory multiple myeloma?", "slug": "outcomes-multiple-myeloma-refractory-cd38-monoclonal-antibody-therapy", "legacy_canonical_url": "https://5minutehematology.com/programs/outcomes-multiple-myeloma-refractory-cd38-monoclonal-antibody-therapy", "description": "Multicenter retrospective cohort study (Leukemia, 2019) of 275 multiple myeloma patients across 14 academic centers refractory to CD38-targeted monoclonal antibodies, reporting OS, PFS, and post-refractory treatment outcomes.", "scientific_summary": "Multicenter retrospective cohort study of 275 multiple myeloma patients refractory to CD38-targeted monoclonal antibodies.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are survival outcomes after CD38 monoclonal antibody refractory multiple myeloma?", "language": null, "original_publication_date": "2026-03-15T14:37:19.574Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094569/horizontal/small_2cc43fc3-28f6-461a-8612-dc4b47e97b64.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "CD38 monoclonal antibody", "daratumumab", "isatuximab", "refractory disease", "penta-refractory", "overall survival", "progression-free survival", "retrospective cohort", "salvage therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094569", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30858549", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ISATUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "isatuximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094580", "editorial": {"original_title": "Does upfront ASCT improve outcomes over RVD alone in newly diagnosed multiple myeloma?", "public_title": "Does upfront ASCT improve outcomes over RVD alone in newly diagnosed multiple myeloma?", "slug": "triplet-therapy-asct-lenalidomide-maintenance-progression-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/triplet-therapy-asct-lenalidomide-maintenance-progression-myeloma", "description": "Phase 3 randomized DETERMINATION trial in NEJM (2022) comparing RVD alone vs RVD plus high-dose melphalan/ASCT, with lenalidomide maintenance until progression.", "scientific_summary": "Phase 3 randomized DETERMINATION trial comparing RVD alone vs RVD plus high-dose melphalan/ASCT, with lenalidomide maintenance.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Original Studies", "Plasma Cell & Myeloma"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does upfront ASCT improve outcomes over RVD alone in newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-03-15T14:47:59.249Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094580/horizontal/small_6209436f-c85f-454f-adae-7af0ff8b4142.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed", "RVD", "lenalidomide", "bortezomib", "dexamethasone", "ASCT", "high-dose melphalan", "maintenance therapy", "progression-free survival", "DETERMINATION trial", "NEJM 2022"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094580", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4337657", "relation": "same_documented_source", "shared_reference_ids": ["PMID_28379796"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_28379796", "role": "reviewed_original_source", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "DIRECT", "source_field": "existing_physician_review", "source_value": "EV_PMID_28379796", "provenance": "data/content_mapping/evidence_content_review.csv + corrections"}], "clinical_trial_names": ["IFM 2009"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_28379796", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_35660812", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_37708911", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_38084760", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "RVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_DARAVRD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE", "via_therapy_id": "TX_MM_DARAVRD", "graph_edge_ids": ["EDGE_MM_DARAVRD_HAS_OPTION", "EDGE_MM_DARAVRD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Dara-VRd (PERSEUS, transplant eligible) resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/myeloma/dara_vrd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4094585", "editorial": {"original_title": "Does brentuximab vedotin plus lenalidomide and rituximab improve survival in relapsed or refractory DLBCL?", "public_title": "Does brentuximab vedotin plus lenalidomide and rituximab improve survival in relapsed or refractory DLBCL?", "slug": "brentuximab-vedotin-lenalidomide-rituximab-relapsed-refractory-dlbcl-echelon-3", "legacy_canonical_url": "https://5minutehematology.com/programs/brentuximab-vedotin-lenalidomide-rituximab-relapsed-refractory-dlbcl-echelon-3", "description": "Review of ECHELON-3, a randomized double-blind placebo-controlled multicenter phase 3 trial (Journal of Clinical Oncology, 2025) comparing brentuximab vedotin + lenalidomide + rituximab vs placebo + lenalidomide + rituximab in R/R DLBCL.", "scientific_summary": "Review of ECHELON-3 comparing brentuximab vedotin + lenalidomide + rituximab vs placebo + lenalidomide + rituximab in R/R DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does brentuximab vedotin plus lenalidomide and rituximab improve survival in relapsed or refractory DLBCL?", "language": null, "original_publication_date": "2026-03-15T14:57:21.673Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4094585/horizontal/small_8465b2ce-af93-49f7-8c76-c7063fc7fa5e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["diffuse large B-cell lymphoma", "DLBCL", "relapsed refractory", "brentuximab vedotin", "lenalidomide", "rituximab", "ECHELON-3", "phase 3 trial", "overall survival", "progression-free survival", "objective response rate", "CD30"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4094585", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_39772655", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4116917", "editorial": {"original_title": "Is fixed-duration venetoclax-based therapy noninferior to continuous ibrutinib in untreated CLL?", "public_title": "Is fixed-duration venetoclax-based therapy noninferior to continuous ibrutinib in untreated CLL?", "slug": "fixed-duration-continuous-treatment-cll-phase-3-trial", "legacy_canonical_url": "https://5minutehematology.com/programs/fixed-duration-continuous-treatment-cll-phase-3-trial", "description": "Investigator-initiated phase 3 randomized trial (NEJM, 2026) in previously untreated CLL comparing continuous ibrutinib vs fixed-duration venetoclax-obinutuzumab or venetoclax-ibrutinib for PFS, MRD, OS, and safety.", "scientific_summary": "CLL17 in previously untreated CLL comparing continuous ibrutinib vs fixed-duration venetoclax-obinutuzumab or venetoclax-ibrutinib.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Free Hematology Videos", "Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is fixed-duration venetoclax-based therapy noninferior to continuous ibrutinib in untreated CLL?", "language": null, "original_publication_date": "2026-03-27T01:30:18.835Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4116917/horizontal/small_8449a474-010e-479a-8ff1-b8a42e00a659.jpg", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "fixed-duration therapy", "continuous therapy", "venetoclax", "obinutuzumab", "ibrutinib", "BTK inhibitor", "progression-free survival", "minimal residual disease", "phase 3 randomized trial", "CLL17"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4116917", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41358601", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS"}], "evidence_relations": [{"target_id": "EV_PMID_39082668", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_39976417", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_40521799", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_41358601", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4119003", "editorial": {"original_title": "In relapsed CNS lymphoma in complete remission, should consolidation be ASCT or CAR-T?", "public_title": "In relapsed CNS lymphoma in complete remission, should consolidation be ASCT or CAR-T?", "slug": "relapsed-cns-lymphoma-cr-consolidation-asct-vs-cart", "legacy_canonical_url": "https://5minutehematology.com/programs/relapsed-cns-lymphoma-cr-consolidation-asct-vs-cart", "description": "Retrospective observational cohort (Beijing Gobroad Hospital, 2021-2024) reported in Cancer Immunology, Immunotherapy (2026) comparing ASCT vs CAR-T consolidation after CR in relapsed CNSL.", "scientific_summary": "Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In relapsed CNS lymphoma in complete remission, should consolidation be ASCT or CAR-T?", "language": null, "original_publication_date": "2026-03-28T21:09:07.494Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4119003/horizontal/small_f03465ce-9b81-4b0e-8170-cb6019c6bd92.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CNS lymphoma", "relapsed refractory", "complete remission", "ASCT", "autologous transplant", "CAR-T", "consolidation therapy", "progression-free survival", "relapse rate", "DLBCL secondary CNS"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4119003", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41874671", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4128062", "editorial": {"original_title": "Does apixaban reduce bleeding versus rivaroxaban for acute VTE?", "public_title": "Does apixaban reduce bleeding versus rivaroxaban for acute VTE?", "slug": "bleeding-risk-apixaban-vs-rivaroxaban-acute-vte", "legacy_canonical_url": "https://5minutehematology.com/programs/bleeding-risk-apixaban-vs-rivaroxaban-acute-vte", "description": "Randomized clinical trial (COBRRA; NCT03266783) in acute venous thromboembolism comparing apixaban vs rivaroxaban; NEJM 2026 3-month bleeding outcomes.", "scientific_summary": "Randomized clinical trial in acute venous thromboembolism comparing apixaban vs rivaroxaban; NEJM 2026 3-month bleeding outcomes.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Non-Malignant Hematology", "Free Hematology Videos", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Non-Malignant Hematology"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does apixaban reduce bleeding versus rivaroxaban for acute VTE?", "language": null, "original_publication_date": "2026-03-31T22:58:25.076Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4128062/horizontal/small_1905df5d-044b-48c6-b2ef-6cbaf1c6720c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["apixaban", "rivaroxaban", "acute venous thromboembolism", "VTE", "DOAC", "bleeding risk", "clinically relevant bleeding", "anticoagulation", "COBRRA trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4128062", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": ["NCT03266783"], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4135226", "editorial": {"original_title": "Does romiplostim prevent chemotherapy dose modifications in persistent chemotherapy-induced thrombocytopenia?", "public_title": "Does romiplostim prevent chemotherapy dose modifications in persistent chemotherapy-induced thrombocytopenia?", "slug": "romiplostim-placebo-chemotherapy-induced-thrombocytopenia", "legacy_canonical_url": "https://5minutehematology.com/programs/romiplostim-placebo-chemotherapy-induced-thrombocytopenia", "description": "Phase 3 international double-blind randomized placebo-controlled trial in NEJM (2026) testing romiplostim vs placebo for persistent CIT during oxaliplatin-based chemotherapy for GI cancers.", "scientific_summary": "Phase 3 international double-blind randomized trial testing romiplostim vs placebo for persistent CIT during chemotherapy for GI cancers.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does romiplostim prevent chemotherapy dose modifications in persistent chemotherapy-induced thrombocytopenia?", "language": null, "original_publication_date": "2026-04-03T23:22:48.899Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4135226/horizontal/small_9046fff9-d871-43c5-88af-08db75d6dff2.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["romiplostim", "chemotherapy-induced thrombocytopenia", "CIT", "oxaliplatin-based chemotherapy", "gastrointestinal cancers", "colorectal cancer", "dose delay", "dose reduction", "relative dose intensity", "thromboembolism", "randomized controlled trial", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4135226", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4135775", "editorial": {"original_title": "In newly diagnosed multiple myeloma, does busulfan-melphalan improve PFS versus melphalan conditioning?", "public_title": "In newly diagnosed multiple myeloma, does busulfan-melphalan improve PFS versus melphalan conditioning?", "slug": "high-dose-busulfan-melphalan-vs-melphalan-reinforced-vrd-newly-diagnosed-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/high-dose-busulfan-melphalan-vs-melphalan-reinforced-vrd-newly-diagnosed-myeloma", "description": "Phase 3 GEM randomized trial in newly diagnosed multiple myeloma comparing high-dose busulfan-melphalan vs melphalan plus reinforced VRD; Blood 2025.", "scientific_summary": "Phase 3 GEM randomized trial in newly diagnosed multiple myeloma comparing high-dose busulfan-melphalan vs melphalan plus reinforced VRD.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In newly diagnosed multiple myeloma, does busulfan-melphalan improve PFS versus melphalan conditioning?", "language": null, "original_publication_date": "2026-04-04T14:10:13.138Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4135775/horizontal/small_2774656b-1e3c-44d4-9678-d48d01170b8e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed", "busulfan-melphalan", "melphalan", "VRD", "phase 3 trial", "GEM2012", "progression-free survival", "ISS stage", "transplant conditioning"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4135775", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40499010", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_MELPHALAN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "melphalan", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4135805", "editorial": {"original_title": "In intermediate-risk acute PE, what is the role of ultrasound-facilitated catheter-directed fibrinolysis?", "public_title": "In intermediate-risk acute PE, what is the role of ultrasound-facilitated catheter-directed fibrinolysis?", "slug": "ultrasound-facilitated-catheter-directed-fibrinolysis-acute-pulmonary-embolism", "legacy_canonical_url": "https://5minutehematology.com/programs/ultrasound-facilitated-catheter-directed-fibrinolysis-acute-pulmonary-embolism", "description": "Review of the HI-PEITHO randomized controlled trial (NEJM, 2026) comparing ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation vs anticoagulation alone in intermediate-risk acute PE.", "scientific_summary": "HI-PEITHO trial comparing ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation vs anticoagulation alone in acute PE.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In intermediate-risk acute PE, what is the role of ultrasound-facilitated catheter-directed fibrinolysis?", "language": null, "original_publication_date": "2026-04-04T14:25:15.973Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4135805/horizontal/small_6e26c376-df09-44a7-897a-2e0a6afd7705.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["pulmonary embolism", "intermediate-risk PE", "catheter-directed thrombolysis", "ultrasound-assisted thrombolysis", "fibrinolysis", "anticoagulation", "HI-PEITHO", "randomized controlled trial", "hemostasis"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4135805", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4147283", "editorial": {"original_title": "What is the optimal empiric antibiotic strategy for febrile neutropenia?", "public_title": "What is the optimal empiric antibiotic strategy for febrile neutropenia?", "slug": "treat-febrile-neutropenia", "legacy_canonical_url": "https://5minutehematology.com/programs/treat-febrile-neutropenia", "description": "Physician-focused review article (Mediterranean Journal of Hematology and Infectious Diseases, 2021) outlining evaluation, prophylaxis, empiric antibiotics, escalation, and discontinuation in febrile neutropenia.", "scientific_summary": "Review article outlining evaluation, prophylaxis, empiric antibiotics, escalation, and discontinuation in febrile neutropenia.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What is the optimal empiric antibiotic strategy for febrile neutropenia?", "language": null, "original_publication_date": "2026-04-11T22:02:13.422Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4147283/horizontal/small_f5d62467-4722-461a-a399-89d790ef0af5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["febrile neutropenia", "empiric antibiotics", "antibacterial prophylaxis", "antifungal prophylaxis", "initial workup", "hematologic malignancies", "antibiotic escalation", "discontinuation criteria"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4147283", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4147299", "editorial": {"original_title": "How should tumor lysis syndrome be prevented and treated in high-risk patients?", "public_title": "How should tumor lysis syndrome be prevented and treated in high-risk patients?", "slug": "tumor-lysis-syndrome-risk-prevention-treatment", "legacy_canonical_url": "https://5minutehematology.com/programs/tumor-lysis-syndrome-risk-prevention-treatment", "description": "Physician-focused review of Tumor Lysis Syndrome based on a narrative clinical review (New England Journal of Medicine, 2025), covering risk stratification, prophylaxis, and acute management.", "scientific_summary": "Physician-focused review of Tumor Lysis Syndrome based on a narrative clinical review covering risk, prophylaxis, and acute management.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should tumor lysis syndrome be prevented and treated in high-risk patients?", "language": null, "original_publication_date": "2026-04-11T22:17:54.046Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4147299/horizontal/small_8c7c6eb9-53fe-431f-bce4-695cde6f9825.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["tumor lysis syndrome", "TLS", "hyperuricemia", "hyperkalemia", "hyperphosphatemia", "hypocalcemia", "acute kidney injury", "risk stratification", "prophylaxis", "supportive care", "rasburicase", "allopurinol"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4147299", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4147370", "editorial": {"original_title": "In relapsed DLBCL, should R-ICE or R-DHAP be preferred before autologous stem-cell transplant?", "public_title": "In relapsed DLBCL, should R-ICE or R-DHAP be preferred before autologous stem-cell transplant?", "slug": "salvage-regimens-autologous-transplantation-relapsed-large-b-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/salvage-regimens-autologous-transplantation-relapsed-large-b-cell-lymphoma", "description": "Randomized phase III trial (Journal of Clinical Oncology, 2010) comparing R-ICE vs R-DHAP salvage chemotherapy followed by high-dose therapy and ASCT in relapsed/refractory CD20+ DLBCL in the rituximab era.", "scientific_summary": "Randomized phase III trial comparing R-ICE vs R-DHAP salvage chemotherapy followed by high-dose therapy and ASCT in R/R CD20+ DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In relapsed DLBCL, should R-ICE or R-DHAP be preferred before autologous stem-cell transplant?", "language": null, "original_publication_date": "2026-04-11T23:54:22.853Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4147370/horizontal/small_396f9408-5043-4a17-a03b-696398c4d40c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "relapsed large B-cell lymphoma", "salvage chemotherapy", "R-ICE", "R-DHAP", "rituximab era", "autologous stem cell transplant", "ASCT", "high-dose therapy", "event-free survival", "overall survival", "IPI"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4147370", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_20660832", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_RICE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-ICE", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RDHAP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-DHAP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "CALC_IPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "IPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4147382", "editorial": {"original_title": "Does Pola-R-CHP improve 5-year outcomes versus R-CHOP in untreated high-risk DLBCL?", "public_title": "Does Pola-R-CHP improve 5-year outcomes versus R-CHOP in untreated high-risk DLBCL?", "slug": "polarixt-study-five-year-outcomes-pola-r-chp-r-chop-dlbcl", "legacy_canonical_url": "https://5minutehematology.com/programs/polarixt-study-five-year-outcomes-pola-r-chp-r-chop-dlbcl", "description": "Review of the POLARIX phase 3 randomized trial 5-year update in Journal of Clinical Oncology (2025), comparing frontline Pola-R-CHP vs R-CHOP in untreated intermediate/high-risk DLBCL.", "scientific_summary": "Review of the POLARIX phase 3 trial 5-year update comparing frontline Pola-R-CHP vs R-CHOP in untreated intermediate/high-risk DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does Pola-R-CHP improve 5-year outcomes versus R-CHOP in untreated high-risk DLBCL?", "language": null, "original_publication_date": "2026-04-12T00:04:58.400Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4147382/horizontal/small_5f5b4508-f1ce-4d30-a4e3-bc7974c90c6f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["POLARIX", "diffuse large B-cell lymphoma", "DLBCL", "Pola-R-CHP", "R-CHOP", "polatuzumab vedotin", "progression-free survival", "overall survival", "frontline therapy", "phase 3 randomized trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4147382", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40991874", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_POLARCHP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "Pola-R-CHP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_POLARCHP_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_POLARCHP", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_POLARCHP", "EDGE_POLARCHP_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved Pola-R-CHP resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/pola_r_chp.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_LIMITED_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4147409", "editorial": {"original_title": "Does brentuximab vedotin consolidation improve 5-year PFS after ASCT in high-risk Hodgkin lymphoma?", "public_title": "Does brentuximab vedotin consolidation improve 5-year PFS after ASCT in high-risk Hodgkin lymphoma?", "slug": "aethera-brentuximab-vedotin-5-year-pfs-high-risk-hodgkin-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/aethera-brentuximab-vedotin-5-year-pfs-high-risk-hodgkin-lymphoma", "description": "Review of the AETHERA randomized, double-blind, placebo-controlled trial (Blood, 2018) evaluating post-ASCT brentuximab vedotin consolidation in high-risk Hodgkin lymphoma and 5-year PFS, subsequent therapy, and long-term tolerability.", "scientific_summary": "Review of the AETHERA randomized trial evaluating post-ASCT brentuximab vedotin consolidation in high-risk Hodgkin lymphoma and 5-year PFS.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does brentuximab vedotin consolidation improve 5-year PFS after ASCT in high-risk Hodgkin lymphoma?", "language": null, "original_publication_date": "2026-04-12T00:23:22.357Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4147409/horizontal/small_01b109b6-36c7-45fb-9f93-5335dbcd0f0a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["AETHERA", "brentuximab vedotin", "Hodgkin lymphoma", "post-ASCT consolidation", "progression-free survival", "high-risk relapse", "peripheral neuropathy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4147409", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30266774", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Five-year PFS From the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_RELAPSED_TRANSPLANT"}], "evidence_relations": [{"target_id": "EV_PMID_25796459", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_33827139", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_RELAPSED_TRANSPLANT", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4151880", "editorial": {"original_title": "Does teclistamab plus daratumumab improve PFS versus DPd or DVd in relapsed or refractory multiple myeloma?", "public_title": "Does teclistamab plus daratumumab improve PFS versus DPd or DVd in relapsed or refractory multiple myeloma?", "slug": "teclistamab-daratumumab-rrmm-pfs-phase3", "legacy_canonical_url": "https://5minutehematology.com/programs/teclistamab-daratumumab-rrmm-pfs-phase3", "description": "Phase 3 randomized trial (NEJM, 2026) in relapsed/refractory multiple myeloma after 1-3 prior lines comparing teclistamab-daratumumab vs daratumumab plus Pd or Vd, with PFS as the primary endpoint.", "scientific_summary": "Phase 3 randomized trial in R/R multiple myeloma after 1-3 prior lines comparing teclistamab-daratumumab vs DPd or DVd.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma", "Free Hematology Videos", "Original Studies", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does teclistamab plus daratumumab improve PFS versus DPd or DVd in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-04-15T00:22:28.829Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4151880/horizontal/small_10b02ac0-b9eb-4119-a9da-6bb43ff2ae56.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["teclistamab", "daratumumab", "bispecific antibody", "BCMA", "CD3", "relapsed refractory multiple myeloma", "phase 3 trial", "progression-free survival", "minimal residual disease", "DPd", "DVd", "pomalidomide"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4151880", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4338004", "relation": "same_documented_source", "shared_reference_ids": ["PMID_42294841"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_41363801", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}, {"reference_id": "PMID_42294841", "role": "reviewed_original_source", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "DIRECT", "source_field": "existing_physician_review", "source_value": "EV_PMID_42294841", "provenance": "data/content_mapping/evidence_content_review.csv + corrections"}], "clinical_trial_names": ["MonumenTAL-3"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS"}], "evidence_relations": [{"target_id": "EV_PMID_42212933", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_42294841", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POMALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "pomalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_TECDARA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "via_therapy_id": "TX_MM_TECDARA", "graph_edge_ids": ["EDGE_MM_TECDARA_HAS_OPTION", "EDGE_MM_TECDARA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Teclistamab + Daratumumab resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/targeted/teclistamab_daratumumab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4153017", "editorial": {"original_title": "Does fitness or venetoclax dose intensity affect outcomes with venetoclax-obinutuzumab in first-line CLL?", "public_title": "Does fitness or venetoclax dose intensity affect outcomes with venetoclax-obinutuzumab in first-line CLL?", "slug": "fitness-dose-intensity-venetoclax-obinutuzumab-cll-outcomes", "legacy_canonical_url": "https://5minutehematology.com/programs/fitness-dose-intensity-venetoclax-obinutuzumab-cll-outcomes", "description": "Post hoc pooled analysis of the phase 3 CLL13 and CLL14 trials (Blood, 2025) evaluating fitness (CIRS/CrCl) and venetoclax dose intensity with Ven-Obi in untreated CLL without TP53 aberrations.", "scientific_summary": "Pooled analysis of the phase 3 CLL13 and CLL14 trials evaluating fitness (CIRS/CrCl) and venetoclax dose intensity Ven-Obi in untreated CLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does fitness or venetoclax dose intensity affect outcomes with venetoclax-obinutuzumab in first-line CLL?", "language": null, "original_publication_date": "2026-04-16T00:59:16.405Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4153017/horizontal/small_ca001b13-feea-4955-a08f-16f63a9f3ed1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "venetoclax", "obinutuzumab", "Ven-Obi", "fitness", "CIRS", "creatinine clearance", "dose intensity", "dose reduction", "progression-free survival", "minimal residual disease", "CLL13"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4153017", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS"}], "evidence_relations": [{"target_id": "EV_PMID_39082668", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4154095", "editorial": {"original_title": "What are the safety and response outcomes of talquetamab in relapsed or refractory multiple myeloma?", "public_title": "What are the safety and response outcomes of talquetamab in relapsed or refractory multiple myeloma?", "slug": "safety-activity-talquetamab-relapsed-refractory-multiple-myeloma-monumental-1-ph", "legacy_canonical_url": "https://5minutehematology.com/programs/safety-activity-talquetamab-relapsed-refractory-multiple-myeloma-monumental-1-ph", "description": "Phase 1-2 multicentre, open-label MonumenTAL-1 study (The Lancet Haematology, 2025) assessing subcutaneous talquetamab dosing, safety, and ORR in R/R multiple myeloma, including prior TCR exposure.", "scientific_summary": "Phase 1-2 multicentre, open-label MonumenTAL-1 study assessing subcutaneous talquetamab dosing, safety, and ORR in R/R multiple myeloma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Free Hematology Videos", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the safety and response outcomes of talquetamab in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-04-16T22:40:25.012Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4154095/horizontal/small_c1f53f73-8af5-4c7a-a4d1-e3f65bf88737.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["talquetamab", "GPRC5D", "CD3", "bispecific antibody", "relapsed refractory multiple myeloma", "MonumenTAL-1", "phase 1-2", "open-label", "subcutaneous dosing", "overall response rate", "cytokine release syndrome", "T-cell redirection therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4154095", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40090350", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_TALQUE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TALQUETAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4156755", "editorial": {"original_title": "Does extended-interval belantamab with KRd improve outcomes in relapsed or refractory multiple myeloma?", "public_title": "Does extended-interval belantamab with KRd improve outcomes in relapsed or refractory multiple myeloma?", "slug": "belantamab-q8w-krd-relapsed-refractory-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/belantamab-q8w-krd-relapsed-refractory-multiple-myeloma", "description": "Phase 1/2 trial (3+3 dose-escalation) in Blood Advances (2026) evaluating belantamab mafodotin q8w plus carfilzomib, lenalidomide, and dexamethasone in RRMM.", "scientific_summary": "Phase 1/2 trial (3+3 dose-escalation) evaluating belantamab mafodotin q8w plus carfilzomib, lenalidomide, and dexamethasone in RRMM.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does extended-interval belantamab with KRd improve outcomes in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-04-17T21:02:24.932Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4156755/horizontal/small_f0aa06d4-1f82-4554-9b68-5c835231d837.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["belantamab mafodotin", "carfilzomib", "lenalidomide", "dexamethasone", "KRd", "RRMM", "BCMA", "antibody-drug conjugate", "keratopathy", "phase 1/2"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4156755", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41719502", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BELANTAMAB_MAFODOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "belantamab mafodotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CARFILZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carfilzomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_KRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "KRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4157986", "editorial": {"original_title": "Does zanubrutinib improve survival versus acalabrutinib in relapsed or refractory mantle cell lymphoma?", "public_title": "Does zanubrutinib improve survival versus acalabrutinib in relapsed or refractory mantle cell lymphoma?", "slug": "zanubrutinib-acalabrutinib-indirect-comparison-relapsed-refractory-mantle-cell", "legacy_canonical_url": "https://5minutehematology.com/programs/zanubrutinib-acalabrutinib-indirect-comparison-relapsed-refractory-mantle-cell", "description": "Unanchored indirect treatment comparison using simulated treatment comparison (STC) of single-arm trials in R/R mantle cell lymphoma (Leukemia & Lymphoma, 2025).", "scientific_summary": "Unanchored indirect treatment comparison using simulated treatment comparison (STC) of single-arm trials in R/R mantle cell lymphoma.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does zanubrutinib improve survival versus acalabrutinib in relapsed or refractory mantle cell lymphoma?", "language": null, "original_publication_date": "2026-04-19T00:47:52.580Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4157986/horizontal/small_66249099-7aeb-4763-9811-c266aa3dd640.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["zanubrutinib", "acalabrutinib", "mantle cell lymphoma", "relapsed refractory", "BTK inhibitor", "indirect treatment comparison", "simulated treatment comparison", "unanchored comparison", "progression-free survival", "overall survival", "overall response rate"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4157986", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40889741", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "mantle cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CLL_ACALABRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ACALABRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4160551", "editorial": {"original_title": "Should blinatumomab be added sequentially after hyper-CVAD in newly diagnosed Ph-negative B-ALL?", "public_title": "Should blinatumomab be added sequentially after hyper-CVAD in newly diagnosed Ph-negative B-ALL?", "slug": "hyper-cvad-sequential-blinatumomab-newly-diagnosed-ph-negative-b-all-phase-2", "legacy_canonical_url": "https://5minutehematology.com/programs/hyper-cvad-sequential-blinatumomab-newly-diagnosed-ph-negative-b-all-phase-2", "description": "Review of a single-arm, single-centre phase 2 trial (The Lancet Haematology, 2022) evaluating hyper-CVAD followed by blinatumomab consolidation in newly diagnosed Ph-negative B-ALL.", "scientific_summary": "Review of a single-centre phase 2 trial evaluating hyper-CVAD followed by blinatumomab consolidation in newly diagnosed Ph-negative B-ALL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should blinatumomab be added sequentially after hyper-CVAD in newly diagnosed Ph-negative B-ALL?", "language": null, "original_publication_date": "2026-04-20T23:14:18.003Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4160551/horizontal/small_187ce595-7e05-4054-81f8-cdbc069cc3eb.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["B-ALL", "Ph-negative", "hyper-CVAD", "blinatumomab", "frontline therapy", "consolidation", "maintenance", "MRD negativity", "relapse-free survival", "cytokine release syndrome", "neurotoxicity infections"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4160551", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_B_ALL_LBL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "B-ALL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_28249141", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_39047240", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_ALL_MRD_DIRECTED", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_HYPERCVAD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "hyper-CVAD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_MRD_DIRECTED", "via_therapy_id": "TX_ALL_BLINA", "graph_edge_ids": ["EDGE_ALL_BLINA_MRD_DIRECTED_HAS_OPTION", "EDGE_ALL_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json", "note": "Approved blinatumomab resource linked to the explicitly curated MRD/consolidation and relapsed/refractory settings; HAS_OPTION does not encode treatment preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json"}]}, {"target_id": "PROT_ALL_HYPERCVAD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_HYPERCVAD", "graph_edge_ids": ["EDGE_ALL_HYPERCVAD_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_HYPERCVAD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json", "note": "Approved Hyper-CVAD resource linked as a non-preferential Ph-negative frontline option. The protocol source itself preserves the AYA/pediatric-inspired treatment context; this edge does not imply superiority or preferred use."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json"}]}, {"target_id": "PROT_ALL_MINIHCV_INO_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_MINIHCV_INO_BLINA", "graph_edge_ids": ["EDGE_ALL_MINIHCV_INO_BLINA_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_MINIHCV_INO_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json", "note": "Approved protocol resource linked only to the Ph-negative frontline decision; the source context is newly diagnosed Philadelphia-negative B-ALL in older adults and is not generalized."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4160617", "editorial": {"original_title": "How should blinatumomab be integrated into frontline therapy for adult B-cell ALL?  ", "public_title": "How should blinatumomab be integrated into frontline therapy for adult B-cell ALL?", "slug": "integrating-blinatumomab-frontline-treatment-b-cell-acute-lymphoblastic-leukemia", "legacy_canonical_url": "https://5minutehematology.com/programs/integrating-blinatumomab-frontline-treatment-b-cell-acute-lymphoblastic-leukemia", "description": "Physician-focused narrative review of frontline blinatumomab strategies in newly diagnosed adult B-ALL, summarizing MRD and outcome data (Journal of Clinical Medicine, 2025).", "scientific_summary": "Physician-focused narrative review of frontline blinatumomab strategies in newly diagnosed adult B-ALL, summarizing MRD and outcome data.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies", "Cellular Therapy & Immunotherapy"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should blinatumomab be integrated into frontline therapy for adult B-cell ALL?", "language": null, "original_publication_date": "2026-04-21T00:45:36.124Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4160617/horizontal/small_276afaf9-2d52-4dc0-84a2-9aab60d5a4e1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["blinatumomab", "BiTE", "B-cell ALL", "frontline therapy", "newly diagnosed", "MRD", "Ph-negative ALL", "Ph-positive ALL", "TKI", "ponatinib", "chemoimmunotherapy", "allo-SCT"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4160617", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40142863", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_30658992", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_ALL_MRD_DIRECTED", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_PONATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_PONATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_MRD_DIRECTED", "via_therapy_id": "TX_ALL_BLINA", "graph_edge_ids": ["EDGE_ALL_BLINA_MRD_DIRECTED_HAS_OPTION", "EDGE_ALL_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json", "note": "Approved blinatumomab resource linked to the explicitly curated MRD/consolidation and relapsed/refractory settings; HAS_OPTION does not encode treatment preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json"}]}, {"target_id": "PROT_ALL_HYPERCVAD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_HYPERCVAD", "graph_edge_ids": ["EDGE_ALL_HYPERCVAD_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_HYPERCVAD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json", "note": "Approved Hyper-CVAD resource linked as a non-preferential Ph-negative frontline option. The protocol source itself preserves the AYA/pediatric-inspired treatment context; this edge does not imply superiority or preferred use."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json"}]}, {"target_id": "PROT_ALL_MINIHCV_INO_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_MINIHCV_INO_BLINA", "graph_edge_ids": ["EDGE_ALL_MINIHCV_INO_BLINA_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_MINIHCV_INO_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json", "note": "Approved protocol resource linked only to the Ph-negative frontline decision; the source context is newly diagnosed Philadelphia-negative B-ALL in older adults and is not generalized."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4165245", "editorial": {"original_title": "Does DA-EPOCH-R improve survival vs R-CHOP as frontline therapy for DLBCL?", "public_title": "Does DA-EPOCH-R improve survival vs R-CHOP as frontline therapy for DLBCL?", "slug": "da-epoch-r-vs-r-chop-frontline-dlbcl-alliance-calgb-50303", "legacy_canonical_url": "https://5minutehematology.com/programs/da-epoch-r-vs-r-chop-frontline-dlbcl-alliance-calgb-50303", "description": "Phase III intergroup randomized trial (Alliance/CALGB 50303) in Journal of Clinical Oncology (2019) comparing DA-EPOCH-R vs R-CHOP for untreated DLBCL: efficacy and toxicity outcomes.", "scientific_summary": "Alliance/CALGB 50303 trial (2019) comparing DA-EPOCH-R vs R-CHOP for for untreated DLBCL: efficacy and toxicity outcomes.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does DA-EPOCH-R improve survival vs R-CHOP as frontline therapy for DLBCL?", "language": null, "original_publication_date": "2026-04-23T21:37:39.375Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4165245/horizontal/small_8db5d42b-ea1e-4897-900c-0e952677da57.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "DA-EPOCH-R", "R-CHOP", "frontline therapy", "phase III trial", "progression-free survival", "overall survival", "toxicity", "febrile neutropenia", "Alliance/CALGB 50303"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4165245", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30939090", "role": "episode_reference_candidate", "source_association_status": "physician_reviewed_direct_source", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Alliance/CALGB 50303"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE"}], "evidence_relations": [{"target_id": "EV_PMID_30939090", "relation": "DIRECT", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_DAEPOCHR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "DA-EPOCH-R", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_POLARCHP_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_POLARCHP", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_POLARCHP", "EDGE_POLARCHP_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved Pola-R-CHP resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/pola_r_chp.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_LIMITED_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4165257", "editorial": {"original_title": "How should transplant-ineligible R/R LBCL be treated in the CAR T era?", "public_title": "How should transplant-ineligible R/R LBCL be treated in the CAR T era?", "slug": "transplant-ineligible-rr-lbcl-car-t-liso-cel-pilot", "legacy_canonical_url": "https://5minutehematology.com/programs/transplant-ineligible-rr-lbcl-car-t-liso-cel-pilot", "description": "Narrative review in Leukemia & Lymphoma (2026) summarizing evidence for transplant-ineligible R/R LBCL, including TRANSFORM and ZUMA-7 trials and the phase II PILOT study of liso-cel.", "scientific_summary": "Narrative review in Leukemia & Lymphoma (2026) summarizing evidence for transplant-ineligible R/R LBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should transplant-ineligible R/R LBCL be treated in the CAR T era?", "language": null, "original_publication_date": "2026-04-23T22:09:34.330Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4165257/horizontal/small_b95b282f-5660-463e-a967-cbf237723987.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["R/R LBCL", "transplant-ineligible", "ASCT-ineligible", "CAR T-cell therapy", "lisocabtagene maraleucel", "axicabtagene ciloleucel", "PILOT study", "TRANSFORM trial", "ZUMA-7 trial", "antibody-drug conjugates", "bispecific antibodies", "second-line therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4165257", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41774434", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "A new era for transplant-ineligible R/R LBCL patients: what's changing?", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [{"target_id": "EV_PMID_34891224", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CART_LISOCEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "lisocabtagene maraleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LISOCABTAGENE_MARALEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lisocabtagene maraleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_AXICEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "axicabtagene ciloleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_AXICABTAGENE_CILOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "axicabtagene ciloleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4167312", "editorial": {"original_title": "How durable are responses to loncastuximab tesirine in relapsed/refractory DLBCL?", "public_title": "How durable are responses to loncastuximab tesirine in relapsed/refractory DLBCL?", "slug": "loncastuximab-tesirine-relapsed-refractory-dlbcl-long-term-efficacy-safety-phase", "legacy_canonical_url": "https://5minutehematology.com/programs/loncastuximab-tesirine-relapsed-refractory-dlbcl-long-term-efficacy-safety-phase", "description": "Phase II single-arm LOTIS-2 trial update in Haematologica (2023) reporting long-term efficacy and safety of loncastuximab tesirine in heavily pretreated R/R DLBCL.", "scientific_summary": "Phase II single-arm LOTIS-2 trial reporting long-term efficacy and safety of loncastuximab tesirine in heavily pretreated R/R DLBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How durable are responses to loncastuximab tesirine in relapsed/refractory DLBCL?", "language": null, "original_publication_date": "2026-04-25T22:23:13.896Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4167312/horizontal/small_74e1fb61-163b-4d87-9d52-23c77d9f1e2d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["loncastuximab tesirine", "anti-CD19 ADC", "diffuse large B-cell lymphoma", "relapsed refractory", "LOTIS-2", "phase II", "complete response", "overall response rate", "progression-free survival", "overall survival", "safety"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4167312", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4094526", "relation": "same_documented_source", "shared_reference_ids": ["PMID_37646659"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_37646659", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_LONCASTUXIMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "loncastuximab tesirine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LONCASTUXIMAB_TESIRINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "loncastuximab tesirine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4167316", "editorial": {"original_title": "In transplant-ineligible R/R DLBCL, does glofitamab-GemOx improve overall survival vs R-GemOx?", "public_title": "In transplant-ineligible R/R DLBCL, does glofitamab-GemOx improve overall survival vs R-GemOx?", "slug": "glofitamab-gemox-vs-rituximab-gemox-relapsed-refractory-dlbcl-starglo", "legacy_canonical_url": "https://5minutehematology.com/programs/glofitamab-gemox-vs-rituximab-gemox-relapsed-refractory-dlbcl-starglo", "description": "Review of STARGLO, a global phase 3 randomized open-label trial (The Lancet, 2024) comparing glofitamab-GemOx vs rituximab-GemOx in transplant-ineligible R/R DLBCL after >=1 prior line.", "scientific_summary": "STARGLO randomized trial comparing glofitamab-GemOx vs rituximab-GemOx in transplant-ineligible R/R DLBCL after >=1 prior line.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In transplant-ineligible R/R DLBCL, does glofitamab-GemOx improve overall survival vs R-GemOx?", "language": null, "original_publication_date": "2026-04-25T22:37:48.039Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4167316/horizontal/small_1a308942-be21-45ce-bfa1-6e893606f279.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["glofitamab", "GemOx", "rituximab", "diffuse large B-cell lymphoma", "relapsed refractory", "transplant ineligible", "phase 3 trial", "overall survival", "cytokine release syndrome", "STARGLO"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4167316", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_GLOFITAMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_GLOFITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RGEMOX", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "GemOx", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4167724", "editorial": {"original_title": "How should relapse timing guide CAR T-cell therapy vs autologous transplant in DLBCL?", "public_title": "How should relapse timing guide CAR T-cell therapy vs autologous transplant in DLBCL?", "slug": "current-treatment-algorithm-diffuse-large-b-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/current-treatment-algorithm-diffuse-large-b-cell-lymphoma", "description": "Physician-only expert review (narrative treatment algorithm) summarizing risk-adapted frontline and relapsed DLBCL management per Blood Cancer Journal 2026 (Ansell SM).", "scientific_summary": "Physician-only expert review (narrative treatment algorithm) summarizing risk-adapted frontline and relapsed DLBCL", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should relapse timing guide CAR T-cell therapy vs autologous transplant in DLBCL?", "language": null, "original_publication_date": "2026-04-28T01:10:05.082Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4167724/horizontal/small_d7cb2a7d-577c-452a-bc87-c4b8fd295f1b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "treatment algorithm", "R-CHOP", "polatuzumab vedotin", "ABC subtype", "MYC BCL2 rearrangements", "relapsed refractory", "CAR T-cell therapy", "autologous stem cell transplant", "salvage chemotherapy", "bispecific antibodies", "antibody-drug conjugates"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4167724", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4169939", "editorial": {"original_title": "Does longer BTK inhibitor bridging before anti-CD19 CAR-T improve response in relapsed/refractory DLBCL?", "public_title": "Does longer BTK inhibitor bridging before anti-CD19 CAR-T improve response in relapsed/refractory DLBCL?", "slug": "predictors-responses-varying-durations-btk-inhibitor-bridging-therapy-anti-cd19", "legacy_canonical_url": "https://5minutehematology.com/programs/predictors-responses-varying-durations-btk-inhibitor-bridging-therapy-anti-cd19", "description": "Retrospective cohort analysis in Frontiers in Immunology (2026) of 33 R/R DLBCL patients comparing BTKi bridging duration >=2 months vs <2 months before anti-CD19 CAR-T infusion.", "scientific_summary": "Retrospective cohort analysis of R/R DLBCL patients comparing BTKi bridging duration >=2 months vs <2 months before anti-CD19 CAR-T infusion", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does longer BTK inhibitor bridging before anti-CD19 CAR-T improve response in relapsed/refractory DLBCL?", "language": null, "original_publication_date": "2026-04-28T01:20:21.179Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4169939/horizontal/small_1588c2d8-d1b0-4213-85a3-7efa93bfdc9e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "relapsed refractory", "anti-CD19 CAR-T", "bridging therapy", "BTK inhibitor", "ibrutinib", "zanubrutinib", "response rate", "PFS", "OS", "hematologic toxicity", "NAMPT"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4169939", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41727499", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4178090", "editorial": {"original_title": "How effective is momelotinib for anemia and symptoms in myelofibrosis?", "public_title": "How effective is momelotinib for anemia and symptoms in myelofibrosis?", "slug": "momelotinib-efficacy-myelofibrosis-multicenter-study", "legacy_canonical_url": "https://5minutehematology.com/programs/momelotinib-efficacy-myelofibrosis-multicenter-study", "description": "Retrospective real-life multicenter Italian cohort study (European Journal of Haematology, 2026) evaluating momelotinib safety and efficacy in 39 consecutive MF patients, including transfusion-dependent and independent groups.", "scientific_summary": "Real-life multicenter Italian cohort study evaluating momelotinib safety and efficacy in 39 consecutive MF patients.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective is momelotinib for anemia and symptoms in myelofibrosis?", "language": null, "original_publication_date": "2026-05-04T00:40:09.514Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4178090/horizontal/small_47f6f7bf-fb9c-4ec8-87e0-a8984526e147.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["momelotinib", "myelofibrosis", "JAK1/2 inhibitor", "ACVR1", "anemia", "transfusion dependence", "spleen volume reduction", "constitutional symptoms", "real-world study", "retrospective cohort", "safety", "response rate"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4178090", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40955124", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4299795", "editorial": {"original_title": "When does incidentally detected splenomegaly warrant evaluation for hematologic cancer or liver disease?", "public_title": "When does incidentally detected splenomegaly warrant evaluation for hematologic cancer or liver disease?", "slug": "incidentally-detected-splenomegaly-risk-hematologic-cancer-liver-disease", "legacy_canonical_url": "https://5minutehematology.com/programs/incidentally-detected-splenomegaly-risk-hematologic-cancer-liver-disease", "description": "Prospective cohort study in 2 general population cohorts from Denmark and the UK assessing absolute and relative risks of hematologic cancers and liver disease by spleen length/volume (JAMA Oncology, 2026).", "scientific_summary": "Prospective cohort study in 2 assessing absolute and relative risks of hematologic cancer and liver disease by spleen length/volume.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Supportive Care & Complications", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": ["Supportive Care & Complications"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "When does incidentally detected splenomegaly warrant evaluation for hematologic cancer or liver disease?", "language": null, "original_publication_date": "2026-08-07T20:17:21.059Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4299795/horizontal/small_b8163414-d844-43f5-9ef6-ef1356465b91.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["splenomegaly", "spleen length", "spleen volume", "hematologic cancer risk", "lymphoid malignancy", "cirrhosis", "liver cancer", "prospective cohort", "population cohort"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4299795", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41538177", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Incidentally Detected Splenomegaly and Risk of Hematologic Cancer and Liver Disease", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4299867", "editorial": {"original_title": "How should infection risk be stratified and prevented after CAR T-cell therapy?", "public_title": "How should infection risk be stratified and prevented after CAR T-cell therapy?", "slug": "infectious-complications-car-t-therapy-risk-stratification-prevention", "legacy_canonical_url": "https://5minutehematology.com/programs/infectious-complications-car-t-therapy-risk-stratification-prevention", "description": "Narrative review summarizing mechanisms, risk stratification, and prophylaxis strategies for infections after CAR T-cell therapy (Blood Research, 2026).", "scientific_summary": "Narrative review summarizing mechanisms, risk stratification, and prophylaxis strategies for infections after CAR T-cell therapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Cellular Therapy & Immunotherapy", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Cellular Therapy & Immunotherapy"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should infection risk be stratified and prevented after CAR T-cell therapy?", "language": null, "original_publication_date": "2026-08-07T21:05:09.337Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4299867/horizontal/small_d3a72136-0b4a-4c5f-8686-c0113a7c02a3.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CAR T-cell therapy", "infections", "risk stratification", "prophylaxis", "cytopenia", "CD4 lymphopenia", "B-cell aplasia", "hypogammaglobulinemia", "IVIG", "PJP prophylaxis", "antiviral prophylaxis", "antifungal prophylaxis"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4299867", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42274870", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4299901", "editorial": {"original_title": "How effective are BCMA or GPRC5D CD3 bispecific antibodies in RRMM with baseline extramedullary disease?", "public_title": "How effective are BCMA or GPRC5D CD3 bispecific antibodies in RRMM with baseline extramedullary disease?", "slug": "bispecific-antibodies-rrmm-extramedullary-disease-meta-analysis", "legacy_canonical_url": "https://5minutehematology.com/programs/bispecific-antibodies-rrmm-extramedullary-disease-meta-analysis", "description": "Systematic review and random-effects meta-analysis of prospective RRMM trials (Cureus, 2026) quantifying ORR with BCMA- or GPRC5D-directed CD3 bispecific antibodies in baseline EMD.", "scientific_summary": "Systematic review and random-effects meta-analysis quantifying ORR with BCMA- or GPRC5D-directed CD3 bispecific antibodies in baseline EMD.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma", "Original Studies"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective are BCMA or GPRC5D CD3 bispecific antibodies in RRMM with baseline extramedullary disease?", "language": null, "original_publication_date": "2026-08-07T21:35:55.964Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4299901/horizontal/small_3f303599-16de-4bd7-872c-4938c3dce1c5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "relapsed refractory", "extramedullary disease", "EMD", "bispecific antibodies", "BCMA", "GPRC5D", "CD3", "teclistamab", "elranatamab", "linvoseltamab", "talquetamab"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4299901", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_ELRA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ELRANATAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_TALQUE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TALQUETAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_TECDARA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "via_therapy_id": "TX_MM_TECDARA", "graph_edge_ids": ["EDGE_MM_TECDARA_HAS_OPTION", "EDGE_MM_TECDARA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Teclistamab + Daratumumab resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/targeted/teclistamab_daratumumab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300974", "editorial": {"original_title": "EP00 — What Practice-Changing Updates Did EHA 2026 Add for CLL and Richter Transformation?", "public_title": "EP00 — What Practice-Changing Updates Did EHA 2026 Add for CLL and Richter Transformation?", "slug": "eha-2026-cll-richter-transformation-what-changed-key-updates", "legacy_canonical_url": "https://5minutehematology.com/programs/eha-2026-cll-richter-transformation-what-changed-key-updates", "description": "Part of the 5MinuteHematology guideline/consensus series covering the EHA 2026 update on chronic lymphocytic leukemia (CLL) and Richter transformation management (Hemasphere, 2026).", "scientific_summary": "Part of the 5MinuteHematology guideline/consensus series covering the EHA 2026 update on CLL) and Richter transformation management.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300974/horizontal/small_97dda0ae-fd8d-4577-a1d6-afb367ce9516.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "guidelines", "chronic lymphocytic leukemia", "CLL", "Richter transformation", "Richter syndrome", "what changed", "practice changing updates", "frontline", "first line", "time limited therapy", "acalabrutinib"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300974", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300987", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ACALABRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ACALABRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300987", "editorial": {"original_title": "EP01 — How to Diagnose CLL vs SLL vs MBL: Minimum Testing and Flow Criteria", "public_title": "EP01 — How to Diagnose CLL vs SLL vs MBL: Minimum Testing and Flow Criteria", "slug": "diagnose-cll-vs-sll-vs-mbl-minimum-testing-flow-criteria", "legacy_canonical_url": "https://5minutehematology.com/programs/diagnose-cll-vs-sll-vs-mbl-minimum-testing-flow-criteria", "description": "Episode 1 in the 5MinuteHematology guideline/consensus series on the EHA Guidelines for CLL and Richter transformation (Hemasphere, 2026). Focus: distinguishing CLL vs SLL vs MBL using peripheral blood counts and flow cytometry.", "scientific_summary": "Focus: distinguishing CLL vs SLL vs MBL using peripheral blood counts and flow cytometry.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300987/horizontal/small_c4858735-221c-4c15-aa12-db235a7d3f89.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "guideline", "consensus", "Hemasphere 2026", "chronic lymphocytic leukemia", "CLL", "small lymphocytic lymphoma", "SLL", "monoclonal B-cell lymphocytosis", "MBL", "diagnosis", "new diagnosis evaluation"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300987", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300991", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300991", "editorial": {"original_title": "EP02 — CLL Biomarkers: What to Order Before Treatment and What to Repeat Each Line", "public_title": "EP02 — CLL Biomarkers: What to Order Before Treatment and What to Repeat Each Line", "slug": "cll-mandatory-biomarkers-ighv-tp53-retesting-eha-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/cll-mandatory-biomarkers-ighv-tp53-retesting-eha-2026", "description": "In this guideline/consensus series episode, learn which CLL biomarkers are mandatory before first-line and before each subsequent line, and how to use IGHV and TP53 testing to guide decisions (Hemasphere, 2026 EHA guideline).", "scientific_summary": "In this guideline/consensus series episode, learn which CLL biomarkers are mandatory before first-line and before each subsequent line.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300991/horizontal/small_bc87f3b1-2916-4c68-9210-b8dafc3bc8f4.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "CLL", "chronic lymphocytic leukemia", "guideline", "consensus", "Hemasphere", "biomarkers", "risk stratification", "pretreatment planning", "first-line", "relapsed refractory", "retesting", "IGHV"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300991", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300993", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic lymphocytic leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300993", "editorial": {"original_title": "EP03 — CLL: When Should I Start Treatment Using iwCLL Active Disease Criteria?", "public_title": "EP03 — CLL: When Should I Start Treatment Using iwCLL Active Disease Criteria?", "slug": "cll-when-to-treat-iwcll-active-disease-criteria-eha-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/cll-when-to-treat-iwcll-active-disease-criteria-eha-2026", "description": "Episode 3 of the EHA 2026 CLL and Richter Transformation Management (5MinuteHematology) guideline/consensus series, summarizing iwCLL active disease indications to treat vs watch-and-wait despite high-risk biology (Hemasphere, 2026).", "scientific_summary": "IwCLL active disease indications to treat vs watch-and-wait despite high-risk biology (Hemasphere, 2026).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300993/horizontal/small_15cf402d-4d00-4b74-b8ac-65ad7c03317b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "guideline", "chronic lymphocytic leukemia", "CLL", "Richter transformation", "iwCLL", "active disease", "when to treat", "treatment indication", "watch and wait", "observation", "surveillance clinic"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300993", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300996", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300996", "editorial": {"original_title": "EP04 — Watch-and-Wait CLL: Which Vaccines, When to Use Ig Replacement, and How to Treat Autoimmune Cytopenias?", "public_title": "EP04 — Watch-and-Wait CLL: Which Vaccines, When to Use Ig Replacement, and How to Treat Autoimmune Cytopenias?", "slug": "watch-and-wait-cll-vaccines-ig-replacement-autoimmune-cytopenias-eha-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/watch-and-wait-cll-vaccines-ig-replacement-autoimmune-cytopenias-eha-2026", "description": "Episode 4 of the EHA 2026 CLL and Richter Transformation Management guideline/consensus series, summarizing Hemasphere 2026 recommendations for vaccines, infection prevention, Ig replacement, and management of CLL-associated autoimmune cytopenias.", "scientific_summary": "Hemasphere 2026 recommendations for vaccines, infection prevention, Ig replacement, and management of CLL-associated autoimmune cytopenias.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300996/horizontal/small_814a8ced-70be-478b-ac91-fcb40238917a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "guidelines", "consensus", "chronic lymphocytic leukemia", "CLL", "watch and wait", "active surveillance", "supportive care", "vaccination", "PCV20", "PPV23", "influenza vaccine"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300996", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300998", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300998", "editorial": {"original_title": "EP05 — CLL Pretreatment Workup: TLS Prevention for Venetoclax and Cardiac Safety for BTK Inhibitors", "public_title": "EP05 — CLL Pretreatment Workup: TLS Prevention for Venetoclax and Cardiac Safety for BTK Inhibitors", "slug": "cll-pretreatment-workup-safety-checks-tls-venetoclax-btki-cardiac", "legacy_canonical_url": "https://5minutehematology.com/programs/cll-pretreatment-workup-safety-checks-tls-venetoclax-btki-cardiac", "description": "In this 5MinuteHematology guideline series episode, we review the EHA recommendations for the immediate pretreatment checklist in CLL: drug interaction review, labs/viral serologies, imaging for venetoclax TLS risk, and ECG/cardiac assessment for BTK inhibitors.", "scientific_summary": "immediate pretreatment checklist in CLL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300998/horizontal/small_6563f119-62a2-4dfa-a3a0-01d8cb23f235.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "guidelines", "consensus", "Hemasphere 2026", "chronic lymphocytic leukemia", "CLL", "pretreatment workup", "pretreatment testing", "safety checks", "baseline assessment", "drug drug interactions", "CYP3A"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300998", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4300999", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4300999", "editorial": {"original_title": "EP06 — Treatment-Naive CLL: Time-Limited Venetoclax Combinations vs Continuous BTK Inhibitor Therapy", "public_title": "EP06 — Treatment-Naive CLL: Time-Limited Venetoclax Combinations vs Continuous BTK Inhibitor Therapy", "slug": "treatment-naive-cll-time-limited-venetoclax-vs-continuous-btk-inhibitor-therapy", "legacy_canonical_url": "https://5minutehematology.com/programs/treatment-naive-cll-time-limited-venetoclax-vs-continuous-btk-inhibitor-therapy", "description": "In this 5MinuteHematology guideline/consensus series episode, we apply the EHA guideline (Hemasphere, 2026) to frontline CLL selection: time-limited venetoclax-based combinations (including acalabrutinib plus venetoclax with or without obinutuzumab) vs continuous therapy.", "scientific_summary": "Time-limited venetoclax-based combinations (including acalabrutinib plus venetoclax with or without obinutuzumab) vs continuous therapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:10:06.479Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4300999/horizontal/small_1633f98d-c249-4971-9085-76b9b5c88d8c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "Hemasphere 2026", "chronic lymphocytic leukemia", "CLL", "frontline", "first line", "treatment naive", "time limited therapy", "continuous therapy", "venetoclax", "acalabrutinib", "obinutuzumab"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4300999", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301000", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301002"}], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CLL_ACALABRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ACALABRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "acalabrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301000", "editorial": {"original_title": "EP07 — In Relapsed CLL After Targeted Therapy, When Should I Re-test TP53, Use Pirtobrutinib, and Suspect Richter Transformation", "public_title": "EP07 — In Relapsed CLL After Targeted Therapy, When Should I Re-test TP53, Use Pirtobrutinib, and Suspect Richter Transformation", "slug": "relapsed-cll-tp53-retesting-pirtobrutinib-after-covalent-btki-richter-transformation", "legacy_canonical_url": "https://5minutehematology.com/programs/relapsed-cll-tp53-retesting-pirtobrutinib-after-covalent-btki-richter-transformation", "description": "Episode 7 of the EHA 2026: CLL and Richter Transformation Management (5MinuteHematology) guideline/consensus series, based on the 2026 EHA guideline in Hemasphere. Covers TP53 re-testing before each line, sequencing with pirtobrutinib after covalent BTKi exposure and suspect Ritcher transformation.", "scientific_summary": "In Relapsed CLL After Targeted Therapy, When Should I Re-test TP53, Use Pirtobrutinib, and Suspect Richter Transformation", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": [], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301000/horizontal/small_cb398f64-0acd-409d-9b28-2e50be27fbe7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2026", "EHA guideline", "Hemasphere 2026", "chronic lymphocytic leukemia", "CLL", "relapsed CLL", "refractory CLL", "relapsed refractory", "treatment sequencing", "TP53", "TP53 retesting", "del(17p)", "BTK inhibitor"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301000", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42293463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation", "provenance": "Collection 4301002; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301035", "editorial": {"original_title": "EP00 — What Practice-Changing Updates in ELN 2025 Change How You Manage Adult CML?", "public_title": "EP00 — What Practice-Changing Updates in ELN 2025 Change How You Manage Adult CML?", "slug": "what-changed-eln-2025-cml-updates", "legacy_canonical_url": "https://5minutehematology.com/programs/what-changed-eln-2025-cml-updates", "description": "Part of the 5MinuteHematology guideline series summarizing the 2025 European LeukemiaNet (ELN) recommendations for chronic myeloid leukemia (Leukemia, 2025). Rapidly reviews what changed vs prior ELN guidance.", "scientific_summary": "Reviews what changed in ELN guidance: phase concept, milestone interpretation, dose reduction vs. switching, asciminib positioning and HSCT.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301035/horizontal/small_ee967abf-2b3b-4e60-9d0c-3915d2f1895a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025 CML Management Recommendations", "European LeukemiaNet", "ELN", "chronic myeloid leukemia", "CML", "guideline", "adult CML", "updates", "phase concept", "WHO 2022 biphasic classification", "molecular milestones", "warning unfavorable favorable"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301035", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301037", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301037", "editorial": {"original_title": "EP01 — At CML diagnosis, which baseline tests are required?", "public_title": "EP01 — At CML diagnosis, which baseline tests are required?", "slug": "eln-2025-cml-diagnosis-baseline-workup-bcr-abl1-transcript-cytogenetics", "legacy_canonical_url": "https://5minutehematology.com/programs/eln-2025-cml-diagnosis-baseline-workup-bcr-abl1-transcript-cytogenetics", "description": "Part of the 5MinuteHematology guideline series covering the 2025 European LeukemiaNet (ELN) recommendations for adult CML management (Leukemia, 2025). This episode reviews baseline diagnostics at diagnosis.", "scientific_summary": "This episode reviews baseline CML diagnostics at diagnosis.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301037/horizontal/small_715dcb31-fe4c-45a8-ab94-d628fdc6b8db.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025", "European LeukemiaNet", "CML", "chronic myeloid leukemia", "guideline", "ELN guideline", "diagnosis", "baseline workup", "BCR::ABL1", "BCR-ABL1", "transcript type", "e13a2", "e14a2"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301037", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301047", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301047", "editorial": {"original_title": "EP02 — How should WHO 2022 biphasic CML classification be reconciled with ELN phase and risk?", "public_title": "EP02 — How should WHO 2022 biphasic CML classification be reconciled with ELN phase and risk?", "slug": "cml-phase-risk-who-2022-biphasic-vs-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-phase-risk-who-2022-biphasic-vs-eln-2025", "description": "Part of the ELN 2025 CML guideline/consensus series (Leukemia, 2025). This episode explains how to apply WHO 2022 biphasic classification alongside prior ELN phase concepts, and highlights high-risk features.", "scientific_summary": "This episode explains how to apply WHO 2022 biphasic classification alongside prior ELN phase concepts, and highlights high-risk features.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301047/horizontal/small_65160b74-4beb-476a-b30c-5e065a6a4465.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025", "European LeukemiaNet", "CML", "chronic myeloid leukemia", "guideline", "Leukemia 2025", "WHO 2022", "biphasic classification", "triphasic classification", "accelerated phase", "blast phase", "disease phase", "risk stratification"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301047", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301052", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301052", "editorial": {"original_title": "EP03 — How Should You Monitor BCR::ABL1 and Use 3/6/12-Month Milestones in CML (ELN 2025)?", "public_title": "EP03 — How Should You Monitor BCR::ABL1 and Use 3/6/12-Month Milestones in CML (ELN 2025)?", "slug": "cml-bcr-abl1-monitoring-milestones-3-6-12-months-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-bcr-abl1-monitoring-milestones-3-6-12-months-eln-2025", "description": "Part of the ELN 2025 CML Management Recommendations (Adult) - 5MinuteHematology guideline series. Based on European LeukemiaNet recommendations (Leukemia, 2025), this episode reviews BCR::ABL1 monitoring frequency, International Scale reporting, DMR definition.", "scientific_summary": "this episode reviews BCR::ABL1 monitoring frequency, International Scale reporting, DMR definition.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301052/horizontal/small_394d372d-9303-4c50-8a65-e60f809ddafc.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025", "European LeukemiaNet", "CML", "chronic myeloid leukemia", "guideline", "ELN guideline", "BCR::ABL1 monitoring", "molecular monitoring", "International Scale", "IS reporting", "EMR", "MMR", "DMR"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301052", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301055", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301055", "editorial": {"original_title": "EP04 — Newly Diagnosed Chronic-Phase CML: How Do You Choose Frontline TKI and Starting Dose?", "public_title": "EP04 — Newly Diagnosed Chronic-Phase CML: How Do You Choose Frontline TKI and Starting Dose?", "slug": "newly-diagnosed-chronic-phase-cml-frontline-tki-choice-starting-dose-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/newly-diagnosed-chronic-phase-cml-frontline-tki-choice-starting-dose-eln-2025", "description": "Part of the ELN 2025 CML guideline/consensus video series (Leukemia, 2025). Covers frontline TKI selection (imatinib vs 2G TKIs vs asciminib where available), goal-driven endpoints (TFR), ELTS risk, comorbidity-based choice, and when to use modified starting dose.", "scientific_summary": "Covers frontline TKI selection (imatinib vs 2G TKIs vs asciminib where available).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:27:52.279Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301055/horizontal/small_363e1712-0d19-4acf-8a00-d4d5e43ca989.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025 CML Management Recommendations", "European LeukemiaNet", "chronic myeloid leukemia", "CML", "chronic phase CML", "guideline", "ELN guideline 2025", "frontline treatment initiation", "first line therapy", "frontline TKI choice", "starting dose", "dose modification", "imatinib"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301055", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301058", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_FRONTLINE_TKI"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_CML_FRONTLINE_TKI", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_IMATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IMATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301058", "editorial": {"original_title": "EP05 — CML TKI Intolerance: When to Reduce Dose vs Switch Therapy?", "public_title": "EP05 — CML TKI Intolerance: When to Reduce Dose vs Switch Therapy?", "slug": "cml-tki-intolerance-dose-reduction-vs-switching-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-tki-intolerance-dose-reduction-vs-switching-eln-2025", "description": "Part of the ELN 2025 guideline/consensus video series, this episode reviews chronic-phase CML toxicity management during ongoing TKI therapy: when to attempt dose reduction, how low to go, and which serious adverse events require switching.", "scientific_summary": "When to attempt dose reduction, how low to go, and which serious adverse events require switching.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301058/horizontal/small_c22e53d0-4229-45c5-afd0-052af961cd29.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025 CML Management Recommendations", "European LeukemiaNet", "chronic myeloid leukemia", "CML", "guideline", "Leukemia 2025", "TKI intolerance", "toxicity management", "dose reduction", "dose modification", "switch TKI", "pleural effusion", "pulmonary hypertension"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301058", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301059", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301059", "editorial": {"original_title": "EP06 — In CML With Rising BCR-ABL1, When to Send Mutation Testing and Which Next TKI?", "public_title": "EP06 — In CML With Rising BCR-ABL1, When to Send Mutation Testing and Which Next TKI?", "slug": "cml-rising-bcr-abl1-mutation-testing-ngs-sanger-next-tki-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-rising-bcr-abl1-mutation-testing-ngs-sanger-next-tki-eln-2025", "description": "Episode 6 of the ELN 2025 CML Management Recommendations (Adult) 5MinuteHematology guideline series. Based on the 2025 European LeukemiaNet recommendations (Leukemia, 2025), this episode covers stepwise resistance workup (adherence and drug interactions).", "scientific_summary": "2025 European LeukemiaNet recommendations (Leukemia, 2025), this episode covers stepwise resistance workup (adherence and drug interactions)", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301059/horizontal/small_d9899608-e5cb-4754-b35a-f21de178f6cb.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025", "European LeukemiaNet", "CML", "chronic myeloid leukemia", "guideline", "ELN guideline", "resistance workup", "TKI resistance", "BCR-ABL1", "BCR::ABL1 mutation testing", "kinase domain mutations", "NGS", "next generation sequencing"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301059", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301061", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301063"}], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "chronic myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301061", "editorial": {"original_title": "EP07 — After 2G TKI Failure in CML: When to Use Ponatinib or Asciminib and When to Refer for alloSCT?", "public_title": "EP07 — After 2G TKI Failure in CML: When to Use Ponatinib or Asciminib and When to Refer for alloSCT?", "slug": "cml-later-line-ponatinib-asciminib-when-to-transplant-eln-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/cml-later-line-ponatinib-asciminib-when-to-transplant-eln-2025", "description": "Part of the ELN 2025 CML guideline/consensus video series, this episode reviews later-line sequencing in CML: positioning ponatinib vs asciminib after first- and second-line failure, OPTIC-informed ponatinib dosing, and when to start donor search.", "scientific_summary": "Later-line sequencing in CML: positioning ponatinib vs asciminib, OPTIC-informed ponatinib dosing, and when to start donor search.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301061/horizontal/small_a971fcc9-12dc-4019-9524-187b401b3f5a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ELN 2025", "European LeukemiaNet", "CML", "chronic myeloid leukemia", "guideline", "ELN 2025 CML Management Recommendations", "later line", "second line", "third line", "treatment sequencing", "ponatinib", "ponatinib dosing", "OPTIC"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301061", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41375-025-02664-w", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40646132", "provenance": "Collection 4301063; episode applicability requires physician review"}, {"reference_id": "PMID_40646132", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "provenance": "Collection 4301063; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CML", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CML_PONATINIB"}], "evidence_relations": [{"target_id": "EV_PMID_34407543", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_CML_ASCIMINIB", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "DEC_CML_PONATINIB", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CML_PONATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_PONATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ponatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301114", "editorial": {"original_title": "EP00 — How to Apply the EHA 2025 LBCL Guideline in Practice From Diagnosis to Relapse", "public_title": "EP00 — How to Apply the EHA 2025 LBCL Guideline in Practice From Diagnosis to Relapse", "slug": "how-to-apply-eha-2025-lbcl-guideline-in-practice-from-diagnosis-to-relapse", "legacy_canonical_url": "https://5minutehematology.com/programs/how-to-apply-eha-2025-lbcl-guideline-in-practice-from-diagnosis-to-relapse", "description": "Part of the 5MinuteHematology guideline/consensus series covering the EHA Clinical Practice Guideline for large B-cell lymphoma (LBCL). This episode provides a practical walkthrough of the HemaSphere 2025 recommendations, including GRADE strength, core algorithms, and common pitfalls from diagnosis through relapse.", "scientific_summary": "A practical walkthrough of the EHA 2025 LBCL guideline, its key recommendations, algorithms, and pitfalls from diagnosis through relapse.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301114/horizontal/small_b26407b9-38db-4bd6-8fc4-9e4b68cdbf7d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "large B-cell lymphoma", "DLBCL", "PMBCL", "EHA 2025", "EHA", "clinical practice guideline", "guideline", "HemaSphere 2025", "GRADE", "practice-changing recommendations", "clinical algorithms"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301114", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301115", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301115", "editorial": {"original_title": "EP01 — Which Pathology and Molecular Tests Confirm and Classify LBCL Before Treatment?", "public_title": "EP01 — Which Pathology and Molecular Tests Confirm and Classify LBCL Before Treatment?", "slug": "lbcl-diagnosis-classification-required-pathology-molecular-tests-ihc-flow-fish-myc-bcl2-bcl", "legacy_canonical_url": "https://5minutehematology.com/programs/lbcl-diagnosis-classification-required-pathology-molecular-tests-ihc-flow-fish-myc-bcl2-bcl", "description": "Episode 1 of the EHA 2025 LBCL guideline series. This episode reviews the pathology and molecular tests required to confirm and classify LBCL before treatment, including reference hematopathology review, essential IHC and flow cytometry, and a FISH strategy for MYC followed by BCL2/BCL6. It also explains the limitations of using IHC cell-of-origin classification alone to restrict therapy.", "scientific_summary": "EHA 2025 guidance on reference pathology, essential IHC and flow cytometry, and FISH for MYC, BCL2, and BCL6 in newly suspected LBCL.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301115/horizontal/small_0c4c9d33-5f0b-4d38-b3b5-c0d3ed38b467.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["EHA 2025", "LBCL", "DLBCL", "PMBCL", "large B-cell lymphoma", "clinical practice guideline", "guideline series", "diagnosis", "classification", "hematopathology", "reference pathology review", "immunohistochemistry", "IHC"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301115", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301116", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301116", "editorial": {"original_title": "EP02 — Baseline LBCL Work-up: PET-CT, IPI/CNS-IPI, and When to Add Marrow Biopsy or CNS MRI/CSF", "public_title": "EP02 — Baseline LBCL Work-up: PET-CT, IPI/CNS-IPI, and When to Add Marrow Biopsy or CNS MRI/CSF", "slug": "lbcl-baseline-work-up-pet-ct-ipi-cns-ipi-marrow-biopsy-cns-mri-csf-eha-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/lbcl-baseline-work-up-pet-ct-ipi-cns-ipi-marrow-biopsy-cns-mri-csf-eha-2025", "description": "Episode 2 of the EHA 2025 LBCL guideline series. This episode summarizes baseline staging and risk stratification with PET-CT, laboratory testing, IPI and CNS-IPI, and explains when bone marrow biopsy or baseline CNS assessment with MRI and CSF should be added.", "scientific_summary": "EHA 2025 LBCL guidance on PET-CT, IPI/CNS-IPI and labs, plus when to add marrow biopsy or baseline CNS MRI and CSF assessment.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301116/horizontal/small_ac812667-b8f7-46a2-a451-31f46bb376a6.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "PMBCL", "EHA 2025", "clinical practice guideline", "HemaSphere 2025", "baseline work-up", "baseline staging", "pretreatment staging", "PET-CT", "staging PET", "International Prognostic Index", "IPI"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301116", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301117", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "CALC_IPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "IPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301117", "editorial": {"original_title": "EP03 — Stage I/II LBCL: When to Give 4 vs 6 Cycles of R-CHOP and Omit Radiotherapy", "public_title": "EP03 — Stage I/II LBCL: When to Give 4 vs 6 Cycles of R-CHOP and Omit Radiotherapy", "slug": "stage-i-ii-lbcl-4-vs-6-cycles-r-chop-interim-pet-omit-radiotherapy", "legacy_canonical_url": "https://5minutehematology.com/programs/stage-i-ii-lbcl-4-vs-6-cycles-r-chop-interim-pet-omit-radiotherapy", "description": "Episode 3 of the EHA 2025 LBCL guideline series. This episode reviews treatment planning for stage I/II disease: selecting abbreviated versus six-cycle R-CHOP, using interim PET in appropriate PET-adapted strategies, defining bulky disease, and determining when consolidative radiotherapy can be omitted.", "scientific_summary": "EHA 2025 guidance for stage I/II LBCL: abbreviated versus six-cycle R-CHOP, interim PET, bulky disease and when radiotherapy may be omitted.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301117/horizontal/small_3fc7a977-3aa8-4e74-9c98-8c40b88ab00e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "early-stage LBCL", "stage I LBCL", "stage II LBCL", "localized DLBCL", "EHA guideline 2025", "EHA clinical practice guideline", "HemaSphere 2025", "frontline treatment", "first-line treatment", "R-CHOP", "abbreviated R-CHOP"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301117", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301118", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_LIMITED_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301118", "editorial": {"original_title": "EP04 — Stage III/IV LBCL: When to Use Pola-R-CHP vs R-CHOP and Add RT for Residual PET+ Disease?", "public_title": "EP04 — Stage III/IV LBCL: When to Use Pola-R-CHP vs R-CHOP and Add RT for Residual PET+ Disease?", "slug": "advanced-lbcl-pola-r-chp-vs-r-chop-residual-pet-positive-radiotherapy", "legacy_canonical_url": "https://5minutehematology.com/programs/advanced-lbcl-pola-r-chp-vs-r-chop-residual-pet-positive-radiotherapy", "description": "Episode 4 of the EHA 2025 LBCL guideline series. This episode summarizes frontline management of stage III/IV LBCL, including when Pola-R-CHP is preferred over R-CHOP according to IPI risk and when radiotherapy should be considered for single-site residual PET-positive disease after systemic therapy.", "scientific_summary": "EHA 2025 guidance for advanced LBCL: Pola-R-CHP versus R-CHOP by IPI risk and radiotherapy for single-site residual PET-positive disease.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301118/horizontal/small_4958a77d-ab4e-443b-82e6-ae1a95a31b92.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "large B-cell lymphoma", "advanced stage", "stage III/IV", "frontline", "first-line treatment", "EHA 2025", "clinical practice guideline", "guideline", "HemaSphere 2025", "Pola-R-CHP", "polatuzumab vedotin"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301118", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301119", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_POLARCHP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "Pola-R-CHP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_POLARCHP_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_POLARCHP", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_POLARCHP", "EDGE_POLARCHP_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved Pola-R-CHP resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/pola_r_chp.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301119", "editorial": {"original_title": "EP05 — LBCL PET Response Assessment: How to Manage Deauville 4-5 Uptake", "public_title": "EP05 — LBCL PET Response Assessment: How to Manage Deauville 4-5 Uptake", "slug": "lbcl-pet-response-assessment-deauville-4-5-biopsy-or-repeat-imaging", "legacy_canonical_url": "https://5minutehematology.com/programs/lbcl-pet-response-assessment-deauville-4-5-biopsy-or-repeat-imaging", "description": "Episode 5 of the EHA 2025 LBCL guideline series. This episode reviews interim and end-of-treatment PET-CT response assessment using Lugano and Deauville criteria, including when residual Deauville 4-5 uptake should prompt biopsy or repeat PET rather than immediate treatment escalation.", "scientific_summary": "EHA 2025 guidance on interim and end-of-treatment PET using Lugano/Deauville and when DS4-5 warrants biopsy or repeat imaging.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301119/horizontal/small_03ea8df5-9468-4a10-b528-e3327f7da2b3.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "PMBCL", "EHA 2025", "HemaSphere 2025", "clinical practice guideline", "guideline", "PET response assessment", "PET-CT", "end-of-treatment PET", "EOT PET", "interim PET", "iPET2"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301119", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301120", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301120", "editorial": {"original_title": "EP06 — How Should First-Line Therapy Be Adapted for PMBCL, Double-Hit, Testicular, and Intravascular LBCL?", "public_title": "EP06 — How Should First-Line Therapy Be Adapted for PMBCL, Double-Hit, Testicular, and Intravascular LBCL?", "slug": "lbcl-special-entities-first-line-pmbcl-double-hit-testicular-intravascular-eha-2025", "legacy_canonical_url": "https://5minutehematology.com/programs/lbcl-special-entities-first-line-pmbcl-double-hit-testicular-intravascular-eha-2025", "description": "Episode 6 of the EHA 2025 LBCL guideline series. This episode covers subtype-specific frontline management for PMBCL, high-grade double- or triple-hit LBCL, primary testicular LBCL and intravascular LBCL, including regimen selection, PET-guided radiotherapy decisions and CNS considerations.", "scientific_summary": "EHA 2025 guidance for PMBCL, double/triple-hit, primary testicular and intravascular LBCL, including PET-guided RT and CNS issues.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301120/horizontal/small_464c9eab-9ad6-4ebf-82b6-f0d4e835f82f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL guideline", "EHA 2025 clinical practice guideline", "HemaSphere 2025", "large B-cell lymphoma", "DLBCL", "PMBCL", "primary mediastinal B-cell lymphoma", "double-hit lymphoma", "triple-hit lymphoma", "high-grade B-cell lymphoma", "primary testicular lymphoma", "testicular LBCL", "intravascular large B-cell lymphoma"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301120", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301122", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_HIGH_GRADE_DOUBLE_HIT"}, {"target_id": "DIS_PMBCL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "primary mediastinal B-cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_HIGH_GRADE_DOUBLE_HIT", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301122", "editorial": {"original_title": "EP07 — Which LBCL Patients Need Baseline CNS Evaluation and When Should CNS Prophylaxis Be Used?", "public_title": "EP07 — Which LBCL Patients Need Baseline CNS Evaluation and When Should CNS Prophylaxis Be Used?", "slug": "lbcl-cns-risk-baseline-evaluation-and-prophylaxis-it-mtx-vs-hd-mtx", "legacy_canonical_url": "https://5minutehematology.com/programs/lbcl-cns-risk-baseline-evaluation-and-prophylaxis-it-mtx-vs-hd-mtx", "description": "Episode 7 of the EHA 2025 LBCL guideline series. This episode reviews which patients need baseline CNS evaluation with MRI and CSF, how CNS-IPI and high-risk extranodal sites inform risk, and the uncertain efficacy and toxicity of CNS prophylaxis with intrathecal methotrexate versus high-dose methotrexate.", "scientific_summary": "EHA 2025 guidance on LBCL CNS risk, baseline MRI/CSF screening and the uncertain role of prophylaxis with IT MTX versus HD-MTX.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:51:00.782Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301122/horizontal/small_9b9293de-318e-4c0b-bc9b-ba6a9970334e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "large B-cell lymphoma", "EHA 2025", "EHA guideline", "clinical practice guideline", "HemaSphere 2025", "CNS risk", "CNS relapse", "CNS-IPI", "extranodal disease", "immune-privileged sites", "testicular lymphoma"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301122", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4301132", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4301112"}], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "CALC_CNS_IPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "CNS-IPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4301132", "editorial": {"original_title": "EP08 — Relapsed/Refractory LBCL: When to Biopsy and Choose 2L CAR-T vs Later Bispecifics", "public_title": "EP08 — Relapsed/Refractory LBCL: When to Biopsy and Choose 2L CAR-T vs Later Bispecifics", "slug": "relapsed-refractory-lbcl-biopsy-cd19-cd20-second-line-car-t-later-bispecifics", "legacy_canonical_url": "https://5minutehematology.com/programs/relapsed-refractory-lbcl-biopsy-cd19-cd20-second-line-car-t-later-bispecifics", "description": "Episode 8 of the EHA 2025 LBCL guideline series. This episode covers mandatory biopsy confirmation at relapse with CD19/CD20 assessment and treatment sequencing according to relapse timing and fitness, including second-line CAR-T for primary refractory or early-relapsed disease and bispecific antibodies in later lines.", "scientific_summary": "EHA 2025 guidance on relapse biopsy with CD19/CD20 testing, second-line CAR-T for early relapse and bispecific antibodies in later lines.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4301132/horizontal/small_0f9d6b64-fba9-4c56-9956-6e5412cba270.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["LBCL", "DLBCL", "PMBCL", "EHA 2025", "clinical practice guideline", "HemaSphere 2025", "relapsed/refractory LBCL", "R/R DLBCL", "relapse biopsy", "biopsy confirmation", "CD19", "CD20", "early relapse"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "episode_number": 8, "editorial_position": 9, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4301132", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1002/hem3.70207", "provenance": "Collection 4301112; episode applicability requires physician review"}, {"reference_id": "PMID_40995463", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "40995463", "provenance": "Collection 4301112; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311339", "editorial": {"original_title": "EP01 — Suspected Hodgkin Lymphoma: Biopsy, PET/CT, Staging and Marrow Evaluation", "public_title": "EP01 — Suspected Hodgkin Lymphoma: Biopsy, PET/CT, Staging and Marrow Evaluation", "slug": "suspected-hodgkin-lymphoma-biopsy-petct-staging-marrow", "legacy_canonical_url": "https://5minutehematology.com/programs/suspected-hodgkin-lymphoma-biopsy-petct-staging-marrow", "description": "Episode 1 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode covers preferred biopsy strategy, why fine-needle aspiration is insufficient, baseline PET/CT staging, required pretreatment assessment and when bone marrow biopsy can be omitted.", "scientific_summary": "EHA 2026 guidance on biopsy choice, baseline PET/CT and work-up, and when bone marrow biopsy can be omitted.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311339/horizontal/small_7efc71e8-e2ed-4ee9-9740-cc6395a41c4f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "clinical practice guideline", "diagnosis", "staging", "excisional biopsy", "core needle biopsy", "PET/CT", "bone marrow biopsy", "baseline work-up", "fertility counseling"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311339", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311340", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "cHL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311340", "editorial": {"original_title": "EP02 — Early-Stage Favorable cHL: 2×ABVD + 20 Gy IS-RT vs RT Omission", "public_title": "EP02 — Early-Stage Favorable cHL: 2×ABVD + 20 Gy IS-RT vs RT Omission", "slug": "early-stage-favorable-chl-abvd-20-gy-isrt-rt-omission", "legacy_canonical_url": "https://5minutehematology.com/programs/early-stage-favorable-chl-abvd-20-gy-isrt-rt-omission", "description": "Episode 2 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode reviews standard combined-modality therapy for early-stage favorable classic Hodgkin lymphoma with two cycles of ABVD plus 20 Gy involved-site radiotherapy, and the circumstances in which radiotherapy omission may be discussed.", "scientific_summary": "EHA 2026 guidance on standard 2×ABVD plus 20 Gy IS-RT and when radiotherapy omission may be discussed.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:48:50.739Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311340/horizontal/small_e8be4a92-27a3-4237-affe-efd1a3c7f8bf.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "early-stage favorable", "stage I", "stage II", "ABVD", "involved-site radiotherapy", "IS-RT", "20 Gy", "PET-negative", "combined modality therapy"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311340", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311341", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT"}], "evidence_relations": [{"target_id": "EV_PMID_25901426", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_37967311", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_HL_ABVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ABVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_HL_ABVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT", "via_therapy_id": "TX_HL_ABVD", "graph_edge_ids": ["EDGE_HL_EARLY_HAS_OPTION_HL_ABVD", "EDGE_HL_ABVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md", "note": "Physician-reviewed link to the approved ABVD resource; HAS_OPTION does not by itself encode preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/abvd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311341", "editorial": {"original_title": "EP03 — Early-Stage Unfavorable cHL: 2+2 vs 4×ABVD and PET-Guided IS-RT", "public_title": "EP03 — Early-Stage Unfavorable cHL: 2+2 vs 4×ABVD and PET-Guided IS-RT", "slug": "early-stage-unfavorable-chl-2plus2-4xabvd-pet-guided-isrt", "legacy_canonical_url": "https://5minutehematology.com/programs/early-stage-unfavorable-chl-2plus2-4xabvd-pet-guided-isrt", "description": "Episode 3 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode compares 2+2 escalated therapy with four cycles of ABVD for early-stage unfavorable classic Hodgkin lymphoma and explains how end-of-treatment PET guides the use of 30 Gy involved-site radiotherapy.", "scientific_summary": "EHA 2026 guidance on 2+2 escalated therapy versus 4×ABVD and end-of-treatment PET-guided 30 Gy IS-RT.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311341/horizontal/small_601c1c6d-3110-4fb7-8b3a-1b94b3a000ed.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "early-stage unfavorable", "stage I", "stage II", "2+2", "eBEACOPP", "eBEACOPDac", "ABVD", "end-of-treatment PET", "30 Gy IS-RT"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311341", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311343", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT"}], "evidence_relations": [{"target_id": "EV_PMID_29061295", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_33539742", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_38971175", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_40652943", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_HL_EBEACOPP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "eBEACOPP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_HL_ABVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ABVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_HL_ABVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT", "via_therapy_id": "TX_HL_ABVD", "graph_edge_ids": ["EDGE_HL_EARLY_HAS_OPTION_HL_ABVD", "EDGE_HL_ABVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md", "note": "Physician-reviewed link to the approved ABVD resource; HAS_OPTION does not by itself encode preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/abvd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311343", "editorial": {"original_title": "EP04 — Advanced cHL Age ≤60: BrECADD vs N-AVD and PET-Adapted Therapy", "public_title": "EP04 — Advanced cHL Age ≤60: BrECADD vs N-AVD and PET-Adapted Therapy", "slug": "advanced-chl-under-60-brecadd-n-avd-interim-pet", "legacy_canonical_url": "https://5minutehematology.com/programs/advanced-chl-under-60-brecadd-n-avd-interim-pet", "description": "Episode 4 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode reviews frontline treatment of advanced classic Hodgkin lymphoma in patients aged 60 or younger, comparing BrECADD with N-AVD and explaining PET-adapted decisions on four versus six cycles and selective 30 Gy involved-site radiotherapy.", "scientific_summary": "EHA 2026 guidance on BrECADD versus N-AVD, interim PET, treatment duration and selective radiotherapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311343/horizontal/small_d0e9d2ba-8952-4e03-a31e-1f6d34853c99.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "advanced stage", "stage III", "stage IV", "BrECADD", "N-AVD", "nivolumab", "interim PET", "PET-adapted therapy", "30 Gy IS-RT"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311343", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311344", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_38971175", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_39413375", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}, {"target_id": "EV_PMID_40652943", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_HL_BRECADD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BrECADD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_HL_NIVOAVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "N-AVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_NIVOLUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "nivolumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_HL_BRECADD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_BRECADD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_BRECADD", "EDGE_HL_BRECADD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/brecadd.json"}]}, {"target_id": "PROT_HL_ABVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_ABVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_HL_ABVD", "EDGE_HL_ABVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md", "note": "Physician-reviewed link to the approved ABVD resource; HAS_OPTION does not by itself encode preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/abvd.json"}]}, {"target_id": "PROT_HL_NIVOAVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_NIVOAVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_NIVOAVD", "EDGE_HL_NIVOAVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/nivo_avd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311344", "editorial": {"original_title": "EP05 — Advanced cHL Over Age 60: Fit vs Unfit Frontline Pathways", "public_title": "EP05 — Advanced cHL Over Age 60: Fit vs Unfit Frontline Pathways", "slug": "advanced-chl-over-60-fit-unfit-frontline-regimens", "legacy_canonical_url": "https://5minutehematology.com/programs/advanced-chl-over-60-fit-unfit-frontline-regimens", "description": "Episode 5 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode reviews fit and unfit frontline pathways for advanced classic Hodgkin lymphoma in patients over age 60, including N-AVD, limits on bleomycin exposure, and lower-intensity brentuximab vedotin or PD-1 inhibitor approaches.", "scientific_summary": "EHA 2026 guidance for older adults with advanced cHL, including fit and unfit treatment pathways.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311344/horizontal/small_e4acb7ca-1b16-4b04-af20-8b8dea5beb80.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "advanced stage", "older adults", "over 60", "fitness assessment", "N-AVD", "ABVD", "AVD", "bleomycin toxicity", "brentuximab vedotin", "PD-1 inhibitor"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311344", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311345", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE"}], "evidence_relations": [{"target_id": "EV_PMID_35830649", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_HL_NIVOAVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "N-AVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_HL_ABVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ABVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_HL_BRECADD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_BRECADD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_BRECADD", "EDGE_HL_BRECADD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/brecadd.json"}]}, {"target_id": "PROT_HL_ABVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_ABVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_HL_ABVD", "EDGE_HL_ABVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md", "note": "Physician-reviewed link to the approved ABVD resource; HAS_OPTION does not by itself encode preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/abvd.json"}]}, {"target_id": "PROT_HL_NIVOAVD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE", "via_therapy_id": "TX_HL_NIVOAVD", "graph_edge_ids": ["EDGE_HL_ADVANCED_HAS_OPTION_NIVOAVD", "EDGE_HL_NIVOAVD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_HODGKIN_V1.md"}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/hodgkin/nivo_avd.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311345", "editorial": {"original_title": "EP06 — R/R cHL: Salvage Therapy, PET CMR and ASCT", "public_title": "EP06 — R/R cHL: Salvage Therapy, PET CMR and ASCT", "slug": "rr-chl-salvage-pet-cmr-asct-isrt-eha-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/rr-chl-salvage-pet-cmr-asct-isrt-eha-2026", "description": "Episode 6 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode covers biopsy confirmation and salvage treatment for transplant-eligible relapsed/refractory classic Hodgkin lymphoma, with the goal of PET complete metabolic response before high-dose therapy and ASCT, plus individualized peri-transplant involved-site radiotherapy.", "scientific_summary": "EHA 2026 guidance on salvage strategy, achieving PET complete metabolic response before ASCT and peri-transplant IS-RT.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311345/horizontal/small_203987f7-c5f2-45dd-b075-fbba54c76d6e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "relapsed/refractory", "salvage therapy", "PD-1 inhibitor", "brentuximab vedotin", "PET CMR", "Deauville score", "ASCT", "BEAM", "peri-transplant radiotherapy"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311345", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311346", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "cHL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_HSCT_BEAM", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BEAM", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311346", "editorial": {"original_title": "EP07 — Post-ASCT cHL: BV Maintenance, Relapse and alloSCT", "public_title": "EP07 — Post-ASCT cHL: BV Maintenance, Relapse and alloSCT", "slug": "post-asct-chl-bv-maintenance-relapse-allosct-eha-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/post-asct-chl-bv-maintenance-relapse-allosct-eha-2026", "description": "Episode 7 of the 5MinuteHematology EHA 2026 Hodgkin lymphoma guideline series. This episode reviews selection for brentuximab vedotin maintenance after ASCT and the management of post-ASCT relapse, including donor search, timing of allogeneic transplantation and PD-1 inhibitor washout before alloSCT.", "scientific_summary": "EHA 2026 guidance on BV maintenance after ASCT and management of relapse, including alloSCT and PD-1 washout.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311346/horizontal/small_ee6335bd-c1fa-4770-9bf7-d7b77797e784.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "cHL", "EHA 2026", "post-ASCT", "brentuximab vedotin", "BV maintenance", "AETHERA", "high risk", "relapse after ASCT", "alloSCT", "donor search", "PD-1 washout", "GVHD"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311346", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_HODGKIN_LYMPHOMA_RELAPSED_TRANSPLANT"}], "evidence_relations": [{"target_id": "EV_PMID_25796459", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_HODGKIN_LYMPHOMA_RELAPSED_TRANSPLANT", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4311347", "editorial": {"original_title": "EP00 — EHA 2026 Hodgkin Lymphoma: What Changed and How to Use the Guideline", "public_title": "EP00 — EHA 2026 Hodgkin Lymphoma: What Changed and How to Use the Guideline", "slug": "hodgkin-lymphoma-eha-2026-what-changed-how-to-use", "legacy_canonical_url": "https://5minutehematology.com/programs/hodgkin-lymphoma-eha-2026-what-changed-how-to-use", "description": "Part of the 5MinuteHematology guideline series summarizing the EHA Clinical Practice Guidelines for Hodgkin lymphoma (HemaSphere, 2026). This episode highlights the principal practice-changing decisions across frontline classic Hodgkin lymphoma, relapsed/refractory disease, ASCT and alloSCT pathways, radiotherapy, follow-up and survivorship.", "scientific_summary": "A practical roadmap to the EHA 2026 Hodgkin lymphoma guideline across frontline therapy, relapse, transplant and follow-up.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4311347/horizontal/small_1cfabf64-a9a8-46c6-a51f-6cfe61660ca8.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "classic Hodgkin lymphoma", "cHL", "EHA 2026", "clinical practice guideline", "HemaSphere 2026", "frontline therapy", "relapsed/refractory", "ASCT", "alloSCT", "radiotherapy", "survivorship"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4311347", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4311339", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4311360"}], "science": {"citations": [{"reference_id": "PMID_42345030", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up", "provenance": "Collection 4311360; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "cHL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330590", "editorial": {"original_title": "How effective and safe is crovalimab for paroxysmal nocturnal hemoglobinuria?", "public_title": "How effective and safe is crovalimab for paroxysmal nocturnal hemoglobinuria?", "slug": "crovalimab-pnh-efficacy-safety-systematic-review-meta-analysis", "legacy_canonical_url": "https://5minutehematology.com/programs/video-46a9d5", "description": "", "scientific_summary": "Systematic review and random-effects meta-analysis of 4 studies (275 patients) evaluating crovalimab efficacy and safety in PNH", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective and safe is crovalimab for paroxysmal nocturnal hemoglobinuria?", "language": null, "original_publication_date": "2026-08-31T16:58:03.249Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330590/horizontal/small_66b0c9a4-4f34-412f-af21-b7e6b31ac395.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["crovalimab", "paroxysmal nocturnal hemoglobinuria", "PNH", "anti-C5", "complement inhibition", "hemolysis control", "breakthrough hemolysis", "transfusion avoidance"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330590", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42037756", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330622", "editorial": {"original_title": "How effective and safe is fostamatinib for ITP in real-world practice?", "public_title": "How effective and safe is fostamatinib for ITP in real-world practice?", "slug": "fostamatinib-effectiveness-safety-immune-thrombocytopenia-clinical-practice", "legacy_canonical_url": "https://5minutehematology.com/programs/video-6e63e3", "description": "", "scientific_summary": "Physician-focused summary of a real-world clinical practice study evaluating fostamatinib effectiveness and safety for immune thrombocytopen", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective and safe is fostamatinib for ITP in real-world practice?", "language": null, "original_publication_date": "2026-08-31T17:03:34.355Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330622/horizontal/small_8a66ee1e-642b-4fd5-82ca-509334099142.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["fostamatinib", "immune thrombocytopenia", "ITP", "effectiveness", "real-world evidence"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330622", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38843478", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ITP", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "immune thrombocytopenia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330980", "editorial": {"original_title": "Does fostamatinib improve platelet response in persistent or chronic ITP?", "public_title": "Does fostamatinib improve platelet response in persistent or chronic ITP?", "slug": "fostamatinib-adult-persistent-chronic-itp-phase-3-trials", "legacy_canonical_url": "https://5minutehematology.com/programs/video-457e82", "description": "", "scientific_summary": "Review of FIT1 and FIT2: two phase 3 multicenter randomized double-blind placebo-controlled trials of fostamatinib for adult persistent/chro", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does fostamatinib improve platelet response in persistent or chronic ITP?", "language": null, "original_publication_date": "2026-08-31T21:30:56.549Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330980/horizontal/small_3873c842-a9d3-43b7-a28f-25f7e9adb668.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": [], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330980", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_29696684", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330982", "editorial": {"original_title": "Does long-term fostamatinib provide durable platelet responses in chronic immune thrombocytopenia?", "public_title": "Does long-term fostamatinib provide durable platelet responses in chronic immune thrombocytopenia?", "slug": "long-term-fostamatinib-treatment-adults-immune-thrombocytopenia-phase-3-clinical", "legacy_canonical_url": "https://5minutehematology.com/programs/video-7552fe", "description": "", "scientific_summary": "Review of the phase 3 randomized, double-blind, placebo-controlled trials and follow-on open-label extension evaluating long-term fostamatin", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does long-term fostamatinib provide durable platelet responses in chronic immune thrombocytopenia?", "language": null, "original_publication_date": "2026-08-31T21:35:05.960Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330982/horizontal/small_3755e95a-f5e3-4137-8771-2309759bcc31.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["immune thrombocytopenia", "ITP", "fostamatinib", "SYK inhibitor", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330982", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30784097", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ITP", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "immune thrombocytopenia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330991", "editorial": {"original_title": "How should suboptimal response to C5 inhibitors be managed in PNH?", "public_title": "How should suboptimal response to C5 inhibitors be managed in PNH?", "slug": "optimizing-care-pnh-managing-suboptimal-response-uncontrolled-disease", "legacy_canonical_url": "https://5minutehematology.com/programs/video-416722", "description": "Physician-focused review discussing management of suboptimal response and uncontrolled disease in PNH on terminal complement inhibition, based on a narrative review (Journal of Blood Medicine, 2026).", "scientific_summary": "Physician-focused review discussing management of suboptimal response and uncontrolled disease in PNH on terminal complement inhibition, bas", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Commentary", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should suboptimal response to C5 inhibitors be managed in PNH?", "language": null, "original_publication_date": "2026-08-31T21:39:35.110Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330991/horizontal/small_5f4d1cca-f6d1-469c-8c41-b635040d683d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["paroxysmal nocturnal hemoglobinuria", "C5 inhibitors", "terminal complement inhibition", "proximal complement inhibitors", "breakthrough hemolysis", "PNH"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330991", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41809517", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4330996", "editorial": {"original_title": "Can oral iptacopan monotherapy improve hemoglobin and control hemolysis through 48 weeks in PNH?", "public_title": "Can oral iptacopan monotherapy improve hemoglobin and control hemolysis through 48 weeks in PNH?", "slug": "oral-iptacopan-monotherapy-pnh-final-48-week-phase-3-apply-pnh-appoint-pnh", "legacy_canonical_url": "https://5minutehematology.com/programs/video-ebfbf0", "description": "Final 48-week results from the open-label, randomized phase 3 APPLY-PNH trial and open-label, single-arm phase 3 APPOINT-PNH trial of oral iptacopan in PNH (The Lancet Haematology, 2025).", "scientific_summary": "Final 48-week results from the open-label, randomized phase 3 APPLY-PNH trial and open-label, single-arm phase 3 APPOINT-PNH trial of oral i", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can oral iptacopan monotherapy improve hemoglobin and control hemolysis through 48 weeks in PNH?", "language": null, "original_publication_date": "2026-08-31T21:44:54.019Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4330996/horizontal/small_60afa09f-4d50-426c-a5b3-cdbfc5de9fda.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["iptacopan", "paroxysmal nocturnal haemoglobinuria", "PNH", "factor B inhibitor", "complement inhibition", "anti-C5", "eculizumab", "ravulizumab"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4330996", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331001", "editorial": {"original_title": "Can fostamatinib be safely tapered and discontinued in chronic immune thrombocytopenia?", "public_title": "Can fostamatinib be safely tapered and discontinued in chronic immune thrombocytopenia?", "slug": "fostamatinib-tapering-discontinuation-immune-thrombocytopenia-platelet-response", "legacy_canonical_url": "https://5minutehematology.com/programs/video-97b5fd", "description": "Retrospective multicenter cohort study (Journal of Clinical Medicine, 2024) evaluating platelet responses and relapse after progressive fostamatinib tapering and discontinuation in adult ITP.", "scientific_summary": "Retrospective multicenter cohort study (Journal of Clinical Medicine, 2024) evaluating platelet responses and relapse after progressive fost", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can fostamatinib be safely tapered and discontinued in chronic immune thrombocytopenia?", "language": null, "original_publication_date": "2026-08-31T21:48:13.699Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331001/horizontal/small_73eea5be-a7ba-45e1-afde-34166c616637.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["immune thrombocytopenia", "fostamatinib", "ITP", "SYK inhibitor", "tapering", "discontinuation", "sustained remission", "predictive factors"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331001", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ITP", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "immune thrombocytopenia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331008", "editorial": {"original_title": "Should a hospitalwide tranexamic acid policy reduce red cell transfusion without increasing VTE after major noncardiac sugery?", "public_title": "Should a hospitalwide tranexamic acid policy reduce red cell transfusion without increasing VTE after major noncardiac sugery?", "slug": "hospital-policy-tranexamic-acid-reduce-transfusion-major-noncardiac-surgery", "legacy_canonical_url": "https://5minutehematology.com/programs/video-c90a19", "description": "Multicenter double-blind cluster-randomized placebo-controlled crossover trial (NEJM, 2026) testing a hospitalwide intraoperative tranexamic acid policy in high-risk major noncardiac surgery.", "scientific_summary": "Multicenter double-blind cluster-randomized placebo-controlled crossover trial (NEJM, 2026) testing a hospitalwide intraoperative tranexamic", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Non-Malignant Hematology"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should a hospitalwide tranexamic acid policy reduce red cell transfusion without increasing VTE after major noncardiac sugery?", "language": null, "original_publication_date": "2026-08-31T21:53:43.558Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331008/horizontal/small_8e8275ff-f94f-4b98-b91c-531aab65cfa7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["tranexamic acid", "TXA", "major noncardiac surgery", "red cell transfusion", "perioperative bleeding", "venous thromboembolism", "hospital policy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331008", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42267805", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331012", "editorial": {"original_title": "Does switching from eculizumab to ravulizumab maintain hemolysis control in real-world PNH?", "public_title": "Does switching from eculizumab to ravulizumab maintain hemolysis control in real-world PNH?", "slug": "ravulizumab-italian-pnh-reaction-observational-study", "legacy_canonical_url": "https://5minutehematology.com/programs/video-846e0c", "description": "", "scientific_summary": "In the REACTION observational cohort study (Annals of Hematology, 2026), Italian PNH patients previously treated with eculizumab received ra", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does switching from eculizumab to ravulizumab maintain hemolysis control in real-world PNH?", "language": null, "original_publication_date": "2026-08-31T22:00:10.324Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331012/horizontal/small_bf7cfdc3-e3cc-4024-823a-62b259d5b9d0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["paroxysmal nocturnal hemoglobinuria", "PNH", "ravulizumab", "C5 inhibitor", "eculizumab", "terminal complement inhibition", "real-world evidence"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331012", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41566054", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331018", "editorial": {"original_title": "How effective and safe is ravulizumab for PNH in real-world practice?", "public_title": "How effective and safe is ravulizumab for PNH in real-world practice?", "slug": "real-world-effectiveness-safety-ravulizumab-paroxysmal-nocturnal-hemoglobinuria", "legacy_canonical_url": "https://5minutehematology.com/programs/video-5a7cc1", "description": "Registry-based observational analysis from the International PNH Registry (NCT01374360), reported in American Journal of Hematology (2026), evaluating ravulizumab effectiveness and safety over up to 24 months.", "scientific_summary": "Registry-based observational analysis from the International PNH Registry (NCT01374360), reported in American Journal of Hematology (2026),", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective and safe is ravulizumab for PNH in real-world practice?", "language": null, "original_publication_date": "2026-08-31T22:03:14.667Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331018/horizontal/small_6b2ed146-d142-4b0f-9054-d5d74f1e8ba5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ravulizumab", "paroxysmal nocturnal hemoglobinuria", "C5 inhibitor", "complement inhibition", "International PNH Registry", "real-world evidence"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331018", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41795103", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": ["NCT01374360"], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331029", "editorial": {"original_title": "Can switching from anti-C5 to iptacopan monotherapy raise hemoglobin in PNH with Hb >=10 g/dL?", "public_title": "Can switching from anti-C5 to iptacopan monotherapy raise hemoglobin in PNH with Hb >=10 g/dL?", "slug": "iptacopan-monotherapy-increased-hemoglobin-pnh-after-anti-c5-therapy", "legacy_canonical_url": "https://5minutehematology.com/programs/video-a056fc", "description": "Phase 3b single-arm open-label APPULSE-PNH trial (Hemasphere, 2026) evaluating switch from stable anti-C5 to oral iptacopan monotherapy for 24 weeks in adult PNH with Hb >=10 g/dL.", "scientific_summary": "Phase 3b single-arm open-label APPULSE-PNH trial (Hemasphere, 2026) evaluating switch from stable anti-C5 to oral iptacopan monotherapy for", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can switching from anti-C5 to iptacopan monotherapy raise hemoglobin in PNH with Hb >=10 g/dL?", "language": null, "original_publication_date": "2026-08-31T22:08:09.086Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331029/horizontal/small_ee313e6b-152b-4000-b303-760cf0a524a7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["PNH", "iptacopan", "factor B inhibitor", "proximal complement inhibition", "anti-C5 therapy", "eculizumab", "ravulizumab", "extravascular hemolysis"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331029", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42255947", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin >=10 g/dL after anti-C5 therapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331033", "editorial": {"original_title": "How should complement inhibitor switching be managed in PNH to minimize hemolysis risk?", "public_title": "How should complement inhibitor switching be managed in PNH to minimize hemolysis risk?", "slug": "pnh-complement-inhibitor-switching-strategy-efficacy-safety", "legacy_canonical_url": "https://5minutehematology.com/programs/video-cb28f2", "description": "International retrospective cohort analysis (Hemasphere, 2026) evaluating strategy, efficacy, and safety of switching between complement inhibitors in PNH, including hemolysis events within 14 days of changes.", "scientific_summary": "International retrospective cohort analysis (Hemasphere, 2026) evaluating strategy, efficacy, and safety of switching between complement inh", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Non-Malignant Hematology", "Original Studies"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Non-Malignant Hematology"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should complement inhibitor switching be managed in PNH to minimize hemolysis risk?", "language": null, "original_publication_date": "2026-08-31T22:11:42.270Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331033/horizontal/small_91df480b-9852-4717-9d49-3f99075fa1dc.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["paroxysmal nocturnal hemoglobinuria", "complement inhibitors", "PNH", "pegcetacoplan", "iptacopan", "danicopan", "treatment switching", "breakthrough hemolysis", "extravascular hemolysis", "overlap therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331033", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42453533", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: analysis of strategy, efficacy, and safety", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331044", "editorial": {"original_title": "Does high-dose methotrexate prevent CNS relapse in ultra high-risk large B-cell lymphoma?", "public_title": "Does high-dose methotrexate prevent CNS relapse in ultra high-risk large B-cell lymphoma?", "slug": "high-dose-methotrexate-cns-prophylaxis-ultra-high-risk-large-b-cell-lymphoma-int", "legacy_canonical_url": "https://5minutehematology.com/programs/video-11d88c", "description": "International multicenter retrospective cohort analysis (Journal of Clinical Oncology, 2026) comparing CNS relapse rates in ultra high-risk LBCL treated with vs without HD-MTX prophylaxis.", "scientific_summary": "International multicenter retrospective cohort analysis (Journal of Clinical Oncology, 2026) comparing CNS relapse rates in ultra high-risk", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Lymphoid Neoplasms"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does high-dose methotrexate prevent CNS relapse in ultra high-risk large B-cell lymphoma?", "language": null, "original_publication_date": "2026-08-31T22:17:34.142Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331044/horizontal/small_f3e9a038-4674-4963-a92f-557e1e38aa14.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["large b-cell lymphoma", "CNS prophylaxis", "HD-MTX", "CNS-IPI", "CNS relapse", "testicular lymphoma", "extranodal disease", "breast involvement", "DLBCL"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331044", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42274647", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "CALC_CNS_IPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "CNS-IPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331175", "editorial": {"original_title": "How should bispecific T-cell engagers be sequenced with BCMA CAR-T in relapsed/refractory multiple myeloma?", "public_title": "How should bispecific T-cell engagers be sequenced with BCMA CAR-T in relapsed/refractory multiple myeloma?", "slug": "bispecific-antibodies-t-cell-engagers-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-68cf85", "description": "Physician-focused narrative review of bispecific antibodies and T-cell engagers in RRMM, covering mechanisms, efficacy, sequencing with CAR-T, toxicity, and resistance (European Journal of Haematology, 2026).", "scientific_summary": "Physician-focused narrative review of bispecific antibodies and T-cell engagers in RRMM, covering mechanisms, efficacy, sequencing with CAR-", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Free Hematology Videos", "Plasma Cell & Myeloma"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should bispecific T-cell engagers be sequenced with BCMA CAR-T in relapsed/refractory multiple myeloma?", "language": null, "original_publication_date": "2026-09-01T00:31:41.477Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331175/horizontal/small_85f655f5-82a1-43ca-a0b0-2cc81b29afec.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "bispecific antibodies", "T-cell engagers", "BCMA", "CAR-T", "T-cell exhaustion"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331175", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42639825", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331177", "editorial": {"original_title": "How should infection risk be prevented in adults receiving bispecific antibodies for B-cell malignancies?", "public_title": "How should infection risk be prevented in adults receiving bispecific antibodies for B-cell malignancies?", "slug": "prevent-infections-bispecific-antibodies-b-cell-malignancies", "legacy_canonical_url": "https://5minutehematology.com/programs/video-1b9c0e", "description": "Practice-focused How I Treat narrative review and case-based framework (Blood, 2026) on preventing and managing infections during and after bispecific antibody therapy in NHL and multiple myeloma.", "scientific_summary": "Practice-focused How I Treat narrative review and case-based framework (Blood, 2026) on preventing and managing infections during and after", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Supportive Care & Complications"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Supportive Care & Complications"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should infection risk be prevented in adults receiving bispecific antibodies for B-cell malignancies?", "language": null, "original_publication_date": "2026-09-01T00:35:15.770Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331177/horizontal/small_b7627144-126f-439d-93c2-56da3079bbf6.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["bispecific antibodies", "T-cell engagers", "infection prevention", "non-Hodgkin lymphoma", "hypogammaglobulinemia", "multiple myeloma", "B-cell aplasia", "immunoglobulin replacement", "vaccination", "infectious disease screening"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331177", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42118692", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_TECDARA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "via_therapy_id": "TX_MM_TECDARA", "graph_edge_ids": ["EDGE_MM_TECDARA_HAS_OPTION", "EDGE_MM_TECDARA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Teclistamab + Daratumumab resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/targeted/teclistamab_daratumumab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4331178", "editorial": {"original_title": "Can bispecific antibodies move from relapsed disease to frontline therapy in B-cell malignancies and multiple myeloma?", "public_title": "Can bispecific antibodies move from relapsed disease to frontline therapy in B-cell malignancies and multiple myeloma?", "slug": "bispecific-antibodies-hematologic-malignancies-attacking-frontline", "legacy_canonical_url": "https://5minutehematology.com/programs/video-a1f030", "description": "Physician-focused narrative review summarizing FDA-approved bispecific antibodies and emerging frontline combinations in lymphoid malignancies and multiple myeloma (BioDrugs, 2025).", "scientific_summary": "Physician-focused narrative review summarizing FDA-approved bispecific antibodies and emerging frontline combinations in lymphoid malignanci", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy", "Lymphoid Neoplasms", "Plasma Cell & Myeloma"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Lymphoid Neoplasms", "Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can bispecific antibodies move from relapsed disease to frontline therapy in B-cell malignancies and multiple myeloma?", "language": null, "original_publication_date": "2026-09-01T00:39:59.771Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4331178/horizontal/small_0bb0da99-dab7-470f-a4dd-330a136a4aa0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["bispecific antibodies", "blinatumomab", "epcoritamab", "glofitamab", "teclistamab", "mosunetuzumab", "talquetamab", "elranatamab", "B-cell lymphoma", "B-ALL", "multiple myeloma"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4331178", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40751114", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_B_ALL_LBL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "B-ALL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_EPCORITAMAB_FL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "epcoritamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_EPCORITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "epcoritamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_GLOFITAMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_GLOFITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "glofitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_MOSUNETUZUMAB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "mosunetuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_MOSUNETUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "mosunetuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_TALQUE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TALQUETAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_ELRA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ELRANATAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "elranatamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4332546", "editorial": {"original_title": "How should CD19 CAR-T be selected and sequenced for relapsed or refractory large B-cell lymphoma?", "public_title": "How should CD19 CAR-T be selected and sequenced for relapsed or refractory large B-cell lymphoma?", "slug": "cd19-car-t-large-b-cell-lymphoma-evidence-resistance-toxicity-precision-strategi", "legacy_canonical_url": "https://5minutehematology.com/programs/video-55692b", "description": "Narrative review in Frontiers in Immunology (2026) summarizing pivotal trials and real-world data for CD19 CAR-T in LBCL, with resistance, toxicity, and precision strategies.", "scientific_summary": "Narrative review in Frontiers in Immunology (2026) summarizing pivotal trials and real-world data for CD19 CAR-T in LBCL, with resistance, t", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should CD19 CAR-T be selected and sequenced for relapsed or refractory large B-cell lymphoma?", "language": null, "original_publication_date": "2026-09-02T00:43:54.826Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4332546/horizontal/small_779c2e63-292f-41a2-a232-1c006806086f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CD19 CAR-T", "large B-cell lymphoma", "relapsed refractory LBCL", "axi-cel", "tisa-cel", "liso-cel", "second-line", "third-line", "bridging therapy", "treatment resistance", "antigen loss", "CAR T-cell fitness"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4332546", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42568509", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CART_AXICEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "axi-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_TISACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "tisa-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_LISOCEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "liso-cel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4332555", "editorial": {"original_title": "Can exa-cel eliminate transfusions or vaso-occlusive crises in pediatric beta-thalassemia or sickle cell disease?", "public_title": "Can exa-cel eliminate transfusions or vaso-occlusive crises in pediatric beta-thalassemia or sickle cell disease?", "slug": "exa-cel-children-transfusion-dependent-beta-thalassemia-sickle-cell-disease", "legacy_canonical_url": "https://5minutehematology.com/programs/video-35d099", "description": "Phase 3 clinical trial context from the New England Journal of Medicine (2026) evaluating CRISPR-Cas9 edited autologous CD34+ exa-cel in children with transfusion-dependent beta-thalassemia or sickle cell disease.", "scientific_summary": "Phase 3 clinical trial context from the New England Journal of Medicine (2026) evaluating CRISPR-Cas9 edited autologous CD34+ exa-cel in chi", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can exa-cel eliminate transfusions or vaso-occlusive crises in pediatric beta-thalassemia or sickle cell disease?", "language": null, "original_publication_date": "2026-09-02T00:50:08.211Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4332555/horizontal/small_70d3b41c-2c31-4538-bc64-737959ecaa7f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["exa-cel", "exagamglogene autotemcel", "CRISPR-Cas9", "BCL11A enhancer", "fetal hemoglobin", "CD34+ cells", "sickle cell disease", "transfusion-dependent beta-thalassemia", "phase 3 trial", "cell therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4332555", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_SICKLE_CELL_DISEASE", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "sickle cell disease", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333717", "editorial": {"original_title": "How should CAR T-cell therapy and bispecific T-cell engagers be sequenced in multiple myeloma?", "public_title": "How should CAR T-cell therapy and bispecific T-cell engagers be sequenced in multiple myeloma?", "slug": "imwg-immunotherapy-sequencing-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-c0c0a4", "description": "Expert consensus recommendations from the International Myeloma Working Group Immunotherapy Committee, published in Leukemia (2025), on sequencing CAR T-cells and bispecific T-cell engagers in multiple myeloma.", "scientific_summary": "Expert consensus recommendations from the International Myeloma Working Group Immunotherapy Committee, published in Leukemia (2025), on sequ", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should CAR T-cell therapy and bispecific T-cell engagers be sequenced in multiple myeloma?", "language": null, "original_publication_date": "2026-09-03T00:01:03.030Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333717/horizontal/small_7064d754-f67c-4737-a956-115cc6bd5669.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "immunotherapy sequencing", "CAR T-cell therapy", "bispecific antibodies", "T-cell redirecting therapy", "BCMA", "GPRC5D", "IMWG", "expert consensus", "Leukemia 2025"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333717", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_39870767", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333730", "editorial": {"original_title": "What is the incidence of non-ICANS neurologic toxicity after BCMA CAR-T in multiple myeloma?", "public_title": "What is the incidence of non-ICANS neurologic toxicity after BCMA CAR-T in multiple myeloma?", "slug": "non-icans-neurologic-toxicity-bcma-car-t-meta-analysis-multiple-myeloma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-b3ad54", "description": "Systematic review and random-effects meta-analysis of prospective trials and real-world cohorts (Blood, 2026) evaluating non-ICANS neurologic toxicity after BCMA CAR-T in multiple myeloma.", "scientific_summary": "Systematic review and random-effects meta-analysis of prospective trials and real-world cohorts (Blood, 2026) evaluating non-ICANS neurologi", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What is the incidence of non-ICANS neurologic toxicity after BCMA CAR-T in multiple myeloma?", "language": null, "original_publication_date": "2026-09-03T00:04:13.805Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333730/horizontal/small_4a93bbcd-e62b-443a-b01d-b6272bbfdb68.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["BCMA CAR-T", "multiple myeloma", "non-ICANS neurotoxicity", "neurologic adverse events", "ciltacabtagene autoleucel", "idecabtagene vicleucel", "cranial nerve palsy", "systematic review", "meta-analysis", "meta-regression"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333730", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART"}], "evidence_relations": [{"target_id": "EV_PMID_36762851", "relation": "RELATED", "basis": "physician_reviewed_evidence_content", "source": "data/content_mapping/evidence_content_review.csv", "review_date": "2026-09-06"}], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_MM_CILTACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CILTACABTAGENE_AUTOLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ciltacabtagene autoleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CART_IDECEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IDECABTAGENE_VICLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "idecabtagene vicleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_CILTACEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_MM_CILTACEL", "graph_edge_ids": ["EDGE_MM_CILTACEL_HAS_OPTION", "EDGE_MM_CILTACEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Ciltacabtagene autoleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/cilta_cel.json"}]}, {"target_id": "PROT_CART_IDECEL_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART", "via_therapy_id": "TX_CART_IDECEL", "graph_edge_ids": ["EDGE_MM_IDECEL_HAS_OPTION", "EDGE_MM_IDECEL_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Idecabtagene vicleucel resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/cell_therapy/ide_cel.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333735", "editorial": {"original_title": "How should CAR T-cell therapy and bispecific antibodies be sequenced in relapsed or refractory multiple myeloma?", "public_title": "How should CAR T-cell therapy and bispecific antibodies be sequenced in relapsed or refractory multiple myeloma?", "slug": "optimising-t-cell-immunotherapy-multiple-myeloma-european-myeloma-network", "legacy_canonical_url": "https://5minutehematology.com/programs/video-42b253", "description": "Review and expert recommendations from the European Myeloma Network (The Lancet Haematology, 2025) on optimising safety, efficacy, sequencing, referral, testing, and supportive care for T-cell immunotherapy in multiple myeloma.", "scientific_summary": "Review and expert recommendations from the European Myeloma Network (The Lancet Haematology, 2025) on optimising safety, efficacy, sequencin", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should CAR T-cell therapy and bispecific antibodies be sequenced in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-09-03T00:08:19.702Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333735/horizontal/small_c71c6115-3628-4292-a492-285536008424.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "CAR T-cell therapy", "bispecific antibodies", "T-cell redirecting therapy", "BCMA", "treatment sequencing", "supportive care", "referral planning", "infection screening", "European Myeloma Network"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333735", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40580975", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "PROT_MM_TECDARA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MULTIPLE_MYELOMA_BISPECIFICS", "via_therapy_id": "TX_MM_TECDARA", "graph_edge_ids": ["EDGE_MM_TECDARA_HAS_OPTION", "EDGE_MM_TECDARA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MYELOMA_V1_REVIEW.md", "note": "Physician-reviewed link to the approved Teclistamab + Daratumumab resource; HAS_OPTION exposes a matching resource and does not encode preference, superiority, or patient-specific eligibility."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/targeted/teclistamab_daratumumab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333737", "editorial": {"original_title": "Can anti-CD19 CAR T-cell therapy achieve decade-long remissions in relapsed or refractory B-cell lymphomas?", "public_title": "Can anti-CD19 CAR T-cell therapy achieve decade-long remissions in relapsed or refractory B-cell lymphomas?", "slug": "ten-year-outcomes-car-t-cell-therapy-b-cell-lymphomas", "legacy_canonical_url": "https://5minutehematology.com/programs/video-dadc5f", "description": "Long-term follow-up cohort analysis of 38 patients treated with CTL019 (tisagenlecleucel) assessing 10-year lymphoma-free survival and late safety outcomes (NEJM, 2026).", "scientific_summary": "Long-term follow-up cohort analysis of 38 patients treated with CTL019 (tisagenlecleucel) assessing 10-year lymphoma-free survival and late", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can anti-CD19 CAR T-cell therapy achieve decade-long remissions in relapsed or refractory B-cell lymphomas?", "language": null, "original_publication_date": "2026-09-03T00:11:54.200Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333737/horizontal/small_3fe18109-5eac-478a-afb2-d08cdee57d68.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CAR T-cell therapy", "anti-CD19", "tisagenlecleucel", "CTL019", "B-cell non-Hodgkin lymphoma", "large B-cell lymphoma", "follicular lymphoma", "long-term follow-up", "lymphoma-free survival", "progression-free survival", "overall survival", "late toxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333737", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42341302", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_CAR_T"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_CAR_T", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_CART_TISACEL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TISAGENLECLEUCEL", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tisagenlecleucel", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333738", "editorial": {"original_title": "How are targeted therapies and CAR T changing cure rates across leukemia subtypes?", "public_title": "How are targeted therapies and CAR T changing cure rates across leukemia subtypes?", "slug": "care-cure-leukemias-2026", "legacy_canonical_url": "https://5minutehematology.com/programs/video-cd8306", "description": "Narrative review in American Journal of Hematology (2026) summarizing advances in targeted agents, MRD monitoring, and CAR T-cell therapy across leukemias.", "scientific_summary": "Narrative review in American Journal of Hematology (2026) summarizing advances in targeted agents, MRD monitoring, and CAR T-cell therapy ac", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How are targeted therapies and CAR T changing cure rates across leukemia subtypes?", "language": null, "original_publication_date": "2026-09-03T00:15:24.295Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333738/horizontal/small_e352ee76-cafb-4732-aed3-af7512b28983.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["leukemia", "targeted therapy", "immunotherapy", "car-t", "mrd", "blinatumomab", "inotuzumab", "bcr-abl1", "tyrosine kinase inhibitors", "venetoclax", "idh inhibitors", "flt3 inhibitors"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333738", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_ALL_INO", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333741", "editorial": {"original_title": "Should CAR T-cell therapy be preferred over bispecific antibodies for relapsed/refractory LBCL?", "public_title": "Should CAR T-cell therapy be preferred over bispecific antibodies for relapsed/refractory LBCL?", "slug": "car-t-versus-bispecific-antibodies-rr-lbcl", "legacy_canonical_url": "https://5minutehematology.com/programs/video-b4f681", "description": "Physician-focused review and debate synthesizing non-randomized evidence for CAR T-cell therapy vs bispecific antibodies in R/R LBCL (Cancers, 2026).", "scientific_summary": "Physician-focused review and debate synthesizing non-randomized evidence for CAR T-cell therapy vs bispecific antibodies in R/R LBCL (Cancer", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Cellular Therapy & Immunotherapy"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should CAR T-cell therapy be preferred over bispecific antibodies for relapsed/refractory LBCL?", "language": null, "original_publication_date": "2026-09-03T00:18:09.310Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333741/horizontal/small_bbbc666e-77ac-4969-a6dc-8010b0aaee73.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["large B-cell lymphoma", "relapsed refractory", "CAR T-cell therapy", "bispecific antibodies", "second-line therapy", "third-line therapy", "complete response", "progression-free survival", "neurotoxicity", "real-world evidence", "patient selection", "frail elderly"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333741", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42588728", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333747", "editorial": {"original_title": "How should anticoagulation be adjusted after breakthrough VTE in cancer?", "public_title": "How should anticoagulation be adjusted after breakthrough VTE in cancer?", "slug": "treat-breakthrough-thrombosis-cancer", "legacy_canonical_url": "https://5minutehematology.com/programs/video-8f5179", "description": "Expert narrative review and evidence appraisal (Blood, 2026) on confirming breakthrough VTE in cancer and evaluating causes to guide anticoagulation adjustments.", "scientific_summary": "Expert narrative review and evidence appraisal (Blood, 2026) on confirming breakthrough VTE in cancer and evaluating causes to guide anticoa", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should anticoagulation be adjusted after breakthrough VTE in cancer?", "language": null, "original_publication_date": "2026-09-03T00:25:21.594Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333747/horizontal/small_86fb1154-007d-4d26-a46d-0c4a6d832e59.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["breakthrough thrombosis", "cancer-associated thrombosis", "venous thromboembolism", "anticoagulation failure", "LMWH", "dose escalation", "drug-drug interactions", "medication adherence", "heparin-induced thrombocytopenia", "acquired antithrombin deficiency"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333747", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41557974", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "How I treat breakthrough thrombosis in patients with cancer", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HIT", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "heparin-induced thrombocytopenia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333748", "editorial": {"original_title": "How do you distinguish HIT from VITT and other anti-PF4 platelet-activating disorders?", "public_title": "How do you distinguish HIT from VITT and other anti-PF4 platelet-activating disorders?", "slug": "platelet-activating-anti-pf4-disorders", "legacy_canonical_url": "https://5minutehematology.com/programs/video-f39817", "description": "Narrative review in New England Journal of Medicine (2026) outlining platelet-activating anti-PF4 disorders, including HIT, autoimmune/spontaneous HIT, VITT, infection-associated VITT-like disease, and diagnostic assays and treatment implic", "scientific_summary": "Narrative review in New England Journal of Medicine (2026) outlining platelet-activating anti-PF4 disorders, including HIT, autoimmune/spont", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How do you distinguish HIT from VITT and other anti-PF4 platelet-activating disorders?", "language": null, "original_publication_date": "2026-09-03T00:27:54.269Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333748/horizontal/small_70702a58-222a-41af-8570-a5dd9baf13b5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["PF4 antibodies", "HIT", "autoimmune HIT", "spontaneous HIT", "VITT", "anti-PF4", "Fc gamma IIa", "platelet activation assay", "ELISA", "IVIG", "BTK inhibitors", "thrombocytopenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333748", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42441431", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Platelet-Activating Anti-Platelet Factor 4 Disorders", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333749", "editorial": {"original_title": "Should anticoagulation be discontinued after a first VTE in inherited thrombophilia?", "public_title": "Should anticoagulation be discontinued after a first VTE in inherited thrombophilia?", "slug": "anticoagulation-discontinuation-first-vte-inherited-thrombophilia-cohort", "legacy_canonical_url": "https://5minutehematology.com/programs/video-33b0a4", "description": "In this 2026 retrospective long-term cohort study in Research and Practice in Thrombosis and Haemostasis, Kim SA et al compared recurrent VTE and major bleeding after continuation vs discontinuation of anticoagulation following first VTE in", "scientific_summary": "In this 2026 retrospective long-term cohort study in Research and Practice in Thrombosis and Haemostasis, Kim SA et al compared recurrent VT", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should anticoagulation be discontinued after a first VTE in inherited thrombophilia?", "language": null, "original_publication_date": "2026-09-03T00:31:50.418Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333749/horizontal/small_f0ccb14c-d134-4ce0-8fe7-9a2b358b5310.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["inherited thrombophilia", "venous thromboembolism", "VTE recurrence", "anticoagulation discontinuation", "indefinite anticoagulation", "protein S deficiency", "protein C deficiency", "antithrombin deficiency", "major bleeding", "retrospective cohort"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333749", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42540434", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Risks of anticoagulation discontinuation after first venous thromboembolism in inherited thrombophilia: a long-term cohort study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333753", "editorial": {"original_title": "How do sex hormone therapies affect venous thromboembolism and cardiovascular risk?", "public_title": "How do sex hormone therapies affect venous thromboembolism and cardiovascular risk?", "slug": "sex-hormone-influences-venous-thrombotic-cardiovascular-risk", "legacy_canonical_url": "https://5minutehematology.com/programs/video-55646e", "description": "Physician-focused review of sex hormone effects on hemostasis and vascular risk, including formulation-specific VTE risk and perioperative management. NEJM narrative review (2026).", "scientific_summary": "Physician-focused review of sex hormone effects on hemostasis and vascular risk, including formulation-specific VTE risk and perioperative m", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How do sex hormone therapies affect venous thromboembolism and cardiovascular risk?", "language": null, "original_publication_date": "2026-09-03T00:34:12.558Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333753/horizontal/small_74ca79fe-acb6-4f5d-a3ce-8cc70de01acb.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["sex hormone therapy", "venous thromboembolism", "VTE", "cardiovascular risk", "estrogen", "progestins", "testosterone", "oral contraceptives", "hormone replacement therapy", "gender-affirming hormones", "thrombophilia", "perioperative management"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333753", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41985134", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333754", "editorial": {"original_title": "How should thrombosis risk be assessed and managed in adult primary ITP?", "public_title": "How should thrombosis risk be assessed and managed in adult primary ITP?", "slug": "thrombosis-immune-thrombocytopenia", "legacy_canonical_url": "https://5minutehematology.com/programs/video-afebe2", "description": "Physician-focused narrative review (In a Nutshell) summarizing hypercoagulability, haemostatic changes, and treatment-related thrombosis risk in adult primary ITP (British Journal of Haematology, 2026).", "scientific_summary": "Physician-focused narrative review (In a Nutshell) summarizing hypercoagulability, haemostatic changes, and treatment-related thrombosis ris", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should thrombosis risk be assessed and managed in adult primary ITP?", "language": null, "original_publication_date": "2026-09-03T00:37:02.044Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333754/horizontal/small_4e9d2c03-5ea0-47c8-a466-feae519bf35d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["immune thrombocytopenia", "ITP", "thrombosis", "venous thromboembolism", "arterial thrombosis", "hypercoagulability", "haemostasis", "platelet count", "ITP treatments", "thrombotic risk"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333754", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ITP", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "immune thrombocytopenia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4333755", "editorial": {"original_title": "Can R-BAC salvage mantle cell lymphoma after BTK inhibitor failure and bridge to alloSCT?", "public_title": "Can R-BAC salvage mantle cell lymphoma after BTK inhibitor failure and bridge to alloSCT?", "slug": "r-bac-relapsed-refractory-mantle-cell-lymphoma-post-btk-inhibitor-therapy", "legacy_canonical_url": "https://5minutehematology.com/programs/video-9a9ca0", "description": "Retrospective cohort study in British Journal of Haematology (2020) evaluating R-BAC (rituximab, bendamustine, cytarabine) for relapsed/refractory mantle cell lymphoma after BTK inhibitor progression, including bridging to alloSCT.", "scientific_summary": "Retrospective cohort study in British Journal of Haematology (2020) evaluating R-BAC (rituximab, bendamustine, cytarabine) for relapsed/refr", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can R-BAC salvage mantle cell lymphoma after BTK inhibitor failure and bridge to alloSCT?", "language": null, "original_publication_date": "2026-09-03T00:41:10.652Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4333755/horizontal/small_8b591048-e5f1-4d3b-97e9-efb76c63af98.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["mantle cell lymphoma", "R-BAC", "rituximab", "bendamustine", "cytarabine", "BTK inhibitor failure", "relapsed refractory", "salvage therapy", "overall response rate", "complete response", "allogeneic stem cell transplant", "bridge to transplant"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4333755", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_32011729", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "mantle cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYTARABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cytarabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334231", "editorial": {"original_title": "Does mini-hyper-CVD plus inotuzumab improve long-term outcomes in older adults with newly diagnosed Ph-negative B-ALL?", "public_title": "Does mini-hyper-CVD plus inotuzumab improve long-term outcomes in older adults with newly diagnosed Ph-negative B-ALL?", "slug": "mini-hyper-cvd-inotuzumab-blinatumomab-older-ph-negative-b-all-phase-2-long-term", "legacy_canonical_url": "https://5minutehematology.com/programs/video-45e547", "description": "Open-label phase 2 trial (The Lancet, 2023) reporting long-term outcomes of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in adults aged 60+ with newly diagnosed Ph-negative B-ALL.", "scientific_summary": "Open-label phase 2 trial (The Lancet, 2023) reporting long-term outcomes of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blina", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does mini-hyper-CVD plus inotuzumab improve long-term outcomes in older adults with newly diagnosed Ph-negative B-ALL?", "language": null, "original_publication_date": "2026-09-03T14:52:27.159Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334231/horizontal/small_9d65de27-5813-4a01-9ca2-47fd43c71c4d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["B-ALL", "Philadelphia chromosome-negative", "older adults", "mini-hyper-CVD", "inotuzumab ozogamicin", "blinatumomab", "low-intensity chemotherapy", "phase 2 trial", "progression-free survival", "sinusoidal obstruction syndrome"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334231", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_B_ALL_LBL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "B-ALL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_INO", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_INOTUZUMAB_OZOGAMICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_HYPERCVAD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_HYPERCVAD", "graph_edge_ids": ["EDGE_ALL_HYPERCVAD_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_HYPERCVAD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json", "note": "Approved Hyper-CVAD resource linked as a non-preferential Ph-negative frontline option. The protocol source itself preserves the AYA/pediatric-inspired treatment context; this edge does not imply superiority or preferred use."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json"}]}, {"target_id": "PROT_ALL_MINIHCV_INO_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_MINIHCV_INO_BLINA", "graph_edge_ids": ["EDGE_ALL_MINIHCV_INO_BLINA_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_MINIHCV_INO_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json", "note": "Approved protocol resource linked only to the Ph-negative frontline decision; the source context is newly diagnosed Philadelphia-negative B-ALL in older adults and is not generalized."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334240", "editorial": {"original_title": "How should recent advances be incorporated into adult ALL treatment strategies?", "public_title": "How should recent advances be incorporated into adult ALL treatment strategies?", "slug": "adult-all-incorporation-recent-advances-current-treatment-strategies", "legacy_canonical_url": "https://5minutehematology.com/programs/video-7e6a57", "description": "Physician education based on a narrative review in Blood Cancer Journal (2026) outlining how recent advances can be integrated into current adult acute lymphoblastic leukemia treatment strategies.", "scientific_summary": "Physician education based on a narrative review in Blood Cancer Journal (2026) outlining how recent advances can be integrated into current", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should recent advances be incorporated into adult ALL treatment strategies?", "language": null, "original_publication_date": "2026-09-03T14:55:12.172Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334240/horizontal/small_2d895f8e-42a9-4de3-ab58-231da59dab19.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["adult acute lymphoblastic leukemia", "adult ALL", "treatment strategies", "recent advances", "targeted therapy", "immunotherapy", "MRD", "blinatumomab", "inotuzumab ozogamicin", "CAR T-cell therapy", "allogeneic stem cell transplant"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334240", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42401567", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Adult Acute Lymphoblastic Leukemia: Incorporation of Recent Advances Into Current Treatment Strategies", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_ALL_INO", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_INOTUZUMAB_OZOGAMICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "via_therapy_id": "TX_ALL_BLINA", "graph_edge_ids": ["EDGE_ALL_BLINA_RELAPSED_IMMUNOTHERAPY_HAS_OPTION", "EDGE_ALL_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json", "note": "Approved blinatumomab resource linked to the explicitly curated MRD/consolidation and relapsed/refractory settings; HAS_OPTION does not encode treatment preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json"}]}, {"target_id": "PROT_ALL_INO_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "via_therapy_id": "TX_ALL_INO", "graph_edge_ids": ["EDGE_ALL_INO_RELAPSED_IMMUNOTHERAPY_HAS_OPTION", "EDGE_ALL_INO_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/inotuzumab_ozogamicin.json", "note": "Approved inotuzumab ozogamicin resource linked to relapsed immunotherapy; HAS_OPTION does not encode sequencing or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/inotuzumab_ozogamicin.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334249", "editorial": {"original_title": "Should bendamustine-rituximab replace R-CHOP as first-line therapy for indolent or mantle-cell lymphoma?", "public_title": "Should bendamustine-rituximab replace R-CHOP as first-line therapy for indolent or mantle-cell lymphoma?", "slug": "bendamustine-rituximab-vs-r-chop-first-line-indolent-mantle-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-a2d7d1", "description": "Review of an open-label, multicentre, randomized phase 3 non-inferiority trial in Lancet (2013) comparing bendamustine-rituximab vs R-CHOP in untreated indolent and mantle-cell lymphomas.", "scientific_summary": "Review of an open-label, multicentre, randomized phase 3 non-inferiority trial in Lancet (2013) comparing bendamustine-rituximab vs R-CHOP i", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should bendamustine-rituximab replace R-CHOP as first-line therapy for indolent or mantle-cell lymphoma?", "language": null, "original_publication_date": "2026-09-03T14:59:06.163Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334249/horizontal/small_959da3ae-87bd-4871-b154-2a2ba669efb5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["bendamustine", "rituximab", "BR", "R-CHOP", "indolent lymphoma", "mantle cell lymphoma", "first-line therapy", "progression-free survival", "phase 3 trial", "non-inferiority trial", "toxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334249", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_BR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BR", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_BR_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE", "via_therapy_id": "TX_LYM_BR", "graph_edge_ids": ["EDGE_MCL_BR_HAS_OPTION", "EDGE_FL_BR_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_MCL_V1_REVIEW.md", "note": "Physician-reviewed link to the approved bendamustine + rituximab resource in the older/transplant-ineligible frontline decision. The stored protocol explicitly includes mantle-cell lymphoma context; HAS_OPTION does not encode preference, BTKi combination, maintenance, or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/bendamustine_rituximab.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334258", "editorial": {"original_title": "Does blinatumomab improve overall survival versus standard chemotherapy in relapsed or refractory B-cell precursor ALL?", "public_title": "Does blinatumomab improve overall survival versus standard chemotherapy in relapsed or refractory B-cell precursor ALL?", "slug": "blinatumomab-versus-chemotherapy-advanced-acute-lymphoblastic-leukemia", "legacy_canonical_url": "https://5minutehematology.com/programs/video-75ea5f", "description": "Phase 3, multi-institutional randomized trial (NEJM 2017) comparing blinatumomab vs standard-of-care chemotherapy in heavily pretreated adults with relapsed/refractory B-cell precursor ALL.", "scientific_summary": "Phase 3, multi-institutional randomized trial (NEJM 2017) comparing blinatumomab vs standard-of-care chemotherapy in heavily pretreated adul", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does blinatumomab improve overall survival versus standard chemotherapy in relapsed or refractory B-cell precursor ALL?", "language": null, "original_publication_date": "2026-09-03T15:02:11.772Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334258/horizontal/small_88f0a9d6-1ebc-4632-a644-595a6970587e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["blinatumomab", "bispecific T-cell engager", "CD19", "CD3", "B-cell precursor ALL", "relapsed refractory", "phase 3 trial", "randomized trial", "overall survival", "remission", "event-free survival", "TOWER trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334258", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_28249141", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["TOWER"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "via_therapy_id": "TX_ALL_BLINA", "graph_edge_ids": ["EDGE_ALL_BLINA_RELAPSED_IMMUNOTHERAPY_HAS_OPTION", "EDGE_ALL_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json", "note": "Approved blinatumomab resource linked to the explicitly curated MRD/consolidation and relapsed/refractory settings; HAS_OPTION does not encode treatment preference."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/blinatumomab.json"}]}, {"target_id": "PROT_ALL_INO_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_RELAPSED_IMMUNOTHERAPY", "via_therapy_id": "TX_ALL_INO", "graph_edge_ids": ["EDGE_ALL_INO_RELAPSED_IMMUNOTHERAPY_HAS_OPTION", "EDGE_ALL_INO_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/inotuzumab_ozogamicin.json", "note": "Approved inotuzumab ozogamicin resource linked to relapsed immunotherapy; HAS_OPTION does not encode sequencing or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/inotuzumab_ozogamicin.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334264", "editorial": {"original_title": "Does brentuximab vedotin induce durable complete remissions in relapsed or refractory systemic ALCL?", "public_title": "Does brentuximab vedotin induce durable complete remissions in relapsed or refractory systemic ALCL?", "slug": "brentuximab-vedotin-relapsed-refractory-systemic-alcl-phase-ii", "legacy_canonical_url": "https://5minutehematology.com/programs/video-0a397e", "description": "Phase II multicenter trial of brentuximab vedotin 1.8 mg/kg IV q3 weeks in relapsed/refractory systemic ALCL, as reported in Journal of Clinical Oncology (2012).", "scientific_summary": "Phase II multicenter trial of brentuximab vedotin 1.8 mg/kg IV q3 weeks in relapsed/refractory systemic ALCL, as reported in Journal of Clin", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does brentuximab vedotin induce durable complete remissions in relapsed or refractory systemic ALCL?", "language": null, "original_publication_date": "2026-09-03T15:04:26.168Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334264/horizontal/small_cd384ff7-588c-40fe-b943-95a558eb9a36.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["brentuximab vedotin", "SGN-35", "systemic ALCL", "anaplastic large-cell lymphoma", "CD30", "relapsed refractory", "phase II trial", "objective response rate", "complete remission", "peripheral neuropathy", "neutropenia", "thrombocytopenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334264", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_22614995", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334272", "editorial": {"original_title": "How can we better identify high-risk DLBCL patients before upfront chemoimmunotherapy?", "public_title": "How can we better identify high-risk DLBCL patients before upfront chemoimmunotherapy?", "slug": "challenges-identifying-dlbcl-patients-poor-outcomes-upfront-chemoimmunotherapy-i", "legacy_canonical_url": "https://5minutehematology.com/programs/video-e292e0", "description": "Physician-focused review of prognostic heterogeneity in DLBCL and why traditional risk models miss poor-risk patients, with implications for frontline trial design (Leukemia & Lymphoma, 2024).", "scientific_summary": "Physician-focused review of prognostic heterogeneity in DLBCL and why traditional risk models miss poor-risk patients, with implications for", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How can we better identify high-risk DLBCL patients before upfront chemoimmunotherapy?", "language": null, "original_publication_date": "2026-09-03T15:10:58.482Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334272/horizontal/small_e6fa6165-0506-4347-b734-c01ad0c365fa.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "prognostic models", "risk stratification", "chemoimmunotherapy", "R-CHOP", "frontline trials", "clinical trial design", "eligibility criteria", "novel prognosticators", "outcomes"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334272", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38180317", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_LIMITED_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334288", "editorial": {"original_title": "Can dose-adjusted EPOCH-rituximab eliminate the need for mediastinal radiotherapy in primary mediastinal B-cell lymphoma", "public_title": "Can dose-adjusted EPOCH-rituximab eliminate the need for mediastinal radiotherapy in primary mediastinal B-cell lymphoma", "slug": "dose-adjusted-epoch-r-primary-mediastinal-b-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-212609", "description": "Single-group, prospective phase 2 study (NEJM, 2013) evaluating DA-EPOCH-R without radiotherapy for untreated primary mediastinal B-cell lymphoma, with retrospective external verification.", "scientific_summary": "Single-group, prospective phase 2 study (NEJM, 2013) evaluating DA-EPOCH-R without radiotherapy for untreated primary mediastinal B-cell lym", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-03T15:25:16.568Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334288/horizontal/small_3ed5dc9b-1a47-44bb-9be3-c18296cf38e4.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["primary mediastinal B-cell lymphoma", "PMBCL", "DA-EPOCH-R", "dose-adjusted EPOCH", "rituximab", "mediastinal radiotherapy", "event-free survival", "overall survival", "phase 2 trial", "diffuse large B-cell lymphoma"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334288", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_23574119", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PMBCL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "primary mediastinal B-cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_DAEPOCHR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "DA-EPOCH-R", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334291", "editorial": {"original_title": "In relapsed or refractory CLL, does fixed-duration venetoclax-rituximab achieve durable uMRD and prolong survival?", "public_title": "In relapsed or refractory CLL, does fixed-duration venetoclax-rituximab achieve durable uMRD and prolong survival?", "slug": "fixed-duration-venetoclax-rituximab-rr-cll-murano-mrd-survival", "legacy_canonical_url": "https://5minutehematology.com/programs/video-552523", "description": "Phase III randomized MURANO trial post-treatment follow-up (Journal of Clinical Oncology, 2018) evaluating fixed-duration venetoclax-rituximab vs bendamustine-rituximab in relapsed/refractory CLL, focusing on MRD kinetics and updated PFS/OS", "scientific_summary": "Phase III randomized MURANO trial post-treatment follow-up (Journal of Clinical Oncology, 2018) evaluating fixed-duration venetoclax-rituxim", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In relapsed or refractory CLL, does fixed-duration venetoclax-rituximab achieve durable uMRD and prolong survival?", "language": null, "original_publication_date": "2026-09-03T15:27:20.731Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334291/horizontal/small_f28cff35-321c-46d0-a114-cd0695599516.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "relapsed refractory", "venetoclax", "rituximab", "MURANO", "phase III trial", "minimal residual disease", "uMRD", "progression-free survival", "overall survival", "bendamustine rituximab"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334291", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CLL_RELAPSED_FIXED_DURATION"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_CLL_RELAPSED_FIXED_DURATION", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_BR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334299", "editorial": {"original_title": "Does fixed-duration ibrutinib plus venetoclax improve depth of response and PFS in first-line CLL?", "public_title": "Does fixed-duration ibrutinib plus venetoclax improve depth of response and PFS in first-line CLL?", "slug": "fixed-duration-ibrutinib-venetoclax-first-line-cll-captivate-fd-cohort", "legacy_canonical_url": "https://5minutehematology.com/programs/video-7035ae", "description": "Primary analysis of the fixed-duration cohort from CAPTIVATE, an international phase 2 study of first-line ibrutinib lead-in followed by ibrutinib plus venetoclax in CLL (Blood, 2022).", "scientific_summary": "Primary analysis of the fixed-duration cohort from CAPTIVATE, an international phase 2 study of first-line ibrutinib lead-in followed by ibr", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does fixed-duration ibrutinib plus venetoclax improve depth of response and PFS in first-line CLL?", "language": null, "original_publication_date": "2026-09-03T15:33:10.143Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334299/horizontal/small_1bbf3ca5-4514-403b-a0e3-5b6b7193251a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "ibrutinib", "venetoclax", "fixed-duration", "CAPTIVATE", "phase 2", "uMRD", "complete response", "progression-free survival", "tumor lysis syndrome", "neutropenia", "hypertension"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334299", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334307", "editorial": {"original_title": "Is GEMOX-R an effective salvage option for relapsed or refractory diffuse large B-cell lymphoma?", "public_title": "Is GEMOX-R an effective salvage option for relapsed or refractory diffuse large B-cell lymphoma?", "slug": "gemox-r-salvage-refractory-relapsing-diffuse-large-b-cell-lymphoma-phase-ii", "legacy_canonical_url": "https://5minutehematology.com/programs/video-92e81b", "description": "Phase II study in the European Journal of Haematology (2008) evaluating the GEMOX-R regimen as salvage therapy in refractory/relapsing diffuse large-cell lymphoma, in the ASCT salvage context.", "scientific_summary": "Phase II study in the European Journal of Haematology (2008) evaluating the GEMOX-R regimen as salvage therapy in refractory/relapsing diffu", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms", "Original Studies"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is GEMOX-R an effective salvage option for relapsed or refractory diffuse large B-cell lymphoma?", "language": null, "original_publication_date": "2026-09-03T15:34:56.307Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334307/horizontal/small_debf33b0-72d2-4cad-8e50-943cbe0b6ab9.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["GEMOX-R", "gemcitabine", "oxaliplatin", "rituximab", "salvage therapy", "relapsed DLBCL", "refractory DLBCL", "diffuse large B-cell lymphoma", "ASCT", "phase II trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334307", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_18005385", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_GEMCITABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "gemcitabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OXALIPLATIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "oxaliplatin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334312", "editorial": {"original_title": "Does adding cyclophosphamide to Adriamycin, vincristine, and prednisone improve remission rates in advanced non-Hodgkin ", "public_title": "Does adding cyclophosphamide to Adriamycin, vincristine, and prednisone improve remission rates in advanced non-Hodgkin", "slug": "adriamycin-combination-chemotherapy-malignant-lymphoma-chop-hop", "legacy_canonical_url": "https://5minutehematology.com/programs/video-6b31e3", "description": "Randomized Southwest Oncology Group trial comparing CHOP vs HOP for pathologically staged stage III-IV non-Hodgkin lymphoma (Cancer, 1976).", "scientific_summary": "Randomized Southwest Oncology Group trial comparing CHOP vs HOP for pathologically staged stage III-IV non-Hodgkin lymphoma (Cancer, 1976).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-03T15:37:26.229Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334312/horizontal/small_e61451ea-70c6-4e8b-ae45-96b890187bc1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CHOP", "HOP", "Adriamycin", "doxorubicin", "non-Hodgkin lymphoma", "advanced stage", "stage III", "stage IV", "complete remission", "overall response", "SWOG trial", "cyclophosphamide"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334312", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_791473", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DOXORUBICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "doxorubicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334315", "editorial": {"original_title": "Can first-line ibrutinib plus venetoclax improve outcomes in high-risk or older CLL?", "public_title": "Can first-line ibrutinib plus venetoclax improve outcomes in high-risk or older CLL?", "slug": "ibrutinib-venetoclax-first-line-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/video-3dbf8e", "description": "Overview of a clinical trial of first-line ibrutinib plus venetoclax in CLL, reported in the New England Journal of Medicine (2019).", "scientific_summary": "Overview of a clinical trial of first-line ibrutinib plus venetoclax in CLL, reported in the New England Journal of Medicine (2019).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can first-line ibrutinib plus venetoclax improve outcomes in high-risk or older CLL?", "language": null, "original_publication_date": "2026-09-03T15:39:28.882Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334315/horizontal/small_e536e600-48aa-40d1-b9ed-887313cd3c74.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "ibrutinib", "venetoclax", "BTK inhibitor", "BCL2 inhibitor", "first-line therapy", "combination therapy", "high-risk CLL", "older patients", "NEJM 2019"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334315", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334319", "editorial": {"original_title": "Can frontline ibrutinib plus rituximab induce deep remissions in indolent mantle cell lymphoma?", "public_title": "Can frontline ibrutinib plus rituximab induce deep remissions in indolent mantle cell lymphoma?", "slug": "ibrutinib-rituximab-indolent-mantle-cell-lymphoma-phase-2-imcl-2015", "legacy_canonical_url": "https://5minutehematology.com/programs/video-be09ac", "description": "Review of the IMCL-2015 multicenter, open-label, single-arm phase II trial of ibrutinib plus rituximab in previously untreated indolent MCL (Journal of Clinical Oncology, 2022).", "scientific_summary": "Review of the IMCL-2015 multicenter, open-label, single-arm phase II trial of ibrutinib plus rituximab in previously untreated indolent MCL", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can frontline ibrutinib plus rituximab induce deep remissions in indolent mantle cell lymphoma?", "language": null, "original_publication_date": "2026-09-03T15:41:29.930Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334319/horizontal/small_df002fa0-8135-4371-a38a-595c7428c6c3.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["mantle cell lymphoma", "indolent MCL", "ibrutinib", "rituximab", "frontline therapy", "phase II trial", "single-arm study", "MRD negativity", "complete response", "TP53 mutation", "GELTAMO"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334319", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "mantle cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334321", "editorial": {"original_title": "In older patients with untreated CLL, do ibrutinib regimens improve outcomes versus chemoimmunotherapy?", "public_title": "In older patients with untreated CLL, do ibrutinib regimens improve outcomes versus chemoimmunotherapy?", "slug": "ibrutinib-regimens-versus-chemoimmunotherapy-older-untreated-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/video-066dbe", "description": "Review of a randomized controlled trial in The New England Journal of Medicine (2018) comparing ibrutinib-based regimens with chemoimmunotherapy in older, treatment-naive CLL patients.", "scientific_summary": "Review of a randomized controlled trial in The New England Journal of Medicine (2018) comparing ibrutinib-based regimens with chemoimmunothe", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In older patients with untreated CLL, do ibrutinib regimens improve outcomes versus chemoimmunotherapy?", "language": null, "original_publication_date": "2026-09-03T15:43:22.145Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334321/horizontal/small_a8b85134-5258-4068-a45b-afa5dcfc4bea.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "ibrutinib", "chemoimmunotherapy", "older patients", "treatment-naive", "randomized trial", "NEJM 2018", "BTK inhibitor"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334321", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30501481", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334323", "editorial": {"original_title": "In previously untreated CLL, should ibrutinib plus rituximab replace FCR?", "public_title": "In previously untreated CLL, should ibrutinib plus rituximab replace FCR?", "slug": "ibrutinib-rituximab-vs-fcr-untreated-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/video-e32a6c", "description": "Phase 3 randomized trial (E1912) in NEJM 2019 comparing ibrutinib-rituximab vs FCR chemoimmunotherapy in previously untreated CLL patients <=70 years, reporting interim PFS/OS and key IGHV subgroup results.", "scientific_summary": "Phase 3 randomized trial (E1912) in NEJM 2019 comparing ibrutinib-rituximab vs FCR chemoimmunotherapy in previously untreated CLL patients <", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In previously untreated CLL, should ibrutinib plus rituximab replace FCR?", "language": null, "original_publication_date": "2026-09-03T15:45:49.684Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334323/horizontal/small_68554301-2147-4d4d-9650-55bc71bc1f6f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "ibrutinib", "rituximab", "FCR", "fludarabine", "cyclophosphamide", "chemoimmunotherapy", "E1912", "phase 3 trial", "progression-free survival", "overall survival", "IGHV mutation status"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334323", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_31365801", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_FLUDARABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "fludarabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334326", "editorial": {"original_title": "Does inotuzumab plus mini-HCVD improve survival versus HCVAD in older adults with Ph-negative ALL?", "public_title": "Does inotuzumab plus mini-HCVD improve survival versus HCVAD in older adults with Ph-negative ALL?", "slug": "inotuzumab-mini-hcvd-blinatumomab-vs-hcvad-older-ph-negative-all-propensity-scor", "legacy_canonical_url": "https://5minutehematology.com/programs/video-065aa2", "description": "Propensity score matched comparative analysis of prospectively treated cohorts (Cancer, 2019) evaluating inotuzumab ozogamicin plus mini-HCVD with or without blinatumomab versus standard HCVAD in older, newly diagnosed Ph-negative ALL.", "scientific_summary": "Propensity score matched comparative analysis of prospectively treated cohorts (Cancer, 2019) evaluating inotuzumab ozogamicin plus mini-HCV", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does inotuzumab plus mini-HCVD improve survival versus HCVAD in older adults with Ph-negative ALL?", "language": null, "original_publication_date": "2026-09-03T15:48:07.113Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334326/horizontal/small_b249ac7b-7fed-4ac7-8ea9-498f3c287474.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute lymphoblastic leukemia", "Ph-negative ALL", "older adults", "inotuzumab ozogamicin", "mini-HCVD", "HCVAD", "blinatumomab", "propensity score matching", "event-free survival", "overall survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334326", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ALL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "TX_ALL_INO", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_INOTUZUMAB_OZOGAMICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "inotuzumab ozogamicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_ALL_BLINA", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BLINATUMOMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "blinatumomab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_ALL_HYPERCVAD_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_HYPERCVAD", "graph_edge_ids": ["EDGE_ALL_HYPERCVAD_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_HYPERCVAD_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json", "note": "Approved Hyper-CVAD resource linked as a non-preferential Ph-negative frontline option. The protocol source itself preserves the AYA/pediatric-inspired treatment context; this edge does not imply superiority or preferred use."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/hyper_cvad.json"}]}, {"target_id": "PROT_ALL_MINIHCV_INO_BLINA_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_ALL_PH_NEGATIVE_FRONTLINE", "via_therapy_id": "TX_ALL_MINIHCV_INO_BLINA", "graph_edge_ids": ["EDGE_ALL_MINIHCV_INO_BLINA_PH_NEGATIVE_FRONTLINE_HAS_OPTION", "EDGE_ALL_MINIHCV_INO_BLINA_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json", "note": "Approved protocol resource linked only to the Ph-negative frontline decision; the source context is newly diagnosed Philadelphia-negative B-ALL in older adults and is not generalized."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/all/mini_hyper_cvd_ino_blina.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334331", "editorial": {"original_title": "How should Hodgkin lymphoma be managed during pregnancy?", "public_title": "How should Hodgkin lymphoma be managed during pregnancy?", "slug": "hodgkin-lymphoma-pregnancy-management-expectant-vinblastine-abvd", "legacy_canonical_url": "https://5minutehematology.com/programs/video-e77f7b", "description": "Literature review with a homogeneous single-center expectant management description (Critical Reviews in Oncology/Hematology, 2024) on HL in pregnancy comparing observation, vinblastine, and ABVD.", "scientific_summary": "Literature review with a homogeneous single-center expectant management description (Critical Reviews in Oncology/Hematology, 2024) on HL in", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should Hodgkin lymphoma be managed during pregnancy?", "language": null, "original_publication_date": "2026-09-03T15:52:18.612Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334331/horizontal/small_4eb8b5ac-a891-4af7-93c1-519a3b9406e6.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "pregnancy", "expectant management", "watchful waiting", "vinblastine", "ABVD", "fetal toxicity", "obstetric complications", "trimester", "chemotherapy in pregnancy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334331", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "Hodgkin lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VINBLASTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "vinblastine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_HL_ABVD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "ABVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334335", "editorial": {"original_title": "In rituximab-refractory indolent NHL, does obinutuzumab plus bendamustine improve progression-free survival vs bendamust", "public_title": "In rituximab-refractory indolent NHL, does obinutuzumab plus bendamustine improve progression-free survival vs bendamust", "slug": "gadolin-obinutuzumab-bendamustine-rituximab-refractory-indolent-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-ba8078", "description": "Phase 3 randomized, controlled, open-label multicentre GADOLIN trial in The Lancet Oncology (2016) comparing obinutuzumab plus bendamustine vs bendamustine in rituximab-refractory CD20+ indolent NHL.", "scientific_summary": "Phase 3 randomized, controlled, open-label multicentre GADOLIN trial in The Lancet Oncology (2016) comparing obinutuzumab plus bendamustine", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-03T15:54:25.252Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334335/horizontal/small_f95f1447-1d98-4a93-82bc-778563a8d18e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["GADOLIN", "obinutuzumab", "bendamustine", "indolent non-Hodgkin lymphoma", "rituximab-refractory", "CD20", "progression-free survival", "phase 3 trial", "maintenance therapy", "toxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334335", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334339", "editorial": {"original_title": "Is obinutuzumab plus chlorambucil superior to rituximab plus chlorambucil in comorbid CLL?", "public_title": "Is obinutuzumab plus chlorambucil superior to rituximab plus chlorambucil in comorbid CLL?", "slug": "video-37c64b", "legacy_canonical_url": "https://5minutehematology.com/programs/video-37c64b", "description": "Review of a randomized phase 3 trial in the New England Journal of Medicine (2014) comparing obinutuzumab-chlorambucil vs rituximab-chlorambucil in comorbid CLL.", "scientific_summary": "Review of a randomized phase 3 trial in the New England Journal of Medicine (2014) comparing obinutuzumab-chlorambucil vs rituximab-chloramb", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is obinutuzumab plus chlorambucil superior to rituximab plus chlorambucil in comorbid CLL?", "language": null, "original_publication_date": "2026-09-03T15:56:25.180Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334339/horizontal/small_6e42c3d6-5f21-4efa-8493-97d8aef69173.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "obinutuzumab", "chlorambucil", "rituximab", "anti-CD20", "phase 3 trial", "comorbidities", "NEJM 2014"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334339", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_24401022", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334343", "editorial": {"original_title": "Does obinutuzumab-based chemotherapy improve outcomes versus rituximab-based regimens in high-tumor burden FL or MZL?", "public_title": "Does obinutuzumab-based chemotherapy improve outcomes versus rituximab-based regimens in high-tumor burden FL or MZL?", "slug": "obinutuzumab-versus-rituximab-chemotherapy-high-tumor-burden-indolent-b-cell-lym", "legacy_canonical_url": "https://5minutehematology.com/programs/video-99c463", "description": "Retrospective real-world comparative cohort (Frontiers in Immunology, 2026) using propensity score overlap weighting to compare obinutuzumab- vs rituximab-based chemotherapy in high-tumor burden follicular lymphoma and marginal zone lymphom", "scientific_summary": "Retrospective real-world comparative cohort (Frontiers in Immunology, 2026) using propensity score overlap weighting to compare obinutuzumab", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does obinutuzumab-based chemotherapy improve outcomes versus rituximab-based regimens in high-tumor burden FL or MZL?", "language": null, "original_publication_date": "2026-09-03T15:58:34.646Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334343/horizontal/small_7636adc0-b317-4cb6-ac1d-f4a62ddd232a.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["obinutuzumab", "rituximab", "follicular lymphoma", "marginal zone lymphoma", "high tumor burden", "indolent B-cell lymphoma", "frontline therapy", "progression-free survival", "overall survival", "POD24", "complete response rate", "propensity score overlap weighting"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334343", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_FOLLICULAR_LYMPHOMA_LOW_TUMOR_BURDEN"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_FOLLICULAR_LYMPHOMA_LOW_TUMOR_BURDEN", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334353", "editorial": {"original_title": "How should oxaliplatin-induced peripheral neuropathy be prevented and treated?", "public_title": "How should oxaliplatin-induced peripheral neuropathy be prevented and treated?", "slug": "oxaliplatin-induced-peripheral-neuropathy-pathogenesis-treatment", "legacy_canonical_url": "https://5minutehematology.com/programs/video-1bc2ff", "description": "Narrative review of oxaliplatin-induced peripheral neuropathy pathogenesis, incidence, risk factors, and management (Supportive Care in Cancer, 2026).", "scientific_summary": "Narrative review of oxaliplatin-induced peripheral neuropathy pathogenesis, incidence, risk factors, and management (Supportive Care in Canc", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should oxaliplatin-induced peripheral neuropathy be prevented and treated?", "language": null, "original_publication_date": "2026-09-03T16:03:57.895Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334353/horizontal/small_09e7ee3a-f937-4111-804a-79f6a507a604.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["oxaliplatin", "peripheral neuropathy", "OIPN", "chemotherapy-induced neuropathy", "platinum chemotherapy", "cold allodynia", "risk factors", "pathogenesis", "symptom management", "painful neuropathy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334353", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41811525", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_OXALIPLATIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "oxaliplatin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334367", "editorial": {"original_title": "Does CHOP-14 improve outcomes versus CHOP-21 in aggressive non-Hodgkin lymphoma?", "public_title": "Does CHOP-14 improve outcomes versus CHOP-21 in aggressive non-Hodgkin lymphoma?", "slug": "phase-iii-trial-chop-21-versus-chop-14-aggressive-non-hodgkins-lymphoma-jcog-980", "legacy_canonical_url": "https://5minutehematology.com/programs/video-aa9d7b", "description": "Review of a randomized phase III trial (JCOG 9809) in Annals of Oncology (2011) comparing dose-dense CHOP-14 vs standard CHOP-21 in untreated stage II-IV aggressive NHL.", "scientific_summary": "Review of a randomized phase III trial (JCOG 9809) in Annals of Oncology (2011) comparing dose-dense CHOP-14 vs standard CHOP-21 in untreate", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does CHOP-14 improve outcomes versus CHOP-21 in aggressive non-Hodgkin lymphoma?", "language": null, "original_publication_date": "2026-09-03T16:05:53.310Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334367/horizontal/small_ba7e2b7d-0bfe-435a-8e89-c31cb216e5b7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["aggressive non-Hodgkin lymphoma", "CHOP-21", "CHOP-14", "dose-dense chemotherapy", "interval shortening", "phase III trial", "JCOG 9809", "progression-free survival", "overall survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334367", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_21196441", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study (JCOG 9809)", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334374", "editorial": {"original_title": "Does pola-R-CHP improve progression-free survival vs R-CHOP in untreated high-risk DLBCL?", "public_title": "Does pola-R-CHP improve progression-free survival vs R-CHOP in untreated high-risk DLBCL?", "slug": "polatuzumab-vedotin-untreated-diffuse-large-b-cell-lymphoma-polarix", "legacy_canonical_url": "https://5minutehematology.com/programs/video-c5fcb1", "description": "Double-blind, placebo-controlled international phase 3 RCT (NEJM, 2022) comparing pola-R-CHP vs R-CHOP in previously untreated intermediate/high-risk DLBCL.", "scientific_summary": "Double-blind, placebo-controlled international phase 3 RCT (NEJM, 2022) comparing pola-R-CHP vs R-CHOP in previously untreated intermediate/", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does pola-R-CHP improve progression-free survival vs R-CHOP in untreated high-risk DLBCL?", "language": null, "original_publication_date": "2026-09-03T16:07:59.215Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334374/horizontal/small_380bd6c6-242b-4ef1-83b6-ffba89c7d2de.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "polatuzumab vedotin", "pola-R-CHP", "R-CHOP", "CD79b", "POLARIX", "phase 3 trial", "progression-free survival", "overall survival", "frontline therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334374", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_34904799", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "relation": "CORE", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_POLARCHP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "pola-R-CHP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": [{"target_id": "PROT_LYM_POLARCHP_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_POLARCHP", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_POLARCHP", "EDGE_POLARCHP_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved Pola-R-CHP resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/pola_r_chp.json"}]}, {"target_id": "PROT_LYM_RCHOP21_001", "type": "Protocol", "relation": "shared_reviewed_decision_context_not_treatment_recommendation", "via_decision_id": "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE", "via_therapy_id": "TX_LYM_RCHOP21", "graph_edge_ids": ["EDGE_ABCL_FRONTLINE_HAS_OPTION_RCHOP21", "EDGE_RCHOP21_HAS_PROTOCOL"], "provenance": [{"review_status": "PHYSICIAN_APPROVED", "source_ref": "docs/CLINICAL_DECISION_GRAPH_AGGRESSIVE_B_CELL_V1_REVIEW.md", "note": "Physician-approved option link to the approved R-CHOP-21 resource; HAS_OPTION does not encode preference or superiority."}, {"review_status": "PHYSICIAN_APPROVED", "source_ref": "data/protocols/lymphoma/r_chop_21.json"}]}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334382", "editorial": {"original_title": "Does adding tafasitamab and lenalidomide to R-CHOP improve outcomes in high-risk untreated DLBCL?", "public_title": "Does adding tafasitamab and lenalidomide to R-CHOP improve outcomes in high-risk untreated DLBCL?", "slug": "tafasitamab-lenalidomide-rchop-versus-rchop-firstline-highrisk-dlbcl-frontmind", "legacy_canonical_url": "https://5minutehematology.com/programs/video-a3e203", "description": "Summary of frontMIND, a global phase 3 randomized double-blind placebo-controlled trial (Lancet, 2026) comparing tafa-len-R-CHOP vs R-CHOP in first-line high-risk DLBCL/HGBL.", "scientific_summary": "Summary of frontMIND, a global phase 3 randomized double-blind placebo-controlled trial (Lancet, 2026) comparing tafa-len-R-CHOP vs R-CHOP i", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding tafasitamab and lenalidomide to R-CHOP improve outcomes in high-risk untreated DLBCL?", "language": null, "original_publication_date": "2026-09-03T16:12:39.402Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334382/horizontal/small_21c94dd5-d3d3-4cff-b37b-704800874ec5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["diffuse large B-cell lymphoma", "DLBCL", "high-grade B-cell lymphoma", "HGBL", "high-risk", "first-line", "R-CHOP", "tafasitamab", "lenalidomide", "anti-CD19", "phase 3 trial", "randomized"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334382", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TAFASITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tafasitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334389", "editorial": {"original_title": "Does first-line ibrutinib improve long-term PFS and OS versus chlorambucil in older patients with CLL without del(17p)?", "public_title": "Does first-line ibrutinib improve long-term PFS and OS versus chlorambucil in older patients with CLL without del(17p)?", "slug": "resonate-2-8-year-follow-up-first-line-ibrutinib-cll", "legacy_canonical_url": "https://5minutehematology.com/programs/video-668244", "description": "Phase 3 randomized RESONATE-2 trial long-term follow-up (Blood, 2022) comparing first-line ibrutinib vs chlorambucil in treatment-naive CLL/SLL age >=65 without del(17p).", "scientific_summary": "Phase 3 randomized RESONATE-2 trial long-term follow-up (Blood, 2022) comparing first-line ibrutinib vs chlorambucil in treatment-naive CLL/", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does first-line ibrutinib improve long-term PFS and OS versus chlorambucil in older patients with CLL without del(17p)?", "language": null, "original_publication_date": "2026-09-03T16:14:45.381Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334389/horizontal/small_1d0dc1b3-97fa-4e4b-8281-cb912c6e0226.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "SLL", "ibrutinib", "BTK inhibitor", "RESONATE-2", "phase 3 trial", "first-line therapy", "progression-free survival", "overall survival", "chlorambucil", "del(11q)", "unmutated IGHV"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334389", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334392", "editorial": {"original_title": "Does venetoclax plus rituximab improve progression-free survival versus bendamustine plus rituximab in relapsed or refra", "public_title": "Does venetoclax plus rituximab improve progression-free survival versus bendamustine plus rituximab in relapsed or refra", "slug": "venetoclax-rituximab-relapsed-refractory-cll-trial", "legacy_canonical_url": "https://5minutehematology.com/programs/video-30fa64", "description": "Randomized, open-label phase 3 trial in NEJM (2018) comparing fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab in relapsed/refractory CLL, focusing on progression-free survival and key safety signals.", "scientific_summary": "Randomized, open-label phase 3 trial in NEJM (2018) comparing fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab in rel", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-03T16:16:49.525Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334392/horizontal/small_28c7ea7b-4cd2-4361-b546-ae255fc00e38.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["venetoclax", "rituximab", "chronic lymphocytic leukemia", "relapsed refractory", "phase 3 trial", "progression-free survival", "bendamustine", "BCL2 inhibitor", "tumor lysis syndrome", "neutropenia", "del17p"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334392", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_29562156", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "existing_reviewed_decision_domain", "source": "data/content_mapping/decision_content_review.csv", "via_decision_id": "DEC_CLL_RELAPSED_FIXED_DURATION"}], "evidence_relations": [], "decision_relations": [{"target_id": "DEC_CLL_RELAPSED_FIXED_DURATION", "relation": "RELATED", "basis": "physician_reviewed_decision_content", "source": "data/content_mapping/decision_content_review.csv", "review_date": "2026-09-06"}], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334394", "editorial": {"original_title": "What are the efficacy and key toxicities of zanubrutinib in relapsed or refractory mantle cell lymphoma?", "public_title": "What are the efficacy and key toxicities of zanubrutinib in relapsed or refractory mantle cell lymphoma?", "slug": "zanubrutinib-relapsed-refractory-mantle-cell-lymphoma", "legacy_canonical_url": "https://5minutehematology.com/programs/video-6149cd", "description": "Phase 1/2 study subgroup analysis in relapsed/refractory mantle cell lymphoma evaluating zanubrutinib 320 mg/day; Blood Advances (2021).", "scientific_summary": "Phase 1/2 study subgroup analysis in relapsed/refractory mantle cell lymphoma evaluating zanubrutinib 320 mg/day; Blood Advances (2021).", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are the efficacy and key toxicities of zanubrutinib in relapsed or refractory mantle cell lymphoma?", "language": null, "original_publication_date": "2026-09-03T16:18:50.040Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334394/horizontal/small_7a241223-dc4e-404a-b228-51438e4bb12e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["zanubrutinib", "BTK inhibitor", "mantle cell lymphoma", "relapsed refractory", "overall response rate", "complete response", "progression-free survival", "duration of response", "adverse events", "infection", "phase 1/2"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334394", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_34152395", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "mantle cell lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334396", "editorial": {"original_title": "In untreated CLL/SLL, does zanubrutinib improve progression-free survival versus bendamustine-rituximab?", "public_title": "In untreated CLL/SLL, does zanubrutinib improve progression-free survival versus bendamustine-rituximab?", "slug": "zanubrutinib-vs-bendamustine-rituximab-untreated-cll-sll-sequoia-phase-3-trial", "legacy_canonical_url": "https://5minutehematology.com/programs/video-fb6700", "description": "Review of SEQUOIA: an open-label, multicentre, randomized controlled phase 3 trial in The Lancet Oncology (2022) comparing frontline zanubrutinib vs bendamustine-rituximab in untreated CLL/SLL.", "scientific_summary": "Review of SEQUOIA: an open-label, multicentre, randomized controlled phase 3 trial in The Lancet Oncology (2022) comparing frontline zanubru", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In untreated CLL/SLL, does zanubrutinib improve progression-free survival versus bendamustine-rituximab?", "language": null, "original_publication_date": "2026-09-03T16:20:53.878Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334396/horizontal/small_0500f649-4b41-4d4a-821b-df57b454d9c0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["zanubrutinib", "bendamustine", "rituximab", "CLL", "SLL", "BTK inhibitor", "frontline therapy", "progression-free survival", "SEQUOIA", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334396", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_35810754", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CLL_ZANUBRUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ZANUBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "zanubrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4334398", "editorial": {"original_title": "How effective is ICE as salvage therapy to bridge relapsed or refractory aggressive NHL to autologous SCT?", "public_title": "How effective is ICE as salvage therapy to bridge relapsed or refractory aggressive NHL to autologous SCT?", "slug": "ice-salvage-relapsed-refractory-aggressive-nhl-stem-cell-mobilization", "legacy_canonical_url": "https://5minutehematology.com/programs/video-18a335", "description": "Prospective clinical trial series (Annals of Oncology, 2003) of 222 patients with relapsed/refractory aggressive non-Hodgkin lymphoma evaluating ICE salvage response, toxicity, and stem cell mobilization for SCT.", "scientific_summary": "Prospective clinical trial series of 222 patients with relapsed/refractory aggressive NHL evaluating ICE salvage, and HSCT.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Lymphoid Neoplasms"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective is ICE as salvage therapy to bridge relapsed or refractory aggressive NHL to autologous SCT?", "language": null, "original_publication_date": "2026-09-03T16:23:00.613Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4334398/horizontal/small_2e5163b0-e5bb-4921-9bba-14b271e0b597.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ICE regimen", "ifosfamide", "carboplatin", "etoposide", "salvage chemotherapy", "relapsed lymphoma", "refractory lymphoma", "aggressive non-Hodgkin lymphoma", "DLBCL", "rituximab", "stem cell mobilization", "autologous stem cell transplant"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4334398", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IFOSFAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ifosfamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CARBOPLATIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carboplatin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ETOPOSIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "etoposide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337615", "editorial": {"original_title": "Should venetoclax be added to DA-EPOCH-R in newly diagnosed double-hit lymphoma?", "public_title": "Should venetoclax be added to DA-EPOCH-R in newly diagnosed double-hit lymphoma?", "slug": "venetoclax-added-dose-adjusted-epoch-r-newly-diagnosed-double-hit-lymphomas-phas", "legacy_canonical_url": null, "description": "Phase 2 results from the open-label, randomized, controlled ALLIANCE A051701 trial (The Lancet Haematology, 2026) evaluating venetoclax plus DA-EPOCH-R vs DA-EPOCH-R alone in newly diagnosed double-hit lymphoma.", "scientific_summary": "Phase 2 results from the open-label, randomized, controlled ALLIANCE A051701 trial (The Lancet Haematology, 2026) evaluating venetoclax plus", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Lymphoid Neoplasms"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should venetoclax be added to DA-EPOCH-R in newly diagnosed double-hit lymphoma?", "language": null, "original_publication_date": "2026-09-05T18:01:40.679Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337615/horizontal/small_bfbae20c-3682-4531-ac9b-62eec33ca410.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["double-hit lymphoma", "high-grade B-cell lymphoma", "DA-EPOCH-R", "venetoclax", "BCL2 inhibitor", "randomized phase 2 trial", "ALLIANCE A051701", "progression-free survival", "overall survival", "treatment-related mortality", "febrile neutropenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337615", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_DAEPOCHR", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "DA-EPOCH-R", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337616", "editorial": {"original_title": "In CML-CP after 2 or more TKIs, does asciminib improve MMR vs bosutinib?", "public_title": "In CML-CP after 2 or more TKIs, does asciminib improve MMR vs bosutinib?", "slug": "phase-3-asciminib-vs-bosutinib-cml-after-2-prior-tkis", "legacy_canonical_url": null, "description": "Phase 3 open-label randomized trial (Blood, 2021) comparing asciminib 40 mg BID vs bosutinib 500 mg QD in CML-CP after 2 prior TKIs; primary endpoint MMR at week 24.", "scientific_summary": "Phase 3 open-label randomized trial (Blood, 2021) comparing asciminib 40 mg BID vs bosutinib 500 mg QD in CML-CP after 2 prior TKIs; primary", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In CML-CP after 2 or more TKIs, does asciminib improve MMR vs bosutinib?", "language": null, "original_publication_date": "2026-09-05T18:04:26.896Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337616/horizontal/small_a062c5a2-893a-4808-9baa-75ab12d25f7b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["asciminib", "STAMP inhibitor", "bosutinib", "CML-CP", "BCR-ABL1", "third-line", "randomized trial", "major molecular response", "week 24", "adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337616", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CML_ASCIMINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ASCIMINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "asciminib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_BOSUTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BOSUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bosutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337617", "editorial": {"original_title": "Can newly diagnosed AML be treated with an all-oral regimen?", "public_title": "Can newly diagnosed AML be treated with an all-oral regimen?", "slug": "all-oral-treatment-newly-diagnosed-acute-myeloid-leukemia", "legacy_canonical_url": null, "description": "Review of a clinical trial evaluating an all-oral treatment strategy for newly diagnosed acute myeloid leukemia, as reported in the New England Journal of Medicine (2026).", "scientific_summary": "Review of a clinical trial evaluating an all-oral treatment strategy for newly diagnosed acute myeloid leukemia, as reported in the New Engl", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can newly diagnosed AML be treated with an all-oral regimen?", "language": null, "original_publication_date": "2026-09-05T18:06:23.604Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337617/horizontal/small_9a6fdfec-4434-4dfb-b3bb-9dc0198b8440.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "AML", "all-oral regimen", "frontline therapy", "newly diagnosed", "clinical trial", "NEJM"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337617", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42235013", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337619", "editorial": {"original_title": "Which anthracycline optimizes induction and consolidation outcomes in adult AML?", "public_title": "Which anthracycline optimizes induction and consolidation outcomes in adult AML?", "slug": "daunorubicin-mitoxantrone-idarubicin-aml-induction-consolidation-aml10", "legacy_canonical_url": null, "description": "Review of the AML-10 randomized clinical trial comparing daunorubicin, mitoxantrone, and idarubicin for induction and consolidation in adults with AML (Journal of Clinical Oncology, 2009).", "scientific_summary": "Review of the AML-10 randomized clinical trial comparing daunorubicin, mitoxantrone, and idarubicin for induction and consolidation in adult", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Which anthracycline optimizes induction and consolidation outcomes in adult AML?", "language": null, "original_publication_date": "2026-09-05T18:09:25.366Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337619/horizontal/small_6e99903e-be96-441b-bf7d-4bab6128be84.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "AML-10", "EORTC", "GIMEMA", "daunorubicin", "mitoxantrone", "idarubicin", "induction chemotherapy", "consolidation chemotherapy", "randomized trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337619", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "acute myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DAUNORUBICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daunorubicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_MITOXANTRONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "mitoxantrone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IDARUBICIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "idarubicin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337623", "editorial": {"original_title": "Can venetoclax be used safely for cytoreduction during ATRA/ATO induction in newly diagnosed APL?", "public_title": "Can venetoclax be used safely for cytoreduction during ATRA/ATO induction in newly diagnosed APL?", "slug": "venetoclax-cytoreduction-induction-newly-diagnosed-apl", "legacy_canonical_url": null, "description": "Single-center retrospective analysis (European Journal of Haematology, 2026) comparing venetoclax vs conventional cytoreduction during ATRA/ATO induction in newly diagnosed APL.", "scientific_summary": "Single-center retrospective analysis (European Journal of Haematology, 2026) comparing venetoclax vs conventional cytoreduction during ATRA/", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can venetoclax be used safely for cytoreduction during ATRA/ATO induction in newly diagnosed APL?", "language": null, "original_publication_date": "2026-09-05T18:13:58.280Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337623/horizontal/small_e7eb722e-3617-4e80-9dea-cd488ea1c82d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute promyelocytic leukemia", "APL", "venetoclax", "cytoreduction", "induction therapy", "ATRA", "arsenic trioxide", "hydroxyurea", "anthracycline", "differentiation syndrome", "hematologic recovery", "molecular remission"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337623", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42442416", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_APL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "APL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337624", "editorial": {"original_title": "Should HMA plus venetoclax be used as induction to transplant in younger AML?", "public_title": "Should HMA plus venetoclax be used as induction to transplant in younger AML?", "slug": "hmai-venetoclax-younger-aml-meta-analysis-transplant", "legacy_canonical_url": null, "description": "Systematic review and meta-analysis (PRISMA) in Cancer (2026) evaluating hypomethylating agents plus venetoclax in younger/fit AML, focusing on CR/CRi, MRD negativity, 1-year OS/EFS, and HSCT rates.", "scientific_summary": "Systematic review and meta-analysis (PRISMA) in Cancer (2026) evaluating hypomethylating agents plus venetoclax in younger/fit AML, focusing", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should HMA plus venetoclax be used as induction to transplant in younger AML?", "language": null, "original_publication_date": "2026-09-05T18:16:00.807Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337624/horizontal/small_d54ce683-4afb-4be0-bb01-fa667f4a85bd.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "younger AML", "hypomethylating agents", "azacitidine", "decitabine", "venetoclax", "induction therapy", "MRD negativity", "complete remission", "event-free survival", "overall survival", "allogeneic HSCT"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337624", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41914434", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "acute myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_TRANSPLANT_CELLULAR_THERAPY", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "allogeneic HSCT", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DECITABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "decitabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337625", "editorial": {"original_title": "Does venetoclax plus azacitidine improve long-term overall survival in chemotherapy-ineligible newly diagnosed AML?", "public_title": "Does venetoclax plus azacitidine improve long-term overall survival in chemotherapy-ineligible newly diagnosed AML?", "slug": "viale-a-long-term-follow-up-venetoclax-azacitidine-chemo-ineligible-untreated-am", "legacy_canonical_url": null, "description": "Final long-term follow-up of the randomized, placebo-controlled phase 3 VIALE-A trial in untreated AML ineligible for intensive chemotherapy (American Journal of Hematology, 2024).", "scientific_summary": "Final long-term follow-up of the randomized, placebo-controlled phase 3 VIALE-A trial in untreated AML ineligible for intensive chemotherapy", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does venetoclax plus azacitidine improve long-term overall survival in chemotherapy-ineligible newly diagnosed AML?", "language": null, "original_publication_date": "2026-09-05T18:18:03.683Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337625/horizontal/small_46c9f515-302d-426b-b53e-2fd17a67fc76.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["AML", "acute myeloid leukemia", "VIALE-A", "venetoclax", "azacitidine", "hypomethylating agent", "overall survival", "CR", "CRi", "MRD", "thrombocytopenia", "neutropenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337625", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38343151", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "acute myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337628", "editorial": {"original_title": "How much life expectancy is lost after an MPN diagnosis in Sweden?", "public_title": "How much life expectancy is lost after an MPN diagnosis in Sweden?", "slug": "loss-life-expectancy-myeloproliferative-neoplasms-sweden", "legacy_canonical_url": null, "description": "Population-based Swedish cohort study (2002-2021; follow-up to 2022) using relative survival period analysis (2012-2021) to estimate life expectancy loss in MPN (Haematologica, 2025).", "scientific_summary": "Population-based Swedish cohort study (2002-2021; follow-up to 2022) using relative survival period analysis (2012-2021) to estimate life ex", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How much life expectancy is lost after an MPN diagnosis in Sweden?", "language": null, "original_publication_date": "2026-09-05T18:20:03.696Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337628/horizontal/small_5a35715c-5369-4c3f-b653-098fbb284a91.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["myeloproliferative neoplasms", "MPN", "life expectancy", "loss of life expectancy", "relative survival", "period analysis", "population-based study", "Sweden", "polycythemia vera", "essential thrombocythemia", "primary myelofibrosis", "RMST"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337628", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40994348", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MPN", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_POLYCYTHEMIA_VERA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "polycythemia vera", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_ESSENTIAL_THROMBOCYTHEMIA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "essential thrombocythemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_PRIMARY_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "primary myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337631", "editorial": {"original_title": "Should venetoclax be given for 14 or 28 days with azacitidine in older adults with newly diagnosed AML?", "public_title": "Should venetoclax be given for 14 or 28 days with azacitidine in older adults with newly diagnosed AML?", "slug": "opti-aml-compare-28-14-days-venetoclax-azacitidine-older-adults-aml", "legacy_canonical_url": null, "description": "Prospective randomized phase 2 OPTI-AML trial comparing 28-day vs 14-day venetoclax with azacitidine induction in genomically agnostic ND-AML age >=60, Journal (via DOI) 2026.", "scientific_summary": "Prospective randomized phase 2 OPTI-AML trial comparing 28-day vs 14-day venetoclax with azacitidine induction in genomically agnostic ND-AM", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Free Hematology Videos", "Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should venetoclax be given for 14 or 28 days with azacitidine in older adults with newly diagnosed AML?", "language": null, "original_publication_date": "2026-09-05T18:21:54.520Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337631/horizontal/small_eab374f9-ce00-4c59-aea1-fdeb2ab3b693.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "AML", "azacitidine", "venetoclax", "induction dosing", "14-day venetoclax", "28-day venetoclax", "older adults", "randomized phase 2 trial", "OPTI-AML", "MRD negativity", "cytopenias"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337631", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42520193", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "OPTI-AML: Prospective Comparison of 28 vs 14 Days of Venetoclax Induction with Azacitidine in Older Adults with AML", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337632", "editorial": {"original_title": "Does ATRA plus arsenic trioxide improve quality of life versus ATRA plus chemotherapy in low- or intermediate-risk APL?", "public_title": "Does ATRA plus arsenic trioxide improve quality of life versus ATRA plus chemotherapy in low- or intermediate-risk APL?", "slug": "atra-arsenic-trioxide-vs-atra-chemotherapy-apl-hrqol", "legacy_canonical_url": null, "description": "HRQOL analysis from a randomized phase III trial in newly diagnosed low- or intermediate-risk APL comparing ATRA plus arsenic trioxide vs ATRA plus chemotherapy (Journal of Clinical Oncology, 2014).", "scientific_summary": "HRQOL analysis from a randomized phase III trial in newly diagnosed low- or intermediate-risk APL comparing ATRA plus arsenic trioxide vs AT", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does ATRA plus arsenic trioxide improve quality of life versus ATRA plus chemotherapy in low- or intermediate-risk APL?", "language": null, "original_publication_date": "2026-09-05T18:24:05.864Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337632/horizontal/small_0f1e9b3e-16fb-4c34-8f4b-9b228f9456fe.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute promyelocytic leukemia", "APL", "ATRA", "arsenic trioxide", "chemotherapy", "randomized phase III trial", "health-related quality of life", "EORTC QLQ-C30", "fatigue", "induction therapy", "consolidation therapy", "low-risk APL"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337632", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_APL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "APL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337633", "editorial": {"original_title": "How can the PRISM model stratify survival risk after HMA plus venetoclax in newly diagnosed AML?", "public_title": "How can the PRISM model stratify survival risk after HMA plus venetoclax in newly diagnosed AML?", "slug": "prism-risk-model-aml-hma-venetoclax-prognostication", "legacy_canonical_url": null, "description": "Multinational prognostic model development and validation study in Journal of Clinical Oncology (2026) deriving and externally validating the PRISM score after HMA plus venetoclax in newly diagnosed AML.", "scientific_summary": "Multinational prognostic model development and validation study in Journal of Clinical Oncology (2026) deriving and externally validating th", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How can the PRISM model stratify survival risk after HMA plus venetoclax in newly diagnosed AML?", "language": null, "original_publication_date": "2026-09-05T18:26:00.540Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337633/horizontal/small_22908cde-0cc5-4b6d-bce1-4fce1b2117d0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["AML", "venetoclax", "hypomethylating agents", "HMA-VEN", "prognostic model", "risk stratification", "overall survival", "PRISM score", "cytogenetics", "molecular mutations", "TP53", "FLT3-ITD"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337633", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42391582", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337637", "editorial": {"original_title": "Does frontline nilotinib improve 10-year molecular responses and treatment-free remission eligibility vs imatinib in chr", "public_title": "Does frontline nilotinib improve 10-year molecular responses and treatment-free remission eligibility vs imatinib in chr", "slug": "enestnd-10-year-frontline-nilotinib-vs-imatinib-cml-chronic-phase", "legacy_canonical_url": null, "description": "Review of the ENESTnd randomized trial 10-year analysis in newly diagnosed chronic-phase CML (Leukemia, 2021), comparing frontline nilotinib vs imatinib for molecular response, progression, TFR eligibility, and cardiovascular risk.", "scientific_summary": "Review of the ENESTnd randomized trial 10-year analysis in newly diagnosed chronic-phase CML (Leukemia, 2021), comparing frontline nilotinib", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T18:28:05.221Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337637/horizontal/small_bef6e170-4270-4218-908d-5b69e378cb52.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CML chronic phase", "ENESTnd", "nilotinib", "imatinib", "frontline therapy", "10-year follow-up", "MMR", "MR4.5", "treatment-free remission", "disease progression", "cardiovascular events", "tyrosine kinase inhibitors"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337637", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4083845", "relation": "same_documented_source", "shared_reference_ids": ["PMID_33414482"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_33414482", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["ENESTnd 10-year"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_CML_NILOTINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_NILOTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "nilotinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_CML_IMATINIB", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_IMATINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "imatinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337642", "editorial": {"original_title": "How effective is VRd induction followed by autologous stem cell transplant in multiple myeloma?", "public_title": "How effective is VRd induction followed by autologous stem cell transplant in multiple myeloma?", "slug": "vrd-asct-multiple-myeloma-outcomes", "legacy_canonical_url": null, "description": "Retrospective single-center cohort (Mayo Clinic) of 243 myeloma patients receiving VRd induction followed by ASCT; Blood Cancer Journal, 2018.", "scientific_summary": "Retrospective single-center cohort (Mayo Clinic) of 243 myeloma patients receiving VRd induction followed by ASCT; Blood Cancer Journal, 201", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How effective is VRd induction followed by autologous stem cell transplant in multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:30:14.139Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337642/horizontal/small_032741e6-4576-4cfa-b569-51cd4d705d3d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "VRd", "bortezomib", "lenalidomide", "dexamethasone", "autologous stem cell transplant", "ASCT", "maintenance therapy", "high-risk cytogenetics", "overall survival", "progression-free survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337642", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30409963", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337650", "editorial": {"original_title": "Is VTD superior to TD for post-ASCT consolidation in newly diagnosed multiple myeloma?", "public_title": "Is VTD superior to TD for post-ASCT consolidation in newly diagnosed multiple myeloma?", "slug": "vtd-vs-td-consolidation-after-autologous-hsct-newly-diagnosed-multiple-myeloma", "legacy_canonical_url": null, "description": "Physician-focused review of a Blood 2012 randomized clinical trial comparing bortezomib-thalidomide-dexamethasone versus thalidomide-dexamethasone consolidation after autologous stem cell transplantation in newly diagnosed multiple myeloma.", "scientific_summary": "Physician-focused review of a Blood 2012 randomized clinical trial comparing bortezomib-thalidomide-dexamethasone versus thalidomide-dexamet", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is VTD superior to TD for post-ASCT consolidation in newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:33:31.026Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337650/horizontal/small_078a1f0f-bc55-4ea9-866d-de9871933fd7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "autologous stem cell transplant", "consolidation therapy", "bortezomib", "thalidomide", "dexamethasone", "VTD", "TD", "randomized trial", "Blood"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337650", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_THALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "thalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VTD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VTD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337652", "editorial": {"original_title": "Does adding daratumumab to bortezomib and dexamethasone improve progression-free survival in relapsed multiple myeloma?", "public_title": "Does adding daratumumab to bortezomib and dexamethasone improve progression-free survival in relapsed multiple myeloma?", "slug": "daratumumab-bortezomib-dexamethasone-relapsed-multiple-myeloma", "legacy_canonical_url": null, "description": "Phase 3 randomized trial (NEJM, 2016) in relapsed or relapsed/refractory multiple myeloma comparing daratumumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone alone.", "scientific_summary": "Phase 3 randomized trial (NEJM, 2016) in relapsed or relapsed/refractory multiple myeloma comparing daratumumab plus bortezomib/dexamethason", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding daratumumab to bortezomib and dexamethasone improve progression-free survival in relapsed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:35:30.941Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337652/horizontal/small_6a64bff8-9a3d-4051-9cdf-2f2ca3091180.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["daratumumab", "bortezomib", "dexamethasone", "multiple myeloma", "relapsed myeloma", "relapsed refractory", "CD38", "progression-free survival", "phase 3 trial", "randomized trial", "infusion-related reactions", "thrombocytopenia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337652", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337654", "editorial": {"original_title": "What are response and 1-year PFS outcomes with D-VCd in newly diagnosed and relapsed multiple myeloma?", "public_title": "What are response and 1-year PFS outcomes with D-VCd in newly diagnosed and relapsed multiple myeloma?", "slug": "daratumumab-bortezomib-cyclophosphamide-dexamethasone-lyra-study", "legacy_canonical_url": null, "description": "US community, multicenter phase 2 study (LYRA) in British Journal of Haematology (2019) evaluating daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in NDMM and RMM, including ASCT-eligible patients and daratumumab maintenanc", "scientific_summary": "US community, multicenter phase 2 study (LYRA) in British Journal of Haematology (2019) evaluating daratumumab plus bortezomib, cyclophospha", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What are response and 1-year PFS outcomes with D-VCd in newly diagnosed and relapsed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:37:24.335Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337654/horizontal/small_0faf93c0-a041-42aa-bbdb-81f96f689df2.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed myeloma", "relapsed myeloma", "daratumumab", "bortezomib", "cyclophosphamide", "dexamethasone", "D-VCd", "LYRA", "phase 2", "autologous stem cell transplant", "maintenance therapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337654", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_30828799", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337655", "editorial": {"original_title": "Does adding daratumumab to lenalidomide and dexamethasone improve overall survival in transplant-ineligible newly diagno", "public_title": "Does adding daratumumab to lenalidomide and dexamethasone improve overall survival in transplant-ineligible newly diagno", "slug": "daratumumab-lenalidomide-dexamethasone-vs-lenalidomide-dexamethasone-maia-overal", "legacy_canonical_url": null, "description": "Prespecified interim overall survival analysis from the randomized, open-label, phase 3 MAIA trial (The Lancet Oncology, 2021) in transplant-ineligible newly diagnosed multiple myeloma comparing D-Rd vs Rd.", "scientific_summary": "Prespecified interim overall survival analysis from the randomized, open-label, phase 3 MAIA trial (The Lancet Oncology, 2021) in transplant", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T18:39:21.696Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337655/horizontal/small_b48a6be7-ee00-4e8a-8fe4-2fb8c5295158.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed", "transplant-ineligible", "daratumumab", "lenalidomide", "dexamethasone", "MAIA", "overall survival", "phase 3 trial", "randomized open-label"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337655", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337656", "editorial": {"original_title": "Does adding isatuximab to carfilzomib-dexamethasone improve progression-free survival in relapsed multiple myeloma?", "public_title": "Does adding isatuximab to carfilzomib-dexamethasone improve progression-free survival in relapsed multiple myeloma?", "slug": "isatuximab-carfilzomib-dexamethasone-ikema-updated-results-relapsed-multiple-mye", "legacy_canonical_url": null, "description": "Updated follow-up analysis of IKEMA, a randomized Phase 3 trial (Blood Cancer Journal, 2023) evaluating isatuximab plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in relapsed/refractory multiple myeloma.", "scientific_summary": "Updated follow-up analysis of IKEMA, a randomized Phase 3 trial (Blood Cancer Journal, 2023) evaluating isatuximab plus carfilzomib-dexameth", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding isatuximab to carfilzomib-dexamethasone improve progression-free survival in relapsed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:41:25.787Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337656/horizontal/small_87b6ce88-35fe-4c24-8408-c10a32af3f64.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["isatuximab", "carfilzomib", "dexamethasone", "IKEMA", "relapsed multiple myeloma", "randomized phase 3 trial", "progression-free survival", "MRD negativity", "complete response", "anti-CD38"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337656", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_ISATUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "isatuximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CARFILZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carfilzomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_ISAKD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "IKEMA", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337657", "editorial": {"original_title": "Does early autologous stem cell transplantation improve outcomes after RVD induction in newly diagnosed multiple myeloma", "public_title": "Does early autologous stem cell transplantation improve outcomes after RVD induction in newly diagnosed multiple myeloma", "slug": "rvd-early-autologous-transplant-myeloma-ifm-2009", "legacy_canonical_url": null, "description": "Summary of the IFM 2009 randomized controlled trial in The New England Journal of Medicine (2017) comparing RVD plus early autologous transplantation vs RVD alone in newly diagnosed multiple myeloma.", "scientific_summary": "Summary of the IFM 2009 randomized controlled trial in The New England Journal of Medicine (2017) comparing RVD plus early autologous transp", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T18:43:22.006Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337657/horizontal/small_4b9538fb-300a-4ddd-9e26-e71d37cf8e55.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "RVD", "lenalidomide", "bortezomib", "dexamethasone", "autologous stem cell transplantation", "early transplant", "progression-free survival", "overall survival", "IFM 2009", "randomized controlled trial", "NEJM 2017"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337657", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4094580", "relation": "same_documented_source", "shared_reference_ids": ["PMID_28379796"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_28379796", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["IFM 2009"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "RVD", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337658", "editorial": {"original_title": "How should AL amyloidosis be diagnosed, staged, and treated in 2026?", "public_title": "How should AL amyloidosis be diagnosed, staged, and treated in 2026?", "slug": "immunoglobulin-light-chain-amyloidosis-2026-diagnosis-prognosis-treatment", "legacy_canonical_url": null, "description": "Physician update based on a narrative clinical review (Annual Clinical Updates) in the American Journal of Hematology (2026) covering Congo red diagnosis, biomarker staging, and modern therapy.", "scientific_summary": "Physician update based on a narrative clinical review (Annual Clinical Updates) in the American Journal of Hematology (2026) covering Congo", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should AL amyloidosis be diagnosed, staged, and treated in 2026?", "language": null, "original_publication_date": "2026-09-05T18:45:26.683Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337658/horizontal/small_e55d8068-6dc3-4123-91e8-88fb417c038f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["AL amyloidosis", "light chain amyloid", "Congo red", "NT-proBNP", "troponin", "free light chain difference", "staging", "daratumumab", "bortezomib", "cyclophosphamide", "dexamethasone", "VGPR"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337658", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41723627", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AL_AMYLOIDOSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AL amyloidosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337659", "editorial": {"original_title": "Can BelaRd improve outcomes in frail, transplant-ineligible newly diagnosed multiple myeloma?", "public_title": "Can BelaRd improve outcomes in frail, transplant-ineligible newly diagnosed multiple myeloma?", "slug": "belantamab-mafodotin-lenalidomide-dexamethasone-frail-ndmm-belard-trial", "legacy_canonical_url": null, "description": "Phase 1/2 BelaRd trial in Blood (2025) evaluating belantamab mafodotin plus lenalidomide and dexamethasone in intermediate-fit/frail, transplant-ineligible NDMM, including randomized ocular-toxicity monitoring strategies.", "scientific_summary": "Phase 1/2 BelaRd trial in Blood (2025) evaluating belantamab mafodotin plus lenalidomide and dexamethasone in intermediate-fit/frail, transp", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can BelaRd improve outcomes in frail, transplant-ineligible newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T18:47:34.058Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337659/horizontal/small_312dac7a-d593-443b-9cab-c7cb3a0328db.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["belantamab mafodotin", "dexamethasone", "BelaRd", "newly diagnosed multiple myeloma", "frail patients", "intermediate-fit", "ocular adverse events", "keratopathy", "vision-related anamnestic tool", "phase 1/2 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337659", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41346230", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BELANTAMAB_MAFODOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "belantamab mafodotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337663", "editorial": {"original_title": "Should zoledronic acid be continued beyond 2 years in myeloma patients achieving VGPR or better?", "public_title": "Should zoledronic acid be continued beyond 2 years in myeloma patients achieving VGPR or better?", "slug": "zoledronic-acid-continue-beyond-2-years-vgpr-myeloma-bone-markers", "legacy_canonical_url": null, "description": "Post-hoc subgroup analysis of the Magnolia randomized trial (British Journal of Haematology, 2026) evaluating continued monthly zoledronic acid beyond 2 years in VGPR+ multiple myeloma and the prognostic value of bone turnover markers after", "scientific_summary": "Post-hoc subgroup analysis of the Magnolia randomized trial (British Journal of Haematology, 2026) evaluating continued monthly zoledronic a", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should zoledronic acid be continued beyond 2 years in myeloma patients achieving VGPR or better?", "language": null, "original_publication_date": "2026-09-05T18:55:22.923Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337663/horizontal/small_1e43a3ec-da2b-46b4-9ae4-2e693e1c57ec.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "zoledronic acid", "bisphosphonate duration", "very good partial response", "progressive bone disease", "bone turnover markers", "CTX", "TRAcP", "P1NP", "BAP", "Magnolia trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337663", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42581608", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337677", "editorial": {"original_title": "Should lenalidomide maintenance be continuous or fixed for standard-risk newly diagnosed multiple myeloma without up-fro", "public_title": "Should lenalidomide maintenance be continuous or fixed for standard-risk newly diagnosed multiple myeloma without up-fro", "slug": "continuous-fixed-duration-lenalidomide-maintenance-standard-risk-ndmm-no-asct", "legacy_canonical_url": null, "description": "Phase 3 randomized trial in standard-risk newly diagnosed multiple myeloma without up-front ASCT comparing continuous vs 2-year fixed-duration lenalidomide maintenance after induction (NEJM 2026).", "scientific_summary": "Phase 3 randomized trial in standard-risk newly diagnosed multiple myeloma without up-front ASCT comparing continuous vs 2-year fixed-durati", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T19:43:16.111Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337677/horizontal/small_c3de9cf1-d193-4318-aaa9-2f4c549d3cf5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "lenalidomide maintenance", "maintenance duration", "continuous therapy", "fixed duration", "phase 3 trial", "overall survival", "progression-free survival", "standard-risk", "non-transplant", "second primary malignancy", "adverse events"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337677", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337678", "editorial": {"original_title": "Should daratumumab be added to VRd for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma?", "public_title": "Should daratumumab be added to VRd for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma?", "slug": "daratumumab-added-vrd-transplant-ineligible-deferred-ndmm-cepheus", "legacy_canonical_url": null, "description": "Randomized phase 3 trial (CEPHEUS; Nature Medicine, 2025) comparing subcutaneous daratumumab plus VRd vs VRd in transplant-ineligible or transplant-deferred NDMM, with MRD negativity as the primary endpoint.", "scientific_summary": "Randomized phase 3 trial (CEPHEUS; Nature Medicine, 2025) comparing subcutaneous daratumumab plus VRd vs VRd in transplant-ineligible or tra", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should daratumumab be added to VRd for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T19:45:07.620Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337678/horizontal/small_b5901833-0fe0-4584-bb48-ae29bbb58030.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["daratumumab", "VRd", "D-VRd", "newly diagnosed multiple myeloma", "transplant-ineligible", "transplant-deferred", "MRD negativity", "next-generation sequencing", "progression-free survival", "CEPHEUS trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337678", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_DARAVRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "D-VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337992", "editorial": {"original_title": "Does adding daratumumab to lenalidomide and dexamethasone improve overall survival in transplant-ineligible NDMM?", "public_title": "Does adding daratumumab to lenalidomide and dexamethasone improve overall survival in transplant-ineligible NDMM?", "slug": "daratumumab-lenalidomide-dexamethasone-transplant-ineligible-ndmm-maia-final-sur", "legacy_canonical_url": null, "description": "Final overall survival analysis of the MAIA randomized phase 3 trial (Leukemia, 2026) comparing daratumumab-Rd vs Rd in transplant-ineligible newly diagnosed multiple myeloma with long-term follow-up.", "scientific_summary": "Final overall survival analysis of the MAIA randomized phase 3 trial (Leukemia, 2026) comparing daratumumab-Rd vs Rd in transplant-ineligibl", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does adding daratumumab to lenalidomide and dexamethasone improve overall survival in transplant-ineligible NDMM?", "language": null, "original_publication_date": "2026-09-05T20:54:28.106Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337992/horizontal/small_9cf51b57-ca2b-4015-8b42-d56b8334996d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed", "transplant-ineligible", "daratumumab", "lenalidomide", "dexamethasone", "D-Rd", "Rd", "MAIA trial", "overall survival", "progression-free survival", "phase 3"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337992", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42637879", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337993", "editorial": {"original_title": "What are the emerging first-line treatment options for newly diagnosed DLBCL beyond R-CHOP?", "public_title": "What are the emerging first-line treatment options for newly diagnosed DLBCL beyond R-CHOP?", "slug": "emerging-treatment-strategies-newly-diagnosed-dlbcl", "legacy_canonical_url": null, "description": "Review article summarizing emerging first-line strategies for newly diagnosed diffuse large B-cell lymphoma, including pola-R-CHP, targeted agents, CAR-T, and CD20xCD3 bispecifics (International Journal of Clinical Oncology, 2026).", "scientific_summary": "Review article summarizing emerging first-line strategies for newly diagnosed diffuse large B-cell lymphoma, including pola-R-CHP, targeted", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_area_corrected_from_explicit_DLBCL_subject_original_categories_preserved", "clinical_question": "What are the emerging first-line treatment options for newly diagnosed DLBCL beyond R-CHOP?", "language": null, "original_publication_date": "2026-09-05T20:56:40.299Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337993/horizontal/small_76d94e83-dad8-4ae9-a097-e7ec011b71b1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["DLBCL", "newly diagnosed", "first-line therapy", "R-CHOP", "pola-R-CHP", "polatuzumab vedotin", "targeted therapy", "cell of origin", "molecular subtypes", "golcadomide", "tafasitamab", "CAR-T"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337993", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42286378", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_POLARCHP", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "pola-R-CHP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POLATUZUMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "polatuzumab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TAFASITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "tafasitamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337996", "editorial": {"original_title": "How should solitary plasmacytoma be diagnosed and followed to exclude multiple myeloma?", "public_title": "How should solitary plasmacytoma be diagnosed and followed to exclude multiple myeloma?", "slug": "imwg-recommendations-diagnosis-management-solitary-plasmacytomas", "legacy_canonical_url": null, "description": "Physician-focused summary of International Myeloma Working Group clinical practice guideline recommendations for diagnosis, evaluation, treatment, and response assessment of solitary plasmacytomas (J Clin Oncol, 2026).", "scientific_summary": "Physician-focused summary of International Myeloma Working Group clinical practice guideline recommendations for diagnosis, evaluation, trea", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should solitary plasmacytoma be diagnosed and followed to exclude multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T20:58:37.752Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337996/horizontal/small_d146a88a-d6eb-4fd0-972f-4bf5b6c0df39.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["solitary plasmacytoma", "solitary bone plasmacytoma", "extramedullary plasmacytoma", "IMWG guidelines", "multiple myeloma exclusion", "bone marrow infiltration", "advanced imaging", "radiotherapy", "response assessment", "surveillance"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337996", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4338012", "relation": "same_documented_source", "shared_reference_ids": ["PMID_42485589"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_42485589", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_SOLITARY_BONE_PLASMACYTOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "solitary bone plasmacytoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_EXTRAMEDULLARY_PLASMACYTOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "extramedullary plasmacytoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337998", "editorial": {"original_title": "Should lenalidomide plus dexamethasone be used in transplant-ineligible multiple myeloma?", "public_title": "Should lenalidomide plus dexamethasone be used in transplant-ineligible multiple myeloma?", "slug": "lenalidomide-dexamethasone-transplant-ineligible-myeloma", "legacy_canonical_url": null, "description": "Review of a randomized controlled trial in transplant-ineligible multiple myeloma evaluating lenalidomide plus dexamethasone (NEJM, 2014).", "scientific_summary": null, "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should lenalidomide plus dexamethasone be used in transplant-ineligible multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:00:34.046Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337998/horizontal/small_62394e6a-abb4-4e13-9eee-9d8dd2907922.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "transplant-ineligible", "lenalidomide", "dexamethasone", "Rd regimen", "randomized trial", "NEJM", "overall survival", "progression-free survival", "toxicity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337998", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_25184863", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4337999", "editorial": {"original_title": "Does lenalidomide maintenance after ASCT improve overall survival in newly diagnosed multiple myeloma?", "public_title": "Does lenalidomide maintenance after ASCT improve overall survival in newly diagnosed multiple myeloma?", "slug": "lenalidomide-maintenance-asct-newly-diagnosed-multiple-myeloma-meta-analysis", "legacy_canonical_url": null, "description": "Patient-level meta-analysis of three randomized controlled trials in NDMM post-ASCT (Journal of Clinical Oncology, 2017) comparing lenalidomide maintenance vs placebo/observation for PFS, OS, and second primary malignancies.", "scientific_summary": "Patient-level meta-analysis of three randomized controlled trials in NDMM post-ASCT (Journal of Clinical Oncology, 2017) comparing lenalidom", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does lenalidomide maintenance after ASCT improve overall survival in newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:02:56.309Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4337999/horizontal/small_c8c977ad-926f-4a93-8b7e-b66b13fac591.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["lenalidomide", "maintenance therapy", "autologous stem-cell transplantation", "multiple myeloma", "newly diagnosed", "meta-analysis", "randomized controlled trials", "overall survival", "second primary malignancy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4337999", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_28742454", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338000", "editorial": {"original_title": "Does adding ixazomib to lenalidomide-dexamethasone improve progression-free survival in transplant-ineligible newly diag", "public_title": "Does adding ixazomib to lenalidomide-dexamethasone improve progression-free survival in transplant-ineligible newly diag", "slug": "ixazomib-lenalidomide-dexamethasone-transplant-ineligible-newly-diagnosed-multip", "legacy_canonical_url": null, "description": "Double-blind, placebo-controlled randomized TOURMALINE-MM2 trial in Blood (2021) evaluating ixazomib-Rd vs placebo-Rd in transplant-ineligible NDMM.", "scientific_summary": "Double-blind, placebo-controlled randomized TOURMALINE-MM2 trial in Blood (2021) evaluating ixazomib-Rd vs placebo-Rd in transplant-ineligib", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:05:01.529Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338000/horizontal/small_e979f991-cfee-4b29-82fb-d1bf0cd22aeb.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["ixazomib", "lenalidomide", "dexamethasone", "Rd", "ixazomib-Rd", "newly diagnosed multiple myeloma", "transplant-ineligible", "TOURMALINE-MM2", "progression-free survival", "high-risk cytogenetics", "oral triplet", "randomized trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338000", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338003", "editorial": {"original_title": "What salvage regimen is most effective at first relapse during lenalidomide maintenance after autologous transplant in m", "public_title": "What salvage regimen is most effective at first relapse during lenalidomide maintenance after autologous transplant in m", "slug": "salvage-treatment-patterns-multiple-myeloma-progressing-lenalidomide-maintenance", "legacy_canonical_url": null, "description": "Real-life multicenter observational cohort study (British Journal of Haematology, 2026) from EMN Italy evaluating post-AHSCT patients relapsing on lenalidomide maintenance and comparing licensed salvage regimens (e.g., Isa-KD, D-PD, D-VD) a", "scientific_summary": "Real-life multicenter observational cohort study (British Journal of Haematology, 2026) from EMN Italy evaluating post-AHSCT patients relaps", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:07:11.486Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338003/horizontal/small_a570bbfd-dd78-4184-8a42-664b2e783d5e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "lenalidomide maintenance", "lenalidomide refractory", "first relapse", "AHSCT", "salvage therapy", "isatuximab carfilzomib dexamethasone", "daratumumab pomalidomide dexamethasone", "daratumumab bortezomib dexamethasone", "anti-CD38", "progression-free survival", "overall survival"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338003", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338004", "editorial": {"original_title": "Does talquetamab plus daratumumab improve progression-free survival versus DPd in relapsed or refractory multiple myelom", "public_title": "Does talquetamab plus daratumumab improve progression-free survival versus DPd in relapsed or refractory multiple myelom", "slug": "talquetamab-daratumumab-relapsed-refractory-myeloma-pfs-vs-dpd", "legacy_canonical_url": null, "description": "Phase 3 randomized trial (MonumenTAL-3) in NEJM 2026 comparing talquetamab-daratumumab regimens vs daratumumab-pomalidomide-dexamethasone in RRMM.", "scientific_summary": "Phase 3 randomized trial (MonumenTAL-3) in NEJM 2026 comparing talquetamab-daratumumab regimens vs daratumumab-pomalidomide-dexamethasone in", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:09:05.406Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338004/horizontal/small_f2df8597-09be-4863-86fc-c5ac23afefba.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["talquetamab", "daratumumab", "relapsed refractory multiple myeloma", "MonumenTAL-3", "NCT05455320", "progression-free survival", "DPd", "pomalidomide", "dexamethasone", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338004", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4151880", "relation": "same_documented_source", "shared_reference_ids": ["PMID_42294841"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_42294841", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Talquetamab-Daratumumab in Relapsed or Refractory Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["MonumenTAL-3"], "nct_ids": ["NCT05455320"], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_TALQUE", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TALQUETAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "talquetamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POMALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "pomalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338008", "editorial": {"original_title": "Should teclistamab be used after 1 to 3 prior lines in relapsed or refractory multiple myeloma?", "public_title": "Should teclistamab be used after 1 to 3 prior lines in relapsed or refractory multiple myeloma?", "slug": "teclistamab-multiple-myeloma-one-three-previous-lines-therapy", "legacy_canonical_url": null, "description": "Randomized phase 3 trial (NEJM 2026) comparing teclistamab vs investigator choice PVd or Kd in RRMM after 1-3 prior lines; highlights PFS/OS, responses, CRS/ICANS, and infection risk.", "scientific_summary": "Randomized phase 3 trial (NEJM 2026) comparing teclistamab vs investigator choice PVd or Kd in RRMM after 1-3 prior lines; highlights PFS/OS", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should teclistamab be used after 1 to 3 prior lines in relapsed or refractory multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:10:54.980Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338008/horizontal/small_1c466900-ce80-4e2f-96f9-18b4b9d04cb7.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["teclistamab", "bispecific antibody", "BCMA", "CD3", "multiple myeloma", "relapsed refractory", "early line therapy", "PVd", "Kd", "progression free survival", "overall survival", "cytokine release syndrome"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338008", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42212933", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["MajesTEC-9"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_TEC", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_TECLISTAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "teclistamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338010", "editorial": {"original_title": "Should transplant-ineligible multiple myeloma patients receive quadruplet vs triplet frontline therapy based on frailty?", "public_title": "Should transplant-ineligible multiple myeloma patients receive quadruplet vs triplet frontline therapy based on frailty?", "slug": "frontline-intensity-transplant-ineligible-multiple-myeloma-quadruplet-vs-triplet", "legacy_canonical_url": null, "description": "Review of subgroup analyses from the IMROZ and CE-PHEUS clinical trials (Journal of the Advanced Practitioner in Oncology, 2026) comparing frontline quadruplet vs triplet regimens in transplant-ineligible multiple myeloma by IMWG frailty st", "scientific_summary": "Review of subgroup analyses from the IMROZ and CE-PHEUS clinical trials (Journal of the Advanced Practitioner in Oncology, 2026) comparing f", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should transplant-ineligible multiple myeloma patients receive quadruplet vs triplet frontline therapy based on frailty?", "language": null, "original_publication_date": "2026-09-05T21:12:46.434Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338010/horizontal/small_7eb1eb32-baff-4ce2-a511-c93d3b1b493e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "transplant-ineligible", "frontline therapy", "quadruplet regimen", "triplet regimen", "frailty", "IMWG frailty index", "IMROZ", "CE-PHEUS", "progression-free survival", "MRD negativity"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338010", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42170496", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_MM_ISAVRD_TI", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "IMROZ", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338011", "editorial": {"original_title": "In t(11;14) relapsed/refractory multiple myeloma, should venetoclax-dexamethasone replace pomalidomide-dexamethasone?", "public_title": "In t(11;14) relapsed/refractory multiple myeloma, should venetoclax-dexamethasone replace pomalidomide-dexamethasone?", "slug": "canova-venetoclax-dexamethasone-vs-pomalidomide-dexamethasone-t1114-relapsed-ref", "legacy_canonical_url": null, "description": "Primary results from CANOVA, a randomized open-label phase III trial in J Clin Oncol (2026) comparing venetoclax-dexamethasone vs pomalidomide-dexamethasone in t(11;14)+ RRMM.", "scientific_summary": "Primary results from CANOVA, a randomized open-label phase III trial in J Clin Oncol (2026) comparing venetoclax-dexamethasone vs pomalidomi", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In t(11;14) relapsed/refractory multiple myeloma, should venetoclax-dexamethasone replace pomalidomide-dexamethasone?", "language": null, "original_publication_date": "2026-09-05T21:14:27.666Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338011/horizontal/small_fbd97634-3567-4c9b-a283-41b35758013f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["venetoclax", "dexamethasone", "pomalidomide", "t(11;14)", "relapsed refractory multiple myeloma", "CANOVA", "phase III trial", "progression-free survival", "overall response rate", "MRD negativity", "infection risk"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338011", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41370738", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_POMALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "pomalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338012", "editorial": {"original_title": "How should solitary plasmacytoma be diagnosed, staged, treated, and followed to exclude multiple myeloma?", "public_title": "How should solitary plasmacytoma be diagnosed, staged, treated, and followed to exclude multiple myeloma?", "slug": "imwg-solitary-plasmacytoma-diagnosis-management-recommendations", "legacy_canonical_url": null, "description": "Physician-focused summary of the 2026 International Myeloma Working Group clinical practice guideline recommendations for diagnosing, evaluating, treating, and monitoring solitary plasmacytomas (J Clin Oncol, 2026).", "scientific_summary": "Physician-focused summary of the 2026 International Myeloma Working Group clinical practice guideline recommendations for diagnosing, evalua", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should solitary plasmacytoma be diagnosed, staged, treated, and followed to exclude multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:16:15.610Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338012/horizontal/small_a24360b8-fca6-4645-9872-18b596ebc09d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["solitary plasmacytoma", "solitary bone plasmacytoma", "extramedullary plasmacytoma", "IMWG", "guidelines", "multiple myeloma exclusion", "bone marrow infiltration", "advanced imaging", "local radiotherapy", "response assessment", "follow-up strategy", "progression risk"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338012", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4337996", "relation": "same_documented_source", "shared_reference_ids": ["PMID_42485589"], "shared_evidence_ids": []}], "science": {"citations": [{"reference_id": "PMID_42485589", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_SOLITARY_BONE_PLASMACYTOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "solitary bone plasmacytoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_EXTRAMEDULLARY_PLASMACYTOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "extramedullary plasmacytoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338013", "editorial": {"original_title": "Should isatuximab be added to VRd for transplant-ineligible newly diagnosed multiple myeloma?", "public_title": "Should isatuximab be added to VRd for transplant-ineligible newly diagnosed multiple myeloma?", "slug": "isatuximab-vrd-versus-vrd-transplant-ineligible-newly-diagnosed-myeloma-phase-3", "legacy_canonical_url": null, "description": "International open-label phase 3 randomized trial (NEJM, 2024) comparing isatuximab-VRd vs VRd in transplant-ineligible newly diagnosed multiple myeloma, assessing PFS and MRD.", "scientific_summary": "International open-label phase 3 randomized trial (NEJM, 2024) comparing isatuximab-VRd vs VRd in transplant-ineligible newly diagnosed mult", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Should isatuximab be added to VRd for transplant-ineligible newly diagnosed multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:18:03.270Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338013/horizontal/small_ab8bf807-6e0c-41a8-b858-b903cdb7d71e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "newly diagnosed", "transplant ineligible", "isatuximab", "VRd", "bortezomib", "lenalidomide", "dexamethasone", "anti-CD38", "progression-free survival", "MRD negativity", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338013", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38832972", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_ISATUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "isatuximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_MM_VRD", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "VRd", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338014", "editorial": {"original_title": "Should weekly bortezomib be added to isatuximab-lenalidomide-dexamethasone in transplant-ineligible newly diagnosed mult", "public_title": "Should weekly bortezomib be added to isatuximab-lenalidomide-dexamethasone in transplant-ineligible newly diagnosed mult", "slug": "isatuximab-lenalidomide-dexamethasone-bortezomib-transplant-ineligible-multiple", "legacy_canonical_url": null, "description": "Review of the randomized phase 3 BENEFIT trial (Nature Medicine, 2024) comparing IsaRd vs Isa-VRd in transplant-ineligible NDMM, focusing on MRD negativity and safety.", "scientific_summary": "Review of the randomized phase 3 BENEFIT trial (Nature Medicine, 2024) comparing IsaRd vs Isa-VRd in transplant-ineligible NDMM, focusing on", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:20:47.856Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338014/horizontal/small_011161a2-6ceb-47f2-891b-849f9325cb8b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "transplant-ineligible", "newly diagnosed", "isatuximab", "lenalidomide", "dexamethasone", "bortezomib", "Isa-VRd", "IsaRd", "MRD negativity", "next-generation sequencing", "phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338014", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_38830994", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_ISATUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "isatuximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BORTEZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bortezomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338017", "editorial": {"original_title": "How should bispecific antibody toxicities be managed in multiple myeloma?", "public_title": "How should bispecific antibody toxicities be managed in multiple myeloma?", "slug": "management-bispecific-antibody-toxicities-multiple-myeloma", "legacy_canonical_url": null, "description": "Physician-focused review from the ASCO Educational Book (Annual Meeting, 2026) summarizing management of bispecific antibody toxicities in multiple myeloma, including CRS, ICANS, infections, and prophylaxis.", "scientific_summary": "Physician-focused review from the ASCO Educational Book (Annual Meeting, 2026) summarizing management of bispecific antibody toxicities in m", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should bispecific antibody toxicities be managed in multiple myeloma?", "language": null, "original_publication_date": "2026-09-05T21:24:30.588Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338017/horizontal/small_64771500-9e3d-4537-a3df-0a1ae5d14c70.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["bispecific antibodies", "multiple myeloma", "CRS", "ICANS", "tocilizumab", "glucocorticoids", "infection prophylaxis", "hypogammaglobulinemia", "IVIG", "BCMA", "GPRC5D", "tumor flare"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338017", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42275618", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338019", "editorial": {"original_title": "How do daratumumab and isatuximab differ mechanistically in multiple myeloma, and can 1q gain guide selection?", "public_title": "How do daratumumab and isatuximab differ mechanistically in multiple myeloma, and can 1q gain guide selection?", "slug": "daratumumab-isatuximab-mechanistic-clinical-differences-myeloma-1q-gain-immune-r", "legacy_canonical_url": null, "description": "Physician-focused video summarizing a mechanistic narrative review in Cells (2026) comparing daratumumab vs isatuximab in multiple myeloma, highlighting 1q gain, the PBX1-FOXM1 axis, and immune remodeling implications for sequencing.", "scientific_summary": "Physician-focused video summarizing a mechanistic narrative review in Cells (2026) comparing daratumumab vs isatuximab in multiple myeloma,", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How do daratumumab and isatuximab differ mechanistically in multiple myeloma, and can 1q gain guide selection?", "language": null, "original_publication_date": "2026-09-05T21:26:09.291Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338019/horizontal/small_e6c8e714-f029-4b06-b9ea-7daa0114dc1f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "daratumumab", "isatuximab", "CD38", "1q gain", "PBX1-FOXM1 axis", "immune remodeling", "tumor microenvironment", "residual disease", "treatment sequencing"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338019", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42587741", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_DARATUMUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "daratumumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_ISATUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "isatuximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338020", "editorial": {"original_title": "In anti-CD38 and lenalidomide-exposed relapsed/refractory myeloma, does adding mezigdomide to carfilzomib-dexamethasone ", "public_title": "In anti-CD38 and lenalidomide-exposed relapsed/refractory myeloma, does adding mezigdomide to carfilzomib-dexamethasone", "slug": "mezigdomide-carfilzomib-dexamethasone-vs-carfilzomib-dexamethasone-relapsed-refr", "legacy_canonical_url": null, "description": "Phase 3 open-label randomized controlled trial (SUCCESSOR-2; Lancet 2026) comparing mezigdomide plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in relapsed/refractory multiple myeloma.", "scientific_summary": "Phase 3 open-label randomized controlled trial (SUCCESSOR-2; Lancet 2026) comparing mezigdomide plus carfilzomib-dexamethasone vs carfilzomi", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Plasma Cell & Myeloma"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:27:57.972Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338020/horizontal/small_5f10e8a6-80e8-4637-848b-59ea210f225c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["mezigdomide", "carfilzomib", "dexamethasone", "multiple myeloma", "relapsed refractory", "SUCCESSOR-2", "phase 3", "randomized controlled trial", "progression-free survival", "anti-CD38 refractory", "lenalidomide refractory", "cereblon E3 ligase modulator"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338020", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_CARFILZOMIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carfilzomib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338026", "editorial": {"original_title": "Can serum FGL1 distinguish iron deficiency anemia from health and chronic disease-associated anemia?", "public_title": "Can serum FGL1 distinguish iron deficiency anemia from health and chronic disease-associated anemia?", "slug": "fgl1-hepatokine-marker-iron-deficiency", "legacy_canonical_url": null, "description": "Cross-sectional study (Frontiers in Nutrition, 2026) measuring serum FGL1 in controls, primary IDA, and IDA+chronic disease; includes ROC and PCA to assess diagnostic performance.", "scientific_summary": "Cross-sectional study (Frontiers in Nutrition, 2026) measuring serum FGL1 in controls, primary IDA, and IDA+chronic disease; includes ROC an", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can serum FGL1 distinguish iron deficiency anemia from health and chronic disease-associated anemia?", "language": null, "original_publication_date": "2026-09-05T21:29:45.627Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338026/horizontal/small_f021906b-fccf-4250-a259-ebddb437eae8.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["FGL1", "fibrinogen-like protein 1", "hepatokine", "hepcidin", "BMP pathway", "iron deficiency anemia", "anemia of chronic disease", "iron-restricted erythropoiesis", "ROC curve", "principal component analysis"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338026", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41867684", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Evaluation of FGL1 as a hepatokine marker in iron deficiency", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_IRON_DEFICIENCY_ANEMIA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "iron deficiency anemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338028", "editorial": {"original_title": "In PNH with persistent anemia on eculizumab, does switching to pegcetacoplan improve hemoglobin and transfusion independ", "public_title": "In PNH with persistent anemia on eculizumab, does switching to pegcetacoplan improve hemoglobin and transfusion independ", "slug": "pegcetacoplan-versus-eculizumab-paroxysmal-nocturnal-hemoglobinuria", "legacy_canonical_url": null, "description": "Phase 3 open-label randomized controlled trial (PEGASUS) in NEJM 2021 comparing pegcetacoplan vs eculizumab in adults with PNH and Hb <10.5 g/dL despite eculizumab.", "scientific_summary": "Phase 3 open-label randomized controlled trial (PEGASUS) in NEJM 2021 comparing pegcetacoplan vs eculizumab in adults with PNH and Hb <10.5", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:31:54.957Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338028/horizontal/small_36f10b62-8c3b-4a45-ac78-2afbdd4c4521.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["paroxysmal nocturnal hemoglobinuria", "PNH", "pegcetacoplan", "eculizumab", "C3 inhibitor", "C5 inhibitor", "complement inhibition", "extravascular hemolysis", "intravascular hemolysis", "hemoglobin", "transfusion independence", "PEGASUS trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338028", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PNH", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "paroxysmal nocturnal hemoglobinuria", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338029", "editorial": {"original_title": "Does sutimlimab improve hemoglobin and reduce transfusion need in cold agglutinin disease?", "public_title": "Does sutimlimab improve hemoglobin and reduce transfusion need in cold agglutinin disease?", "slug": "sutimlimab-cold-agglutinin-disease-cadenza-phase3", "legacy_canonical_url": null, "description": "In the CADENZA randomized, placebo-controlled phase 3 trial (Blood, 2022), sutimlimab was evaluated in non-recently transfused CAD patients for hemoglobin response, transfusion avoidance, and fatigue improvement over 26 weeks.", "scientific_summary": "In the CADENZA randomized, placebo-controlled phase 3 trial (Blood, 2022), sutimlimab was evaluated in non-recently transfused CAD patients", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does sutimlimab improve hemoglobin and reduce transfusion need in cold agglutinin disease?", "language": null, "original_publication_date": "2026-09-05T21:33:41.042Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338029/horizontal/small_2fd56899-111a-465e-be0f-a2343fe725f5.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["sutimlimab", "cold agglutinin disease", "CADENZA", "phase 3 trial", "randomized placebo-controlled", "C1s inhibitor", "classical complement pathway", "hemolysis", "anemia", "FACIT-Fatigue", "transfusion avoidance"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338029", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_35687757", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_COLD_AGGLUTININ_DISEASE", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "cold agglutinin disease", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338031", "editorial": {"original_title": "When should you suspect macro-B12 in unexplained high vitamin B12?", "public_title": "When should you suspect macro-B12 in unexplained high vitamin B12?", "slug": "unexplained-elevated-vitamin-b12-macro-b12-peg-precipitation", "legacy_canonical_url": null, "description": "Case report plus observational cohort study in International Journal of Laboratory Hematology (2026) evaluating PEG precipitation to identify macro-B12 in persistent B12 elevation.", "scientific_summary": "Case report plus observational cohort study in International Journal of Laboratory Hematology (2026) evaluating PEG precipitation to identif", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "When should you suspect macro-B12 in unexplained high vitamin B12?", "language": null, "original_publication_date": "2026-09-05T21:35:24.656Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338031/horizontal/small_0368c84b-686f-42ec-bf02-8d95ea86ffc0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["macro-B12", "vitamin B12 elevation", "PEG precipitation", "transcobalamin", "immunoglobulin complexes", "methylmalonic acid", "functional B12 deficiency", "myeloid malignancy", "bone marrow biopsy avoidance", "laboratory hematology"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338031", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41498143", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Unexplained Elevated Vitamin B12: Consider Macro-B12", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338032", "editorial": {"original_title": "How should IRIDA be diagnosed and managed in children and adults?", "public_title": "How should IRIDA be diagnosed and managed in children and adults?", "slug": "treat-iron-refractory-iron-deficiency-anaemia-guidance-children-adults", "legacy_canonical_url": null, "description": "Expert opinion-based narrative review and case-informed guidance from the British Journal of Haematology (2025) on diagnosis and patient-tailored treatment of TMPRSS6-related IRIDA, including oral vs IV iron and hepcidin interpretation.", "scientific_summary": "Expert opinion-based narrative review and case-informed guidance from the British Journal of Haematology (2025) on diagnosis and patient-tai", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Non-Malignant Hematology"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should IRIDA be diagnosed and managed in children and adults?", "language": null, "original_publication_date": "2026-09-05T21:37:10.921Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338032/horizontal/small_1628942c-e846-4495-9175-67a776f8e014.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["IRIDA", "iron-refractory iron deficiency anemia", "TMPRSS6", "hepcidin", "microcytic anemia", "oral iron resistance", "intravenous iron", "ferritin", "transferrin saturation", "TSAT hepcidin ratio", "iron distribution disorder", "hereditary anemia"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338032", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_39985323", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "How I treat iron-refractory iron deficiency anaemia: An expert opinion-based treatment guidance for children and adults", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338033", "editorial": {"original_title": "How should myelodysplastic neoplasms be risk stratified and treated in 2026, including transplant candidacy?", "public_title": "How should myelodysplastic neoplasms be risk stratified and treated in 2026, including transplant candidacy?", "slug": "myelodysplastic-neoplasms-update-risk-stratification-therapy-transplant", "legacy_canonical_url": null, "description": "Physician-focused summary of a narrative Review in Nature Reviews Clinical Oncology (2026) outlining updated MDS epidemiology, classification, risk stratification, therapies, and the role of allogeneic HSCT.", "scientific_summary": "Physician-focused summary of a narrative Review in Nature Reviews Clinical Oncology (2026) outlining updated MDS epidemiology, classificatio", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should myelodysplastic neoplasms be risk stratified and treated in 2026, including transplant candidacy?", "language": null, "original_publication_date": "2026-09-05T21:39:04.136Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338033/horizontal/small_d46ef5ce-cbe9-439f-8292-19fe0c8d0703.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["myelodysplastic neoplasms", "myelodysplastic syndromes", "risk stratification", "classification", "molecular genetics", "hypomethylating agents", "azacitidine", "decitabine", "venetoclax", "allogeneic stem cell transplant", "HMA failure", "cytopenias"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338033", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DECITABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "decitabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338034", "editorial": {"original_title": "What GVHD prophylaxis is optimal in matched sibling donor transplantation: PTCy, ATG, or CNI-based regimens?", "public_title": "What GVHD prophylaxis is optimal in matched sibling donor transplantation: PTCy, ATG, or CNI-based regimens?", "slug": "optimal-gvhd-prophylaxis-matched-sibling-donor-transplantation-network-meta-anal", "legacy_canonical_url": null, "description": "Prospectively registered systematic review and network meta-analysis of randomized trials comparing PTCy-, ATG-, and conventional CNI-based GVHD prophylaxis in MSD transplantation (Transplantation and Cellular Therapy, 2026).", "scientific_summary": "Prospectively registered systematic review and network meta-analysis of randomized trials comparing PTCy-, ATG-, and conventional CNI-based", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "What GVHD prophylaxis is optimal in matched sibling donor transplantation: PTCy, ATG, or CNI-based regimens?", "language": null, "original_publication_date": "2026-09-05T21:40:40.676Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338034/horizontal/small_a6ffb282-bb68-46af-b927-de6f5ff1eace.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["GVHD prophylaxis", "matched sibling donor", "allogeneic stem cell transplant", "post-transplant cyclophosphamide", "anti-thymocyte globulin", "calcineurin inhibitor", "network meta-analysis", "randomized trials"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338034", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42097206", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338035", "editorial": {"original_title": "When should autologous vs allogeneic HCT be used in relapsed or refractory Hodgkin lymphoma?", "public_title": "When should autologous vs allogeneic HCT be used in relapsed or refractory Hodgkin lymphoma?", "slug": "autologous-allogeneic-hct-adult-hodgkin-lymphoma-ebmt-recommendations", "legacy_canonical_url": null, "description": "Consensus guideline recommendations based on a structured literature review and 2-day expert workshop (The Lancet Haematology, 2026) on autoHCT and alloHCT in adult relapsed/refractory Hodgkin lymphoma.", "scientific_summary": "Consensus guideline recommendations based on a structured literature review and 2-day expert workshop (The Lancet Haematology, 2026) on auto", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guideline or Consensus", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "When should autologous vs allogeneic HCT be used in relapsed or refractory Hodgkin lymphoma?", "language": null, "original_publication_date": "2026-09-05T21:42:25.382Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338035/horizontal/small_69a35258-1b32-4c36-bdc7-8c3e6811bbeb.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Hodgkin lymphoma", "autologous HCT", "allogeneic HCT", "EBMT guidelines", "relapsed refractory", "salvage therapy", "brentuximab vedotin", "checkpoint inhibitors", "BEAM conditioning", "PET response", "consolidation", "reduced intensity conditioning"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338035", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_HODGKIN_CHL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "Hodgkin lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_BRENTUXIMAB_VEDOTIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "brentuximab vedotin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338036", "editorial": {"original_title": "Is TEAM safer and as effective as BEAM for autologous transplant conditioning in lymphoma?", "public_title": "Is TEAM safer and as effective as BEAM for autologous transplant conditioning in lymphoma?", "slug": "team-beam-conditioning-autologous-transplant-lymphoma", "legacy_canonical_url": null, "description": "Physician-focused review of a peer-reviewed comparative study in Haematologica (2026) evaluating safety and efficacy of TEAM versus BEAM conditioning before autologous transplantation in lymphoma.", "scientific_summary": "Physician-focused review of a peer-reviewed comparative study in Haematologica (2026) evaluating safety and efficacy of TEAM versus BEAM con", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Is TEAM safer and as effective as BEAM for autologous transplant conditioning in lymphoma?", "language": null, "original_publication_date": "2026-09-05T21:43:51.476Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338036/horizontal/small_5cdfde11-e9de-486a-99fe-5f28da768c4d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["TEAM", "BEAM", "conditioning regimen", "autologous transplantation", "lymphoma", "safety", "efficacy", "Haematologica"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338036", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42489071", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_HSCT_BEAM", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "BEAM", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338038", "editorial": {"original_title": "Does adding epcoritamab to R-DHAX improve response durability before transplant in R/R DLBCL?", "public_title": "Does adding epcoritamab to R-DHAX improve response durability before transplant in R/R DLBCL?", "slug": "epcoritamab-plus-r-dhax-transplant-eligible-relapsed-refractory-dlbcl-epcore-nhl", "legacy_canonical_url": null, "description": "Physician-focused review of EPCORE NHL-2, a clinical trial reported in Haematologica (2026), evaluating epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin in transplant-eligible R/R DLBCL.", "scientific_summary": "Physician-focused review of EPCORE NHL-2, a clinical trial reported in Haematologica (2026), evaluating epcoritamab plus rituximab, dexameth", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "physician_approved_browse_area_correction_2026-10-18_original_Uscreen_category_preserved", "clinical_question": "Does adding epcoritamab to R-DHAX improve response durability before transplant in R/R DLBCL?", "language": null, "original_publication_date": "2026-09-05T21:45:29.533Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338038/horizontal/small_ecc1bb5f-5d2c-4b62-9771-65c371087e34.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["epcoritamab", "R-DHAX", "rituximab", "dexamethasone", "cytarabine", "oxaliplatin", "carboplatin", "relapsed refractory DLBCL", "transplant eligible", "EPCORE NHL-2"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338038", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_EPCORITAMAB_FL", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "epcoritamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_EPCORITAMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "epcoritamab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "TX_LYM_DHAOX", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-DHAX", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DEXAMETHASONE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "dexamethasone", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CYTARABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cytarabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OXALIPLATIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "oxaliplatin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_CARBOPLATIN", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carboplatin", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338039", "editorial": {"original_title": "In newly diagnosed PCNSL after MATRix, is thiotepa-based HCT-ASCT superior to non-myeloablative R-DeVIC consolidation?", "public_title": "In newly diagnosed PCNSL after MATRix, is thiotepa-based HCT-ASCT superior to non-myeloablative R-DeVIC consolidation?", "slug": "high-dose-chemotherapy-autologous-stem-cell-transplantation-versus-non-myeloabla", "legacy_canonical_url": null, "description": "Review of the MATRix/IELSG43 open-label randomized phase 3 trial (The Lancet, 2026) comparing thiotepa-based HCT-ASCT versus non-myeloablative R-DeVIC consolidation after MATRix induction in newly diagnosed primary CNS lymphoma.", "scientific_summary": "Review of the MATRix/IELSG43 open-label randomized phase 3 trial (The Lancet, 2026) comparing thiotepa-based HCT-ASCT versus non-myeloablati", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "In newly diagnosed PCNSL after MATRix, is thiotepa-based HCT-ASCT superior to non-myeloablative R-DeVIC consolidation?", "language": null, "original_publication_date": "2026-09-05T21:47:16.144Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338039/horizontal/small_4b5fad00-96bd-4237-9369-2f16ba0acfab.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["primary CNS lymphoma", "PCNSL", "MATRix", "IELSG43", "autologous stem cell transplantation", "HCT-ASCT", "high-dose chemotherapy", "thiotepa", "carmustine", "R-DeVIC", "consolidation therapy", "randomized phase 3 trial"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338039", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_PRIMARY_CNS_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "PCNSL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_CARMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "carmustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338040", "editorial": {"original_title": "Does alloHCT improve outcomes in high-risk single- or double-refractory CLL after cBTKi and/or BCL2i failure?", "public_title": "Does alloHCT improve outcomes in high-risk single- or double-refractory CLL after cBTKi and/or BCL2i failure?", "slug": "allohct-high-risk-single-double-refractory-cll-cbtki-bcl2i", "legacy_canonical_url": null, "description": "Retrospective cohort study (Blood, 2026) of 47 TP53-aberrant and/or complex-karyotype CLL patients with cBTKi and/or BCL2i refractoriness, assessing prognosis and alloHCT feasibility and outcomes.", "scientific_summary": "Retrospective cohort study (Blood, 2026) of 47 TP53-aberrant and/or complex-karyotype CLL patients with cBTKi and/or BCL2i refractoriness, a", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does alloHCT improve outcomes in high-risk single- or double-refractory CLL after cBTKi and/or BCL2i failure?", "language": null, "original_publication_date": "2026-09-05T21:49:02.159Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338040/horizontal/small_9181238b-6ff6-4d48-9361-c676784e25ef.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["CLL", "alloHCT", "allogeneic transplant", "cBTKi refractory", "BCL2i refractory", "double refractory", "TP53 abnormality", "complex karyotype", "event-free survival", "overall survival", "nonrelapse mortality", "relapse incidence"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338040", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42284699", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_CLL", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "CLL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338042", "editorial": {"original_title": "In AML patients aged 65 or older in remission, should conditioning be reduced-intensity or non-myeloablative for allo-HC", "public_title": "In AML patients aged 65 or older in remission, should conditioning be reduced-intensity or non-myeloablative for allo-HC", "slug": "nma-vs-ric-conditioning-allo-hct-aml-65-ebmt-alwp", "legacy_canonical_url": null, "description": "Retrospective EBMT ALWP registry analysis of 2900 AML patients aged >=65 in CR undergoing allo-HCT (2004-2021), reported in Bone Marrow Transplantation (2026), comparing RIC vs NMA outcomes and GVHD patterns.", "scientific_summary": "Retrospective EBMT ALWP registry analysis of 2900 AML patients aged >=65 in CR undergoing allo-HCT (2004-2021), reported in Bone Marrow Tran", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": null, "language": null, "original_publication_date": "2026-09-05T21:50:45.069Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338042/horizontal/small_a4bcbe70-c707-49ba-9424-c30f8387c563.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "AML", "allogeneic hematopoietic stem cell transplantation", "allo-HCT", "conditioning intensity", "reduced-intensity conditioning", "RIC", "non-myeloablative conditioning", "NMA", "EBMT", "ALWP", "older adults"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338042", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "AML", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4338045", "editorial": {"original_title": "Does rituximab maintenance improve outcomes after ibrutinib-based therapy in younger untreated mantle cell lymphoma?", "public_title": "Does rituximab maintenance improve outcomes after ibrutinib-based therapy in younger untreated mantle cell lymphoma?", "slug": "rituximab-maintenance-ibrutinib-mantle-cell-lymphoma-triangle", "legacy_canonical_url": null, "description": "Secondary analysis of the TRIANGLE randomized trial (Journal of Clinical Oncology, 2026) assessing rituximab maintenance after response to ibrutinib-containing therapy with or without ASCT in younger, untreated MCL.", "scientific_summary": "Secondary analysis of the TRIANGLE randomized trial (Journal of Clinical Oncology, 2026) assessing rituximab maintenance after response to i", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation"], "primary_browse_area": "Transplantation", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does rituximab maintenance improve outcomes after ibrutinib-based therapy in younger untreated mantle cell lymphoma?", "language": null, "original_publication_date": "2026-09-05T21:52:33.948Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4338045/horizontal/small_74465a0a-19e5-4b8b-8a08-35af1a40ec40.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["mantle cell lymphoma", "MCL", "rituximab maintenance", "ibrutinib", "BTK inhibitor", "TRIANGLE trial", "progression-free survival", "overall survival", "infectious toxicity", "autologous stem cell transplantation", "ASCT", "younger untreated"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4338045", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42447409", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MANTLE_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_IBRUTINIB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "ibrutinib", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4339335", "editorial": {"original_title": "Can anemia-supporting therapy maintain ruxolitinib dose intensity in anemic myelofibrosis?", "public_title": "Can anemia-supporting therapy maintain ruxolitinib dose intensity in anemic myelofibrosis?", "slug": "myelofibrosis-ruxolitinib-anemia-support-esa-danazol-jump-trial-outcomes", "legacy_canonical_url": null, "description": "Post hoc analysis of the phase 3b JUMP trial (Hematology, 2026) assessing outcomes when ESAs or danazol were added to ruxolitinib in anemic myelofibrosis.", "scientific_summary": "Post hoc analysis of the phase 3b JUMP trial (Hematology, 2026) assessing outcomes when ESAs or danazol were added to ruxolitinib in anemic", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Myeloid Neoplasms", "Original Studies"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Can anemia-supporting therapy maintain ruxolitinib dose intensity in anemic myelofibrosis?", "language": null, "original_publication_date": "2026-09-06T19:08:59.331Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4339335/horizontal/small_bc0a09d8-6d67-4838-9912-191a2fdeded8.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["myelofibrosis", "ruxolitinib", "anemia", "erythropoiesis-stimulating agent", "ESA", "danazol", "JUMP trial", "spleen response", "FACT-Lym"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4339335", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42698151", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": ["Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications"], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4339362", "editorial": {"original_title": "How do JAK2, CALR, and MPL mutations drive classic myeloproliferative neoplasms and guide therapy?", "public_title": "How do JAK2, CALR, and MPL mutations drive classic myeloproliferative neoplasms and guide therapy?", "slug": "myeloproliferative-neoplasms-jak2-calr-mpl-mutations-targeted-therapy", "legacy_canonical_url": null, "description": "Physician-focused overview of classic MPN biology, diagnosis, and treatment based on a narrative clinical review in the New England Journal of Medicine (2026).", "scientific_summary": "Physician-focused overview of classic MPN biology, diagnosis, and treatment based on a narrative clinical review in the New England Journal", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Free Hematology Videos", "Myeloid Neoplasms"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How do JAK2, CALR, and MPL mutations drive classic myeloproliferative neoplasms and guide therapy?", "language": null, "original_publication_date": "2026-09-06T19:52:07.418Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4339362/horizontal/small_6a09d6cc-ba32-47fd-8e79-2a62f2cdac0b.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["myeloproliferative neoplasms", "essential thrombocythemia", "polycythemia vera", "primary myelofibrosis", "JAK2 V617F", "CALR", "MPL", "myelofibrosis", "thrombosis", "secondary AML", "pegylated interferon alfa"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4339362", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42617115", "role": "documented_migration_source", "source_association_status": "documentarily_corroborated_migration_source", "original_association_status": "documentarily_corroborated_pending_physician_approval", "source_field": "preserved_approved_migration_source", "source_value": "Myeloproliferative Neoplasms.", "provenance": "sources/verified-reference-supplements.json"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_ESSENTIAL_THROMBOCYTHEMIA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "essential thrombocythemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_POLYCYTHEMIA_VERA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "polycythemia vera", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_PRIMARY_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "primary myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}, {"target_id": "DIS_MPN_MYELOFIBROSIS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "myelofibrosis", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4339365", "editorial": {"original_title": "Does cyclophosphamide plus cyclosporin prevent graft-versus-host disease after allogeneic transplant?", "public_title": "Does cyclophosphamide plus cyclosporin prevent graft-versus-host disease after allogeneic transplant?", "slug": "gvhd-prophylaxis-cyclophosphamide-cyclosporin-nejm-2025", "legacy_canonical_url": null, "description": "Physician-focused review of a clinical trial on graft-versus-host disease prophylaxis using cyclophosphamide and cyclosporin, published in The New England Journal of Medicine (2025).", "scientific_summary": "Physician-focused review of a clinical trial on graft-versus-host disease prophylaxis using cyclophosphamide and cyclosporin, published in T", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Transplantation", "Supportive Care & Complications", "Original Studies"], "primary_browse_area": "Transplantation", "secondary_browse_areas": ["Supportive Care & Complications"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does cyclophosphamide plus cyclosporin prevent graft-versus-host disease after allogeneic transplant?", "language": null, "original_publication_date": "2026-09-06T19:55:36.311Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4339365/horizontal/small_684a5f95-a8f3-4027-8cff-486c044dd576.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["graft-versus-host disease", "GVHD prophylaxis", "cyclophosphamide", "cyclosporin", "allogeneic transplant", "hematopoietic stem cell transplantation"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4339365", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_40513032", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_CYCLOPHOSPHAMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "cyclophosphamide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347418", "editorial": {"original_title": "How should therapy be individualized across newly diagnosed and relapsed multiple myeloma?", "public_title": "How should therapy be individualized across newly diagnosed and relapsed multiple myeloma?", "slug": "treatment-decisions-multiple-myeloma", "legacy_canonical_url": null, "description": "Physician-focused overview of a narrative review framework for treatment selection in multiple myeloma, synthesizing trial evidence and biologic risk stratification (NEJM, 2026).", "scientific_summary": "Physician-focused overview of a narrative review framework for treatment selection in multiple myeloma, synthesizing trial evidence and biol", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Free Hematology Videos", "Cellular Therapy & Immunotherapy", "Plasma Cell & Myeloma"], "primary_browse_area": "Cellular Therapy & Immunotherapy", "secondary_browse_areas": ["Plasma Cell & Myeloma"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should therapy be individualized across newly diagnosed and relapsed multiple myeloma?", "language": null, "original_publication_date": "2026-09-13T18:57:38.418Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347418/horizontal/small_9b086f8d-6ae2-4072-b9a3-856d2e92c0ee.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["multiple myeloma", "quadruplet induction", "autologous stem cell transplant", "MRD", "cytogenetic risk", "genomic risk", "BCMA", "CAR T", "bispecific antibodies", "antibody-drug conjugates", "T-cell fitness", "smoldering myeloma"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4347418", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_42715563", "role": "documented_migration_source", "source_association_status": "documentarily_corroborated_migration_source", "original_association_status": "documentarily_corroborated_pending_physician_approval", "source_field": "preserved_approved_migration_source", "source_value": "Treatment Decisions in Multiple Myeloma.", "provenance": "sources/verified-reference-supplements.json"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MULTIPLE_MYELOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "multiple myeloma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347650", "editorial": {"original_title": "EP00 — How Should Clinicians Apply the Key 2026 MDS Updates From Diagnosis to Transplant Referral?", "public_title": "EP00 — How Should Clinicians Apply the Key 2026 MDS Updates From Diagnosis to Transplant Referral?", "slug": "mds-2026-updates-diagnosis-to-transplant-referral", "legacy_canonical_url": null, "description": "Episode 0 of the 5MinuteHematology guideline/consensus series. A physician-focused overview of practice-relevant changes in MDS classification, molecular risk assessment, therapy selection, and transplant referral, based on Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Practice-relevant 2026 MDS updates spanning classification, molecular risk, therapy selection, and transplant referral.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347650/horizontal/small_925fb48e-c3c8-4aef-b2d5-48364469058c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "myelodysplastic syndromes", "MDS", "2026 update", "classification", "molecular risk", "therapy selection", "transplant referral", "Nature Reviews Clinical Oncology"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347650", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347652", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347652", "editorial": {"original_title": "EP01 — Suspected MDS: What Minimum Diagnostic Work-up Confirms MDS and Excludes Mimics?", "public_title": "EP01 — Suspected MDS: What Minimum Diagnostic Work-up Confirms MDS and Excludes Mimics?", "slug": "suspected-mds-minimum-diagnostic-work-up-and-mimics", "legacy_canonical_url": null, "description": "Episode 1 of the 5MinuteHematology guideline/consensus series. Reviews the minimum diagnostic work-up for unexplained cytopenias, confirmation of MDS, and exclusion of common mimics before therapy or transplant planning, based on Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Minimum diagnostic work-up for suspected MDS and key mimics to exclude before treatment and transplant planning.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347652/horizontal/small_63ec76ad-e231-4414-bda7-0b4cc7d94a8d.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "diagnosis", "suspected MDS", "unexplained cytopenias", "diagnostic work-up", "mimics", "CBC", "transplant planning"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347652", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347653", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347653", "editorial": {"original_title": "EP02 — How Do WHO-5 vs ICC MDS Classifications Change Treatment and Transplant Decisions?", "public_title": "EP02 — How Do WHO-5 vs ICC MDS Classifications Change Treatment and Transplant Decisions?", "slug": "mds-who5-vs-icc-classification-changes-clinical-consequences-2026", "legacy_canonical_url": null, "description": "Episode 2 of the 5MinuteHematology guideline/consensus series. Compares WHO-5 and ICC classification changes—including SF3B1-defined and multi-hit TP53 disease—and explains their implications for prognosis, treatment intensity, transplant urgency, and trial eligibility, based on Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "WHO-5 versus ICC classification changes and their implications for prognosis, treatment, transplant, and trials.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347653/horizontal/small_99f637ef-b534-459e-98ce-f8b90ed715f1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "WHO-5", "WHO 2022", "ICC", "classification", "SF3B1", "TP53", "transplant"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347653", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347654", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347654", "editorial": {"original_title": "EP03 — When to Order NGS in MDS and How to Confirm Somatic vs Germline Variants", "public_title": "EP03 — When to Order NGS in MDS and How to Confirm Somatic vs Germline Variants", "slug": "when-to-order-ngs-in-mds-and-confirm-somatic-vs-germline-variants", "legacy_canonical_url": null, "description": "Episode 3 of the 5MinuteHematology guideline/consensus series. Covers when to order NGS in suspected or confirmed MDS, how results inform prognosis and targeted therapy, and when variants require germline confirmation for counseling, transplant planning, and donor selection, based on Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Practical NGS use in MDS for prognosis and targets, including germline confirmation and donor-selection implications.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:38:42.649Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347654/horizontal/small_253a60ec-7a6f-4e17-bf59-de594e356dfe.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "NGS", "next generation sequencing", "molecular profiling", "somatic variants", "germline confirmation", "donor selection", "risk stratification"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347654", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347655", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347655", "editorial": {"original_title": "EP04 — How Do You Sequence Anemia Therapies in Lower-Risk MDS?", "public_title": "EP04 — How Do You Sequence Anemia Therapies in Lower-Risk MDS?", "slug": "lower-risk-mds-anemia-therapy-selection-esa-luspatercept-lenalidomide-del5q-imetelstat", "legacy_canonical_url": null, "description": "Episode 4 of the 5MinuteHematology guideline/consensus series. Reviews selection and sequencing of anemia-directed therapy in lower-risk MDS, including ESAs, luspatercept, lenalidomide for del(5q), and imetelstat, based on disease features and transfusion burden. Source: Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Selecting and sequencing ESAs, luspatercept, lenalidomide for del(5q), and imetelstat in lower-risk MDS.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347655/horizontal/small_c6a2b23a-88a6-48b2-b143-14664f872be0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "lower-risk MDS", "anemia", "transfusion dependence", "ESA", "luspatercept", "lenalidomide", "imetelstat", "del(5q)"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347655", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347657", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_LENALIDOMIDE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "lenalidomide", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347657", "editorial": {"original_title": "EP05 — Higher-Risk MDS: How to Choose and Escalate HMA Therapy", "public_title": "EP05 — Higher-Risk MDS: How to Choose and Escalate HMA Therapy", "slug": "higher-risk-mds-hma-strategy-when-to-intensify", "legacy_canonical_url": null, "description": "Episode 5 of the 5MinuteHematology guideline/consensus series. Reviews HMA selection and monitoring in higher-risk MDS—including azacitidine, decitabine, and oral decitabine/cedazuridine—and when to consider venetoclax, intensive chemotherapy, IDH-directed therapy, or transplant bridging. Source: Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "HMA selection and monitoring in higher-risk MDS, plus when to intensify therapy or bridge to transplant.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347657/horizontal/small_f8c7e2bd-4241-429a-a5b0-3ef086699098.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "higher-risk MDS", "hypomethylating agents", "HMA", "azacitidine", "decitabine", "venetoclax", "IDH inhibitors", "transplant"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347657", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347658", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_AZACITIDINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "azacitidine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_DECITABINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "decitabine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_VENETOCLAX", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "venetoclax", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347658", "editorial": {"original_title": "EP06 — After HMA Failure in Higher-Risk MDS: What Are the Next Steps?", "public_title": "EP06 — After HMA Failure in Higher-Risk MDS: What Are the Next Steps?", "slug": "after-hma-failure-higher-risk-mds-next-steps-trials-transplant-reassessment", "legacy_canonical_url": null, "description": "Episode 6 of the 5MinuteHematology guideline/consensus series. Covers prognosis discussions after HMA failure, urgent clinical-trial referral, interim disease-control options, and reassessment of transplant eligibility. Source: Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Practical next steps after HMA failure: prognosis, clinical trials, interim disease control, and transplant reassessment.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347658/horizontal/small_90bfdd56-029e-4573-8ce2-f1e5de640f1c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "higher-risk MDS", "HMA failure", "azacitidine failure", "decitabine failure", "relapsed refractory MDS", "clinical trials", "transplant reassessment"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347658", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4347659", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4347669"}], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4347659", "editorial": {"original_title": "EP07 — Which MDS Patients Should Be Referred for Allo-HCT, and How Does Special Biology Change Care?", "public_title": "EP07 — Which MDS Patients Should Be Referred for Allo-HCT, and How Does Special Biology Change Care?", "slug": "mds-allo-hct-referral-timing-candidacy-germline-donor-conditioning-high-risk-biology", "legacy_canonical_url": null, "description": "Episode 7 of the 5MinuteHematology guideline/consensus series. Reviews allo-HCT referral timing and candidacy in MDS, the pre-transplant evaluation, germline implications for donor and conditioning choices, and how high-risk biology—including multi-hit TP53—can affect urgency and strategy. Source: Bewersdorf JP et al., Nature Reviews Clinical Oncology (2026).", "scientific_summary": "Allo-HCT referral and candidacy in MDS, including germline evaluation, donor selection, conditioning, and high-risk biology.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4347659/horizontal/small_13530171-d2e6-4711-a3ee-dd268d59498c.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["5MinuteHematology", "myelodysplastic neoplasms", "MDS", "allogeneic transplant", "allo-HCT", "transplant referral", "transplant candidacy", "germline predisposition", "donor selection", "conditioning", "TP53", "high-risk biology"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4347659", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.1038/s41571-026-01141-2", "provenance": "Collection 4347669; episode applicability requires physician review"}, {"reference_id": "PMID_41981151", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions", "provenance": "Collection 4347669; episode applicability requires physician review"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_MDS", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "MDS", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355937", "editorial": {"original_title": "EP00 — GELTAMO 2025 FL: What Changed & How to Use It", "public_title": "EP00 — GELTAMO 2025 FL: What Changed & How to Use It", "slug": "follicular-lymphoma-geltamo-2025-what-changed-how-to-use-it", "legacy_canonical_url": null, "description": "Episode 0 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Provides a clinician-focused overview of the GELTAMO 2025 guideline and its main decision pathways, from localized versus advanced disease and low versus high tumor burden to relapse, POD24, and referral for CAR-T or bispecific antibodies. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Overview of GELTAMO 2025 pathways for follicular lymphoma: diagnosis, frontline therapy, relapse, and cellular immunotherapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355937/horizontal/small_1941ece9-808c-4ecc-9b03-6a984341b861.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "algorithm", "POD24", "CAR-T", "bispecific", "ASCT"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355937", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355941", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355941", "editorial": {"original_title": "EP01 — Biopsy Strategy in FL (and When to Suspect Transformation)", "public_title": "EP01 — Biopsy Strategy in FL (and When to Suspect Transformation)", "slug": "follicular-lymphoma-biopsy-strategy-excisional-vs-core-and-pet-guided-biopsy-for-transform", "legacy_canonical_url": null, "description": "Episode 1 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Reviews excisional versus core needle biopsy, tissue sampling at initial diagnosis and relapse, and the role of PET/CT-guided biopsy when transformation is suspected. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Biopsy selection in follicular lymphoma and PET-guided assessment of suspected transformation at diagnosis or relapse.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355941/horizontal/small_73f74171-3655-45ca-8ef8-6bb161fee77e.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "biopsy", "excisional biopsy", "core needle biopsy", "PET-guided biopsy", "transformation"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355941", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355942", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355942", "editorial": {"original_title": "EP02 — Staging & Risk: PET-CT, Bone Marrow, and What Not to Use to Pick Therapy", "public_title": "EP02 — Staging & Risk: PET-CT, Bone Marrow, and What Not to Use to Pick Therapy", "slug": "follicular-lymphoma-baseline-staging-pet-ct-bone-marrow-flipi-mrd-ctdna-geltamo-2026", "legacy_canonical_url": null, "description": "Episode 2 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Covers baseline PET-CT, bone marrow assessment, laboratory tests, and viral screening. Discusses prognostic scores, including FLIPI, and the clinical roles and limitations of MRD and ctDNA in treatment decisions. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Follicular lymphoma staging with PET-CT and bone marrow assessment, plus the clinical roles and limits of FLIPI, MRD, and ctDNA.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Free Hematology Videos"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": "2026-09-24T00:43:31.206Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355942/horizontal/small_7ff1976e-5797-464b-a258-4268643dcbe0.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "PET-CT", "Lugano", "bone marrow biopsy", "FLIPI", "MRD", "ctDNA", "POD24"], "publication_status": "published", "effective_visibility": "visible_individually_and_via_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355942", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355943", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "CALC_FLIPI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "FLIPI", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355943", "editorial": {"original_title": "EP03 — Localized FL: Curative-Intent Radiotherapy Decisions", "public_title": "EP03 — Localized FL: Curative-Intent Radiotherapy Decisions", "slug": "localized-follicular-lymphoma-isrt-24-gy-vs-4-gy-rituximab-geltamo-2026", "legacy_canonical_url": null, "description": "Episode 3 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Reviews curative-intent radiotherapy decisions in contiguous, non-bulky stage I–II follicular lymphoma, including ISRT 24 Gy, selected use of 4 Gy, addition of anti-CD20 therapy, and options when radiotherapy is unsuitable. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Radiotherapy decisions in localized follicular lymphoma: ISRT 24 Gy, selected use of 4 Gy, and anti-CD20 options.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355943/horizontal/small_377870ae-3ff8-43d7-a52c-ce5fb95e280f.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "localized FL", "ISRT", "24 Gy", "4 Gy", "rituximab", "radiotherapy"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355943", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355944", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355944", "editorial": {"original_title": "EP04 — Advanced FL: When to Treat vs Watchful Waiting", "public_title": "EP04 — Advanced FL: When to Treat vs Watchful Waiting", "slug": "advanced-follicular-lymphoma-when-to-treat-vs-watchful-waiting-geltamo-2026", "legacy_canonical_url": null, "description": "Episode 4 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Explores treatment initiation versus watchful waiting in stage III/IV or bulky localized follicular lymphoma, with a focus on tumor burden, symptoms, and the role of rituximab monotherapy. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "When to observe or treat advanced follicular lymphoma, using tumor burden and symptoms, and the role of rituximab monotherapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355944/horizontal/small_8ef8061c-7905-4d8b-82ec-9338d72dd6ab.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "watchful waiting", "tumor burden", "GELF", "advanced FL", "rituximab monotherapy"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355944", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355946", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355946", "editorial": {"original_title": "EP05 — Frontline High Tumor Burden: Picking Induction + Maintenance", "public_title": "EP05 — Frontline High Tumor Burden: Picking Induction + Maintenance", "slug": "high-tumor-burden-follicular-lymphoma-induction-and-maintenance-geltamo-2026", "legacy_canonical_url": null, "description": "Episode 5 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Reviews frontline induction choices for high-tumor-burden follicular lymphoma, including R-bendamustine, R-CHOP, R-CVP, and obinutuzumab-based immunochemotherapy. Discusses anti-CD20 maintenance and efficacy, toxicity, and infection-risk considerations. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Induction and maintenance choices for high-tumor-burden follicular lymphoma, including efficacy, toxicity, and infection risk.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355946/horizontal/small_c2e23f0b-bf16-484e-89bf-b85e4e4533e1.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "R-CHOP", "bendamustine", "R-CVP", "obinutuzumab", "maintenance rituximab", "toxicity"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355946", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355948", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_RCHOP21", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R-CHOP", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_BENDAMUSTINE", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "bendamustine", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "DRUG_OBINUTUZUMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "obinutuzumab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355948", "editorial": {"original_title": "EP06 — Relapse Workup & Low-Burden Relapse Options", "public_title": "EP06 — Relapse Workup & Low-Burden Relapse Options", "slug": "follicular-lymphoma-relapse-rebiopsy-pet-isrt-low-burden-rituximab-geltamo-2026", "legacy_canonical_url": null, "description": "Episode 6 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Covers evaluation of suspected relapse or progression, repeat biopsy and PET-guided sampling to assess transformation, and management of localized or disseminated low-burden relapse with radiotherapy, observation, or anti-CD20 monotherapy. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "Relapse evaluation in follicular lymphoma: repeat biopsy, localized radiotherapy, observation, and anti-CD20 monotherapy.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355948/horizontal/small_b56abcdf-6e48-40ef-ae01-d227c46c3dcd.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "relapse", "re-biopsy", "ISRT", "low tumor burden", "rituximab"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355948", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [{"content_id": "VID_4355951", "relation": "next_guideline_episode", "basis": "original_explicit_episode_order", "collection_id": "VID_4355998"}], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "DRUG_RITUXIMAB", "type": "Drug", "relation": "explicit_original_editorial_subject", "source_value": "rituximab", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4355951", "editorial": {"original_title": "EP07 — POD24 & Later Lines: ASCT vs Bispecifics vs CAR-T (and When AlloSCT)", "public_title": "EP07 — POD24 & Later Lines: ASCT vs Bispecifics vs CAR-T (and When AlloSCT)", "slug": "pod24-later-line-follicular-lymphoma-asct-bispecifics-car-t-allo-sct", "legacy_canonical_url": null, "description": "Episode 7 of the 5MinuteHematology GELTAMO 2025 follicular lymphoma guideline series. Reviews early relapse (POD24) and later-line follicular lymphoma, including regimen selection, clinical trials, ASCT consolidation, referral for bispecific antibodies or CAR-T, unresolved sequencing questions, and selected consideration of alloSCT. Source: Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers (2026). DOI: 10.3390/cancers18030395. https://doi.org/10.3390/cancers18030395", "scientific_summary": "POD24 and later-line follicular lymphoma: treatment sequencing, ASCT, bispecific antibodies, CAR-T, and selected alloSCT use.", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Guidelines", "original_resource_type": "guideline_episode", "original_categories": ["Guidelines"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "existing_KB_domain_display_crosswalk_unique_area; original categories preserved separately", "clinical_question": null, "language": null, "original_publication_date": null, "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4355951/horizontal/small_66faa1cb-8ca3-4bb3-9e11-4fe675f62cac.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["follicular lymphoma", "GELTAMO", "POD24", "R2", "ASCT", "CAR-T", "bispecific antibodies", "CRS", "ICANS", "alloSCT", "sequencing"], "publication_status": "unpublished", "effective_visibility": "visible_via_published_collection"}, "collection": {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_EP_number_in_source_title"}, "analytics": {"video_id": "VID_4355951", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_41681868", "role": "series_main_candidate", "source_association_status": "documented_collection_main_reference", "original_association_status": "proposed", "source_field": "description", "source_value": "10.3390/cancers18030395", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_FOLLICULAR_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "follicular lymphoma", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [{"target_id": "TX_LYM_R2", "type": "Therapy", "relation": "explicit_original_editorial_subject", "source_value": "R2", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4358442", "editorial": {"original_title": "How should palliative care be integrated into hematology practice based on current evidence?", "public_title": "How should palliative care be integrated into hematology practice based on current evidence?", "slug": "advancing-palliative-care-integration-hematology-existing-evidence", "legacy_canonical_url": null, "description": "Physician-focused review of evidence and practical models for integrating palliative care into hematology, based on a 2023 narrative review in Current Treatment Options in Oncology.", "scientific_summary": "Physician-focused review of evidence and practical models for integrating palliative care into hematology, based on a 2023 narrative review", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Supportive Care & Complications", "Myeloid Neoplasms", "Lymphoid Neoplasms"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Myeloid Neoplasms", "Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should palliative care be integrated into hematology practice based on current evidence?", "language": null, "original_publication_date": "2026-09-21T22:06:55.040Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4358442/horizontal/small_08436276-da32-4f8e-8073-c9b2fff0ed40.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["palliative care", "hematology", "hematologic malignancies", "integrated palliative care", "supportive care", "serious illness communication", "symptom management", "care models"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4358442", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_37017909", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4358446", "editorial": {"original_title": "How should palliative care be integrated for hematologic malignancies?", "public_title": "How should palliative care be integrated for hematologic malignancies?", "slug": "palliative-end-life-care-hematologic-malignancies", "legacy_canonical_url": null, "description": "Physician-focused review article summarizing evidence and barriers for integrating palliative and end-of-life care in hematologic malignancies (Journal of Clinical Oncology, 2020).", "scientific_summary": "Physician-focused review article summarizing evidence and barriers for integrating palliative and end-of-life care in hematologic malignanci", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Review", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Supportive Care & Complications", "Myeloid Neoplasms", "Lymphoid Neoplasms"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Myeloid Neoplasms", "Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How should palliative care be integrated for hematologic malignancies?", "language": null, "original_publication_date": "2026-09-21T22:09:32.768Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4358446/horizontal/small_61743acf-bb7e-4c04-9df0-56730cdb0505.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["palliative care", "end-of-life care", "hematologic malignancies", "hospice", "ICU utilization", "goals of care", "prognostic awareness", "quality of life"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4358446", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_32023164", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Palliative and End-of-Life Care for Patients With Hematologic Malignancies", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4358450", "editorial": {"original_title": "How often is palliative care initiated late in aggressive non-Hodgkin lymphoma before death?", "public_title": "How often is palliative care initiated late in aggressive non-Hodgkin lymphoma before death?", "slug": "palliative-care-utilization-aggressive-nonhodgkin-lymphoma", "legacy_canonical_url": null, "description": "Retrospective population-based cohort study using Ontario, Canada health administrative data (Blood, 2025 ASH Abstract Poster 906) describing timing and setting of palliative care in decedents with DLBCL or transformed follicular lymphoma", "scientific_summary": "Retrospective population-based cohort study using Ontario, Canada health administrative data (Blood, 2025 ASH Abstract Poster 906) describin", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Supportive Care & Complications", "Lymphoid Neoplasms"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Lymphoid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "How often is palliative care initiated late in aggressive non-Hodgkin lymphoma before death?", "language": null, "original_publication_date": "2026-09-21T22:12:30.461Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4358450/horizontal/small_61520166-a23d-4cea-a30a-3e2ec1fc74dc.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["aggressive non-Hodgkin lymphoma", "DLBCL", "transformed follicular lymphoma", "palliative care", "end-of-life care", "utilization patterns", "retrospective cohort", "population-based study", "health administrative data", "community palliative care", "inpatient palliative care"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4358450", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AGGRESSIVE_B_CELL_LYMPHOMA", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "DLBCL", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4358454", "editorial": {"original_title": "Does integrated palliative and oncology care improve quality of life during AML induction chemotherapy?", "public_title": "Does integrated palliative and oncology care improve quality of life during AML induction chemotherapy?", "slug": "integrated-palliative-oncology-care-aml-induction-rct", "legacy_canonical_url": null, "description": "Multisite randomized clinical trial comparing integrated palliative and oncology care vs usual care for AML patients receiving intensive chemotherapy (JAMA Oncology, 2021).", "scientific_summary": "Multisite randomized clinical trial comparing integrated palliative and oncology care vs usual care for AML patients receiving intensive che", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Original Studies", "Supportive Care & Complications", "Myeloid Neoplasms"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Myeloid Neoplasms"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Does integrated palliative and oncology care improve quality of life during AML induction chemotherapy?", "language": null, "original_publication_date": "2026-09-21T22:15:13.023Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4358454/horizontal/small_4b330c85-ab8f-42a8-acea-532488d29694.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["acute myeloid leukemia", "integrated palliative care", "oncology care", "randomized clinical trial", "quality of life", "depression", "anxiety", "ptsd symptoms", "end-of-life care", "induction chemotherapy"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4358454", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_33331857", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title", "source_value": "Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [{"target_id": "DIS_AML", "basis": "exact_original_editorial_tag_to_unique_existing_registry_identity", "source": "PR337 video_manifest.csv tags", "source_value": "acute myeloid leukemia", "scope": "editorial_subject_only_not_evidence_or_decision_placement"}], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": []}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_4369283", "editorial": {"original_title": "Which cancer outpatients on chemotherapy are at high risk for VTE?", "public_title": "Which cancer outpatients on chemotherapy are at high risk for VTE?", "slug": "predictive-model-chemotherapy-associated-thrombosis-khorana-score", "legacy_canonical_url": null, "description": "Prospective observational derivation and validation study (Blood, 2008) developing the Khorana score to predict chemotherapy-associated VTE in cancer outpatients.", "scientific_summary": "Prospective observational derivation and validation study (Blood, 2008) developing the Khorana score to predict chemotherapy-associated VTE", "summary_source": "original_Uscreen_short_description_no_new_clinical_claims", "content_group": "Original Study", "original_resource_type": "standalone_video", "original_categories": ["Supportive Care & Complications", "Non-Malignant Hematology"], "primary_browse_area": "Supportive Care & Complications", "secondary_browse_areas": ["Non-Malignant Hematology"], "category_basis": "exact_original_Uscreen_category_order", "clinical_question": "Which cancer outpatients on chemotherapy are at high risk for VTE?", "language": null, "original_publication_date": "2026-09-27T12:14:34.142Z", "thumbnail": {"url": "https://alpha.uscreencdn.com/images/programs/4369283/horizontal/small_4f8808eb-cfff-42e5-a89d-3402ebffb8f6.png", "source": "original_Uscreen_program_thumbnail"}, "cover": null, "tags": ["Khorana score", "chemotherapy-associated thrombosis", "cancer-associated thrombosis", "venous thromboembolism", "risk prediction", "outpatients", "thromboprophylaxis", "platelet count", "hemoglobin", "leukocytosis", "body mass index", "cancer site"], "publication_status": "published", "effective_visibility": "visible_individually"}, "collection": null, "analytics": {"video_id": "VID_4369283", "entry_points": ["catalog", "original_studies", "guidelines", "knowledge_base", "related_videos"]}, "related_videos": [], "science": {"citations": [{"reference_id": "PMID_18216292", "role": "episode_reference_candidate", "source_association_status": "exact_preserved_source_title", "original_association_status": "proposed", "source_field": "meta_title (trailing citation removed)", "source_value": "Development and validation of a predictive model for chemotherapy-associated thrombosis", "provenance": "PR336 source snapshot + exact bibliographic match; physician review required"}], "clinical_trial_names": [], "nct_ids": [], "scientific_update_date": null, "disease_relations": [], "evidence_relations": [], "decision_relations": [], "treatment_relations": [], "concept_relations": [], "related_resources": [{"target_id": "CALC_KHORANA", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "Khorana score", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}, {"target_id": "CALC_BMI", "type": "Calculator", "relation": "explicit_original_editorial_subject", "source_value": "body mass index", "provenance": "PR337 video_manifest.csv exact tag to unique existing entity identity"}]}, "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000008", "editorial": {"original_title": "What’s New + How to Use These Pediatric CML-CP Recommendations", "public_title": "What’s New + How to Use These Pediatric CML-CP Recommendations", "slug": "wave2-what-s-new-how-to-use-these-pediatric-cml-cp-recommendations-900000000008", "legacy_canonical_url": null, "description": "2025 Leukemia international pediatric CML expert panel recommendations; where pediatric data are limited, adapted adult principles are noted by the panel", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the headline practice changes and the stepwise pathway (diagnosis → ELTS risk → TKI choice → milestones → switch/TFR/HSCT) recommended for pediatric CML-CP?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000008c7310340833d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["pediatric CML", "CML-CP", "expert panel", "ELTS", "TKI", "monitoring", "HSCT", "TFR"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000008", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000007", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000007", "editorial": {"original_title": "Workup and Phase Assignment at Diagnosis", "public_title": "Workup and Phase Assignment at Diagnosis", "slug": "wave2-workup-and-phase-assignment-at-diagnosis-900000000007", "legacy_canonical_url": null, "description": "Diagnostic procedures, phase definitions (WHO/ICC/ELN differences), baseline cytogenetics/molecular testing, and what the panel does/does not recommend routinely", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Which baseline tests are essential to confirm CML and assign chronic vs advanced phase/high-risk features, and what is optional in pediatrics (e.g., marrow trephine, routine HLA typing, somatic variant profiling)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000007a56b53e663f3/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnosis", "BCR-ABL1", "cytogenetics", "WHO 2022", "phase", "baseline workup"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000007", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000006", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000006", "editorial": {"original_title": "Day 0–7: Hyperleukocytosis, Leukostasis, Bleeding, Priapism", "public_title": "Day 0–7: Hyperleukocytosis, Leukostasis, Bleeding, Priapism", "slug": "wave2-day-0-7-hyperleukocytosis-leukostasis-bleeding-priapism-900000000006", "legacy_canonical_url": null, "description": "Hydration and hydroxyurea use, when to use leukapheresis/exchange transfusion, AVWS recognition/treatment, priapism emergency pathway, splenic complication approach", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should children/adolescents with newly diagnosed CML-CP be stabilized when presenting with hyperleukocytosis or leukostasis, and how should key complications (bleeding/AVWS, priapism, splenic infarction/rupture risk) be managed while initiating definitive therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000066fc9a9b538b6/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["hyperleukocytosis", "leukostasis", "hydroxyurea", "leukapheresis", "AVWS", "priapism", "splenomegaly"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000006", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000005", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000005", "editorial": {"original_title": "Choosing First-Line TKI Using ELTS (Pediatric Dosing Included)", "public_title": "Choosing First-Line TKI Using ELTS (Pediatric Dosing Included)", "slug": "wave2-choosing-first-line-tki-using-elts-pediatric-dosing-included-900000000005", "legacy_canonical_url": null, "description": "ELTS as preferred prognostic tool in pediatrics; first-line imatinib for low/intermediate risk; 2G-TKI consideration for ELTS high-risk; dosing for imatinib/dasatinib/nilotinib/bosutinib; access/generic considerations as framed by the panel", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In pediatric CML-CP, when should imatinib be used versus a second-generation TKI based on ELTS risk group, and what starting doses are recommended?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000005932203db6415/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ELTS", "imatinib", "dasatinib", "nilotinib", "bosutinib", "frontline therapy", "pediatric dosing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000005", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000004", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000004", "editorial": {"original_title": "Monitoring Milestones and When It’s Actually Failure", "public_title": "Monitoring Milestones and When It’s Actually Failure", "slug": "wave2-monitoring-milestones-and-when-it-s-actually-failure-900000000004", "legacy_canonical_url": null, "description": "Hematologic monitoring early; qPCR every 3 months; milestone thresholds (e.g., ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months); nuances such as not switching solely for >10% at 3 months if slope is declining; optional role of marrow cytogenetics given correlation with molecular response", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What monitoring schedule and response milestones (3/6/12 months) define optimal response, warning, and failure in pediatric CML-CP, and when is bone marrow cytogenetics optional versus required?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000041a8905a337b4/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["RT-qPCR", "BCR-ABL1 IS", "milestones", "optimal response", "treatment failure", "bone marrow"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000004", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000003", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000003", "editorial": {"original_title": "Suboptimal Response: Adherence, Drug Levels, Mutations, Switching", "public_title": "Suboptimal Response: Adherence, Drug Levels, Mutations, Switching", "slug": "wave2-suboptimal-response-adherence-drug-levels-mutations-switching-900000000003", "legacy_canonical_url": null, "description": "Definitions of primary vs secondary resistance; when to check imatinib plasma concentration and dose escalate; when failure mandates switch; KD mutation-driven selection; when to start donor search (with third-line therapy) and consider investigational agents (e.g., asciminib/ponatinib in selected centers/trials)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "When response is suboptimal or lost, what is the recommended stepwise approach: adherence assessment, imatinib plasma level and dose escalation, kinase domain mutation testing, and selection of next-line therapy (2G/3G/investigational)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000003c58b8481e5eb/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["adherence", "imatinib level", "dose escalation", "ABL1 mutation", "switch TKI", "ponatinib", "asciminib"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000003", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000001", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000001", "editorial": {"original_title": "TKI Toxicity in Kids: Acute AEs and Long-Term Growth/Puberty Issues", "public_title": "TKI Toxicity in Kids: Acute AEs and Long-Term Growth/Puberty Issues", "slug": "wave2-tki-toxicity-in-kids-acute-aes-and-long-term-growth-puberty-issues-900000000001", "legacy_canonical_url": null, "description": "AE management principles (avoid early dose interruptions when possible; supportive measures); indications to interrupt/reduce/switch; chronic toxicity concepts (growth deceleration, bone density, pubertal delay, fertility counseling, contraception and pregnancy cautions)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should clinicians manage acute hematologic/non-hematologic TKI adverse events while preserving early response, and what longitudinal monitoring is recommended for pediatric-specific chronic toxicities (growth, puberty, bone health, fertility, cardiac/metabolic)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000001b02c71b0c775/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["toxicity", "growth", "puberty", "bone density", "fertility", "cardiac monitoring", "dose interruption"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000001", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000002", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000002", "editorial": {"original_title": "TFR and When to Transplant (HSCT) in Pediatric CML-CP", "public_title": "TFR and When to Transplant (HSCT) in Pediatric CML-CP", "slug": "wave2-tfr-and-when-to-transplant-hsct-in-pediatric-cml-cp-900000000002", "legacy_canonical_url": null, "description": "TFR criteria (years on same TKI, sustained deep molecular response, exclusions), relapse definition (loss of MMR) and monitoring cadence; HSCT indications (progression/advanced phase, multiple-line failure), timing of donor search, bridging concepts, preference for well-matched donors, conditioning intensity considerations, bone marrow as preferred source to reduce GVHD, and post-HSCT pre-emptive TKI/asciminib approach when MMR is lost", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Who is eligible for TKI discontinuation (TFR) in pediatrics and how should post-stop monitoring and relapse be handled, and in which scenarios should allogeneic HSCT be pursued (including donor/conditioning/source and post-HSCT MRD strategy)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000002d80ced626640/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["TFR", "discontinuation", "MR4.0", "molecular relapse", "HSCT indication", "donor search", "conditioning", "GVHD"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40044960", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000002", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000016", "editorial": {"original_title": "PMBCL 2026 BSH: What to Do Differently", "public_title": "PMBCL 2026 BSH: What to Do Differently", "slug": "wave2-pmbcl-2026-bsh-what-to-do-differently-900000000016", "legacy_canonical_url": null, "description": "Guideline navigation; highest-impact recommendations (GRADE strength/quality where provided) and workflow sequencing", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the key practice-changing recommendations in the 2026 BSH PMBCL guideline across diagnosis, first-line therapy, PET/RT decisions, and relapse management?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000163e6845a192b4/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["PMBCL", "BSH", "Guideline", "GRADE", "MDT", "PET-CT", "Radiotherapy", "CAR-T"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000016", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000015", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000015", "editorial": {"original_title": "Diagnosis: Tissue, Pathology, and Key Differentials", "public_title": "Diagnosis: Tissue, Pathology, and Key Differentials", "slug": "wave2-diagnosis-tissue-pathology-and-key-differentials-900000000015", "legacy_canonical_url": null, "description": "Biopsy approach (core vs surgical), adequacy considerations (e.g., gauge/number of cores), immunophenotype, and when FISH/NGS is useful to support diagnosis", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should I obtain and process tissue to confirm PMBCL and distinguish it from cHL, mediastinal grey zone lymphoma, and other B-cell lymphomas?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000001548a290cadf93/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["PMBCL", "Mediastinal mass", "Core biopsy", "Haematopathology", "FISH", "NGS", "PDL1", "CIITA"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000015", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000014", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000014", "editorial": {"original_title": "Baseline Staging and Urgent Presentations", "public_title": "Baseline Staging and Urgent Presentations", "slug": "wave2-baseline-staging-and-urgent-presentations-900000000014", "legacy_canonical_url": null, "description": "Baseline PET-CT timing (ideally pre-steroid), acceptable alternatives if delay is unsafe, bone marrow biopsy considerations, and use of contrast-enhanced CT when vascular compromise/thrombosis is suspected", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What baseline imaging and staging tests are recommended in PMBCL, and how do I handle urgency (steroids, SVCO, vascular compromise) without compromising staging?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000014102de7c5a478/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["PET-CT", "Steroids", "SVCO", "Contrast CT", "Staging", "Bone marrow biopsy", "Vascular compromise"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000014", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000013", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000013", "editorial": {"original_title": "Frontline Therapy Selection (and What to Avoid)", "public_title": "Frontline Therapy Selection (and What to Avoid)", "slug": "wave2-frontline-therapy-selection-and-what-to-avoid-900000000013", "legacy_canonical_url": null, "description": "Recommended regimens (R-CHOP-14 x6 or DA-R-EPOCH x6), rationale for dose-intensity, trial/registry evidence summaries cited by guideline, and trial participation recommendation", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For newly diagnosed PMBCL, which first-line chemoimmunotherapy regimens are recommended, and when should R-CHOP-21 be avoided?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000013c8e59ab89efb/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["R-CHOP-14", "DA-R-EPOCH", "R-CHOP-21", "Frontline", "Dose intensive", "Clinical trial"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000013", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000012", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000012", "editorial": {"original_title": "Supportive Care: Thrombosis, Anti-Infective Prophylaxis, Fertility", "public_title": "Supportive Care: Thrombosis, Anti-Infective Prophylaxis, Fertility", "slug": "wave2-supportive-care-thrombosis-anti-infective-prophylaxis-fertility-900000000012", "legacy_canonical_url": null, "description": "High VTE risk and prophylactic anticoagulation threshold, therapeutic anticoagulation for proven thrombosis, approach to venous compression without proven VTE, antimicrobial prophylaxis per local practice, and fertility/pregnancy referral principles", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What supportive care should be routine in PMBCL during frontline therapy—especially thromboprophylaxis, antimicrobial prophylaxis, and fertility/pregnancy considerations?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000012549d5d286d88/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["VTE", "Thromboprophylaxis", "Antimicrobial prophylaxis", "Fertility preservation", "Pregnancy", "Supportive care"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000012", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000011", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000011", "editorial": {"original_title": "Response Assessment: Interim Imaging and EOT PET Standards", "public_title": "Response Assessment: Interim Imaging and EOT PET Standards", "slug": "wave2-response-assessment-interim-imaging-and-eot-pet-standards-900000000011", "legacy_canonical_url": null, "description": "Interim imaging for assessment (not for treatment modification), EOT PET timing (~6 weeks after cycle 6 day 1), Deauville scoring nuances, need for lesion and liver SUVmax reporting, and use of conventional OSEM/research-accredited reconstructions when Deauville informs management", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should I use interim imaging and end-of-treatment PET-CT in PMBCL, and what reporting/technical details matter for Deauville-based decisions?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000117b030e850f1f/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Interim PET", "EOT PET", "Deauville", "OSEM", "SUVmax", "Lugano"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000011", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000010", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000010", "editorial": {"original_title": "Consolidative Radiotherapy: DS 1–3 vs DS 4 vs DS 5", "public_title": "Consolidative Radiotherapy: DS 1–3 vs DS 4 vs DS 5", "slug": "wave2-consolidative-radiotherapy-ds-1-3-vs-ds-4-vs-ds-5-900000000010", "legacy_canonical_url": null, "description": "Omission of RT in CMR (DS 1–3), DS 4 individualized strategy (MDT review, consider biopsy, RT vs short-interval surveillance imaging), DS 5 approach (biopsy when feasible; systemic relapse therapy; limited scenarios for RT alone)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After frontline chemoimmunotherapy, who should receive mediastinal radiotherapy based on EOT PET Deauville score, and how should DS 4 and DS 5 be managed?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000010606d8507f50b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Radiotherapy", "ISRT", "IELSG37", "Deauville 4", "Deauville 5", "Biopsy", "MDT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000010", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000009", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000009", "editorial": {"original_title": "Relapsed/Refractory PMBCL: CAR-T, Novel Agents, Transplant, and RT", "public_title": "Relapsed/Refractory PMBCL: CAR-T, Novel Agents, Transplant, and RT", "slug": "wave2-relapsed-refractory-pmbcl-car-t-novel-agents-transplant-and-rt-900000000009", "legacy_canonical_url": null, "description": "Second-line liso-cel for relapse within 12 months (licensed/NICE-approved per guideline), third-line axi-cel or liso-cel, limited effectiveness of salvage chemo in PMBCL, role of RT in localized refractory sites, options post–CAR-T/AHSCT (PD-1 inhibitor + brentuximab considered), bispecific antibodies and loncastuximab in later lines, and selective role for allogeneic transplant", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In relapsed or refractory PMBCL, how should I sequence CAR-T, chemotherapy/AHSCT, radiotherapy, bispecifics, loncastuximab, PD-1–based approaches, and when is allogeneic transplant considered?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000000902ecdfc28ff4/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Relapsed PMBCL", "CAR-T", "Lisocabtagene maraleucel", "Axicabtagene ciloleucel", "Bispecific antibody", "Epcoritamab", "Glofitamab", "Loncastuximab", "Allogeneic transplant", "Radiotherapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42634099", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000009", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000024", "editorial": {"original_title": "ITP 2019 Consensus: What Changed", "public_title": "ITP 2019 Consensus: What Changed", "slug": "wave2-itp-2019-consensus-what-changed-900000000024", "legacy_canonical_url": null, "description": "High-level updates: diagnostic work-up simplification (eg, bone marrow not routinely required), expanded second-line options (TPO-RAs, rituximab, fostamatinib), de-emphasis of splenectomy and chronic steroid reliance, and attention to QoL/fatigue.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the major practice-changing updates since the 2010 International Consensus Report for primary ITP investigation and management?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000002423c4f73f0829/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ITP", "consensus", "what-changed", "treatment-sequencing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000024", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000023", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000023", "editorial": {"original_title": "Diagnosing Primary ITP: Core Work-up", "public_title": "Diagnosing Primary ITP: Core Work-up", "slug": "wave2-diagnosing-primary-itp-core-work-up-900000000023", "legacy_canonical_url": null, "description": "History, physical exam, CBC, and expert peripheral smear review; exclusion of pseudothrombocytopenia and alternative hematologic diagnoses; classification (primary vs secondary; newly diagnosed/persistent/chronic).", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient with isolated thrombocytopenia, what minimum evaluation supports a presumptive diagnosis of primary ITP and excludes common mimics?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000023fc76ed1fb082/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnosis", "peripheral-smear", "pseudothrombocytopenia", "differential"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000023", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000022", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000022", "editorial": {"original_title": "ITP Testing: What to Order (and Not)", "public_title": "ITP Testing: What to Order (and Not)", "slug": "wave2-itp-testing-what-to-order-and-not-900000000022", "legacy_canonical_url": null, "description": "Routine/typical testing patterns (HIV/HCV/HBV, H pylori in appropriate regions, quantitative immunoglobulins); tests of potential utility (DAT when indicated, ANA/APLA/thyroid tests selectively); antiplatelet antibody testing not routine; bone marrow not required with isolated thrombocytopenia and normal exam/smear, but considered in nonresponse/relapse, before splenectomy, or if other abnormalities.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Which baseline tests are recommended routinely vs selectively in suspected primary ITP, and when is bone marrow examination indicated?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000002238a2478f4840/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["workup", "bone-marrow", "HIV", "HCV", "HBV", "H-pylori", "immunoglobulins"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000022", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000021", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000021", "editorial": {"original_title": "Treat or Observe: Thresholds and Context", "public_title": "Treat or Observe: Thresholds and Context", "slug": "wave2-treat-or-observe-thresholds-and-context-900000000021", "legacy_canonical_url": null, "description": "Treatment individualized by bleeding, comorbidities, age, concurrent antiplatelet/anticoagulation needs, planned procedures/trauma risk, lifestyle, and fatigue/QoL; consensus that treatment is rarely indicated with platelets >20×10^9/L in the absence of additional risk factors; bridging concepts for procedures (including reported use of TPO-RAs).", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "When should adults with primary ITP be treated rather than observed, and what patient factors raise the treatment threshold beyond the platelet count alone?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000021a614b9f353af/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["observation", "bleeding-risk", "platelet-threshold", "procedures", "QoL", "fatigue"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000021", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000020", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000020", "editorial": {"original_title": "First-Line Therapy: Steroids, IVIg, Anti-D", "public_title": "First-Line Therapy: Steroids, IVIg, Anti-D", "slug": "wave2-first-line-therapy-steroids-ivig-anti-d-900000000020", "legacy_canonical_url": null, "description": "Prednisone vs high-dose dexamethasone (faster response with dexamethasone in meta-analysis; similar 6-month responses); when to add IVIg for rapid rise; anti-D cautions including hemolysis risk and black box warning; practical monitoring and avoidance of prolonged steroids.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For newly diagnosed adult primary ITP requiring treatment, how should clinicians choose among prednisone, high-dose dexamethasone, IVIg, and (rarely) IV anti-D?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000020ca380cebc382/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["first-line", "dexamethasone", "prednisone", "IVIg", "anti-D"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000020", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000019", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000019", "editorial": {"original_title": "Life-Threatening Bleeding in ITP", "public_title": "Life-Threatening Bleeding in ITP", "slug": "wave2-life-threatening-bleeding-in-itp-900000000019", "legacy_canonical_url": null, "description": "Immediate combined approach: IV corticosteroids + usually IVIg; platelet transfusions not delayed in life-threatening bleeding; escalation options if inadequate response (consider TPO-RA, vinca alkaloids, antifibrinolytics with caution, rarely emergency splenectomy); measures to stop platelet-affecting drugs and address contributing factors.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What is the recommended emergency management for life-threatening bleeding in ITP, including how to combine therapies to achieve an urgent platelet rise?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000190d121a368d4b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["emergency", "ICH", "platelet-transfusion", "IVIg", "TPO-RA", "tranexamic-acid"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000019", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000018", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000018", "editorial": {"original_title": "Second-Line: TPO-RAs vs Rituximab vs Fostamatinib", "public_title": "Second-Line: TPO-RAs vs Rituximab vs Fostamatinib", "slug": "wave2-second-line-tpo-ras-vs-rituximab-vs-fostamatinib-900000000018", "legacy_canonical_url": null, "description": "Consensus strategy principles (avoid steroid overuse; many medical options; individualize; some require ongoing therapy); robust-evidence options: TPO-RAs with high response rates and potential for some treatment-free responses after taper; rituximab response rates with smaller durable fraction and required viral screening/vaccination considerations; fostamatinib as alternative mechanism with more modest stable responses.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In persistent or chronic primary ITP after relapse or steroid dependence, how should clinicians select among TPO-RAs, rituximab, and fostamatinib based on goals (durable remission vs maintenance), safety, and logistics?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000180d45681a23f6/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["second-line", "TPO-RA", "romiplostim", "eltrombopag", "avatrombopag", "rituximab", "fostamatinib", "steroid-sparing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000018", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000017", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000017", "editorial": {"original_title": "When to Consider Splenectomy", "public_title": "When to Consider Splenectomy", "slug": "wave2-when-to-consider-splenectomy-900000000017", "legacy_canonical_url": null, "description": "Consensus positioning of splenectomy after failure of medical therapies; deferring for ≥1 year when possible to allow for spontaneous remission; incorporating age/comorbidities and thrombosis/infection considerations into shared decision-making (without detailing perioperative protocols not fully provided in excerpt).", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Non-Malignant Hematology", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In adult primary ITP, when is splenectomy appropriate in the modern era, and why should it typically be deferred?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000177cde317e7f42/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["splenectomy", "shared-decision-making", "remission", "second-line"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_31489694", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000017", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000032", "editorial": {"original_title": "What Changed in 2026: ASCO–OH Living Myeloma Guidance", "public_title": "What Changed in 2026: ASCO–OH Living Myeloma Guidance", "slug": "wave2-what-changed-in-2026-asco-oh-living-myeloma-guidance-900000000032", "legacy_canonical_url": null, "description": "Summary of updated recommendations and decision algorithms; emphasis on new/expanded roles for anti-CD38 quadruplets, smoldering myeloma treatment option, and principles for CAR T/bispecifics.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the major practice-changing recommendations in the 2026 ASCO–Ontario Health living guideline, and how should clinicians navigate decisions across smoldering, frontline, maintenance, and relapse settings?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000320484d6ad9953/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ASCO", "Ontario Health", "living guideline", "multiple myeloma", "practice update"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000032", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000031", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000031", "editorial": {"original_title": "High-Risk Smoldering Myeloma: Treat or Monitor?", "public_title": "High-Risk Smoldering Myeloma: Treat or Monitor?", "slug": "wave2-high-risk-smoldering-myeloma-treat-or-monitor-900000000031", "legacy_canonical_url": null, "description": "Smoldering myeloma recommendations and qualifying statements; indirectness/uncertainty due to changing IMWG criteria and heterogeneous risk models; principles for ensuring complete workup before treating.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient labeled as high-risk smoldering myeloma, when should you offer systemic therapy versus active monitoring, and what diagnostic steps are critical to exclude active myeloma first?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000031d69ad6d8a424/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["smoldering myeloma", "high-risk SMM", "IMWG SLiM-CRAB", "active monitoring", "advanced imaging"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000031", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000026", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000026", "editorial": {"original_title": "High-Risk Smoldering: Daratumumab vs Lenalidomide", "public_title": "High-Risk Smoldering: Daratumumab vs Lenalidomide", "slug": "wave2-high-risk-smoldering-daratumumab-vs-lenalidomide-900000000026", "legacy_canonical_url": null, "description": "Trial-informed rationale distinguishing daratumumab option (conditional) from lenalidomide (not routinely recommended) and the role of patient-centered discussion given indirectness of older trials and evolving downstream frontline therapies.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For high-risk smoldering myeloma where treatment is being considered, when does the guideline support daratumumab, and why does it not recommend routine lenalidomide therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000268620ce7e9a12/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["daratumumab", "lenalidomide", "SMM trials", "conditional recommendation", "toxicity"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000026", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000030", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000030", "editorial": {"original_title": "Frontline Transplant-Eligible: Induction Quadruplets", "public_title": "Frontline Transplant-Eligible: Induction Quadruplets", "slug": "wave2-frontline-transplant-eligible-induction-quadruplets-900000000030", "legacy_canonical_url": null, "description": "Recommendation to offer anti-CD38 (daratumumab or isatuximab) + bortezomib/lenalidomide/dexamethasone as initial therapy; practical considerations when substituting carfilzomib for bortezomib due to neuropathy/discontinuation concerns.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In newly diagnosed transplant-eligible myeloma, what induction regimen should be offered, and how should you choose between anti-CD38 quadruplet options and alternatives when toxicity or access issues arise?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000030ec8d6c1b4074/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["transplant-eligible", "induction", "quadruplet", "anti-CD38", "VRd", "Isa-VRd"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000030", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000029", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000029", "editorial": {"original_title": "Up-Front ASCT & Stem Cell Collection: Timing Decisions", "public_title": "Up-Front ASCT & Stem Cell Collection: Timing Decisions", "slug": "wave2-up-front-asct-stem-cell-collection-timing-decisions-900000000029", "legacy_canonical_url": null, "description": "Recommendations supporting offering up-front ASCT; evidence context for up-front vs deferred strategies; guidance to collect sufficient stem cells within ~4 months of starting therapy and enough for at least two rescues.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For transplant-eligible patients receiving modern induction, should ASCT be offered up-front, and what is the guideline’s recommended stem cell collection approach (including collecting for ≥2 rescues)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000029f9f20f1590c9/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ASCT", "up-front transplant", "stem cell collection", "timing", "transplant program"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000029", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000025", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000025", "editorial": {"original_title": "Post-ASCT: Consolidation—When Does It Add Value?", "public_title": "Post-ASCT: Consolidation—When Does It Add Value?", "slug": "wave2-post-asct-consolidation-when-does-it-add-value-900000000025", "legacy_canonical_url": null, "description": "Conditional recommendation regarding consolidation in the context of daratumumab-based strategies; explanation that key quadruplet trials bundled induction+consolidation and do not isolate consolidation’s independent effect.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After ASCT in a patient treated with anti-CD38-based induction, when should consolidation be used, and what are the limits of the evidence for consolidation as an independent decision?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000258aedbd942e66/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["consolidation", "post-ASCT", "daratumumab", "evidence limitations", "treatment strategy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000025", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000028", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000028", "editorial": {"original_title": "Maintenance After ASCT: Lenalidomide and Intensification", "public_title": "Maintenance After ASCT: Lenalidomide and Intensification", "slug": "wave2-maintenance-after-asct-lenalidomide-and-intensification-900000000028", "legacy_canonical_url": null, "description": "Lenalidomide as foundational maintenance (at least) and counseling about toxicity/secondary malignancy risk; circumstances where adding daratumumab (e.g., MRD+ post-ASCT without prior anti-CD38 exposure) or adding carfilzomib ± dexamethasone may be reasonable; uncertainty in the quadruplet era.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After ASCT, what maintenance is recommended (minimum and duration), how should you counsel about long-term risks (including secondary malignancy), and when is adding daratumumab and/or carfilzomib reasonable (e.g., MRD+ or high-risk disease)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000282551acc787d1/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["maintenance", "lenalidomide", "secondary malignancy", "MRD", "high-risk", "daratumumab maintenance", "carfilzomib maintenance"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000028", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000027", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000027", "editorial": {"original_title": "Relapsed Myeloma: Triplets vs CAR T vs Bispecifics", "public_title": "Relapsed Myeloma: Triplets vs CAR T vs Bispecifics", "slug": "wave2-relapsed-myeloma-triplets-vs-car-t-vs-bispecifics-900000000027", "legacy_canonical_url": null, "description": "Guideline principles for offering triplets when eligible; offering CAR T to eligible patients with shared decision-making and recognizing manufacturing delays; offering bispecific antibodies including for older/frail patients; sequencing based on patient/disease factors and prior responses.", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In relapsed/refractory myeloma, how should you choose among triplet regimens, CAR T-cell therapy, and bispecific antibodies across first and later relapses, accounting for prior therapies, pace of relapse, frailty, and access/manufacturing timelines?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000279d6f9e43bf80/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapse", "RRMM", "CAR T", "bispecific antibody", "triplet therapy", "sequencing", "frailty"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41494138", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000027", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000040", "editorial": {"original_title": "CLL Treatment Selection: What This Consensus Changes", "public_title": "CLL Treatment Selection: What This Consensus Changes", "slug": "wave2-cll-treatment-selection-what-this-consensus-changes-900000000040", "legacy_canonical_url": null, "description": "Consensus statements and decision algorithm (16 key statements; emphasis on targeted-first, molecular testing, sequencing, and AE-driven switching)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should clinicians navigate this multiregional consensus algorithm to choose between continuous BTKi and fixed-duration venetoclax-based therapy, and how does it prioritize molecular risk and real-world constraints?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000040b4e0e8488ba3/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["CLL", "consensus", "treatment-selection", "sequencing", "BTKi", "venetoclax", "resource-constraints"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000040", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000039", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000039", "editorial": {"original_title": "Treat or Observe: Applying Watch-and-Wait", "public_title": "Treat or Observe: Applying Watch-and-Wait", "slug": "wave2-treat-or-observe-applying-watch-and-wait-900000000039", "legacy_canonical_url": null, "description": "Consensus endorsement of watch-and-wait; rationale from trials showing no OS benefit to early treatment; shared decision-making context", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In an asymptomatic early-stage CLL patient, when should you continue observation versus initiate therapy, and how should you counsel high-risk biology in the absence of iwCLL treatment criteria?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000039cd171bbbbfc7/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["watch-and-wait", "iwCLL", "early-stage", "treatment-indications"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000039", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000038", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000038", "editorial": {"original_title": "Baseline Testing That Changes Therapy in 2025", "public_title": "Baseline Testing That Changes Therapy in 2025", "slug": "wave2-baseline-testing-that-changes-therapy-in-2025-900000000038", "legacy_canonical_url": null, "description": "FISH del(17p), TP53 mutation testing before therapy and at relapse; IGHV before first line; consideration of complex karyotype; how access influences decision utility", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What molecular/cytogenetic tests must be obtained before first-line therapy and at relapse to guide CLL treatment selection, and what is their practical impact in different resource settings?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000038eaf763893ff9/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["TP53", "del17p", "IGHV", "FISH", "molecular-testing", "complex-karyotype"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000038", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000037", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000037", "editorial": {"original_title": "Frontline Strategy: Continuous BTKi vs Fixed-Duration Venetoclax", "public_title": "Frontline Strategy: Continuous BTKi vs Fixed-Duration Venetoclax", "slug": "wave2-frontline-strategy-continuous-btki-vs-fixed-duration-venetoclax-900000000037", "legacy_canonical_url": null, "description": "Consensus preference for targeted agents; factors for regimen selection (duration preference, comorbidities such as CV/renal, logistics, AE profiles); second-gen BTKi favored over ibrutinib for safety", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For a treatment-naïve patient meeting treatment criteria without TP53 aberration, how do you choose between continuous BTKi-based therapy and time-limited venetoclax-based combinations?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000372954106a357f/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["frontline", "BTKi", "acalabrutinib", "zanubrutinib", "venetoclax", "fixed-duration", "shared-decision-making"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000037", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000036", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000036", "editorial": {"original_title": "High-Risk del(17p)/TP53: Preferred First-Line Path", "public_title": "High-Risk del(17p)/TP53: Preferred First-Line Path", "slug": "wave2-high-risk-del-17p-tp53-preferred-first-line-path-900000000036", "legacy_canonical_url": null, "description": "Consensus: continuous 2nd-gen covalent BTKi preferred; fixed-duration BTKi+BCL2i may be considered in select fit patients; BCL2i+anti-CD20 as option if BTKi contraindicated", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In treatment-naïve CLL with del(17p) and/or TP53 mutation, what is the preferred first-line regimen and when is a fixed-duration approach reasonable if the patient strongly prefers time-limited therapy or has contraindications?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000365bb5e3ef1f9b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["TP53", "del17p", "high-risk", "continuous-therapy", "BTKi", "venetoclax"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000036", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000034", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000034", "editorial": {"original_title": "IGHV-Unmutated (No TP53 Aberration): Practical Choices", "public_title": "IGHV-Unmutated (No TP53 Aberration): Practical Choices", "slug": "wave2-ighv-unmutated-no-tp53-aberration-practical-choices-900000000034", "legacy_canonical_url": null, "description": "Consensus against CIT in uIGHV; targeted therapy recommended; regimen tailoring driven more by comorbidity (CV risk/renal function) and preference than by 'fitness' alone", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For uIGHV CLL without del(17p)/TP53 mutation, how should you choose between continuous BTKi and fixed-duration venetoclax-based therapy, and why is chemoimmunotherapy discouraged?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000034dd05058db713/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["uIGHV", "frontline", "BTKi", "venetoclax", "CIT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000034", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000033", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000033", "editorial": {"original_title": "IGHV-Mutated (Low-Risk): Time-Limited Preferred", "public_title": "IGHV-Mutated (Low-Risk): Time-Limited Preferred", "slug": "wave2-ighv-mutated-low-risk-time-limited-preferred-900000000033", "legacy_canonical_url": null, "description": "Consensus preference for time-limited venetoclax-based combinations in low-risk; BTKi monotherapy for frail patients; CIT only in constrained access after informed discussion", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For mIGHV CLL without del(17p)/TP53 mutation, when should time-limited venetoclax-based therapy be preferred, when is continuous BTKi reasonable, and when is CIT only a resource-limited fallback?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000033bff0ec2d72d8/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["mIGHV", "low-risk", "venetoclax-obinutuzumab", "BTKi", "resource-limited", "CIT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000033", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000035", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000035", "editorial": {"original_title": "Relapse Sequencing & Toxicity-Driven Switching", "public_title": "Relapse Sequencing & Toxicity-Driven Switching", "slug": "wave2-relapse-sequencing-toxicity-driven-switching-900000000035", "legacy_canonical_url": null, "description": "Consensus: switch class at progression (post-BTKi → venetoclax-based; post-venetoclax → BTKi-based); venetoclax retreatment after long remission (≥3 years) in selected patients; AE thresholds for modifying/switching including severe cardiac events, major bleeding, recurrent hospitalizing infections; incorporate frailty/comorbidities", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After progression or intolerance on (1) continuous covalent BTKi or (2) fixed-duration venetoclax-based therapy, what is the preferred next treatment class, when is venetoclax retreatment reasonable, and how should severe AEs trigger switching decisions?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000035b08a9141cc8a/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapse", "sequencing", "BTKi", "venetoclax", "retreatment", "adverse-events", "switch-class"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_39871707", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000035", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000048", "editorial": {"original_title": "Myeloma 2026: What Changed & How to Use This Update", "public_title": "Myeloma 2026: What Changed & How to Use This Update", "slug": "wave2-myeloma-2026-what-changed-how-to-use-this-update-900000000048", "legacy_canonical_url": null, "description": "High-level synthesis of the AJH 2026 update recommendations and decision framework", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the practice-changing updates in 2026 for diagnosis, risk, frontline therapy, maintenance, and relapse strategies, and how should clinicians navigate the decision tree?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000004872fb3ea410f4/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["multiple myeloma", "2026 update", "mSMART", "IMWG", "treatment algorithm"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000048", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000047", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000047", "editorial": {"original_title": "Diagnosing Active Myeloma: IMWG MDEs, CRAB, and Biomarkers", "public_title": "Diagnosing Active Myeloma: IMWG MDEs, CRAB, and Biomarkers", "slug": "wave2-diagnosing-active-myeloma-imwg-mdes-crab-and-biomarkers-900000000047", "legacy_canonical_url": null, "description": "IMWG diagnostic criteria including CRAB attribution and biomarker-defined myeloma (≥60% clonal PCs, FLC ratio ≥100 with conditions, >1 MRI focal lesion)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "When a patient has a monoclonal protein and/or marrow plasmacytosis, what specific criteria establish symptomatic multiple myeloma requiring therapy versus MGUS/SMM?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000474a31f614fcce/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["IMWG", "CRAB", "myeloma-defining events", "FLC ratio", "MRI focal lesions"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000047", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000046", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000046", "editorial": {"original_title": "Baseline Testing & Monitoring: Labs, Marrow Genetics, Imaging, MRD", "public_title": "Baseline Testing & Monitoring: Labs, Marrow Genetics, Imaging, MRD", "slug": "wave2-baseline-testing-monitoring-labs-marrow-genetics-imaging-mrd-900000000046", "legacy_canonical_url": null, "description": "SPEP/SIFE/FLC (and role of mass spectrometry), marrow FISH/NGS panel targets, WB-CT vs PET/CT vs MRI, measurable M-protein criteria, response/MRD per IMWG", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What baseline studies should be ordered at suspected/confirmed myeloma, how is measurable disease defined, and what is the recommended monitoring cadence on- and off-therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000046258f7a4bde29/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["SPEP", "immunofixation", "mass spectrometry", "FISH", "PET-CT", "WB-CT", "MRD"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000046", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000045", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000045", "editorial": {"original_title": "Risk Stratification 2026: Defining High-Risk Cytogenetics", "public_title": "Risk Stratification 2026: Defining High-Risk Cytogenetics", "slug": "wave2-risk-stratification-2026-defining-high-risk-cytogenetics-900000000045", "legacy_canonical_url": null, "description": "High-risk definitions (del17p/p53 mutation, biallelic del1p, IgH translocations with gain1q or del1p, gain1q plus del1p) and practical implications referenced in the update", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Which cytogenetic findings define high-risk multiple myeloma in 2026, and how should risk classification influence intensity and duration of therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000045197337d05472/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["high-risk myeloma", "del17p", "p53", "gain1q", "del1p", "t(4;14)", "t(14;16)", "t(14;20)"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000045", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000044", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000044", "editorial": {"original_title": "Frontline (Transplant-Eligible): Quadruplets and Early vs Delayed ASCT", "public_title": "Frontline (Transplant-Eligible): Quadruplets and Early vs Delayed ASCT", "slug": "wave2-frontline-transplant-eligible-quadruplets-and-early-vs-delayed-asct-900000000044", "legacy_canonical_url": null, "description": "Quadruplet induction (3–4 cycles pre-collection), early vs delayed ASCT (PFS vs OS), timing of collection, mobilization considerations with lenalidomide, tandem/consolidation positioning", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In transplant-eligible newly diagnosed myeloma, when should clinicians use Dara-VRd vs Isa-VRd, when can ASCT be safely delayed, and what are the key logistics around stem-cell collection?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000044ad990696aa6b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Dara-VRd", "Isa-VRd", "ASCT", "stem cell collection", "delayed transplant", "tandem transplant"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000044", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000043", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000043", "editorial": {"original_title": "Frontline (Transplant-Ineligible): Frailty-Directed Regimen Choice", "public_title": "Frontline (Transplant-Ineligible): Frailty-Directed Regimen Choice", "slug": "wave2-frontline-transplant-ineligible-frailty-directed-regimen-choice-900000000043", "legacy_canonical_url": null, "description": "Quadruplets for non-frail patients, triplets for frail, practical steroid/lenalidomide dose reductions and de-escalation", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For transplant-ineligible or older patients, how should frailty determine selection of quadruplet therapy versus DRd/Isa-Rd/VRd and dose modifications?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000004338c55d418714/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["frailty", "transplant-ineligible", "DRd", "Isa-Rd", "VRd", "dose reduction"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000043", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000042", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000042", "editorial": {"original_title": "Maintenance 2026: Anti-CD38 + Lenalidomide, Duration, High-Risk Options", "public_title": "Maintenance 2026: Anti-CD38 + Lenalidomide, Duration, High-Risk Options", "slug": "wave2-maintenance-2026-anti-cd38-lenalidomide-duration-high-risk-options-900000000042", "legacy_canonical_url": null, "description": "Lenalidomide + daratumumab/isatuximab maintenance; stopping lenalidomide at 2 years in standard-risk; continuation in high-risk; bortezomib+lenalidomide alternative; second cancer counseling", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After induction ± ASCT, what maintenance regimen is recommended, how long should lenalidomide continue in standard- vs high-risk disease, and when is bortezomib-based maintenance preferred?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000429ea598b74fb6/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["maintenance", "lenalidomide", "daratumumab", "isatuximab", "bortezomib maintenance", "second primary malignancy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000042", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000041", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000041", "editorial": {"original_title": "Relapsed Myeloma: First vs Later Relapse, CAR-T, Bispecifics, Belantamab", "public_title": "Relapsed Myeloma: First vs Later Relapse, CAR-T, Bispecifics, Belantamab", "slug": "wave2-relapsed-myeloma-first-vs-later-relapse-car-t-bispecifics-belantamab-900000000041", "legacy_canonical_url": null, "description": "TRAP framework, first-relapse strategy including Tec-Dara and cellular therapy prioritization, lenalidomide-refractory shift to pomalidomide-based triplets, later-line sequencing including talquetamab and venetoclax for t(11;14), infection risk and IVIG with bispecifics, CRS mitigation principles noted in the update", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Plasma Cell & Myeloma", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "At relapse, how should timing (first vs later), refractoriness (e.g., anti-CD38 or lenalidomide), and access determine selection among CAR-T, BCMA/GPRC5D bispecifics, triplet regimens, and belantamab-based approaches?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000041999af5a97c8d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapsed myeloma", "CAR-T", "bispecific antibodies", "teclistamab", "talquetamab", "belantamab mafodotin", "IVIG", "CRS"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42613778", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000041", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000056", "editorial": {"original_title": "Adult cHL 2026: What Changed & How to Use This Review", "public_title": "Adult cHL 2026: What Changed & How to Use This Review", "slug": "wave2-adult-chl-2026-what-changed-how-to-use-this-review-900000000056", "legacy_canonical_url": null, "description": "JAMA 2026 review synthesis plus referenced NCCN/ESMO-aligned recommendations; highlights on novel-agent integration and de-escalation", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the major practice-changing updates in first-line cHL (PD-1–chemo and brentuximab-containing regimens) and where do PET-adapted de-escalation and RT decisions fit?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000005670fc36b0b73d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["cHL", "practice-update", "PD-1", "brentuximab-vedotin", "PET-adapted", "radiotherapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000056", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000055", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000055", "editorial": {"original_title": "Diagnosis & Baseline Workup: Biopsy, Markers, PET Staging", "public_title": "Diagnosis & Baseline Workup: Biopsy, Markers, PET Staging", "slug": "wave2-diagnosis-baseline-workup-biopsy-markers-pet-staging-900000000055", "legacy_canonical_url": null, "description": "Diagnostic criteria (Reed–Sternberg cell immunophenotype), preference for excisional biopsy, Lugano/Ann Arbor-derived staging with FDG-PET/CT, baseline assessment items emphasized in the review", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In suspected cHL, what biopsy approach and baseline tests (including FDG-PET/CT and labs) are recommended to confidently establish diagnosis and stage disease?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000559e8daedb307d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["excisional-biopsy", "CD30", "CD15", "PAX5", "FDG-PET/CT", "Lugano-staging"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000055", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000054", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000054", "editorial": {"original_title": "Early-Stage Risk Stratification: Favorable vs Unfavorable & Bulky", "public_title": "Early-Stage Risk Stratification: Favorable vs Unfavorable & Bulky", "slug": "wave2-early-stage-risk-stratification-favorable-vs-unfavorable-bulky-900000000054", "legacy_canonical_url": null, "description": "Risk-factor frameworks (NCCN/EORTC/GHSG-style factors), bulky disease definitions, and practical implications for selecting RT and/or novel-agent regimens", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For stage I–II cHL, how do you classify favorable vs unfavorable disease (including bulky mediastinal/nodal definitions), and how does this classification change first-line therapy choices?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000054bc1cd00e5f43/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["early-stage", "favorable", "unfavorable", "bulky-disease", "ESR", "B-symptoms"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000054", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000053", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000053", "editorial": {"original_title": "Early-Stage Favorable: Chemo Alone vs Add RT (PET-Adapted)", "public_title": "Early-Stage Favorable: Chemo Alone vs Add RT (PET-Adapted)", "slug": "wave2-early-stage-favorable-chemo-alone-vs-add-rt-pet-adapted-900000000053", "legacy_canonical_url": null, "description": "ABVD-based approaches; interim PET (typically after 2 cycles) to guide de-escalation/RT omission; evidence that RT improves PFS but not OS in PET-negative responders", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In early-stage favorable cHL, when should you use combined-modality therapy vs a PET-adapted chemotherapy-only approach, and what trade-offs should be discussed with patients?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000053ce596135d4b3/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ABVD", "AVD", "interim-PET", "radiation-omission", "PFS-vs-OS", "late-toxicity"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000053", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000052", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000052", "editorial": {"original_title": "Early-Stage Unfavorable: Choose PET-Adapted Chemo vs Novel-Agent + RT", "public_title": "Early-Stage Unfavorable: Choose PET-Adapted Chemo vs Novel-Agent + RT", "slug": "wave2-early-stage-unfavorable-choose-pet-adapted-chemo-vs-novel-agent-rt-900000000052", "legacy_canonical_url": null, "description": "Evidence for PET-guided ABVD→AVD de-escalation; phase 2 data supporting brentuximab vedotin-AVD + RT and nivolumab-AVD + RT; practical RT morbidity considerations", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For stage I–II unfavorable cHL, how do you choose between PET-adapted chemotherapy-only strategies (including bleomycin omission after PET response) and combined-modality regimens using brentuximab vedotin-AVD or nivolumab-AVD followed by RT?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000522d8a4da0f80a/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["unfavorable-early-stage", "bleomycin-omission", "BV-AVD", "nivolumab-AVD", "combined-modality", "radiotherapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000052", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000051", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000051", "editorial": {"original_title": "Advanced-Stage (III–IV): First-Line Regimen Selection", "public_title": "Advanced-Stage (III–IV): First-Line Regimen Selection", "slug": "wave2-advanced-stage-iii-iv-first-line-regimen-selection-900000000051", "legacy_canonical_url": null, "description": "Phase 3 comparative data summarized in the review (nivolumab-AVD vs brentuximab vedotin-AVD); alternatives for patients with autoimmune disease/active immunosuppression; mention of BrECADD as a brentuximab-containing option", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In advanced-stage cHL, how do you select among nivolumab-AVD, brentuximab vedotin-AVD, and other brentuximab-containing options, particularly when PD-1 therapy is contraindicated?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000512a8da3f4ec13/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["advanced-stage", "nivolumab-AVD", "BV-AVD", "BrECADD", "autoimmune-disease", "older-adults"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000051", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000050", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000050", "editorial": {"original_title": "Relapsed/Refractory: Salvage to Autologous SCT (Decision Path)", "public_title": "Relapsed/Refractory: Salvage to Autologous SCT (Decision Path)", "slug": "wave2-relapsed-refractory-salvage-to-autologous-sct-decision-path-900000000050", "legacy_canonical_url": null, "description": "Recommendation to confirm relapse with biopsy; standard intent-to-cure pathway of salvage therapy followed by HDT/ASCR; overview of commonly used salvage approaches (immunotherapy- and brentuximab-based combinations) without asserting superiority in absence of randomized comparisons", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For relapsed or refractory cHL, when should you re-biopsy, how do you assess transplant eligibility, and how should salvage therapy be sequenced to high-dose therapy and autologous SCT?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000050022cd6ce5739/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapsed-refractory", "rebiopsy", "salvage-therapy", "autologous-transplant", "HDT-ASCR", "transplant-eligibility"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000050", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000049", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000049", "editorial": {"original_title": "After ASCT: BV Maintenance, When to Consider Allo-SCT, Survivorship", "public_title": "After ASCT: BV Maintenance, When to Consider Allo-SCT, Survivorship", "slug": "wave2-after-asct-bv-maintenance-when-to-consider-allo-sct-survivorship-900000000049", "legacy_canonical_url": null, "description": "AETHERA-style high-risk criteria and BV maintenance if not previously exposed; role and risks of allo-SCT after ASCT relapse; NCCN-style follow-up (clinical exams, imaging only if clinically indicated) and late toxicity monitoring (secondary malignancies, cardiovascular, pulmonary, thyroid, fertility)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["LYMPHOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Post-autologous SCT, who should receive brentuximab vedotin maintenance, when is allogeneic SCT appropriate after post-ASCT relapse, and what surveillance/late-effects monitoring should be implemented for long-term survivors?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000049cda92bf475b6/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["post-ASCT", "BV-maintenance", "AETHERA", "allogeneic-transplant", "surveillance", "late-effects"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42545803", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Classic Hodgkin Lymphoma A Review", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000049", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000064", "editorial": {"original_title": "RR CLL/SLL 2026: Sequencing Map & What’s New", "public_title": "RR CLL/SLL 2026: Sequencing Map & What’s New", "slug": "wave2-rr-cll-sll-2026-sequencing-map-what-s-new-900000000064", "legacy_canonical_url": null, "description": "Proposed sequencing framework; key therapeutic classes and where they fit now", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should clinicians navigate the 2026 RR CLL/SLL sequencing approach across BTKi, venetoclax, ncBTKi, CAR-T, and alloHCT, and what practical updates change decisions?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000643c4137255bea/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["CLL", "relapsed", "sequencing", "BTKi", "venetoclax", "pirtobrutinib", "CAR-T", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000064", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000063", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000063", "editorial": {"original_title": "Assessing Relapse: When to Treat, MRD, and Bridging", "public_title": "Assessing Relapse: When to Treat, MRD, and Bridging", "slug": "wave2-assessing-relapse-when-to-treat-mrd-and-bridging-900000000063", "legacy_canonical_url": null, "description": "Treatment indications vs relapse; progression kinetics; MRD re-emergence limitations; continuation of BTKi/venetoclax during transition", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient with biochemical/clinical relapse of CLL/SLL, what triggers re-treatment (iwCLL indications plus kinetics), and can BTKi or venetoclax be continued while arranging next therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000063d6e8eceaec78/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["iwCLL", "MRD", "progression", "bridge", "BTKi withdrawal", "venetoclax"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000063", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000062", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000062", "editorial": {"original_title": "Rule Out Richter Transformation (RT)", "public_title": "Rule Out Richter Transformation (RT)", "slug": "wave2-rule-out-richter-transformation-rt-900000000062", "legacy_canonical_url": null, "description": "RT suspicion triggers; FDG PET-CT interpretation; low threshold for tissue biopsy of highest SUV lesion; clonal relatedness concept", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "When relapse looks aggressive, how should clinicians evaluate for Richter transformation (including PET-CT thresholds and biopsy strategy), and what pitfalls exist after targeted-agent therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000624c0cd59c6a27/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Richter transformation", "PET-CT", "biopsy", "LDH", "targeted therapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000062", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000061", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000061", "editorial": {"original_title": "Genomic Reassessment at Relapse: What to Order and Why", "public_title": "Genomic Reassessment at Relapse: What to Order and Why", "slug": "wave2-genomic-reassessment-at-relapse-what-to-order-and-why-900000000061", "legacy_canonical_url": null, "description": "What changes over time vs what doesn’t (IGHV); acquired resistance mutations; practical interpretation limits (VAF, subclones)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "At first and subsequent relapse, which tests should be repeated (TP53 aberrations, karyotypic complexity, BTK/PLCG2 mutations, BCL2 mutations), and how should results influence next therapy selection?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000061ab4e2bd96fb9/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["TP53", "BTK mutations", "PLCG2", "BCL2 G101V", "complex karyotype", "molecular testing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000061", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000060", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000060", "editorial": {"original_title": "Second-Line After Fixed-Duration Venetoclax Regimens", "public_title": "Second-Line After Fixed-Duration Venetoclax Regimens", "slug": "wave2-second-line-after-fixed-duration-venetoclax-regimens-900000000060", "legacy_canonical_url": null, "description": "Response-duration–driven sequencing; rationale for class switch in early relapse; feasibility concepts for venetoclax retreatment in selected patients", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For relapse after fixed-duration venetoclax-based frontline therapy (e.g., Ven-O or Ven-BTKi combinations), when should clinicians choose a cBTKi vs venetoclax retreatment vs switching class based on remission duration (<1–2 years vs longer)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000607a9e30d67b45/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["Ven-O", "fixed duration", "retreatment", "class switch", "second line", "early relapse"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000060", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000059", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000059", "editorial": {"original_title": "Second-Line After cBTKi: Intolerance vs Progression", "public_title": "Second-Line After cBTKi: Intolerance vs Progression", "slug": "wave2-second-line-after-cbtki-intolerance-vs-progression-900000000059", "legacy_canonical_url": null, "description": "Second-generation cBTKi safety/efficacy; limited benefit of switching cBTKi for progression; cardiovascular/bleeding toxicity considerations", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In patients previously treated with a covalent BTKi, how should management differ for BTKi intolerance (switch to acalabrutinib/zanubrutinib) versus true disease progression (avoid within-class switching and select a different class/strategy)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000059c4ec37ca1d27/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ibrutinib intolerance", "acalabrutinib", "zanubrutinib", "atrial fibrillation", "hypertension", "bleeding"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000059", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000058", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000058", "editorial": {"original_title": "Post-BTKi and/or Post-Venetoclax: Where Pirtobrutinib Fits", "public_title": "Post-BTKi and/or Post-Venetoclax: Where Pirtobrutinib Fits", "slug": "wave2-post-btki-and-or-post-venetoclax-where-pirtobrutinib-fits-900000000058", "legacy_canonical_url": null, "description": "ncBTKi mechanism; efficacy and tolerability; cross-resistance considerations; practical role vs other options", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For patients with RR CLL/SLL after prior BTKi exposure (and especially after both BTKi and BCL2i), when should clinicians use noncovalent BTKi (pirtobrutinib), and how do specific BTK mutations (e.g., T474, L528W, A428D) affect expectations?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000058abe3adfac79d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["pirtobrutinib", "ncBTKi", "double-class refractory", "BTK T474", "BTK L528W", "PLCG2"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000058", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000057", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000057", "editorial": {"original_title": "Cellular Therapy & Transplant: CAR-T vs AlloHCT in RR CLL", "public_title": "Cellular Therapy & Transplant: CAR-T vs AlloHCT in RR CLL", "slug": "wave2-cellular-therapy-transplant-car-t-vs-allohct-in-rr-cll-900000000057", "legacy_canonical_url": null, "description": "CAR-T efficacy/toxicities (CRS/ICANS, cytopenias), role relative to ncBTKi; alloHCT candidacy in double-class refractory disease; framing NRM and curative potential", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In heavily pretreated RR CLL/SLL, who should be referred for CAR-T (liso-cel) versus considered for allogeneic HCT, and how should clinicians weigh disease control, toxicity, logistics, and goals of care when choosing between ncBTKi, CAR-T, and alloHCT?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000577b4449e5702c/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["liso-cel", "CAR-T", "CRS", "ICANS", "alloHCT", "double-class refractory", "referral timing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42566728", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000057", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000072", "editorial": {"original_title": "HCL/HCLv 2026 Update: What Changed", "public_title": "HCL/HCLv 2026 Update: What Changed", "slug": "wave2-hcl-hclv-2026-update-what-changed-900000000072", "legacy_canonical_url": null, "description": "Summary of updated international consensus statements; emphasis on new trial data (chemoimmunotherapy depth of response, BRAF/MEK combinations, MRD perspective)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the key practice-changing updates since the 2017 guidance that should alter how I diagnose and treat HCL vs HCLv in 2026?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000727e10c1a89f5a/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["HCL", "HCLv", "guideline_update", "BRAF", "rituximab", "MRD"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000072", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000071", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000071", "editorial": {"original_title": "Diagnosis: HCL vs HCLv", "public_title": "Diagnosis: HCL vs HCLv", "slug": "wave2-diagnosis-hcl-vs-hclv-900000000071", "legacy_canonical_url": null, "description": "Morphology; immunophenotype (CD25/CD103/CD123/Annexin-1/CD200); BRAF-V600E testing by IHC/PCR/NGS; MAP2K1 and IGHV (incl. IGHV4-34); pitfalls when BRAF-negative", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient with splenomegaly and cytopenias/lymphocytosis, what minimal workup reliably distinguishes classical HCL from HCLv and mimics (SMZL/SDRPL, MCL, B-PLL)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000007138fddfac5bcf/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnosis", "immunophenotype", "BRAF_V600E", "MAP2K1", "IGHV4-34", "SDRPL", "SMZL"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000071", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000070", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000070", "editorial": {"original_title": "When to Treat vs Observe", "public_title": "When to Treat vs Observe", "slug": "wave2-when-to-treat-vs-observe-900000000070", "legacy_canonical_url": null, "description": "Indications for treatment (symptoms; cytopenia thresholds: Hb <10 g/dL, ANC <1.0 x 10^9/L, platelets <100 x 10^9/L); rationale to treat before extreme cytopenias due to myelosuppressive therapy; special considerations in low-proliferation disease", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What clinical and laboratory triggers should prompt starting therapy in HCL/HCLv, and when is observation appropriate?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000007026f5111fc12b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["indications", "watch_and_wait", "cytopenias", "splenomegaly", "infections"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000070", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000069", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000069", "editorial": {"original_title": "Frontline HCL: Purine Analog ± Anti-CD20", "public_title": "Frontline HCL: Purine Analog ± Anti-CD20", "slug": "wave2-frontline-hcl-purine-analog-anti-cd20-900000000069", "legacy_canonical_url": null, "description": "Purine analog efficacy/toxicity; operational differences (5-day cladribine vs q14d pentostatin with titration); data for cladribine + rituximab (sequential and concurrent) improving uMRD and durability; practical toxicity note (early platelet drop with concurrent rituximab); convenience and comorbidity-driven selection", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For classical HCL needing therapy, how do I choose cladribine vs pentostatin, and when should I add rituximab (concurrent vs delayed)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000697e37cca0a4e9/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["cladribine", "pentostatin", "rituximab", "frontline", "uMRD", "chemoimmunotherapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000069", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000065", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000065", "editorial": {"original_title": "Response & MRD: What to Measure, When", "public_title": "Response & MRD: What to Measure, When", "slug": "wave2-response-mrd-what-to-measure-when-900000000065", "legacy_canonical_url": null, "description": "CR/PR/relapse definitions; timing of assessment; marrow biopsy role to distinguish CR vs PR; MRD methods and sensitivities; explicit uncertainty about MRD clinical utility and lack of standardization; suggestion to test to gather data without over-interpreting isolated MRD positivity", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After therapy for HCL, when should I assess response, when is marrow biopsy needed, and how should MRD results (if obtained) influence management today?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000065ce5d13fc4014/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["response_assessment", "bone_marrow_biopsy", "MRD", "IHC", "flow_cytometry", "PCR"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000065", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000068", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000068", "editorial": {"original_title": "Relapsed/Refractory HCL: Sequencing", "public_title": "Relapsed/Refractory HCL: Sequencing", "slug": "wave2-relapsed-refractory-hcl-sequencing-900000000068", "legacy_canonical_url": null, "description": "Need to reconfirm diagnosis (especially early relapse/refractory); retreatment triggers same as frontline; expert-opinion approach: relapse >24 months after purine analog monotherapy—purine analog + rituximab; early relapse (<24 months) or relapse <60 months after chemoimmunotherapy—alternate purine analog + rituximab or bendamustine-rituximab; when to prefer less myelotoxic targeted strategies in frailty/serious infection", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should I select therapy for relapsed/refractory HCL based on time to relapse, prior rituximab exposure, and patient fitness/comorbidities?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000685a42945e90af/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapse", "refractory", "retreatment", "bendamustine", "rituximab", "sequencing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000068", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000067", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000067", "editorial": {"original_title": "Targeted Therapy in HCL: BRAF/MEK, BTK, BCL2", "public_title": "Targeted Therapy in HCL: BRAF/MEK, BTK, BCL2", "slug": "wave2-targeted-therapy-in-hcl-braf-mek-btk-bcl2-900000000067", "legacy_canonical_url": null, "description": "Vemurafenib monotherapy vs vemurafenib + rituximab (time-limited regimens; evidence of deeper responses with combination); consensus indications (purine-analog refractory, early relapse, ≥2 relapses, serious infections); dabrafenib ± trametinib (continuous therapy in trial; toxicity considerations); BTK inhibitors (ibrutinib/zanubrutinib) as options with slower kinetics; venetoclax limited data; note off-label status for some agents; brief mention of cellular therapies and alloHCT as last resort after exhausting other options", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "When should I use BRAF inhibitor-based therapy (± anti-CD20, ± MEK inhibitor) and what alternative targeted options exist if BRAF therapy is not suitable or accessible?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000067ee8f37e047fc/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["vemurafenib", "dabrafenib", "trametinib", "BRAF", "MEK", "ibrutinib", "zanubrutinib", "venetoclax", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000067", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000066", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000066", "editorial": {"original_title": "HCL-Variant: Diagnosis-to-Treatment Pathway", "public_title": "HCL-Variant: Diagnosis-to-Treatment Pathway", "slug": "wave2-hcl-variant-diagnosis-to-treatment-pathway-900000000066", "legacy_canonical_url": null, "description": "HCLv diagnostic hallmarks (often CD25-/CD123-/Annexin-1-/BRAF-V600E-; frequent unmutated IGHV4-34 and MAP2K1; possible del17p/TP53 dysfunction); frontline standard: cladribine + rituximab; poor outcomes with purine analog monotherapy; role of MRD/TP53 per available prospective data; limited evidence for alternative chemoimmunotherapy (pentostatin-rituximab, bendamustine-rituximab); targeted options (BTK inhibitor; MEK inhibitor in MAP2K1-mutated disease); when splenectomy is diagnostic vs therapeutic", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["GUIDELINES"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For suspected or confirmed HCLv, what is the recommended initial therapy, how do I use MRD/TP53-risk information, and what are the main relapse options including splenectomy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000006695725ac9b852/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["HCLv", "cladribine", "rituximab", "TP53", "del17p", "MAP2K1", "splenectomy", "BTK_inhibitor"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "W2_SOURCE_009", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000066", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000080", "editorial": {"original_title": "What’s new in unfit ND-AML (2026 algorithms)", "public_title": "What’s new in unfit ND-AML (2026 algorithms)", "slug": "wave2-what-s-new-in-unfit-nd-aml-2026-algorithms-900000000080", "legacy_canonical_url": null, "description": "Algorithmic approach; emphasis on shared decision-making, genomics-driven heterogeneity of benefit, MRD/response depth, dose optimization, and bridging to transplant", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the key practice-changing themes in 2026 algorithms for newly diagnosed AML patients unfit for intensive chemotherapy, and how should clinicians navigate decisions from diagnosis to consolidation?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000008023050e1d7e4e/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["ND-AML", "unfit", "venetoclax", "HMA", "genomics", "MRD", "ASCT", "quality-of-life"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000080", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000079", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000079", "editorial": {"original_title": "Defining “unfit”: tools and bedside thresholds", "public_title": "Defining “unfit”: tools and bedside thresholds", "slug": "wave2-defining-unfit-tools-and-bedside-thresholds-900000000079", "legacy_canonical_url": null, "description": "Unfitness criteria (age/comorbidities/ECOG/social factors), role of geriatric assessment domains, practical incorporation into regimen selection", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should clinicians operationalize “unfit for intensive therapy” in ND-AML, and when should geriatric assessment or comorbidity indices change the treatment plan?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000794675c363ab50/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["fitness", "frailty", "geriatric assessment", "HCT-CI", "ECOG", "treatment selection"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000079", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000078", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000078", "editorial": {"original_title": "Start now or wait? Genomics and temporizing measures", "public_title": "Start now or wait? Genomics and temporizing measures", "slug": "wave2-start-now-or-wait-genomics-and-temporizing-measures-900000000078", "legacy_canonical_url": null, "description": "Recommendation to await genetics when feasible; hyperleukocytosis management (hydroxyurea ± cytarabine, leukapheresis) as a bridge to definitive regimen selection", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In ND-AML unfit patients, when is it appropriate to delay therapy to obtain actionable genomic results, and what temporizing measures are recommended for hyperleukocytosis or clinical instability?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000078f1e9050a8da8/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnostic workflow", "NGS", "actionable mutations", "hyperleukocytosis", "bridging therapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000078", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000077", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000077", "editorial": {"original_title": "Choosing first-line backbone: Ven-HMA vs targeted options", "public_title": "Choosing first-line backbone: Ven-HMA vs targeted options", "slug": "wave2-choosing-first-line-backbone-ven-hma-vs-targeted-options-900000000077", "legacy_canonical_url": null, "description": "Ven-HMA as common standard; exceptions/alternatives highlighted (IDH1 preference considerations; TP53 where venetoclax may not add benefit); aligning regimen with QoL goals", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For ND-AML patients unfit for intensive chemo, how should clinicians choose between venetoclax-HMA, targeted doublets (e.g., azacitidine-ivosidenib for IDH1), and HMA alone (e.g., TP53-mut), based on goals and genetics?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000077b434564b7ba2/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["venetoclax", "azacitidine", "decitabine", "IDH1", "TP53", "shared decision-making"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000077", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000076", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000076", "editorial": {"original_title": "Ven-HMA in practice: dosing, myelosuppression, monitoring", "public_title": "Ven-HMA in practice: dosing, myelosuppression, monitoring", "slug": "wave2-ven-hma-in-practice-dosing-myelosuppression-monitoring-900000000076", "legacy_canonical_url": null, "description": "Evidence supporting shortened venetoclax exposure (e.g., 14–21 days) vs 28 days; toxicity patterns; practical administration considerations", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should venetoclax dose/duration be adjusted (especially cycle 1) to reduce cytopenias and infections while preserving efficacy, and what monitoring is needed during ramp-up and early cycles?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000007653c7b52716f5/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["venetoclax duration", "cycle 1", "cytopenias", "infections", "TLS monitoring", "outpatient AML"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000076", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000075", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000075", "editorial": {"original_title": "Actionable genomics: FLT3, IDH, menin (triplets and caveats)", "public_title": "Actionable genomics: FLT3, IDH, menin (triplets and caveats)", "slug": "wave2-actionable-genomics-flt3-idh-menin-triplets-and-caveats-900000000075", "legacy_canonical_url": null, "description": "Data summaries for FLT3 inhibitor + HMA, azacitidine-ivosidenib, IDH-inhibitor triplets, and menin-inhibitor combinations; explicit uncertainty about incremental survival benefit of triplets pending randomized trials", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In unfit ND-AML with FLT3, IDH1/2, or NPM1/KMT2Ar, when should clinicians consider targeted therapy (doublet vs triplet), and what is known vs still investigational about survival benefit?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000007554178c0da354/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["FLT3", "gilteritinib", "IDH1", "ivosidenib", "IDH2", "menin inhibitor", "KMT2A", "NPM1", "triplet therapy", "clinical trials"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000075", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000074", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000074", "editorial": {"original_title": "Response/MRD and the transplant bridge in “unfit” AML", "public_title": "Response/MRD and the transplant bridge in “unfit” AML", "slug": "wave2-response-mrd-and-the-transplant-bridge-in-unfit-aml-900000000074", "legacy_canonical_url": null, "description": "Prognostic importance of achieving CR/CRi and MRD-negative status; using Ven-HMA to improve performance status; outcomes reported with bridging to ASCT and relapse risk considerations", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After lower-intensity induction (e.g., Ven-HMA), how should CR vs CRi and MRD status guide the decision and timing to pursue allogeneic transplant in patients initially deemed unfit for intensive therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000074b9eed61f8554/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["CR", "CRi", "MRD", "transplant bridge", "ASCT", "older AML", "risk stratification"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000074", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000073", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000073", "editorial": {"original_title": "Too frail for Ven-HMA & when to stop therapy (TFR)", "public_title": "Too frail for Ven-HMA & when to stop therapy (TFR)", "slug": "wave2-too-frail-for-ven-hma-when-to-stop-therapy-tfr-900000000073", "legacy_canonical_url": null, "description": "Algorithm for Ven-HMA-ineligible patients using targeted inhibitors; evidence and criteria associated with successful treatment discontinuation (e.g., MRD-negative CR and prolonged prior therapy) with explicit limits of available data", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For ND-AML patients considered too frail for venetoclax-HMA, what mutation-directed monotherapy/sequential options are discussed, and in responders to Ven-based therapy when can treatment discontinuation (treatment-free remission) be considered?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000007393de5387110e/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["frailty", "Ven-HMA ineligible", "targeted monotherapy", "treatment discontinuation", "treatment-free remission", "MRD-negative"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40818987", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000073", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000088", "editorial": {"original_title": "2026 Fit AML Algorithm: What Changed", "public_title": "2026 Fit AML Algorithm: What Changed", "slug": "wave2-2026-fit-aml-algorithm-what-changed-900000000088", "legacy_canonical_url": null, "description": "High-level synthesis of the 2026 treatment algorithms, highlighting where venetoclax-based and targeted approaches create equipoise with intensive chemotherapy and how MRD/transplant recommendations are framed", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a newly diagnosed fit AML patient, what are the key 2026 decision pivots (intensive vs venetoclax-based therapy, targeted add-ons, MRD, and transplant in CR1) that most change management?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000880c35e10c10ea/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "fit patient", "treatment algorithm", "venetoclax", "targeted therapy", "MRD", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000088", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000087", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000087", "editorial": {"original_title": "Intensive vs Ven-HMA in Fit AML", "public_title": "Intensive vs Ven-HMA in Fit AML", "slug": "wave2-intensive-vs-ven-hma-in-fit-aml-900000000087", "legacy_canonical_url": null, "description": "Evidence and rationale for clinical equipoise between intensive induction (7+3/CPX-351) and venetoclax-HMA in selected fit patients, plus practical considerations (toxicity, inpatient days, proceeding to transplant)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For a fit newly diagnosed AML patient without an immediately defining favorable genotype, when is venetoclax + hypomethylating agent a reasonable alternative to intensive induction, and what trade-offs matter (response depth, toxicity, transplant feasibility)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000087bb39256b327b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "induction", "7+3", "CPX-351", "venetoclax", "azacitidine", "decitabine", "fitness"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000087", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000086", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000086", "editorial": {"original_title": "FLT3-Mutated AML: Induction → Transplant → Maintenance", "public_title": "FLT3-Mutated AML: Induction → Transplant → Maintenance", "slug": "wave2-flt3-mutated-aml-induction-transplant-maintenance-900000000086", "legacy_canonical_url": null, "description": "Frontline FLT3 inhibitor choices with intensive chemotherapy (midostaurin vs quizartinib; gilteritinib data noted as not frontline-approved), transplant recommendations for FLT3-ITD, MRD considerations, and post-transplant maintenance concepts", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In newly diagnosed fit FLT3-mutated AML, how do you choose the FLT3 inhibitor with intensive induction, who should go to transplant in CR1, and when is post-transplant FLT3 inhibitor maintenance favored (especially by peri-transplant MRD)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000086f9855abdf603/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "FLT3", "midostaurin", "quizartinib", "gilteritinib", "MRD", "maintenance", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000086", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000085", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000085", "editorial": {"original_title": "NPM1-Mutated AML: When to Skip CR1 Transplant", "public_title": "NPM1-Mutated AML: When to Skip CR1 Transplant", "slug": "wave2-npm1-mutated-aml-when-to-skip-cr1-transplant-900000000085", "legacy_canonical_url": null, "description": "Recommended intensive approach, typical deferral of ASCT in CR1, impact of co-mutations (including FLT3) on decision-making, and practical NPM1 MRD monitoring thresholds and timing", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In fit NPM1-mutated AML, when is intensive chemotherapy with cytarabine/anthracycline preferred and when should allogeneic transplant in CR1 be reserved (e.g., relapse or MRD-positive), including how NPM1 MRD is monitored and interpreted?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000085905500df0dca/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "NPM1", "MRD", "PCR", "consolidation", "alloHCT decision"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000085", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000083", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000083", "editorial": {"original_title": "CBF-AML: Add GO? MRD Drives Transplant", "public_title": "CBF-AML: Add GO? MRD Drives Transplant", "slug": "wave2-cbf-aml-add-go-mrd-drives-transplant-900000000083", "legacy_canonical_url": null, "description": "Intensive chemotherapy backbone, evidence/considerations for adding CD33-directed GO and its toxicity considerations, and MRD response thresholds that inform relapse risk and transplant consideration", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In fit core-binding factor AML, when should you add gemtuzumab ozogamicin to intensive induction, how should PCR-based MRD be followed, and when does persistent/rising MRD trigger consideration of allogeneic transplant?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000834bdbbeb40666/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "CBF", "t(8;21)", "inv(16)", "gemtuzumab ozogamicin", "MRD", "PCR"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000083", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000082", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000082", "editorial": {"original_title": "IDH1/2-Mutated AML: Intensive vs Targeted Combos", "public_title": "IDH1/2-Mutated AML: Intensive vs Targeted Combos", "slug": "wave2-idh1-2-mutated-aml-intensive-vs-targeted-combos-900000000082", "legacy_canonical_url": null, "description": "Rationale for trial enrollment, emerging combinations challenging intensive approaches, and how co-existing NPM1 or FLT3 mutations redirect to corresponding genotype-driven pathways", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In fit newly diagnosed IDH1/2-mutated AML, when should you favor clinical trials or targeted combinations (e.g., adding an IDH inhibitor to venetoclax-HMA) versus standard intensive induction, and how do concomitant mutations affect the plan?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000082c6c80b8c10f0/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "IDH1", "IDH2", "ivosidenib", "enasidenib", "venetoclax", "azacitidine", "clinical trials"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000082", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000084", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000084", "editorial": {"original_title": "TP53-Mutated & Adverse-Risk: Trial First, Transplant When Possible", "public_title": "TP53-Mutated & Adverse-Risk: Trial First, Transplant When Possible", "slug": "wave2-tp53-mutated-adverse-risk-trial-first-transplant-when-possible-900000000084", "legacy_canonical_url": null, "description": "Emphasis on clinical trials, limitations of intensive and venetoclax-HMA outcomes, and positioning of allogeneic transplant as the main potentially durable option when feasible", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In fit newly diagnosed TP53-mutated AML (or other clearly adverse biology), how should you prioritize clinical trials, what off-trial options are considered reasonable, and how should transplant candidacy be integrated despite limited durability of standard therapies?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000845612508a3c3b/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "TP53", "adverse risk", "clinical trials", "venetoclax", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000084", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000081", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000081", "editorial": {"original_title": "KMT2A-Rearranged & Menin Inhibitors: How to Sequence With Transplant", "public_title": "KMT2A-Rearranged & Menin Inhibitors: How to Sequence With Transplant", "slug": "wave2-kmt2a-rearranged-menin-inhibitors-how-to-sequence-with-transplant-900000000081", "legacy_canonical_url": null, "description": "KMT2Ar risk and transplant rationale, quantitative RT-PCR MRD thresholds and prognostic impact, and early-phase menin inhibitor plus intensive therapy signals (with emphasis on investigational status where applicable)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["TRANSPLANT"], "primary_browse_area": "Myeloid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In fit newly diagnosed KMT2A-rearranged AML (and related NPM1/HOX-driven biology), how should you integrate intensive therapy, MRD assessment, and evolving menin-inhibitor combinations, and when is transplant in CR1 favored?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000081e951c5b8904c/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["AML", "KMT2A", "menin inhibitor", "MRD", "RT-PCR", "alloHCT"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_42471330", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000081", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000096", "editorial": {"original_title": "MCL 2025: What Changed & How to Use This Guideline", "public_title": "MCL 2025: What Changed & How to Use This Guideline", "slug": "wave2-mcl-2025-what-changed-how-to-use-this-guideline-900000000096", "legacy_canonical_url": null, "description": "Top-line recommendations across diagnosis, staging, frontline (including cBTKi integration), R/R sequencing (CAR-T, pirtobrutinib, T-cell engagers), and follow-up", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What are the key practice-changing recommendations in the 2025 EHA–EU MCL guideline and how should clinicians navigate frontline, relapse, and cellular therapy decisions?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000968203777fbf62/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["MCL", "EHA", "guideline", "BTKi", "CAR-T", "treatment-sequencing"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000096", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000095", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000095", "editorial": {"original_title": "Diagnosing MCL: Pathology Must-Haves & Re-biopsy", "public_title": "Diagnosing MCL: Pathology Must-Haves & Re-biopsy", "slug": "wave2-diagnosing-mcl-pathology-must-haves-re-biopsy-900000000095", "legacy_canonical_url": null, "description": "Excision biopsy preference; cyclin D1/CCND1 rearrangement; SOX11 and cyclin D1-negative cases; morphologic variants; why fine-needle aspiration is inappropriate; expert hematopathology review; re-biopsy at relapse", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient with suspected or relapsed MCL, what specimen and markers are required to confirm diagnosis and what must be repeated at progression?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000009525b76aae106d/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnosis", "cyclinD1", "CCND1", "SOX11", "biopsy", "relapse"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000095", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000094", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000094", "editorial": {"original_title": "Baseline Workup: Staging, Risk, and TP53 Testing", "public_title": "Baseline Workup: Staging, Risk, and TP53 Testing", "slug": "wave2-baseline-workup-staging-risk-and-tp53-testing-900000000094", "legacy_canonical_url": null, "description": "CT neck/chest/abdomen/pelvis; bone marrow aspirate with flow + trephine; PET-CT role (esp limited stage); GI endoscopy in limited stage; PET-CT limitations for marrow/GI; MIPI and c-MIPI; Ki-67 cutoffs and method; TP53 mutation testing (sequencing preferred) vs p53 IHC cutoff; viral screening (HBV/HCV/HIV)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What staging studies and prognostic tests should be ordered at baseline (and when are PET-CT, GI endoscopy, CNS evaluation, Ki-67, and TP53 required)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000094da855a7ace49/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["staging", "MIPI", "Ki-67", "TP53", "PET-CT", "bone-marrow", "endoscopy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000094", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000093", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000093", "editorial": {"original_title": "When to Observe: Indolent/Leukemic Nonnodal MCL", "public_title": "When to Observe: Indolent/Leukemic Nonnodal MCL", "slug": "wave2-when-to-observe-indolent-leukemic-nonnodal-mcl-900000000093", "legacy_canonical_url": null, "description": "Definition/features of indolent presentations; guideline watch-and-wait recommendation and surveillance intervals; position on early targeted therapy only in clinical trials; when to initiate treatment at progression", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Which newly diagnosed MCL patients can be managed with watch-and-wait, and what monitoring schedule is recommended?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000009349e5d17b2192/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["watch-and-wait", "indolent", "nonnodal", "SOX11-negative", "monitoring"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000093", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000089", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000089", "editorial": {"original_title": "Limited-stage MCL: radiation vs systemic therapy", "public_title": "Limited-stage MCL: radiation vs systemic therapy", "slug": "wave2-limited-stage-mcl-radiation-vs-systemic-therapy-900000000089", "legacy_canonical_url": null, "description": "Need for thorough staging (PET-CT, BM biopsy, endoscopy with biopsies); low-risk stage I options (observe or ISRT 24–36 Gy); intermediate risk/tumor load (shortened systemic therapy + RT consideration); stage II bulky/high-risk MIPI or high-risk biology (treat as advanced stage)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In stage I–II MCL, when is observation or involved-site radiotherapy appropriate, and when should you escalate to systemic therapy (with or without radiation)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000089d5a406c3d111/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["limited_stage", "ISRT", "radiotherapy", "stage_I_II", "tumor_load"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000089", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000092", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000092", "editorial": {"original_title": "Frontline Fit/Younger: cBTKi, Cytarabine, ASCT, Maintenance", "public_title": "Frontline Fit/Younger: cBTKi, Cytarabine, ASCT, Maintenance", "slug": "wave2-frontline-fit-younger-cbtki-cytarabine-asct-maintenance-900000000092", "legacy_canonical_url": null, "description": "Dose-intensified rituximab/cytarabine-based approaches; evolving role of ASCT; TRIANGLE trial implications (cBTKi-containing approach as current standard; potential to omit ASCT with less toxicity while maintaining outcomes in overall population); maintenance rituximab considerations; access/reimbursement caveats; second-generation cBTKi substitution where ibrutinib unavailable (acknowledging lack of phase III data)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In transplant-eligible or otherwise fit patients, how should induction, the addition of a covalent BTK inhibitor, ASCT, and maintenance be selected in 2025?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000092b316f13e537f/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["frontline", "transplant-eligible", "ASCT", "cytarabine", "TRIANGLE", "ibrutinib", "maintenance"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000092", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000091", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000091", "editorial": {"original_title": "Frontline Older/Frail: BR, VR-CAP, cBTKi+BR, Maintenance", "public_title": "Frontline Older/Frail: BR, VR-CAP, cBTKi+BR, Maintenance", "slug": "wave2-frontline-older-frail-br-vr-cap-cbtki-br-maintenance-900000000091", "legacy_canonical_url": null, "description": "Comparative considerations: BR vs R-CHOP; VR-CAP as alternative (including rationale re bendamustine-associated T-cell immunosuppression for future T-cell–engaging therapies); R-BAC option with toxicity caveats; SHINE (ibrutinib+BR) and ECHO (acalabrutinib+BR) PFS benefit with toxicity considerations and regulatory status; ENRICH (R-ibrutinib vs ICT) context and approval caveats; maintenance rituximab for at least 2 years after BR/VR-CAP/R-CHOP per guideline", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For patients not suitable for intensive therapy, how do you choose among BR, VR-CAP, R-CHOP, BR+cBTKi, or chemo-free cBTKi+rituximab strategies, and when is maintenance rituximab recommended?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000091375533dd3887/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["older", "frail", "BR", "VR-CAP", "acalabrutinib", "maintenance-rituximab", "toxicity"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000091", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000090", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000090", "editorial": {"original_title": "Relapse Sequencing: BTKi, CAR-T, Pirtobrutinib, Allo-SCT & Follow-up", "public_title": "Relapse Sequencing: BTKi, CAR-T, Pirtobrutinib, Allo-SCT & Follow-up", "slug": "wave2-relapse-sequencing-btki-car-t-pirtobrutinib-allo-sct-follow-up-900000000090", "legacy_canonical_url": null, "description": "Second-line preference for cBTKi after frontline ICT; switching cBTKi for intolerance; BTKi+venetoclax option with non-approval caveat; post-cBTKi options (CAR-T; pirtobrutinib; immunochemotherapy; rechallenge scenarios); notes on bridging and avoiding bendamustine pre-apheresis; allo-SCT role when CAR-T unavailable/failed and in select high-risk/TP53 cases; baseline and longitudinal follow-up schedules; post–CAR-T late infection risk, IVIG criteria, antimicrobial prophylaxis (HSV/PJP), lab/viral monitoring and revaccination timing", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Guideline or Consensus", "original_resource_type": "guideline_episode", "original_categories": ["CELL_THERAPY"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "At relapse, how should therapy be sequenced across BTKi-naïve relapse, post-cBTKi progression, CAR-T eligibility, use of pirtobrutinib, and when to consider allo-SCT—and what follow-up is recommended post-treatment (including post–CAR-T prophylaxis)?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000090c4e0cc91f854/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapse", "cBTKi", "CAR-T", "brexu-cel", "liso-cel", "pirtobrutinib", "allo-SCT", "post-CAR-T", "infection-prophylaxis"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_41132246", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000090", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000104", "editorial": {"original_title": "WM 2025: What to Do Differently", "public_title": "WM 2025: What to Do Differently", "slug": "wave2-wm-2025-what-to-do-differently-900000000104", "legacy_canonical_url": null, "description": "High-level synthesis: diagnostic threshold (IgM + ≥10% clonal LPL in marrow), symptom-driven treatment initiation (no IgM threshold), preferred induction options (BR without maintenance vs zanubrutinib), and complication-first thinking (hyperviscosity, IgM flare, IgM-mediated syndromes)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In 2025, what are the key practice-changing takeaways for diagnosing, deciding when to treat, and selecting first-line therapy in WM?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh90000000010453a9e91013ee/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["WM", "2025 update", "practice changes", "mSMART", "BTK inhibitor", "bendamustine-rituximab"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 0, "editorial_position": 1, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000104", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000103", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000103", "editorial": {"original_title": "Diagnosing WM vs IgM MGUS vs IgM Myeloma", "public_title": "Diagnosing WM vs IgM MGUS vs IgM Myeloma", "slug": "wave2-diagnosing-wm-vs-igm-mgus-vs-igm-myeloma-900000000103", "legacy_canonical_url": null, "description": "WHO WM definition; marrow involvement threshold (≥10% clonal lymphoplasmacytic cells); role and limits of MYD88 L265P; distinguishing IgM myeloma (lytic lesions, t(14), CD138/plasmacytic phenotype, MYD88 absent) and overlap with marginal zone lymphoma", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "What minimum criteria and distinguishing features should be used to confirm WM and avoid misclassifying IgM MGUS, marginal zone lymphoma, or IgM multiple myeloma?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000001033f8cc9a3857f/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["diagnosis", "IgM MGUS", "MYD88", "CXCR4", "IgM myeloma", "marginal zone lymphoma"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 1, "editorial_position": 2, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000103", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000102", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000102", "editorial": {"original_title": "New WM Workup: Tests You Actually Need", "public_title": "New WM Workup: Tests You Actually Need", "slug": "wave2-new-wm-workup-tests-you-actually-need-900000000102", "legacy_canonical_url": null, "description": "Recommended diagnostic evaluation (SPEP/IFE, quantitative Ig, urine studies, marrow biopsy, MYD88 (all cases), CXCR4 if available, β2M/LDH/albumin, CT or PET/CT, viscosity and ophthalmology when indicated, complication-directed labs including Coombs/cryoglobulin/vWD/Factor VIII/amyloid stains, HBV/HCV screening if rituximab planned)", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For a new suspected/confirmed WM patient, what baseline testing should be ordered to guide prognosis, detect IgM-mediated complications, and plan therapy safely?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000102853de6a33202/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["baseline workup", "bone marrow", "serum viscosity", "ophthalmology", "hepatitis B", "acquired von Willebrand"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 2, "editorial_position": 3, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000102", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000101", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000101", "editorial": {"original_title": "Treat Now or Observe?", "public_title": "Treat Now or Observe?", "slug": "wave2-treat-now-or-observe-900000000101", "legacy_canonical_url": null, "description": "No IgM threshold alone for therapy; symptom- and complication-driven indications (anemia, thrombocytopenia, organomegaly/adenopathy symptoms, hyperviscosity, IgM-mediated neuropathy, cold agglutinin hemolysis, cryoglobulinemia/vasculitis, amyloid); inflammatory fatigue/CRP concept", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "In a patient who meets WM criteria, when is observation appropriate and what findings should trigger starting systemic therapy?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000101d247e9ef1001/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["smoldering WM", "watchful waiting", "treatment indication", "IgM complications", "CRP", "neuropathy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 3, "editorial_position": 4, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000101", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000097", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000097", "editorial": {"original_title": "Risk Stratification: What It’s For (and What It Isn’t)", "public_title": "Risk Stratification: What It’s For (and What It Isn’t)", "slug": "wave2-risk-stratification-what-it-s-for-and-what-it-isn-t-900000000097", "legacy_canonical_url": null, "description": "Variables linked to outcomes (age, albumin, Hb, platelets, β2M, LDH, IgM); risk scores intended for patients requiring treatment; age as dominant driver; cause-specific survival/competing risks and non-WM mortality", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "Which prognostic models are recommended in WM, and how should they (and competing-risk thinking) be applied without using them to decide whether to treat?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000097e42cb27ea508/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["prognosis", "LDH", "beta-2 microglobulin", "albumin", "competing risks", "counseling"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 4, "editorial_position": 5, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000097", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000100", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000100", "editorial": {"original_title": "Hyperviscosity & IgM Flare: Don’t Miss This", "public_title": "Hyperviscosity & IgM Flare: Don’t Miss This", "slug": "wave2-hyperviscosity-igm-flare-don-t-miss-this-900000000100", "legacy_canonical_url": null, "description": "Symptom pattern (epistaxis/gingival bleeding/visual changes), when to check viscosity (especially if IgM >4000 mg/dL with symptoms), viscosity threshold concept (>4), role of plasmapheresis as temporizing measure, ophthalmologic evaluation, and delaying rituximab in some regimens to avoid flare-related hyperviscosity", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "How should hyperviscosity be screened, confirmed, and managed in WM, and how should therapy be sequenced to reduce rituximab-associated IgM flare risk?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000100e807414adc19/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["hyperviscosity", "plasmapheresis", "IgM flare", "rituximab timing", "retinal exam", "urgent WM"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 5, "editorial_position": 6, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000100", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000099", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000099", "editorial": {"original_title": "Frontline WM: BR vs BTK Inhibitor", "public_title": "Frontline WM: BR vs BTK Inhibitor", "slug": "wave2-frontline-wm-br-vs-btk-inhibitor-900000000099", "legacy_canonical_url": null, "description": "Preferred Mayo induction options (BR without rituximab maintenance; zanubrutinib); why rituximab monotherapy is inferior for most; considerations of fixed-duration vs indefinite therapy, toxicity tradeoffs (myelosuppression vs atrial fibrillation/HTN/bleeding), adherence importance with ibrutinib-class agents, and dose modification considerations; BR dose adjustment considerations in older/heavily marrow-infiltrated patients", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "For a symptomatic, treatment-naïve WM patient, how do you choose between bendamustine-rituximab (time-limited) and a covalent BTK inhibitor (continuous), and what are the key practical caveats?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh9000000000991d7d923f12c7/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["first-line", "bendamustine-rituximab", "zanubrutinib", "ibrutinib", "fixed duration", "continuous therapy"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 6, "editorial_position": 7, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000099", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [{"content_id": "VID_900000000098", "relation": "next_series_episode"}], "access": {"entitlement": "unknown", "authorization_required": true}}, {"content_id": "VID_900000000098", "editorial": {"original_title": "Relapsed/Refractory WM: Sequencing & Options", "public_title": "Relapsed/Refractory WM: Sequencing & Options", "slug": "wave2-relapsed-refractory-wm-sequencing-options-900000000098", "legacy_canonical_url": null, "description": "Active agents in relapsed WM (bortezomib-based, cyclophosphamide- or fludarabine-based approaches, thalidomide/lenalidomide, everolimus, carfilzomib, bendamustine, venetoclax, pirtobrutinib as non-covalent BTKi option, others noted); emphasis on reducing cumulative toxicity given indolent natural history; practical issue of IgM rebound/hyperviscosity risk on stopping ibrutinib-class therapy", "scientific_summary": null, "summary_source": "original_Drive_source_focus_verbatim", "content_group": "Review", "original_resource_type": "educational_review_episode", "original_categories": ["MYELOID"], "primary_browse_area": "Lymphoid Neoplasms", "secondary_browse_areas": [], "category_basis": "editorial_navigation_from_explicit_source_disease_title_no_clinical_graph_relation", "clinical_question": "After relapse (including after covalent BTK inhibitor exposure), what therapies have activity in WM and how should you approach selection with toxicity minimization in mind?", "language": null, "original_publication_date": null, "thumbnail": {"url": "https://imagedelivery.net/EH2uhc4oTG_316ZwBRMJrg/5mh900000000098ed1c6265b447/5mhposter", "source": "verified_original_first_slide_cloudflare_images"}, "cover": null, "tags": ["relapse", "refractory", "pirtobrutinib", "venetoclax", "proteasome inhibitor", "IgM rebound"], "publication_status": "staging_preview", "effective_visibility": "restricted_pending_entitlement"}, "science": {"clinical_trial_names": [], "nct_ids": [], "disease_relations": [], "evidence_relations": [], "decision_relations": [], "related_resources": [], "treatment_relations": [], "concept_relations": [], "scientific_update_date": null, "citations": [{"reference_id": "PMID_40095219", "role": "documented_episode_source", "source_association_status": "exact_preserved_source_title", "original_association_status": "source_metadata_unreviewed", "source_field": "metadata.json title/doi/pmid", "source_value": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "provenance": "Audited source metadata, not independent bibliographic or physician review"}]}, "collection": {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "episode_number": 7, "editorial_position": 8, "order_basis": "explicit_original_episode_number"}, "analytics": {"video_id": "VID_900000000098", "entry_points": ["catalog", "guidelines", "related_videos"]}, "related_videos": [], "access": {"entitlement": "unknown", "authorization_required": true}}], "collections": [{"collection_id": "VID_4301002", "uscreen_collection_id": "4301002", "canonical_guideline_id": "GUIDE_EHA_2026_CLL_RICHTER", "title": "EHA 2026 Guidelines: CLL & Richter Transformation", "description": "A practical, section-by-section review of the 2026 EHA Guidelines for chronic lymphocytic leukemia (CLL) and Richter transformation. This collection covers the key recommendations for diagnosis, active surveillance, treatment selection, first-line therapy, relapsed/refractory disease, and the management of Richter transformation. Each episode focuses on a specific clinical question, translating the guideline into concise, clinically relevant take-home messages. Source: Eichhorst B, et al. EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. HemaSphere. 2026;10(6):e70403. Independent educational summary. Please refer to the original guideline for the complete recommendations.", "society": "European Hematology Association (EHA)", "society_provenance": "Verified abstract explicitly identifies the current guideline as written on behalf of EHA", "edition_year": 2026, "version": null, "source_type": "guideline", "main_reference_id": "PMID_42293463", "main_reference_basis": "Exact source title and Eichhorst citation in collection description match the verified publication", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-08-08T20:43:21.415Z", "original_canonical_url": "https://5minutehematology.com/programs/eha-2026-cll-richter-transformation", "cover": {"slug": "eha-2026-cll-richter-transformation", "url": "https://alpha.uscreencdn.com/images/programs/4301002/horizontal/9b15f30a-d42d-4ff0-a0e9-8ef2b289093b.png?auto=webp&width=900", "title": "EHA 2026 Guidelines: CLL and Richter Transformation", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4300974", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4300987", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4300991", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4300993", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4300996", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4300998", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4300999", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4301000", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["version"], "scientific_publication_date": "2026-06-10", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/42293463/"}, {"collection_id": "VID_4301063", "uscreen_collection_id": "4301063", "canonical_guideline_id": "GUIDE_ELN_2025_CML", "title": "ELN 2025 Guidelines: CML Management", "description": "A practical, episode-by-episode review of the 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia in adults. Across 8 focused episodes, this collection covers the major practice-changing updates from ELN 2025: diagnostic and baseline workup, CML phase and risk assessment, molecular monitoring and treatment milestones, frontline TKI selection, dose reduction for intolerance, resistance and mutation testing, later-line therapy with ponatinib or asciminib, and timing of referral for allogeneic stem cell transplantation. Each episode addresses a specific clinical decision, translating the guideline into concise, clinically relevant take-home messages. Source: Apperley JF, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025; 39:17 97–1813. DOI: 10.1038/s41375-025-02664-w. PMID: 40646132. Independent educational summary. Please refer to the original guideline for the complete recommendations.", "society": "European LeukemiaNet (ELN)", "society_provenance": "Full society/network name in verified publication title and collection description", "edition_year": 2025, "version": null, "source_type": "guideline", "main_reference_id": "PMID_40646132", "main_reference_basis": "Collection description explicitly cites PMID 40646132 and DOI 10.1038/s41375-025-02664-w", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-08-08T22:16:13.721Z", "original_canonical_url": "https://5minutehematology.com/programs/eln-2025-cml-management", "cover": {"slug": "eln-2025-cml-management", "url": "https://alpha.uscreencdn.com/images/programs/4301063/horizontal/21904579-5c9d-4f7c-b7a1-dfec5487cdc1.png?auto=webp&width=900", "title": "ELN 2025 Recommendations: CML Management", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4301035", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4301037", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4301047", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4301052", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4301055", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4301058", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4301059", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4301061", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["version"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_4301112", "uscreen_collection_id": "4301112", "canonical_guideline_id": "GUIDE_EHA_2025_LBCL", "title": "LBCL (DLBCL/PMBCL and Special Entities): EHA 2025 Guideline", "description": "A practical, episode-by-episode review of the 2025 European Hematology Association Clinical Practice Guidelines for large B-cell lymphoma (LBCL). Across nine focused episodes, this collection covers guideline use in practice, diagnosis and classification, baseline staging, early- and advanced-stage treatment, PET response assessment, special LBCL entities, CNS risk and prophylaxis, and relapsed/refractory treatment sequencing. Each episode addresses a specific clinical decision and translates the guideline into concise, clinically relevant take-home messages. Source: Thieblemont C et al. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2025. DOI: 10.1002/hem3.70207. PMID: 40995463. Independent educational summary; refer to the original guideline for complete recommendations.", "society": "European Hematology Association (EHA)", "society_provenance": "Collection description and verified EHA publication title", "edition_year": 2025, "version": null, "source_type": "guideline", "main_reference_id": "PMID_40995463", "main_reference_basis": "Collection description explicitly cites PMID 40995463, DOI 10.1002/hem3.70207 and European Hematology Association", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-08-09T00:55:25.732Z", "original_canonical_url": "https://5minutehematology.com/programs/collection-g2u71f_u8ec", "cover": {"slug": "eha-2025-large-b-cell-lymphoma", "url": "https://alpha.uscreencdn.com/images/programs/4301112/horizontal/b7fdc351-bbda-42fb-b363-b06b36b7f982.png?auto=webp&width=900", "title": "EHA 2025 Guidelines: Large B-Cell Lymphoma", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4301114", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4301115", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4301116", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4301117", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4301118", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4301119", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4301120", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4301122", "episode_number": 7, "editorial_position": 8, "migrated": true}, {"content_id": "VID_4301132", "episode_number": 8, "editorial_position": 9, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["version"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_4311360", "uscreen_collection_id": "4311360", "canonical_guideline_id": "GUIDE_EHA_2026_HODGKIN", "title": "EHA 2026 Guidelines: Hodgkin Lymphoma", "description": "A practical, episode-by-episode review of the 2026 EHA Clinical Practice Guidelines for Hodgkin lymphoma. This collection covers the key recommendations for diagnosis, staging, first-line treatment, response assessment, relapsed/refractory disease, transplant-related considerations, and follow-up. Each episode focuses on a specific clinical question, translating the guideline into concise, clinically relevant take-home messages. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2026.</p> Independent educational summary. Please refer to the original guideline for the complete recommendations.", "society": "European Hematology Association (EHA)", "society_provenance": "EHA named in publication title; expansion verified in PMID 42293463 abstract", "edition_year": 2026, "version": null, "source_type": "guideline", "main_reference_id": "PMID_42345030", "main_reference_basis": "Exact source title in collection description matches the verified publication", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-08-18T02:08:46.597Z", "original_canonical_url": "https://5minutehematology.com/programs/eha-2026-hodgkin-lymphoma-guidelines", "cover": {"slug": "eha-2026-hodgkin-lymphoma", "url": "https://alpha.uscreencdn.com/images/programs/4311360/horizontal/b12b1187-3ca8-4ce8-b510-484f4097d4a5.png?auto=webp&width=900", "title": "EHA 2026 Guidelines: Hodgkin Lymphoma", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4311347", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4311339", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4311340", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4311341", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4311343", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4311344", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4311345", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4311346", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["version"], "scientific_publication_date": null, "scientific_publication_year": 2026, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_4347669", "uscreen_collection_id": "4347669", "canonical_guideline_id": null, "title": "MDS 2026 Update: Practical Decisions & Transplant Integration", "description": "A practical 2026 update on myelodysplastic neoplasms (MDS), focused on the decisions that matter in clinical practice. This 8-episode series reviews the current approach to MDS from diagnosis to transplant, including minimum diagnostic work-up, WHO-5 versus ICC classification, molecular testing and germline predisposition, risk stratification, treatment of lower- and higher-risk disease, management after HMA failure, and integration of allogeneic hematopoietic cell transplantation. Each episode is organized around a practical clinical question to help hematologists translate contemporary evidence into day-to-day decision-making. Topics include: • Diagnostic work-up and MDS mimics • WHO-5 versus ICC classification • NGS, prognosis and germline predisposition • Lower-risk MDS and anemia-directed therapy • Higher-risk MDS and HMA-based strategies • Management after HMA failure • Timing and selection for allogeneic HCT Source: Bewersdorf J, Mina A, Stahl M, Zeidan A. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions . Nature Reviews Clinical Oncology. 2026. DOI: 10.1038/s41571-026-01141-2. For healthcare professionals. Educational content only.", "society": null, "society_provenance": "No sponsoring scientific society identified in the exported citation or bibliographic record; source is a review, not a society guideline", "edition_year": 2026, "version": null, "source_type": "review", "main_reference_id": "PMID_41981151", "main_reference_basis": "Collection description explicitly cites DOI 10.1038/s41571-026-01141-2 and the source review title", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-09-14T01:55:00.291Z", "original_canonical_url": null, "cover": {"slug": "mds-2026-update", "url": "https://alpha.uscreencdn.com/images/programs/4347669/horizontal/eb33b797-1ebd-4d1a-a8e3-203ef0be0c7e.png?auto=webp&width=900", "title": "MDS 2026 Update: Practical Decisions & Transplant Integration", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4347650", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4347652", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4347653", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4347654", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4347655", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4347657", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4347658", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4347659", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["canonical_guideline_id", "version", "society"], "scientific_publication_date": null, "scientific_publication_year": 2026, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_4355998", "uscreen_collection_id": "4355998", "canonical_guideline_id": null, "title": "GELTAMO 2025 Follicular Lymphoma Guidelines", "description": "A practical 5MinuteHematology review of the GELTAMO 2025 guidelines for follicular lymphoma, covering diagnosis, staging and risk assessment, localized and advanced disease, frontline treatment, relapse, POD24, radiotherapy, anti-CD20 therapy, ASCT, CAR-T, bispecific antibodies, and follow-up. The series translates the guideline into clinically focused decision pathways for everyday hematology practice.", "society": "Spanish Lymphoma Group (GELTAMO)", "society_provenance": "Verified publication title and abstract, PMID 41681868", "edition_year": 2025, "version": null, "source_type": "guideline", "main_reference_id": "PMID_41681868", "main_reference_basis": "All eight episode descriptions explicitly cite DOI 10.3390/cancers18030395; verified title names GELTAMO 2025 follicular lymphoma, matching the collection title", "main_reference_clinical_review_status": "bibliographic_metadata_verified_clinical_review_pending", "publication_date": "2026-09-19T18:54:55.971Z", "original_canonical_url": null, "cover": {"slug": "geltamo-2025-follicular-lymphoma", "url": "https://alpha.uscreencdn.com/images/programs/4355998/horizontal/5989ea06-af79-4529-8f46-4db9a90bae99.png?auto=webp&width=900", "title": "GELTAMO 2025 Guidelines: Follicular Lymphoma", "source": "feature/render-homepage-migration-20261011@e06cb712d12c44692d3e87bc495ba903c0354f09"}, "episodes": [{"content_id": "VID_4355937", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_4355941", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_4355942", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_4355943", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_4355944", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_4355946", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_4355948", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_4355951", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_EP_number_in_source_title; API_listing_order_not_used", "pending_fields": ["canonical_guideline_id", "version"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000001", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Pediatric CML-CP (2025): International Expert Panel Recommendations in 5 Minutes", "description": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_40044960", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-cml-in-children-leukemia-2025", "url": "/images/guidelines/wave2-cml-in-children-leukemia-2025.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-cml-in-children-leukemia-2025-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-cml-in-children-leukemia-2025-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000008", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000007", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000006", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000005", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000004", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000003", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000001", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000002", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000002", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "BSH 2026: Primary Mediastinal B-Cell Lymphoma (PMBCL) Diagnosis & Management", "description": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_42634099", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-uk-1o-mesdiastino", "url": "/images/guidelines/wave2-uk-1o-mesdiastino.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-uk-1o-mesdiastino-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-uk-1o-mesdiastino-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000016", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000015", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000014", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000013", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000012", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000011", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000010", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000009", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2026-08-23", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/42634099/"}, {"collection_id": "VID_910000000003", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "5MinuteHematology: Primary ITP (2019 Updated International Consensus)", "description": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_31489694", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-pti-ash-2020", "url": "/images/guidelines/wave2-pti-ash-2020.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-pti-ash-2020-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-pti-ash-2020-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000024", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000023", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000022", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000021", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000020", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000019", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000018", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000017", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2019, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000004", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "5MinuteHematology: ASCO–Ontario Health Living Guideline 2026—Treatment of Multiple Myeloma", "description": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_41494138", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-asco-mm-2026", "url": "/images/guidelines/wave2-asco-mm-2026.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-asco-mm-2026-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-asco-mm-2026-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000032", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000031", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000026", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000030", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000029", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000025", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000028", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000027", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2026-01-06", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/41494138/"}, {"collection_id": "VID_910000000005", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "CLL Targeted Therapy Selection & Sequencing: Multiregional Expert Consensus (AJH 2025)", "description": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_39871707", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-multinacional-cll-guide", "url": "/images/guidelines/wave2-multinacional-cll-guide.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-multinacional-cll-guide-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-multinacional-cll-guide-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000040", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000039", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000038", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000037", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000036", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000034", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000033", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000035", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000006", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Multiple Myeloma 2026 Update: Diagnosis, Risk-Stratification & Management (AJH)", "description": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_42613778", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-amj-2026-myeloma", "url": "/images/guidelines/wave2-amj-2026-myeloma.webp", "source": "verified_original_first_slide", "responsive": {"width": 1672, "height": 941, "sources": [{"url": "/images/guidelines-responsive/wave2-amj-2026-myeloma-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-amj-2026-myeloma-1110.webp", "width": 1110, "height": 625}]}}, "episodes": [{"content_id": "VID_900000000048", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000047", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000046", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000045", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000044", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000043", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000042", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000041", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2026, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000007", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "5MinuteHematology: Adult Classic Hodgkin Lymphoma (cHL) — Evidence Review With Treatment Recommendations (JAMA 2026)", "description": "Classic Hodgkin Lymphoma A Review", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_42545803", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-hl-jama-2026", "url": "/images/guidelines/wave2-hl-jama-2026.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-hl-jama-2026-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-hl-jama-2026-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000056", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000055", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000054", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000053", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000052", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000051", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000050", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000049", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2026-09-08", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/42545803/"}, {"collection_id": "VID_910000000008", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Contemporary Management of Relapsed or Refractory CLL/SLL (2026): Sequencing, Cellular Therapy, and Transplant", "description": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_42566728", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-cll-relapse-refractory-2026", "url": "/images/guidelines/wave2-cll-relapse-refractory-2026.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-cll-relapse-refractory-2026-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-cll-relapse-refractory-2026-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000064", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000063", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000062", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000061", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000060", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000059", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000058", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000057", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2026-08-07", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/42566728/"}, {"collection_id": "VID_910000000009", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "5MinuteHematology: 2026 Updated Consensus for Hairy Cell Leukemia (HCL) and HCL-Variant (HCLv)", "description": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "W2_SOURCE_009", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-ash-hcl-2025", "url": "/images/guidelines/wave2-ash-hcl-2025.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-ash-hcl-2025-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-ash-hcl-2025-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000072", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000071", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000070", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000069", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000065", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000068", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000067", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000066", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2026, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000010", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Newly Diagnosed AML in Unfit Patients: 2026 Treatment Algorithms (5MinuteHematology)", "description": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_40818987", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-ajh-aml-unfit-2026", "url": "/images/guidelines/wave2-ajh-aml-unfit-2026.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-ajh-aml-unfit-2026-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-ajh-aml-unfit-2026-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000080", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000079", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000078", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000077", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000076", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000075", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000074", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000073", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2025-08-16", "scientific_publication_year": 2025, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/40818987/"}, {"collection_id": "VID_910000000011", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Newly Diagnosed AML in Fit Patients (2026): Molecularly Guided Treatment & Transplant Algorithms", "description": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_42471330", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-ajh-aml-fit-2026", "url": "/images/guidelines/wave2-ajh-aml-fit-2026.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-ajh-aml-fit-2026-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-ajh-aml-fit-2026-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000088", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000087", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000086", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000085", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000083", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000082", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000084", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000081", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": "2026-07-18", "scientific_publication_year": 2026, "scientific_date_precision": "day", "scientific_publication_status": "pubmed_verified", "scientific_date_source": "https://pubmed.ncbi.nlm.nih.gov/42471330/"}, {"collection_id": "VID_910000000012", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "EHA–EU MCL Network 2025: Diagnosis & Treatment of Mantle Cell Lymphoma (MCL)", "description": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "guideline_or_consensus", "main_reference_id": "PMID_41132246", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-eha-2025-mcl", "url": "/images/guidelines/wave2-eha-2025-mcl.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-eha-2025-mcl-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-eha-2025-mcl-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000096", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000095", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000094", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000093", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000089", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000092", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000091", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000090", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}, {"collection_id": "VID_910000000013", "uscreen_collection_id": null, "canonical_guideline_id": null, "title": "Waldenström Macroglobulinemia (WM) 2025: Diagnosis, Risk Stratification, and Management — 5MinuteHematology", "description": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "society": null, "society_provenance": null, "edition_year": null, "version": null, "source_type": "educational_review", "main_reference_id": "PMID_40095219", "main_reference_basis": "explicit_preserved_source_metadata", "main_reference_clinical_review_status": "source_metadata_only_not_physician_reviewed", "publication_date": null, "original_canonical_url": null, "cover": {"slug": "wave2-mayo-clinic-mw-2025", "url": "/images/guidelines/wave2-mayo-clinic-mw-2025.webp", "source": "verified_original_first_slide", "responsive": {"width": 1600, "height": 900, "sources": [{"url": "/images/guidelines-responsive/wave2-mayo-clinic-mw-2025-740.webp", "width": 740, "height": 416}, {"url": "/images/guidelines-responsive/wave2-mayo-clinic-mw-2025-1110.webp", "width": 1110, "height": 624}]}}, "episodes": [{"content_id": "VID_900000000104", "episode_number": 0, "editorial_position": 1, "migrated": true}, {"content_id": "VID_900000000103", "episode_number": 1, "editorial_position": 2, "migrated": true}, {"content_id": "VID_900000000102", "episode_number": 2, "editorial_position": 3, "migrated": true}, {"content_id": "VID_900000000101", "episode_number": 3, "editorial_position": 4, "migrated": true}, {"content_id": "VID_900000000097", "episode_number": 4, "editorial_position": 5, "migrated": true}, {"content_id": "VID_900000000100", "episode_number": 5, "editorial_position": 6, "migrated": true}, {"content_id": "VID_900000000099", "episode_number": 6, "editorial_position": 7, "migrated": true}, {"content_id": "VID_900000000098", "episode_number": 7, "editorial_position": 8, "migrated": true}], "order_basis": "explicit_original_episode_number", "pending_fields": ["society", "edition_year", "independent_bibliographic_review", "clinical_review", "commercial_entitlement"], "scientific_publication_date": null, "scientific_publication_year": 2025, "scientific_date_precision": "year", "scientific_publication_status": "pending_bibliographic_verification", "scientific_date_source": null}], "references": [{"reference_id": "PMID_18005385", "original_article_title": "GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.", "authors": ["López A", "Gutiérrez A", "Palacios A", "Blancas I", "Navarrete M", "Morey M", "Perelló A", "Alarcón J", "Martínez J", "Rodríguez J"], "authors_original": "López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J.", "first_author": "López A", "first_author_display": "López A, et al.", "citation": "López A, et al.. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. European journal of haematology. 2008;80(2):127-132. doi:10.1111/j.1600-0609.2007.00996.x. PMID:18005385.", "journal": "European journal of haematology", "year": 2008, "volume": "80", "issue": "2", "pages_or_article_id": "127-132", "doi": "10.1111/j.1600-0609.2007.00996.x", "pmid": "18005385", "publication_date": "2007-11-20", "publication_types": ["Clinical Trial, Phase II", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:31.238054+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_18216292", "original_article_title": "Development and validation of a predictive model for chemotherapy-associated thrombosis.", "authors": ["Khorana AA", "Kuderer NM", "Culakova E", "Lyman GH", "Francis CW"], "authors_original": "Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.", "first_author": "Khorana AA", "first_author_display": "Khorana AA, et al.", "citation": "Khorana AA, et al.. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. doi:10.1182/blood-2007-10-116327. PMID:18216292.", "journal": "Blood", "year": 2008, "volume": "111", "issue": "10", "pages_or_article_id": "4902-4907", "doi": "10.1182/blood-2007-10-116327", "pmid": "18216292", "publication_date": "2008-01-23", "publication_types": ["Research Support, Non-U.S. Gov't", "research-article", "Validation Study", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:12.345559+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_20660832", "original_article_title": "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.", "authors": ["Gisselbrecht C", "Glass B", "Mounier N", "Singh Gill D", "Linch DC", "Trneny M", "Bosly A", "Ketterer N", "Shpilberg O", "Hagberg H", "Ma D", "Brière J", "Moskowitz CH", "Schmitz N"], "authors_original": "Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N.", "first_author": "Gisselbrecht C", "first_author_display": "Gisselbrecht C, et al.", "citation": "Gisselbrecht C, et al.. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(27):4184-4190. doi:10.1200/jco.2010.28.1618. PMID:20660832.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2010, "volume": "28", "issue": "27", "pages_or_article_id": "4184-4190", "doi": "10.1200/jco.2010.28.1618", "pmid": "20660832", "publication_date": "2010-07-26", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.658415+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_21196441", "original_article_title": "Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.", "authors": ["Ohmachi K", "Tobinai K", "Kobayashi Y", "Itoh K", "Nakata M", "Shibata T", "Morishima Y", "Ogura M", "Suzuki T", "Ueda R", "Aikawa K", "Nakamura S", "Fukuda H", "Shimoyama M", "Hotta T", "members of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG)"], "authors_original": "Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, Morishima Y, Ogura M, Suzuki T, Ueda R, Aikawa K, Nakamura S, Fukuda H, Shimoyama M, Hotta T, members of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG).", "first_author": "Ohmachi K", "first_author_display": "Ohmachi K, et al.", "citation": "Ohmachi K, et al.. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Annals of oncology : official journal of the European Society for Medical Oncology. 2011;22(6):1382-1391. doi:10.1093/annonc/mdq619. PMID:21196441.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "year": 2011, "volume": "22", "issue": "6", "pages_or_article_id": "1382-1391", "doi": "10.1093/annonc/mdq619", "pmid": "21196441", "publication_date": "2010-12-31", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:41.150375+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_22614995", "original_article_title": "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.", "authors": ["Pro B", "Advani R", "Brice P", "Bartlett NL", "Rosenblatt JD", "Illidge T", "Matous J", "Ramchandren R", "Fanale M", "Connors JM", "Yang Y", "Sievers EL", "Kennedy DA", "Shustov A"], "authors_original": "Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.", "first_author": "Pro B", "first_author_display": "Pro B, et al.", "citation": "Pro B, et al.. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(18):2190-2196. doi:10.1200/jco.2011.38.0402. PMID:22614995.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2012, "volume": "30", "issue": "18", "pages_or_article_id": "2190-2196", "doi": "10.1200/jco.2011.38.0402", "pmid": "22614995", "publication_date": "2012-05-21", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:23.688473+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_22851556", "original_article_title": "Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.", "authors": ["d'Amore F", "Relander T", "Lauritzsen GF", "Jantunen E", "Hagberg H", "Anderson H", "Holte H", "Österborg A", "Merup M", "Brown P", "Kuittinen O", "Erlanson M", "Østenstad B", "Fagerli UM", "Gadeberg OV", "Sundström C", "Delabie J", "Ralfkiaer E", "Vornanen M", "Toldbod HE"], "authors_original": "d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.", "first_author": "d'Amore F", "first_author_display": "d'Amore F, et al.", "citation": "d'Amore F, et al.. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(25):3093-3099. doi:10.1200/jco.2011.40.2719. PMID:22851556.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2012, "volume": "30", "issue": "25", "pages_or_article_id": "3093-3099", "doi": "10.1200/jco.2011.40.2719", "pmid": "22851556", "publication_date": "2012-07-30", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:46.761381+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_23574119", "original_article_title": "Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.", "authors": ["Dunleavy K", "Pittaluga S", "Maeda LS", "Advani R", "Chen CC", "Hessler J", "Steinberg SM", "Grant C", "Wright G", "Varma G", "Staudt LM", "Jaffe ES", "Wilson WH"], "authors_original": "Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.", "first_author": "Dunleavy K", "first_author_display": "Dunleavy K, et al.", "citation": "Dunleavy K, et al.. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. The New England journal of medicine. 2013;368(15):1408-1416. doi:10.1056/nejmoa1214561. PMID:23574119.", "journal": "The New England journal of medicine", "year": 2013, "volume": "368", "issue": "15", "pages_or_article_id": "1408-1416", "doi": "10.1056/nejmoa1214561", "pmid": "23574119", "publication_date": "2013-04-01", "publication_types": ["Clinical Trial, Phase II", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:12.491321+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_24401022", "original_article_title": "Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.", "authors": ["Goede V", "Fischer K", "Busch R", "Engelke A", "Eichhorst B", "Wendtner CM", "Chagorova T", "de la Serna J", "Dilhuydy MS", "Illmer T", "Opat S", "Owen CJ", "Samoylova O", "Kreuzer KA", "Stilgenbauer S", "Döhner H", "Langerak AW", "Ritgen M", "Kneba M", "Asikanius E", "Humphrey K", "Wenger M", "Hallek M"], "authors_original": "Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M.", "first_author": "Goede V", "first_author_display": "Goede V, et al.", "citation": "Goede V, et al.. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014;370(12):1101-1110. doi:10.1056/nejmoa1313984. PMID:24401022.", "journal": "The New England journal of medicine", "year": 2014, "volume": "370", "issue": "12", "pages_or_article_id": "1101-1110", "doi": "10.1056/nejmoa1313984", "pmid": "24401022", "publication_date": "2014-01-08", "publication_types": ["Comparative Study", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:16.417805+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_25184863", "original_article_title": "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.", "authors": ["Benboubker L", "Dimopoulos MA", "Dispenzieri A", "Catalano J", "Belch AR", "Cavo M", "Pinto A", "Weisel K", "Ludwig H", "Bahlis N", "Banos A", "Tiab M", "Delforge M", "Cavenagh J", "Geraldes C", "Lee JJ", "Chen C", "Oriol A", "de la Rubia J", "Qiu L", "White DJ", "Binder D", "Anderson K", "Fermand JP", "Moreau P", "Attal M", "Knight R", "Chen G", "Van Oostendorp J", "Jacques C", "Ervin-Haynes A", "Avet-Loiseau H", "Hulin C", "Facon T", "FIRST Trial Team"], "authors_original": "Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T, FIRST Trial Team.", "first_author": "Benboubker L", "first_author_display": "Benboubker L, et al.", "citation": "Benboubker L, et al.. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England journal of medicine. 2014;371(10):906-917. doi:10.1056/nejmoa1402551. PMID:25184863.", "journal": "The New England journal of medicine", "year": 2014, "volume": "371", "issue": "10", "pages_or_article_id": "906-917", "doi": "10.1056/nejmoa1402551", "pmid": "25184863", "publication_date": "2014-09-01", "publication_types": ["Comparative Study", "Research Support, Non-U.S. Gov't", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:35.924607+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_26282650", "original_article_title": "Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.", "authors": ["Sehn LH", "Goy A", "Offner FC", "Martinelli G", "Caballero MD", "Gadeberg O", "Baetz T", "Zelenetz AD", "Gaidano G", "Fayad LE", "Buckstein R", "Friedberg JW", "Crump M", "Jaksic B", "Zinzani PL", "Padmanabhan Iyer S", "Sahin D", "Chai A", "Fingerle-Rowson G", "Press OW"], "authors_original": "Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW.", "first_author": "Sehn LH", "first_author_display": "Sehn LH, et al.", "citation": "Sehn LH, et al.. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(30):3467-3474. doi:10.1200/jco.2014.59.2139. PMID:26282650.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2015, "volume": "33", "issue": "30", "pages_or_article_id": "3467-3474", "doi": "10.1200/jco.2014.59.2139", "pmid": "26282650", "publication_date": "2015-08-17", "publication_types": ["Clinical Trial, Phase II", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:42.202445+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_28249141", "original_article_title": "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.", "authors": ["Kantarjian H", "Stein A", "Gökbuget N", "Fielding AK", "Schuh AC", "Ribera JM", "Wei A", "Dombret H", "Foà R", "Bassan R", "Arslan Ö", "Sanz MA", "Bergeron J", "Demirkan F", "Lech-Maranda E", "Rambaldi A", "Thomas X", "Horst HA", "Brüggemann M", "Klapper W", "Wood BL", "Fleishman A", "Nagorsen D", "Holland C", "Zimmerman Z", "Topp MS"], "authors_original": "Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.", "first_author": "Kantarjian H", "first_author_display": "Kantarjian H, et al.", "citation": "Kantarjian H, et al.. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. The New England journal of medicine. 2017;376(9):836-847. doi:10.1056/nejmoa1609783. PMID:28249141.", "journal": "The New England journal of medicine", "year": 2017, "volume": "376", "issue": "9", "pages_or_article_id": "836-847", "doi": "10.1056/nejmoa1609783", "pmid": "28249141", "publication_date": "2017-03-01", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:10.855285+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_28379796", "original_article_title": "Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.", "authors": ["Attal M", "Lauwers-Cances V", "Hulin C", "Leleu X", "Caillot D", "Escoffre M", "Arnulf B", "Macro M", "Belhadj K", "Garderet L", "Roussel M", "Payen C", "Mathiot C", "Fermand JP", "Meuleman N", "Rollet S", "Maglio ME", "Zeytoonjian AA", "Weller EA", "Munshi N", "Anderson KC", "Richardson PG", "Facon T", "Avet-Loiseau H", "Harousseau JL", "Moreau P", "IFM 2009 Study"], "authors_original": "Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study.", "first_author": "Attal M", "first_author_display": "Attal M, et al.", "citation": "Attal M, et al.. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. The New England journal of medicine. 2017;376(14):1311-1320. doi:10.1056/nejmoa1611750. PMID:28379796.", "journal": "The New England journal of medicine", "year": 2017, "volume": "376", "issue": "14", "pages_or_article_id": "1311-1320", "doi": "10.1056/nejmoa1611750", "pmid": "28379796", "publication_date": "2017-04-01", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.857874+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_28742454", "original_article_title": "Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.", "authors": ["McCarthy PL", "Holstein SA", "Petrucci MT", "Richardson PG", "Hulin C", "Tosi P", "Bringhen S", "Musto P", "Anderson KC", "Caillot D", "Gay F", "Moreau P", "Marit G", "Jung SH", "Yu Z", "Winograd B", "Knight RD", "Palumbo A", "Attal M"], "authors_original": "McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M.", "first_author": "McCarthy PL", "first_author_display": "McCarthy PL, et al.", "citation": "McCarthy PL, et al.. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(29):3279-3289. doi:10.1200/jco.2017.72.6679. PMID:28742454.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2017, "volume": "35", "issue": "29", "pages_or_article_id": "3279-3289", "doi": "10.1200/jco.2017.72.6679", "pmid": "28742454", "publication_date": "2017-07-25", "publication_types": ["Meta-Analysis", "research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:35.772611+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_28774879", "original_article_title": "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.", "authors": ["Crump M", "Neelapu SS", "Farooq U", "Van Den Neste E", "Kuruvilla J", "Westin J", "Link BK", "Hay A", "Cerhan JR", "Zhu L", "Boussetta S", "Feng L", "Maurer MJ", "Navale L", "Wiezorek J", "Go WY", "Gisselbrecht C"], "authors_original": "Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.", "first_author": "Crump M", "first_author_display": "Crump M, et al.", "citation": "Crump M, et al.. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620. PMID:28774879.", "journal": "Blood", "year": 2017, "volume": "130", "issue": "16", "pages_or_article_id": "1800-1808", "doi": "10.1182/blood-2017-03-769620", "pmid": "28774879", "publication_date": "2017-08-03", "publication_types": ["Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:40.046584+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_29499750", "original_article_title": "Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.", "authors": ["Porter D", "Frey N", "Wood PA", "Weng Y", "Grupp SA"], "authors_original": "Porter D, Frey N, Wood PA, Weng Y, Grupp SA.", "first_author": "Porter D", "first_author_display": "Porter D, et al.", "citation": "Porter D, et al.. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. Journal of hematology & oncology. 2018;11(1):35. doi:10.1186/s13045-018-0571-y. PMID:29499750.", "journal": "Journal of hematology & oncology", "year": 2018, "volume": "11", "issue": "1", "pages_or_article_id": "35", "doi": "10.1186/s13045-018-0571-y", "pmid": "29499750", "publication_date": "2018-03-02", "publication_types": ["Research Support, Non-U.S. Gov't", "review-article", "Review", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:31.704866+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_29562156", "original_article_title": "Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.", "authors": ["Seymour JF", "Kipps TJ", "Eichhorst B", "Hillmen P", "D'Rozario J", "Assouline S", "Owen C", "Gerecitano J", "Robak T", "De la Serna J", "Jaeger U", "Cartron G", "Montillo M", "Humerickhouse R", "Punnoose EA", "Li Y", "Boyer M", "Humphrey K", "Mobasher M", "Kater AP"], "authors_original": "Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.", "first_author": "Seymour JF", "first_author_display": "Seymour JF, et al.", "citation": "Seymour JF, et al.. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England journal of medicine. 2018;378(12):1107-1120. doi:10.1056/nejmoa1713976. PMID:29562156.", "journal": "The New England journal of medicine", "year": 2018, "volume": "378", "issue": "12", "pages_or_article_id": "1107-1120", "doi": "10.1056/nejmoa1713976", "pmid": "29562156", "publication_date": "2018-03-01", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:19.279527+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_29696684", "original_article_title": "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.", "authors": ["Bussel J", "Arnold DM", "Grossbard E", "Mayer J", "Treliński J", "Homenda W", "Hellmann A", "Windyga J", "Sivcheva L", "Khalafallah AA", "Zaja F", "Cooper N", "Markovtsov V", "Zayed H", "Duliege AM"], "authors_original": "Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM.", "first_author": "Bussel J", "first_author_display": "Bussel J, et al.", "citation": "Bussel J, et al.. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. American journal of hematology. 2018;93(7):921-930. doi:10.1002/ajh.25125. PMID:29696684.", "journal": "American journal of hematology", "year": 2018, "volume": "93", "issue": "7", "pages_or_article_id": "921-930", "doi": "10.1002/ajh.25125", "pmid": "29696684", "publication_date": "2018-05-15", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:31.080734+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30184451", "original_article_title": "Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.", "authors": ["Morschhauser F", "Fowler NH", "Feugier P", "Bouabdallah R", "Tilly H", "Palomba ML", "Fruchart C", "Libby EN", "Casasnovas RO", "Flinn IW", "Haioun C", "Maisonneuve H", "Ysebaert L", "Bartlett NL", "Bouabdallah K", "Brice P", "Ribrag V", "Daguindau N", "Le Gouill S", "Pica GM", "Martin Garcia-Sancho A", "López-Guillermo A", "Larouche JF", "Ando K", "Gomes da Silva M", "André M", "Zachée P", "Sehn LH", "Tobinai K", "Cartron G", "Liu D", "Wang J", "Xerri L", "Salles GA", "RELEVANCE Trial Investigators"], "authors_original": "Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, RELEVANCE Trial Investigators.", "first_author": "Morschhauser F", "first_author_display": "Morschhauser F, et al.", "citation": "Morschhauser F, et al.. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. The New England journal of medicine. 2018;379(10):934-947. doi:10.1056/nejmoa1805104. PMID:30184451.", "journal": "The New England journal of medicine", "year": 2018, "volume": "379", "issue": "10", "pages_or_article_id": "934-947", "doi": "10.1056/nejmoa1805104", "pmid": "30184451", "publication_date": "2018-09-01", "publication_types": ["Clinical Trial, Phase III", "Equivalence Trial", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.657414+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30266774", "original_article_title": "Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.", "authors": ["Moskowitz CH", "Walewski J", "Nademanee A", "Masszi T", "Agura E", "Holowiecki J", "Abidi MH", "Chen AI", "Stiff P", "Viviani S", "Bachanova V", "Sureda A", "McClendon T", "Lee C", "Lisano J", "Sweetenham J"], "authors_original": "Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J.", "first_author": "Moskowitz CH", "first_author_display": "Moskowitz CH, et al.", "citation": "Moskowitz CH, et al.. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-2642. doi:10.1182/blood-2018-07-861641. PMID:30266774.", "journal": "Blood", "year": 2018, "volume": "132", "issue": "25", "pages_or_article_id": "2639-2642", "doi": "10.1182/blood-2018-07-861641", "pmid": "30266774", "publication_date": "2018-09-28", "publication_types": ["Clinical Trial, Phase III", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.724332+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30409963", "original_article_title": "Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.", "authors": ["Sidiqi MH", "Aljama MA", "Bin Riaz I", "Dispenzieri A", "Muchtar E", "Buadi FK", "Warsame R", "Lacy MQ", "Dingli D", "Leung N", "Gonsalves WI", "Kapoor P", "Kourelis TV", "Hogan WJ", "Rajkumar SV", "Kumar SK", "Gertz MA"], "authors_original": "Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.", "first_author": "Sidiqi MH", "first_author_display": "Sidiqi MH, et al.", "citation": "Sidiqi MH, et al.. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood cancer journal. 2018;8(11):106. doi:10.1038/s41408-018-0147-7. PMID:30409963.", "journal": "Blood cancer journal", "year": 2018, "volume": "8", "issue": "11", "pages_or_article_id": "106", "doi": "10.1038/s41408-018-0147-7", "pmid": "30409963", "publication_date": "2018-11-08", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:23.327451+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30501481", "original_article_title": "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.", "authors": ["Woyach JA", "Ruppert AS", "Heerema NA", "Zhao W", "Booth AM", "Ding W", "Bartlett NL", "Brander DM", "Barr PM", "Rogers KA", "Parikh SA", "Coutre S", "Hurria A", "Brown JR", "Lozanski G", "Blachly JS", "Ozer HG", "Major-Elechi B", "Fruth B", "Nattam S", "Larson RA", "Erba H", "Litzow M", "Owen C", "Kuzma C", "Abramson JS", "Little RF", "Smith SE", "Stone RM", "Mandrekar SJ", "Byrd JC"], "authors_original": "Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.", "first_author": "Woyach JA", "first_author_display": "Woyach JA, et al.", "citation": "Woyach JA, et al.. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England journal of medicine. 2018;379(26):2517-2528. doi:10.1056/nejmoa1812836. PMID:30501481.", "journal": "The New England journal of medicine", "year": 2018, "volume": "379", "issue": "26", "pages_or_article_id": "2517-2528", "doi": "10.1056/nejmoa1812836", "pmid": "30501481", "publication_date": "2018-12-01", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.228331+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30784097", "original_article_title": "Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.", "authors": ["Bussel JB", "Arnold DM", "Boxer MA", "Cooper N", "Mayer J", "Zayed H", "Tong S", "Duliege AM"], "authors_original": "Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM.", "first_author": "Bussel JB", "first_author_display": "Bussel JB, et al.", "citation": "Bussel JB, et al.. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. American journal of hematology. 2019;94(5):546-553. doi:10.1002/ajh.25444. PMID:30784097.", "journal": "American journal of hematology", "year": 2019, "volume": "94", "issue": "5", "pages_or_article_id": "546-553", "doi": "10.1002/ajh.25444", "pmid": "30784097", "publication_date": "2019-03-13", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:36.641822+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30828799", "original_article_title": "Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.", "authors": ["Yimer H", "Melear J", "Faber E", "Bensinger WI", "Burke JM", "Narang M", "Stevens D", "Gunawardena S", "Lutska Y", "Qi K", "Ukropec J", "Qi M", "Lin TS", "Rifkin RM"], "authors_original": "Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, Stevens D, Gunawardena S, Lutska Y, Qi K, Ukropec J, Qi M, Lin TS, Rifkin RM.", "first_author": "Yimer H", "first_author_display": "Yimer H, et al.", "citation": "Yimer H, et al.. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. British journal of haematology. 2019;185(3):492-502. doi:10.1111/bjh.15806. PMID:30828799.", "journal": "British journal of haematology", "year": 2019, "volume": "185", "issue": "3", "pages_or_article_id": "492-502", "doi": "10.1111/bjh.15806", "pmid": "30828799", "publication_date": "2019-03-03", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:26.691612+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30858549", "original_article_title": "Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.", "authors": ["Gandhi UH", "Cornell RF", "Lakshman A", "Gahvari ZJ", "McGehee E", "Jagosky MH", "Gupta R", "Varnado W", "Fiala MA", "Chhabra S", "Malek E", "Mansour J", "Paul B", "Barnstead A", "Kodali S", "Neppalli A", "Liedtke M", "Narayana S", "Godby KN", "Kang Y", "Kansagra A", "Umyarova E", "Scott EC", "Hari P", "Vij R", "Usmani SZ", "Callander NS", "Kumar SK", "Costa LJ"], "authors_original": "Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.", "first_author": "Gandhi UH", "first_author_display": "Gandhi UH, et al.", "citation": "Gandhi UH, et al.. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275. doi:10.1038/s41375-019-0435-7. PMID:30858549.", "journal": "Leukemia", "year": 2019, "volume": "33", "issue": "9", "pages_or_article_id": "2266-2275", "doi": "10.1038/s41375-019-0435-7", "pmid": "30858549", "publication_date": "2019-03-11", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:16.557387+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_30939090", "original_article_title": "Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.", "authors": ["Bartlett NL", "Wilson WH", "Jung SH", "Hsi ED", "Maurer MJ", "Pederson LD", "Polley MC", "Pitcher BN", "Cheson BD", "Kahl BS", "Friedberg JW", "Staudt LM", "Wagner-Johnston ND", "Blum KA", "Abramson JS", "Reddy NM", "Winter JN", "Chang JE", "Gopal AK", "Chadburn A", "Mathew S", "Fisher RI", "Richards KL", "Schöder H", "Zelenetz AD", "Leonard JP"], "authors_original": "Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.", "first_author": "Bartlett NL", "first_author_display": "Bartlett NL, et al.", "citation": "Bartlett NL, et al.. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37(21):1790-1799. doi:10.1200/jco.18.01994. PMID:30939090.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2019, "volume": "37", "issue": "21", "pages_or_article_id": "1790-1799", "doi": "10.1200/jco.18.01994", "pmid": "30939090", "publication_date": "2019-04-02", "publication_types": ["Clinical Trial, Phase III", "research-article", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:27.096524+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_31365801", "original_article_title": "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.", "authors": ["Shanafelt TD", "Wang XV", "Kay NE", "Hanson CA", "O'Brien S", "Barrientos J", "Jelinek DF", "Braggio E", "Leis JF", "Zhang CC", "Coutre SE", "Barr PM", "Cashen AF", "Mato AR", "Singh AK", "Mullane MP", "Little RF", "Erba H", "Stone RM", "Litzow M", "Tallman M"], "authors_original": "Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M.", "first_author": "Shanafelt TD", "first_author_display": "Shanafelt TD, et al.", "citation": "Shanafelt TD, et al.. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England journal of medicine. 2019;381(5):432-443. doi:10.1056/nejmoa1817073. PMID:31365801.", "journal": "The New England journal of medicine", "year": 2019, "volume": "381", "issue": "5", "pages_or_article_id": "432-443", "doi": "10.1056/nejmoa1817073", "pmid": "31365801", "publication_date": "2019-08-01", "publication_types": ["Clinical Trial, Phase III", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.246232+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_31914241", "original_article_title": "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.", "authors": ["Fenaux P", "Platzbecker U", "Mufti GJ", "Garcia-Manero G", "Buckstein R", "Santini V", "Díez-Campelo M", "Finelli C", "Cazzola M", "Ilhan O", "Sekeres MA", "Falantes JF", "Arrizabalaga B", "Salvi F", "Giai V", "Vyas P", "Bowen D", "Selleslag D", "DeZern AE", "Jurcic JG", "Germing U", "Götze KS", "Quesnel B", "Beyne-Rauzy O", "Cluzeau T", "Voso MT", "Mazure D", "Vellenga E", "Greenberg PL", "Hellström-Lindberg E", "Zeidan AM", "Adès L", "Verma A", "Savona MR", "Laadem A", "Benzohra A", "Zhang J", "Rampersad A", "Dunshee DR", "Linde PG", "Sherman ML", "Komrokji RS", "List AF"], "authors_original": "Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.", "first_author": "Fenaux P", "first_author_display": "Fenaux P, et al.", "citation": "Fenaux P, et al.. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England journal of medicine. 2020;382(2):140-151. doi:10.1056/nejmoa1908892. PMID:31914241.", "journal": "The New England journal of medicine", "year": 2020, "volume": "382", "issue": "2", "pages_or_article_id": "140-151", "doi": "10.1056/nejmoa1908892", "pmid": "31914241", "publication_date": "2020-01-01", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:16.326923+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_32011729", "original_article_title": "Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.", "authors": ["McCulloch R", "Visco C", "Eyre TA", "Frewin R", "Phillips N", "Tucker DL", "Quaglia FM", "McMillan A", "Lambert J", "Crosbie N", "Rule S"], "authors_original": "McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J, Crosbie N, Rule S.", "first_author": "McCulloch R", "first_author_display": "McCulloch R, et al.", "citation": "McCulloch R, et al.. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. British journal of haematology. 2020;189(4):684-688. doi:10.1111/bjh.16416. PMID:32011729.", "journal": "British journal of haematology", "year": 2020, "volume": "189", "issue": "4", "pages_or_article_id": "684-688", "doi": "10.1111/bjh.16416", "pmid": "32011729", "publication_date": "2020-02-03", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.711054+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_32023164", "original_article_title": "Palliative and End-of-Life Care for Patients With Hematologic Malignancies.", "authors": ["El-Jawahri A", "Nelson AM", "Gray TF", "Lee SJ", "LeBlanc TW"], "authors_original": "El-Jawahri A, Nelson AM, Gray TF, Lee SJ, LeBlanc TW.", "first_author": "El-Jawahri A", "first_author_display": "El-Jawahri A, et al.", "citation": "El-Jawahri A, et al.. Palliative and End-of-Life Care for Patients With Hematologic Malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(9):944-953. doi:10.1200/jco.18.02386. PMID:32023164.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2020, "volume": "38", "issue": "9", "pages_or_article_id": "944-953", "doi": "10.1200/jco.18.02386", "pmid": "32023164", "publication_date": "2020-02-05", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.237476+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_32242358", "original_article_title": "KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.", "authors": ["Wang M", "Munoz J", "Goy A", "Locke FL", "Jacobson CA", "Hill BT", "Timmerman JM", "Holmes H", "Jaglowski S", "Flinn IW", "McSweeney PA", "Miklos DB", "Pagel JM", "Kersten MJ", "Milpied N", "Fung H", "Topp MS", "Houot R", "Beitinjaneh A", "Peng W", "Zheng L", "Rossi JM", "Jain RK", "Rao AV", "Reagan PM"], "authors_original": "Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM.", "first_author": "Wang M", "first_author_display": "Wang M, et al.", "citation": "Wang M, et al.. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England journal of medicine. 2020;382(14):1331-1342. doi:10.1056/nejmoa1914347. PMID:32242358.", "journal": "The New England journal of medicine", "year": 2020, "volume": "382", "issue": "14", "pages_or_article_id": "1331-1342", "doi": "10.1056/nejmoa1914347", "pmid": "32242358", "publication_date": "2020-04-01", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.775924+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_33331857", "original_article_title": "Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial.", "authors": ["El-Jawahri A", "LeBlanc TW", "Kavanaugh A", "Webb JA", "Jackson VA", "Campbell TC", "O'Connor N", "Luger SM", "Gafford E", "Gustin J", "Bhatnagar B", "Walker AR", "Fathi AT", "Brunner AM", "Hobbs GS", "Nicholson S", "Davis D", "Addis H", "Vaughn D", "Horick N", "Greer JA", "Temel JS"], "authors_original": "El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS.", "first_author": "El-Jawahri A", "first_author_display": "El-Jawahri A, et al.", "citation": "El-Jawahri A, et al.. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA oncology. 2021;7(2):238-245. doi:10.1001/jamaoncol.2020.6343. PMID:33331857.", "journal": "JAMA oncology", "year": 2021, "volume": "7", "issue": "2", "pages_or_article_id": "238-245", "doi": "10.1001/jamaoncol.2020.6343", "pmid": "33331857", "publication_date": "2021-02-01", "publication_types": ["research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.131402+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_33414482", "original_article_title": "Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.", "authors": ["Kantarjian HM", "Hughes TP", "Larson RA", "Kim DW", "Issaragrisil S", "le Coutre P", "Etienne G", "Boquimpani C", "Pasquini R", "Clark RE", "Dubruille V", "Flinn IW", "Kyrcz-Krzemien S", "Medras E", "Zanichelli M", "Bendit I", "Cacciatore S", "Titorenko K", "Aimone P", "Saglio G", "Hochhaus A"], "authors_original": "Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A.", "first_author": "Kantarjian HM", "first_author_display": "Kantarjian HM, et al.", "citation": "Kantarjian HM, et al.. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-453. doi:10.1038/s41375-020-01111-2. PMID:33414482.", "journal": "Leukemia", "year": 2021, "volume": "35", "issue": "2", "pages_or_article_id": "440-453", "doi": "10.1038/s41375-020-01111-2", "pmid": "33414482", "publication_date": "2021-01-07", "publication_types": ["Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:36.654707+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_34152395", "original_article_title": "Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.", "authors": ["Tam CS", "Opat S", "Simpson D", "Cull G", "Munoz J", "Phillips TJ", "Kim WS", "Rule S", "Atwal SK", "Wei R", "Novotny W", "Huang J", "Wang M", "Trotman J"], "authors_original": "Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J.", "first_author": "Tam CS", "first_author_display": "Tam CS, et al.", "citation": "Tam CS, et al.. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood advances. 2021;5(12):2577-2585. doi:10.1182/bloodadvances.2020004074. PMID:34152395.", "journal": "Blood advances", "year": 2021, "volume": "5", "issue": "12", "pages_or_article_id": "2577-2585", "doi": "10.1182/bloodadvances.2020004074", "pmid": "34152395", "publication_date": "2021-06-01", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:19.548320+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_34438444", "original_article_title": "Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.", "authors": ["Pavlovsky C", "Abello Polo V", "Pagnano K", "Varela AI", "Agudelo C", "Bianchini M", "Boquimpani C", "Centrone R", "Conchon M", "Delgado N", "Funke V", "Giere I", "Luise I", "Meillon L", "Moiraghi B", "Navarro JR", "Pilleux L", "Prado AI", "Undurraga S", "Cortes J"], "authors_original": "Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M, Boquimpani C, Centrone R, Conchon M, Delgado N, Funke V, Giere I, Luise I, Meillon L, Moiraghi B, Navarro JR, Pilleux L, Prado AI, Undurraga S, Cortes J.", "first_author": "Pavlovsky C", "first_author_display": "Pavlovsky C, et al.", "citation": "Pavlovsky C, et al.. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood advances. 2021;5(23):4855-4863. doi:10.1182/bloodadvances.2020003235. PMID:34438444.", "journal": "Blood advances", "year": 2021, "volume": "5", "issue": "23", "pages_or_article_id": "4855-4863", "doi": "10.1182/bloodadvances.2020003235", "pmid": "34438444", "publication_date": "2021-12-01", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:46.263104+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_34904798", "original_article_title": "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.", "authors": ["Bishop MR", "Dickinson M", "Purtill D", "Barba P", "Santoro A", "Hamad N", "Kato K", "Sureda A", "Greil R", "Thieblemont C", "Morschhauser F", "Janz M", "Flinn I", "Rabitsch W", "Kwong YL", "Kersten MJ", "Minnema MC", "Holte H", "Chan EHL", "Martinez-Lopez J", "Martinez-Lopez J", "Müller AMS", "Maziarz RT", "McGuirk JP", "Bachy E", "Le Gouill S", "Dreyling M", "Harigae H", "Bond D", "Andreadis C", "McSweeney P", "Kharfan-Dabaja M", "Newsome S", "Degtyarev E", "Awasthi R", "Del Corral C", "Andreola G", "Masood A", "Schuster SJ", "Jäger U", "Borchmann P", "Westin JR"], "authors_original": "Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR.", "first_author": "Bishop MR", "first_author_display": "Bishop MR, et al.", "citation": "Bishop MR, et al.. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. The New England journal of medicine. 2022;386(7):629-639. doi:10.1056/nejmoa2116596. PMID:34904798.", "journal": "The New England journal of medicine", "year": 2022, "volume": "386", "issue": "7", "pages_or_article_id": "629-639", "doi": "10.1056/nejmoa2116596", "pmid": "34904798", "publication_date": "2021-12-14", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.939283+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_34904799", "original_article_title": "Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.", "authors": ["Tilly H", "Morschhauser F", "Sehn LH", "Friedberg JW", "Trněný M", "Sharman JP", "Herbaux C", "Burke JM", "Matasar M", "Rai S", "Izutsu K", "Mehta-Shah N", "Oberic L", "Chauchet A", "Jurczak W", "Song Y", "Greil R", "Mykhalska L", "Bergua-Burgués JM", "Cheung MC", "Pinto A", "Shin HJ", "Hapgood G", "Munhoz E", "Abrisqueta P", "Gau JP", "Hirata J", "Jiang Y", "Yan M", "Lee C", "Flowers CR", "Salles G"], "authors_original": "Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G.", "first_author": "Tilly H", "first_author_display": "Tilly H, et al.", "citation": "Tilly H, et al.. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2022;386(4):351-363. doi:10.1056/nejmoa2115304. PMID:34904799.", "journal": "The New England journal of medicine", "year": 2022, "volume": "386", "issue": "4", "pages_or_article_id": "351-363", "doi": "10.1056/nejmoa2115304", "pmid": "34904799", "publication_date": "2021-12-14", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.640865+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_35687757", "original_article_title": "Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.", "authors": ["Röth A", "Berentsen S", "Barcellini W", "D'Sa S", "Jilma B", "Michel M", "Weitz IC", "Yamaguchi M", "Nishimura JI", "Vos JMI", "Storek M", "Wong N", "Patel P", "Jiang X", "Vagge DS", "Wardęcki M", "Shafer F", "Lee M", "Broome CM"], "authors_original": "Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM.", "first_author": "Röth A", "first_author_display": "Röth A, et al.", "citation": "Röth A, et al.. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140(9):980-991. doi:10.1182/blood.2021014955. PMID:35687757.", "journal": "Blood", "year": 2022, "volume": "140", "issue": "9", "pages_or_article_id": "980-991", "doi": "10.1182/blood.2021014955", "pmid": "35687757", "publication_date": "2022-09-01", "publication_types": ["Clinical Trial, Phase III", "research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:44.146319+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_35810754", "original_article_title": "Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.", "authors": ["Tam CS", "Brown JR", "Kahl BS", "Ghia P", "Giannopoulos K", "Jurczak W", "Šimkovič M", "Shadman M", "Österborg A", "Laurenti L", "Walker P", "Opat S", "Chan H", "Ciepluch H", "Greil R", "Tani M", "Trněný M", "Brander DM", "Flinn IW", "Grosicki S", "Verner E", "Tedeschi A", "Li J", "Tian T", "Zhou L", "Marimpietri C", "Paik JC", "Cohen A", "Huang J", "Robak T", "Hillmen P"], "authors_original": "Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P.", "first_author": "Tam CS", "first_author_display": "Tam CS, et al.", "citation": "Tam CS, et al.. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet. Oncology. 2022;23(8):1031-1043. doi:10.1016/s1470-2045(22)00293-5. PMID:35810754.", "journal": "The Lancet. Oncology", "year": 2022, "volume": "23", "issue": "8", "pages_or_article_id": "1031-1043", "doi": "10.1016/s1470-2045(22)00293-5", "pmid": "35810754", "publication_date": "2022-07-07", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:47.322432+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_35869266", "original_article_title": "Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.", "authors": ["Mesa R", "Harrison C", "Oh ST", "Gerds AT", "Gupta V", "Catalano J", "Cervantes F", "Devos T", "Hus M", "Kiladjian JJ", "Lech-Maranda E", "McLornan D", "Vannucchi AM", "Platzbecker U", "Huang M", "Strouse B", "Klencke B", "Verstovsek S"], "authors_original": "Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S.", "first_author": "Mesa R", "first_author_display": "Mesa R, et al.", "citation": "Mesa R, et al.. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022;36(9):2261-2268. doi:10.1038/s41375-022-01637-7. PMID:35869266.", "journal": "Leukemia", "year": 2022, "volume": "36", "issue": "9", "pages_or_article_id": "2261-2268", "doi": "10.1038/s41375-022-01637-7", "pmid": "35869266", "publication_date": "2022-07-22", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:40.730804+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_36507690", "original_article_title": "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.", "authors": ["Dickinson MJ", "Carlo-Stella C", "Morschhauser F", "Bachy E", "Corradini P", "Iacoboni G", "Khan C", "Wróbel T", "Offner F", "Trněný M", "Wu SJ", "Cartron G", "Hertzberg M", "Sureda A", "Perez-Callejo D", "Lundberg L", "Relf J", "Dixon M", "Clark E", "Humphrey K", "Hutchings M"], "authors_original": "Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M.", "first_author": "Dickinson MJ", "first_author_display": "Dickinson MJ, et al.", "citation": "Dickinson MJ, et al.. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2022;387(24):2220-2231. doi:10.1056/nejmoa2206913. PMID:36507690.", "journal": "The New England journal of medicine", "year": 2022, "volume": "387", "issue": "24", "pages_or_article_id": "2220-2231", "doi": "10.1056/nejmoa2206913", "pmid": "36507690", "publication_date": "2022-12-11", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:14.227230+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_36511784", "original_article_title": "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.", "authors": ["Brown JR", "Eichhorst B", "Hillmen P", "Jurczak W", "Kaźmierczak M", "Lamanna N", "O'Brien SM", "Tam CS", "Qiu L", "Zhou K", "Simkovic M", "Mayer J", "Gillespie-Twardy A", "Ferrajoli A", "Ganly PS", "Weinkove R", "Grosicki S", "Mital A", "Robak T", "Osterborg A", "Yimer HA", "Salmi T", "Wang MD", "Fu L", "Li J", "Wu K", "Cohen A", "Shadman M"], "authors_original": "Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M.", "first_author": "Brown JR", "first_author_display": "Brown JR, et al.", "citation": "Brown JR, et al.. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England journal of medicine. 2023;388(4):319-332. doi:10.1056/nejmoa2211582. PMID:36511784.", "journal": "The New England journal of medicine", "year": 2023, "volume": "388", "issue": "4", "pages_or_article_id": "319-332", "doi": "10.1056/nejmoa2211582", "pmid": "36511784", "publication_date": "2022-12-13", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:19.763218+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_36802876", "original_article_title": "Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.", "authors": ["Milling TJ", "Middeldorp S", "Xu L", "Koch B", "Demchuk A", "Eikelboom JW", "Verhamme P", "Cohen AT", "Beyer-Westendorf J", "Gibson CM", "Lopez-Sendon J", "Crowther M", "Shoamanesh A", "Coppens M", "Schmidt J", "Albaladejo P", "Connolly SJ", "ANNEXA-4 Investigators"], "authors_original": "Milling TJ, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ, ANNEXA-4 Investigators.", "first_author": "Milling TJ", "first_author_display": "Milling TJ, et al.", "citation": "Milling TJ, et al.. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 2023;147(13):1026-1038. doi:10.1161/circulationaha.121.057844. PMID:36802876.", "journal": "Circulation", "year": 2023, "volume": "147", "issue": "13", "pages_or_article_id": "1026-1038", "doi": "10.1161/circulationaha.121.057844", "pmid": "36802876", "publication_date": "2023-02-20", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Multicenter Study", "Journal Article", "Clinical Trial, Phase IV"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.013951+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_36812434", "original_article_title": "Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.", "authors": ["Pipe SW", "Leebeek FWG", "Recht M", "Key NS", "Castaman G", "Miesbach W", "Lattimore S", "Peerlinck K", "Van der Valk P", "Coppens M", "Kampmann P", "Meijer K", "O'Connell N", "Pasi KJ", "Hart DP", "Kazmi R", "Astermark J", "Hermans CRJR", "Klamroth R", "Lemons R", "Visweshwar N", "von Drygalski A", "Young G", "Crary SE", "Escobar M", "Gomez E", "Kruse-Jarres R", "Quon DV", "Symington E", "Wang M", "Wheeler AP", "Gut R", "Liu YP", "Dolmetsch RE", "Cooper DL", "Li Y", "Goldstein B", "Monahan PE"], "authors_original": "Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE.", "first_author": "Pipe SW", "first_author_display": "Pipe SW, et al.", "citation": "Pipe SW, et al.. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. The New England journal of medicine. 2023;388(8):706-718. doi:10.1056/nejmoa2211644. PMID:36812434.", "journal": "The New England journal of medicine", "year": 2023, "volume": "388", "issue": "8", "pages_or_article_id": "706-718", "doi": "10.1056/nejmoa2211644", "pmid": "36812434", "publication_date": "2023-02-01", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:13.771838+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37017909", "original_article_title": "Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence.", "authors": ["Robbins-Welty GA", "Webb JA", "Shalev D", "El-Jawahri A", "Jackson V", "Mitchell C", "LeBlanc TW"], "authors_original": "Robbins-Welty GA, Webb JA, Shalev D, El-Jawahri A, Jackson V, Mitchell C, LeBlanc TW.", "first_author": "Robbins-Welty GA", "first_author_display": "Robbins-Welty GA, et al.", "citation": "Robbins-Welty GA, et al.. Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence. Current treatment options in oncology. 2023;24(5):542-564. doi:10.1007/s11864-023-01084-1. PMID:37017909.", "journal": "Current treatment options in oncology", "year": 2023, "volume": "24", "issue": "5", "pages_or_article_id": "542-564", "doi": "10.1007/s11864-023-01084-1", "pmid": "37017909", "publication_date": "2023-04-05", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:09.492510+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37042865", "original_article_title": "Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.", "authors": ["Verstovsek S", "Mesa R", "Gupta V", "Lavie D", "Dubruille V", "Cambier N", "Platzbecker U", "Hus M", "Xicoy B", "Oh ST", "Kiladjian JJ", "Vannucchi AM", "Gerds A", "Egyed M", "Mayer J", "Sacha T", "Kawashima J", "Morris M", "Huang M", "Harrison C"], "authors_original": "Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C.", "first_author": "Verstovsek S", "first_author_display": "Verstovsek S, et al.", "citation": "Verstovsek S, et al.. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood advances. 2023;7(14):3582-3591. doi:10.1182/bloodadvances.2022009311. PMID:37042865.", "journal": "Blood advances", "year": 2023, "volume": "7", "issue": "14", "pages_or_article_id": "3582-3591", "doi": "10.1182/bloodadvances.2022009311", "pmid": "37042865", "publication_date": "2023-07-01", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:38.137615+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37272512", "original_article_title": "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.", "authors": ["San-Miguel J", "Dhakal B", "Yong K", "Spencer A", "Anguille S", "Mateos MV", "Fernández de Larrea C", "Martínez-López J", "Martínez-López J", "Moreau P", "Touzeau C", "Leleu X", "Avivi I", "Cavo M", "Ishida T", "Kim SJ", "Roeloffzen W", "van de Donk NWCJ", "Dytfeld D", "Sidana S", "Costa LJ", "Oriol A", "Popat R", "Khan AM", "Cohen YC", "Ho PJ", "Griffin J", "Lendvai N", "Lonardi C", "Slaughter A", "Schecter JM", "Jackson CC", "Connors K", "Li K", "Zudaire E", "Chen D", "Gilbert J", "Yeh TM", "Nagle S", "Florendo E", "Pacaud L", "Patel N", "Harrison SJ", "Einsele H"], "authors_original": "San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H.", "first_author": "San-Miguel J", "first_author_display": "San-Miguel J, et al.", "citation": "San-Miguel J, et al.. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. The New England journal of medicine. 2023;389(4):335-347. doi:10.1056/nejmoa2303379. PMID:37272512.", "journal": "The New England journal of medicine", "year": 2023, "volume": "389", "issue": "4", "pages_or_article_id": "335-347", "doi": "10.1056/nejmoa2303379", "pmid": "37272512", "publication_date": "2023-06-05", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:11.779057+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37525244", "original_article_title": "The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.", "authors": ["Rejeski K", "Hansen DK", "Bansal R", "Sesques P", "Ailawadhi S", "Logue JM", "Bräunlein E", "Cordas Dos Santos DM", "Freeman CL", "Alsina M", "Theurich S", "Wang Y", "Krackhardt AM", "Locke FL", "Bachy E", "Jain MD", "Lin Y", "Subklewe M"], "authors_original": "Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M.", "first_author": "Rejeski K", "first_author_display": "Rejeski K, et al.", "citation": "Rejeski K, et al.. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. Journal of hematology & oncology. 2023;16(1):88. doi:10.1186/s13045-023-01465-x. PMID:37525244.", "journal": "Journal of hematology & oncology", "year": 2023, "volume": "16", "issue": "1", "pages_or_article_id": "88", "doi": "10.1186/s13045-023-01465-x", "pmid": "37525244", "publication_date": "2023-07-31", "publication_types": ["Research Support, Non-U.S. Gov't", "research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:45.247623+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37528088", "original_article_title": "Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.", "authors": ["Raje N", "Anderson K", "Einsele H", "Efebera Y", "Gay F", "Hammond SP", "Lesokhin AM", "Lonial S", "Ludwig H", "Moreau P", "Patel K", "Ramasamy K", "Mateos MV"], "authors_original": "Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, Lesokhin AM, Lonial S, Ludwig H, Moreau P, Patel K, Ramasamy K, Mateos MV.", "first_author": "Raje N", "first_author_display": "Raje N, et al.", "citation": "Raje N, et al.. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood cancer journal. 2023;13(1):116. doi:10.1038/s41408-023-00879-7. PMID:37528088.", "journal": "Blood cancer journal", "year": 2023, "volume": "13", "issue": "1", "pages_or_article_id": "116", "doi": "10.1038/s41408-023-00879-7", "pmid": "37528088", "publication_date": "2023-08-01", "publication_types": ["Research Support, Non-U.S. Gov't", "review-article", "Review", "Consensus Statement", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:38.245572+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37582952", "original_article_title": "Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.", "authors": ["Lesokhin AM", "Tomasson MH", "Arnulf B", "Bahlis NJ", "Miles Prince H", "Niesvizky R", "Rodrίguez-Otero P", "Martinez-Lopez J", "Martinez-Lopez J", "Koehne G", "Touzeau C", "Jethava Y", "Quach H", "Depaus J", "Yokoyama H", "Gabayan AE", "Stevens DA", "Nooka AK", "Manier S", "Raje N", "Iida S", "Raab MS", "Searle E", "Leip E", "Sullivan ST", "Conte U", "Elmeliegy M", "Czibere A", "Viqueira A", "Mohty M"], "authors_original": "Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M.", "first_author": "Lesokhin AM", "first_author_display": "Lesokhin AM, et al.", "citation": "Lesokhin AM, et al.. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature medicine. 2023;29(9):2259-2267. doi:10.1038/s41591-023-02528-9. PMID:37582952.", "journal": "Nature medicine", "year": 2023, "volume": "29", "issue": "9", "pages_or_article_id": "2259-2267", "doi": "10.1038/s41591-023-02528-9", "pmid": "37582952", "publication_date": "2023-08-15", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.754860+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_37646659", "original_article_title": "Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.", "authors": ["Caimi PF", "Ai WZ", "Alderuccio JP", "Ardeshna KM", "Hamadani M", "Hess B", "Kahl BS", "Radford J", "Solh M", "Stathis A", "Zinzani PL", "Wang Y", "Qin Y", "Wang L", "Xu ZC", "Carlo-Stella C"], "authors_original": "Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C.", "first_author": "Caimi PF", "first_author_display": "Caimi PF, et al.", "citation": "Caimi PF, et al.. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109(4):1184-1193. doi:10.3324/haematol.2023.283459. PMID:37646659.", "journal": "Haematologica", "year": 2024, "volume": "109", "issue": "4", "pages_or_article_id": "1184-1193", "doi": "10.3324/haematol.2023.283459", "pmid": "37646659", "publication_date": "2024-04-01", "publication_types": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:36.180983+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38084760", "original_article_title": "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.", "authors": ["Sonneveld P", "Dimopoulos MA", "Boccadoro M", "Quach H", "Ho PJ", "Beksac M", "Hulin C", "Antonioli E", "Leleu X", "Mangiacavalli S", "Perrot A", "Cavo M", "Belotti A", "Broijl A", "Gay F", "Mina R", "Nijhof IS", "van de Donk NWCJ", "Katodritou E", "Schjesvold F", "Sureda Balari A", "Rosiñol L", "Delforge M", "Roeloffzen W", "Silzle T", "Vangsted A", "Einsele H", "Spencer A", "Hajek R", "Jurczyszyn A", "Lonergan S", "Ahmadi T", "Liu Y", "Wang J", "Vieyra D", "van Brummelen EMJ", "Vanquickelberghe V", "Sitthi-Amorn A", "de Boer CJ", "Carson R", "Rodriguez-Otero P", "Bladé J", "Moreau P", "PERSEUS Trial Investigators"], "authors_original": "Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators.", "first_author": "Sonneveld P", "first_author_display": "Sonneveld P, et al.", "citation": "Sonneveld P, et al.. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2024;390(4):301-313. doi:10.1056/nejmoa2312054. PMID:38084760.", "journal": "The New England journal of medicine", "year": 2024, "volume": "390", "issue": "4", "pages_or_article_id": "301-313", "doi": "10.1056/nejmoa2312054", "pmid": "38084760", "publication_date": "2023-12-12", "publication_types": ["Clinical Trial, Phase III", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:12.008534+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38180317", "original_article_title": "Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.", "authors": ["Atallah-Yunes SA", "Khurana A", "Maurer M"], "authors_original": "Atallah-Yunes SA, Khurana A, Maurer M.", "first_author": "Atallah-Yunes SA", "first_author_display": "Atallah-Yunes SA, et al.", "citation": "Atallah-Yunes SA, et al.. Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials. Leukemia & lymphoma. 2024;65(4):430-439. doi:10.1080/10428194.2023.2298705. PMID:38180317.", "journal": "Leukemia & lymphoma", "year": 2024, "volume": "65", "issue": "4", "pages_or_article_id": "430-439", "doi": "10.1080/10428194.2023.2298705", "pmid": "38180317", "publication_date": "2024-01-05", "publication_types": ["research-article", "Review", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:25.112239+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38235513", "original_article_title": "Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.", "authors": ["Tun AM", "Wang Y", "Maliske S", "Micallef I", "Inwards DJ", "Habermann TM", "Porrata L", "Paludo J", "Bisneto JV", "Rosenthal A", "Kharfan-Dabaja MA", "Ansell SM", "Nowakowski GS", "Farooq U", "Johnston PB"], "authors_original": "Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB.", "first_author": "Tun AM", "first_author_display": "Tun AM, et al.", "citation": "Tun AM, et al.. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024;109(7):2186-2195. doi:10.3324/haematol.2023.284704. PMID:38235513.", "journal": "Haematologica", "year": 2024, "volume": "109", "issue": "7", "pages_or_article_id": "2186-2195", "doi": "10.3324/haematol.2023.284704", "pmid": "38235513", "publication_date": "2024-07-01", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:09.493903+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38343151", "original_article_title": "Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.", "authors": ["Pratz KW", "Jonas BA", "Pullarkat V", "Thirman MJ", "Garcia JS", "Döhner H", "Récher C", "Fiedler W", "Yamamoto K", "Wang J", "Yoon SS", "Wolach O", "Yeh SP", "Leber B", "Esteve J", "Mayer J", "Porkka K", "Illés Á", "Lemoli RM", "Turgut M", "Ku G", "Miller C", "Zhou Y", "Zhang M", "Chyla B", "Potluri J", "DiNardo CD"], "authors_original": "Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD.", "first_author": "Pratz KW", "first_author_display": "Pratz KW, et al.", "citation": "Pratz KW, et al.. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American journal of hematology. 2024;99(4):615-624. doi:10.1002/ajh.27246. PMID:38343151.", "journal": "American journal of hematology", "year": 2024, "volume": "99", "issue": "4", "pages_or_article_id": "615-624", "doi": "10.1002/ajh.27246", "pmid": "38343151", "publication_date": "2024-02-11", "publication_types": ["Research Support, Non-U.S. Gov't", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:36.640856+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38830994", "original_article_title": "Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.", "authors": ["Leleu X", "Hulin C", "Lambert J", "Bobin A", "Perrot A", "Karlin L", "Roussel M", "Montes L", "Cherel B", "Chalopin T", "Slama B", "Chretien ML", "Laribi K", "Dingremont C", "Roul C", "Mariette C", "Rigaudeau S", "Calmettes C", "Dib M", "Tiab M", "Vincent L", "Delaunay J", "Santagostino A", "Macro M", "Bourgeois E", "Orsini-Piocelle F", "Gay J", "Bareau B", "Bigot N", "Vergez F", "Lebreton P", "Tabrizi R", "Waultier-Rascalou A", "Frenzel L", "Le Calloch R", "Chalayer E", "Braun T", "Lachenal F", "Corm S", "Kennel C", "Belkhir R", "Bladé JS", "Joly B", "Richez-Olivier V", "Gardeney H", "Demarquette H", "Robu-Cretu D", "Garderet L", "Newinger-Porte M", "Kasmi A", "Royer B", "Decaux O", "Arnulf B", "Belhadj K", "Touzeau C", "Mohty M", "Manier S", "Moreau P", "Avet-Loiseau H", "Corre J", "Facon T"], "authors_original": "Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T.", "first_author": "Leleu X", "first_author_display": "Leleu X, et al.", "citation": "Leleu X, et al.. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine. 2024;30(8):2235-2241. doi:10.1038/s41591-024-03050-2. PMID:38830994.", "journal": "Nature medicine", "year": 2024, "volume": "30", "issue": "8", "pages_or_article_id": "2235-2241", "doi": "10.1038/s41591-024-03050-2", "pmid": "38830994", "publication_date": "2024-06-03", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:35.024635+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38832972", "original_article_title": "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.", "authors": ["Facon T", "Dimopoulos MA", "Leleu XP", "Beksac M", "Pour L", "Hájek R", "Liu Z", "Minarik J", "Moreau P", "Romejko-Jarosinska J", "Spicka I", "Vorobyev VI", "Besemer B", "Ishida T", "Janowski W", "Kalayoglu-Besisik S", "Parmar G", "Robak P", "Zamagni E", "Goldschmidt H", "Martin TG", "Manier S", "Mohty M", "Oprea C", "Brégeault MF", "Macé S", "Berthou C", "Bregman D", "Klippel Z", "Orlowski RZ", "IMROZ Study Group"], "authors_original": "Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ, IMROZ Study Group.", "first_author": "Facon T", "first_author_display": "Facon T, et al.", "citation": "Facon T, et al.. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2024;391(17):1597-1609. doi:10.1056/nejmoa2400712. PMID:38832972.", "journal": "The New England journal of medicine", "year": 2024, "volume": "391", "issue": "17", "pages_or_article_id": "1597-1609", "doi": "10.1056/nejmoa2400712", "pmid": "38832972", "publication_date": "2024-06-03", "publication_types": ["Clinical Trial, Phase III", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.616094+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_38843478", "original_article_title": "Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.", "authors": ["González-López TJ", "Bermejo-Vega N", "Cardesa-Cabrera R", "Martínez-Robles V", "Aguilar-Monserrate G", "Pérez-Segura G", "Domingo A", "Luis-Navarro J", "Lakhwani S", "Acedo N", "Lozano ML", "Bernat S", "Torres-Tienza A", "Ruano A", "Jarque I", "Galán P", "Benet C", "Marcellini S", "Jimenez-Bárcenas R", "Martínez-Carballeira D", "De Miguel-Llorente D", "Perona-Blázquez A", "Gonzalez-Gascón I", "Lopez-Ansoar E", "Alonso-Alonso JM", "Bengochea-Casado ML", "Díaz-Gálvez FJ", "Moretó A", "Moreno-Jiménez G", "Hernández-Martin R", "de Cabo E", "Dávila-Valls J", "Cuesta A", "Pastoriza C", "Hermida-Fernández GJ", "García C", "Pozas-Mañas MA", "Aguilar C", "Fernandez-Jimenez D", "Navas-Elorza B", "López-Santamaría Castro C", "Lorenzo A", "Ortín X", "García M", "Piernas S", "Díaz-Santa J", "Soto I", "Provan D", "García-Donas Gabaldón G"], "authors_original": "González-López TJ, Bermejo-Vega N, Cardesa-Cabrera R, Martínez-Robles V, Aguilar-Monserrate G, Pérez-Segura G, Domingo A, Luis-Navarro J, Lakhwani S, Acedo N, Lozano ML, Bernat S, Torres-Tienza A, Ruano A, Jarque I, Galán P, Benet C, Marcellini S, Jimenez-Bárcenas R, Martínez-Carballeira D, De Miguel-Llorente D, Perona-Blázquez A, Gonzalez-Gascón I, Lopez-Ansoar E, Alonso-Alonso JM, Bengochea-Casado ML, Díaz-Gálvez FJ, Moretó A, Moreno-Jiménez G, Hernández-Martin R, de Cabo E, Dávila-Valls J, Cuesta A, Pastoriza C, Hermida-Fernández GJ, García C, Pozas-Mañas MA, Aguilar C, Fernandez-Jimenez D, Navas-Elorza B, López-Santamaría Castro C, Lorenzo A, Ortín X, García M, Piernas S, Díaz-Santa J, Soto I, Provan D, García-Donas Gabaldón G.", "first_author": "González-López TJ", "first_author_display": "González-López TJ, et al.", "citation": "González-López TJ, et al.. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood. 2024;144(6):646-656. doi:10.1182/blood.2024024250. PMID:38843478.", "journal": "Blood", "year": 2024, "volume": "144", "issue": "6", "pages_or_article_id": "646-656", "doi": "10.1182/blood.2024024250", "pmid": "38843478", "publication_date": "2024-08-01", "publication_types": ["Research Support, Non-U.S. Gov't", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.954097+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_39093014", "original_article_title": "Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.", "authors": ["Jabbour E", "Kantarjian H"], "authors_original": "Jabbour E, Kantarjian H.", "first_author": "Jabbour E", "first_author_display": "Jabbour E, et al.", "citation": "Jabbour E, et al.. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. American journal of hematology. 2024;99(11):2191-2212. doi:10.1002/ajh.27443. PMID:39093014.", "journal": "American journal of hematology", "year": 2024, "volume": "99", "issue": "11", "pages_or_article_id": "2191-2212", "doi": "10.1002/ajh.27443", "pmid": "39093014", "publication_date": "2024-08-02", "publication_types": ["Research Support, Non-U.S. Gov't", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:25.292414+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_39772655", "original_article_title": "Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.", "authors": ["Bartlett NL", "Hahn U", "Kim WS", "Fleury I", "Laribi K", "Bergua JM", "Bouabdallah K", "Forward N", "Bijou F", "MacDonald D", "Portell CA", "Ghesquieres H", "Nowakowski G", "Yasenchak CA", "Patterson M", "Ho L", "Rustia E", "Fanale M", "Jie F", "Kim JA"], "authors_original": "Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA.", "first_author": "Bartlett NL", "first_author_display": "Bartlett NL, et al.", "citation": "Bartlett NL, et al.. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43(9):1061-1072. doi:10.1200/jco-24-02242. PMID:39772655.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2025, "volume": "43", "issue": "9", "pages_or_article_id": "1061-1072", "doi": "10.1200/jco-24-02242", "pmid": "39772655", "publication_date": "2025-01-07", "publication_types": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:11.062626+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_39870767", "original_article_title": "International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.", "authors": ["Costa LJ", "Banerjee R", "Mian H", "Weisel K", "Bal S", "Derman BA", "Htut MM", "Nagarajan C", "Rodriguez C", "Richter J", "Frigault MJ", "Ye JC", "van de Donk NWCJ", "Voorhees PM", "Puliafito B", "Bahlis N", "Popat R", "Chng WJ", "Ho PJ", "Kaur G", "Kapoor P", "Du J", "Schjesvold F", "Berdeja J", "Einsele H", "Cohen AD", "Mikhael J", "Biru Y", "Rajkumar SV", "Lin Y", "Martin TG", "Chari A"], "authors_original": "Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A.", "first_author": "Costa LJ", "first_author_display": "Costa LJ, et al.", "citation": "Costa LJ, et al.. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554. doi:10.1038/s41375-024-02482-6. PMID:39870767.", "journal": "Leukemia", "year": 2025, "volume": "39", "issue": "3", "pages_or_article_id": "543-554", "doi": "10.1038/s41375-024-02482-6", "pmid": "39870767", "publication_date": "2025-01-27", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.771116+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_39985323", "original_article_title": "How I treat iron-refractory iron deficiency anaemia-An expert opinion-based treatment guidance for children and adults.", "authors": ["Hoving V", "Donker AE", "Schols SEM", "Swinkels DW"], "authors_original": "Hoving V, Donker AE, Schols SEM, Swinkels DW.", "first_author": "Hoving V", "first_author_display": "Hoving V, et al.", "citation": "Hoving V, et al.. How I treat iron-refractory iron deficiency anaemia-An expert opinion-based treatment guidance for children and adults. British journal of haematology. 2025;206(4):1067-1076. doi:10.1111/bjh.20030. PMID:39985323.", "journal": "British journal of haematology", "year": 2025, "volume": "206", "issue": "4", "pages_or_article_id": "1067-1076", "doi": "10.1111/bjh.20030", "pmid": "39985323", "publication_date": "2025-02-22", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:33.033280+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40090350", "original_article_title": "Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.", "authors": ["Chari A", "Touzeau C", "Schinke C", "Minnema MC", "Berdeja JG", "Oriol A", "van de Donk NWCJ", "Rodríguez-Otero P", "Morillo D", "Martinez-Chamorro C", "Mateos MV", "Costa LJ", "Caers J", "Rasche L", "Krishnan A", "Ye JC", "Karlin L", "Lipe B", "Vishwamitra D", "Skerget S", "Verona R", "Ma X", "Qin X", "Ludlage H", "Campagna M", "Masterson T", "Hilder B", "Tolbert J", "Renaud T", "Goldberg JD", "Kane C", "Heuck C", "San-Miguel J", "Moreau P"], "authors_original": "Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P.", "first_author": "Chari A", "first_author_display": "Chari A, et al.", "citation": "Chari A, et al.. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. The Lancet. Haematology. 2025;12(4):e269-e281. doi:10.1016/s2352-3026(24)00385-5. PMID:40090350.", "journal": "The Lancet. Haematology", "year": 2025, "volume": "12", "issue": "4", "pages_or_article_id": "e269-e281", "doi": "10.1016/s2352-3026(24)00385-5", "pmid": "40090350", "publication_date": "2025-03-13", "publication_types": ["Clinical Trial, Phase II", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:43.726351+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40142863", "original_article_title": "Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management.", "authors": ["Canichella M", "De Fazio L", "Molica M"], "authors_original": "Canichella M, De Fazio L, Molica M.", "first_author": "Canichella M", "first_author_display": "Canichella M, et al.", "citation": "Canichella M, et al.. Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management. Journal of clinical medicine. 2025;14(6):2055. doi:10.3390/jcm14062055. PMID:40142863.", "journal": "Journal of clinical medicine", "year": 2025, "volume": "14", "issue": "6", "pages_or_article_id": "2055", "doi": "10.3390/jcm14062055", "pmid": "40142863", "publication_date": "2025-03-18", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.283443+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40246832", "original_article_title": "Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.", "authors": ["Willekens C", "Bazinet A", "Chraibi S", "Bataller A", "Decroocq J", "Arani N", "Carpentier B", "Rausch C", "Lebon D", "Maiti A", "Gauthier N", "Short N", "Bonnet S", "Sasaki K", "Khalife-Hachem S", "Swaminathan M", "Micol JB", "Pasquier F", "Marzac C", "Roos-Weil D", "Pascal L", "Daver N", "Kadia T", "Bouscary D", "Ravandi F", "Pages A", "Kantarjian H", "De Botton S", "DiNardo C"], "authors_original": "Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C.", "first_author": "Willekens C", "first_author_display": "Willekens C, et al.", "citation": "Willekens C, et al.. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood cancer journal. 2025;15(1):68. doi:10.1038/s41408-025-01269-x. PMID:40246832.", "journal": "Blood cancer journal", "year": 2025, "volume": "15", "issue": "1", "pages_or_article_id": "68", "doi": "10.1038/s41408-025-01269-x", "pmid": "40246832", "publication_date": "2025-04-17", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:42.745112+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40246837", "original_article_title": "Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.", "authors": ["Pérez-Lamas L", "Segura Diaz A", "García Delgado R", "Álvarez-Larrán A", "Senin MA", "Mora E", "Fox ML", "Pastor Galan I", "Azaceta G", "Garrido Paniagua S", "Pérez Lopez R", "Trejos Carvajal DM", "Angona A", "Albo López C", "Lorente Alegre P", "Vara M", "Vera Goñi JA", "De Miguel Llorente D", "Fernández Rodríguez Á", "Marín Sanchez A", "Hernando Megido A", "Gómez Casares MT", "Stuckey R", "Carreño-Tarragona G", "De Las Heras Rodriguez N", "Xicoy B", "Pérez Encinas M", "Mata Serna R", "Núñez Martin-Buitrago L", "Ferrer Marín F", "Amer Salas N", "Guillén Rienda C", "Velez P", "Lamarca Eraso L", "Martín S", "Luts Khoroz I", "De Cabo López E", "Gil A", "Martín-Consuegra Ramos S", "Marco De Lucas F", "Otero Martinez-Fornes MJ", "Martín Mateos ML", "Arquero T", "Cabezudo Pérez E", "López Gómez LA", "Martínez Hellin Á", "Tejedor A", "Herrera de Pablo E", "Mata Vazquez MI", "Castillo Valero I", "Fernández MJ", "Aguilar C", "Santaliestra M", "García Menchon A", "Navas Elorza B", "Duran MA", "Pérez Sala M", "Hernández Santamaría T", "Muñoz Jarreño MÁ", "Dávila-Valls J", "Torres Jiménez W", "Gonzálvez Fernández JA", "Torres Mantilla HA", "Cobo Rodríguez T", "Abuin Blanco A", "Pérez F", "Osorio Prendes S", "Beneit Villena P", "Peralta R", "Herrera F", "Cañamero Giro E", "Jiménez Bárcenas R", "Gasior Kabat M", "González De Villambrosia S", "Tercero-Mora Rodriguez MT", "Menéndez Cuevas M", "Cuevas Ruiz B", "Fonseca-Santos M", "Garcés Piquer S", "De La Puerta R", "Lorenzo Vizcaya Á", "Hernández Boluda JC", "García Gutiérrez V"], "authors_original": "Pérez-Lamas L, Segura Diaz A, García Delgado R, Álvarez-Larrán A, Senin MA, Mora E, Fox ML, Pastor Galan I, Azaceta G, Garrido Paniagua S, Pérez Lopez R, Trejos Carvajal DM, Angona A, Albo López C, Lorente Alegre P, Vara M, Vera Goñi JA, De Miguel Llorente D, Fernández Rodríguez Á, Marín Sanchez A, Hernando Megido A, Gómez Casares MT, Stuckey R, Carreño-Tarragona G, De Las Heras Rodriguez N, Xicoy B, Pérez Encinas M, Mata Serna R, Núñez Martin-Buitrago L, Ferrer Marín F, Amer Salas N, Guillén Rienda C, Velez P, Lamarca Eraso L, Martín S, Luts Khoroz I, De Cabo López E, Gil A, Martín-Consuegra Ramos S, Marco De Lucas F, Otero Martinez-Fornes MJ, Martín Mateos ML, Arquero T, Cabezudo Pérez E, López Gómez LA, Martínez Hellin Á, Tejedor A, Herrera de Pablo E, Mata Vazquez MI, Castillo Valero I, Fernández MJ, Aguilar C, Santaliestra M, García Menchon A, Navas Elorza B, Duran MA, Pérez Sala M, Hernández Santamaría T, Muñoz Jarreño MÁ, Dávila-Valls J, Torres Jiménez W, Gonzálvez Fernández JA, Torres Mantilla HA, Cobo Rodríguez T, Abuin Blanco A, Pérez F, Osorio Prendes S, Beneit Villena P, Peralta R, Herrera F, Cañamero Giro E, Jiménez Bárcenas R, Gasior Kabat M, González De Villambrosia S, Tercero-Mora Rodriguez MT, Menéndez Cuevas M, Cuevas Ruiz B, Fonseca-Santos M, Garcés Piquer S, De La Puerta R, Lorenzo Vizcaya Á, Hernández Boluda JC, García Gutiérrez V.", "first_author": "Pérez-Lamas L", "first_author_display": "Pérez-Lamas L, et al.", "citation": "Pérez-Lamas L, et al.. Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Blood cancer journal. 2025;15(1):67. doi:10.1038/s41408-025-01275-z. PMID:40246837.", "journal": "Blood cancer journal", "year": 2025, "volume": "15", "issue": "1", "pages_or_article_id": "67", "doi": "10.1038/s41408-025-01275-z", "pmid": "40246837", "publication_date": "2025-04-17", "publication_types": ["Letter"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:42.702379+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40334072", "original_article_title": "Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.", "authors": ["Mauro MJ", "Minami Y", "Hochhaus A", "Lomaia E", "Voloshin S", "Turkina A", "Kim DW", "Apperley JF", "Cortes JE", "Abdo A", "Fogliatto LM", "Kim DDH", "le Coutre P", "Saussele S", "Annunziata M", "Hughes TP", "Chaudhri N", "Chee L", "García-Gutiérrez V", "Sasaki K", "Boquimpani C", "Kapoor S", "Espurz N", "Dhamal V", "Rea D"], "authors_original": "Mauro MJ, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, García-Gutiérrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz N, Dhamal V, Rea D.", "first_author": "Mauro MJ", "first_author_display": "Mauro MJ, et al.", "citation": "Mauro MJ, et al.. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood advances. 2025;9(16):4248-4259. doi:10.1182/bloodadvances.2025016042. PMID:40334072.", "journal": "Blood advances", "year": 2025, "volume": "9", "issue": "16", "pages_or_article_id": "4248-4259", "doi": "10.1182/bloodadvances.2025016042", "pmid": "40334072", "publication_date": "2025-08-01", "publication_types": ["Clinical Trial, Phase III", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:21.383922+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40459151", "original_article_title": "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.", "authors": ["Jagannath S", "Martin TG", "Lin Y", "Cohen AD", "Raje N", "Htut M", "Deol A", "Agha M", "Berdeja JG", "Lesokhin AM", "Liegel JJ", "Rossi A", "Lieberman-Cribbin A", "Usmani SZ", "Dhakal B", "Parekh S", "Li H", "Wang F", "Montes de Oca R", "Plaks V", "Sun H", "Banerjee A", "Schecter JM", "Lendvai N", "Madduri D", "Lengil T", "Zhu J", "Koneru M", "Akram M", "Patel N", "Costa Filho O", "Jakubowiak AJ", "Voorhees PM"], "authors_original": "Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM.", "first_author": "Jagannath S", "first_author_display": "Jagannath S, et al.", "citation": "Jagannath S, et al.. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43(25):2766-2771. doi:10.1200/jco-25-00760. PMID:40459151.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2025, "volume": "43", "issue": "25", "pages_or_article_id": "2766-2771", "doi": "10.1200/jco-25-00760", "pmid": "40459151", "publication_date": "2025-06-03", "publication_types": ["Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:36.212243+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40499010", "original_article_title": "High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.", "authors": ["Lahuerta JJ", "San-Miguel J", "Jiménez-Ubieto A", "Alonso R", "Paiva B", "Puig N", "Cedena MT", "Gutierrez NC", "Calasanz MJ", "Fernández Guijarro M", "Tamayo RR", "Rocafiguera AO", "Blanchard MJ", "Carrillo Cruz E", "Martínez-Martínez R", "Bargay J", "Sureda Balari A", "Rubia J", "Hernández García MT", "Cabañas V", "Montero FC", "Bernal LP", "Montes YG", "Martínez-Lopez J", "Martínez-Lopez J", "Rodriguez-Otero P", "Krisnik I", "Arguiñano JM", "Gonzalez García ME", "Ocio EM", "Cruz J", "Mateos MV", "Rosiñol L", "Bladé J"], "authors_original": "Lahuerta JJ, San-Miguel J, Jiménez-Ubieto A, Alonso R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernández Guijarro M, Tamayo RR, Rocafiguera AO, Blanchard MJ, Carrillo Cruz E, Martínez-Martínez R, Bargay J, Sureda Balari A, Rubia J, Hernández García MT, Cabañas V, Montero FC, Bernal LP, Montes YG, Martínez-Lopez J, Martínez-Lopez J, Rodriguez-Otero P, Krisnik I, Arguiñano JM, Gonzalez García ME, Ocio EM, Cruz J, Mateos MV, Rosiñol L, Bladé J.", "first_author": "Lahuerta JJ", "first_author_display": "Lahuerta JJ, et al.", "citation": "Lahuerta JJ, et al.. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial. Blood. 2025;146(15):1747-1758. doi:10.1182/blood.2025028313. PMID:40499010.", "journal": "Blood", "year": 2025, "volume": "146", "issue": "15", "pages_or_article_id": "1747-1758", "doi": "10.1182/blood.2025028313", "pmid": "40499010", "publication_date": "2025-10-01", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:32.086003+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40513032", "original_article_title": "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.", "authors": ["Curtis DJ", "Patil SS", "Reynolds J", "Purtill D", "Lewis C", "Ritchie DS", "Gottlieb DJ", "Yeung DT", "Wong E", "Tey SK", "Perera T", "Moore J", "Koldej RM", "De Abreu Lourenco R", "Stubbs J", "Morrissey CO", "Munsef N", "Arenas A", "Hill GR", "Australasian Leukaemia and Lymphoma Group"], "authors_original": "Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR, Australasian Leukaemia and Lymphoma Group.", "first_author": "Curtis DJ", "first_author_display": "Curtis DJ, et al.", "citation": "Curtis DJ, et al.. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. The New England journal of medicine. 2025;393(3):243-254. doi:10.1056/nejmoa2503189. PMID:40513032.", "journal": "The New England journal of medicine", "year": 2025, "volume": "393", "issue": "3", "pages_or_article_id": "243-254", "doi": "10.1056/nejmoa2503189", "pmid": "40513032", "publication_date": "2025-06-13", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:14.595389+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40580975", "original_article_title": "Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network.", "authors": ["van de Donk NWCJ", "Moreau P", "San-Miguel JF", "Mateos MV", "Dimopoulos MA", "Zweegman S", "Gay F", "Engelhardt M", "Mina R", "Zamagni E", "Delforge M", "Beksac M", "Spencer A", "Schjesvold F", "Driessen C", "Kaiser M", "Perrot A", "Wäsch R", "Korst CL", "Broijl A", "Touzeau C", "Manier S", "Hajek R", "Ludwig H", "Fernandez de Larrea C", "Popat R", "Musto P", "Rodriguez-Otero P", "Yong K", "Rasche L", "Terpos E", "Raab MS", "Boccadoro M", "Sonneveld P", "Einsele H", "EMN Guidelines Committee"], "authors_original": "van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C, Popat R, Musto P, Rodriguez-Otero P, Yong K, Rasche L, Terpos E, Raab MS, Boccadoro M, Sonneveld P, Einsele H, EMN Guidelines Committee.", "first_author": "van de Donk NWCJ", "first_author_display": "van de Donk NWCJ, et al.", "citation": "van de Donk NWCJ, et al.. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. The Lancet. Haematology. 2025;12(8):e635-e649. doi:10.1016/s2352-3026(25)00117-6. PMID:40580975.", "journal": "The Lancet. Haematology", "year": 2025, "volume": "12", "issue": "8", "pages_or_article_id": "e635-e649", "doi": "10.1016/s2352-3026(25)00117-6", "pmid": "40580975", "publication_date": "2025-06-25", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:39.683434+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40646132", "original_article_title": "2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.", "authors": ["Apperley JF", "Milojkovic D", "Cross NCP", "Hjorth-Hansen H", "Hochhaus A", "Kantarjian H", "Lipton JH", "Malhotra H", "Niederwieser D", "Radich J", "Rousselot P", "Saussele S", "Schiffer CA", "Silver R", "Soverini S", "Stenke L", "Turkina A", "Casado LF", "Castagnetti F", "Cervantes F", "Clark RE", "Cortes J", "Deininger M", "Hughes TP", "Janssen J", "Jiang Q", "Kim DW", "Larson RA", "Mahon FX", "Mauro M", "Mayer J", "Nicolini FE", "Pane F", "Rea D", "Richter J", "Rosti G", "Saglio G", "Hehlmann R"], "authors_original": "Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R.", "first_author": "Apperley JF", "first_author_display": "Apperley JF, et al.", "citation": "Apperley JF, et al.. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797-1813. doi:10.1038/s41375-025-02664-w. PMID:40646132.", "journal": "Leukemia", "year": 2025, "volume": "39", "issue": "8", "pages_or_article_id": "1797-1813", "doi": "10.1038/s41375-025-02664-w", "pmid": "40646132", "publication_date": "2025-07-11", "publication_types": ["research-article", "Practice Guideline", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:19.922398+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40702148", "original_article_title": "Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.", "authors": ["Zanwar S", "Rajkumar SV"], "authors_original": "Zanwar S, Rajkumar SV.", "first_author": "Zanwar S", "first_author_display": "Zanwar S, et al.", "citation": "Zanwar S, et al.. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. Leukemia. 2025;39(11):2610-2617. doi:10.1038/s41375-025-02654-y. PMID:40702148.", "journal": "Leukemia", "year": 2025, "volume": "39", "issue": "11", "pages_or_article_id": "2610-2617", "doi": "10.1038/s41375-025-02654-y", "pmid": "40702148", "publication_date": "2025-07-23", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:26.052462+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40751114", "original_article_title": "Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.", "authors": ["Shastri T", "Trabolsi A", "Arumov A", "Schatz JH"], "authors_original": "Shastri T, Trabolsi A, Arumov A, Schatz JH.", "first_author": "Shastri T", "first_author_display": "Shastri T, et al.", "citation": "Shastri T, et al.. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2025;39(5):793-814. doi:10.1007/s40259-025-00735-z. PMID:40751114.", "journal": "BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy", "year": 2025, "volume": "39", "issue": "5", "pages_or_article_id": "793-814", "doi": "10.1007/s40259-025-00735-z", "pmid": "40751114", "publication_date": "2025-08-01", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:22.859308+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40889741", "original_article_title": "Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.", "authors": ["Shah B", "Challagulla S", "Xu S", "Williams R", "Ren S", "Srivastava T", "Gautam R", "Yang K", "Saba NS", "Tam CS"], "authors_original": "Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R, Yang K, Saba NS, Tam CS.", "first_author": "Shah B", "first_author_display": "Shah B, et al.", "citation": "Shah B, et al.. Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leukemia & lymphoma. 2025;66(12):2238-2248. doi:10.1080/10428194.2025.2541911. PMID:40889741.", "journal": "Leukemia & lymphoma", "year": 2025, "volume": "66", "issue": "12", "pages_or_article_id": "2238-2248", "doi": "10.1080/10428194.2025.2541911", "pmid": "40889741", "publication_date": "2025-09-01", "publication_types": ["Comparative Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:47.271621+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40955124", "original_article_title": "Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study.", "authors": ["Martorelli MC", "Pugliese N", "Di Perna M", "De Novellis D", "Lombardi A", "De Fazio L", "Loglisci G", "Peluso I", "Molica M", "Copia C", "Ricco A", "Bruzzese A", "Mendicino F", "De Fazio V", "Santeramo TM", "Bianco R", "Monaco G", "Fontana R", "Guariglia R", "Serio B", "Luponio S", "Della Corte AM", "Malandrini A", "Giudice V", "Frigeri F", "Tarantini G", "Guarini A", "Gentile M", "Musto P", "Annunziata M", "Di Renzo N", "Rossi M", "Califano C", "Pane F", "Selleri C"], "authors_original": "Martorelli MC, Pugliese N, Di Perna M, De Novellis D, Lombardi A, De Fazio L, Loglisci G, Peluso I, Molica M, Copia C, Ricco A, Bruzzese A, Mendicino F, De Fazio V, Santeramo TM, Bianco R, Monaco G, Fontana R, Guariglia R, Serio B, Luponio S, Della Corte AM, Malandrini A, Giudice V, Frigeri F, Tarantini G, Guarini A, Gentile M, Musto P, Annunziata M, Di Renzo N, Rossi M, Califano C, Pane F, Selleri C.", "first_author": "Martorelli MC", "first_author_display": "Martorelli MC, et al.", "citation": "Martorelli MC, et al.. Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study. European journal of haematology. 2026;116(1):23-30. doi:10.1111/ejh.70034. PMID:40955124.", "journal": "European journal of haematology", "year": 2026, "volume": "116", "issue": "1", "pages_or_article_id": "23-30", "doi": "10.1111/ejh.70034", "pmid": "40955124", "publication_date": "2025-09-16", "publication_types": ["research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.657451+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40991874", "original_article_title": "Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.", "authors": ["Morschhauser F", "Salles G", "Sehn LH", "Herrera AF", "Friedberg JW", "Trněný M", "Lenz G", "Sharman JP", "Herbaux C", "Burke JM", "Matasar M", "Collins GP", "Mehta-Shah N", "Oberic L", "Chauchet A", "Jurczak W", "Song Y", "Pinto A", "Rai S", "Izutsu K", "Greil R", "Mykhalska L", "Bergua-Burgués JM", "Cheung MC", "Shin HJ", "Hapgood G", "Munhoz E", "Abrisqueta P", "Gau JP", "Jiang Y", "McCall B", "Chohan S", "Sugidono M", "Yan M", "Batlevi CL", "Tilly H", "Flowers CR"], "authors_original": "Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR.", "first_author": "Morschhauser F", "first_author_display": "Morschhauser F, et al.", "citation": "Morschhauser F, et al.. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43(35):3698-3705. doi:10.1200/jco-25-00925. PMID:40991874.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2025, "volume": "43", "issue": "35", "pages_or_article_id": "3698-3705", "doi": "10.1200/jco-25-00925", "pmid": "40991874", "publication_date": "2025-09-24", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.651550+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40994348", "original_article_title": "Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.", "authors": ["Leontyeva Y", "Landtblom AR", "Hultcrantz M", "Lambe M", "Bower H", "Lambert PC", "Andersson TM"], "authors_original": "Leontyeva Y, Landtblom AR, Hultcrantz M, Lambe M, Bower H, Lambert PC, Andersson TM.", "first_author": "Leontyeva Y", "first_author_display": "Leontyeva Y, et al.", "citation": "Leontyeva Y, et al.. Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden. Haematologica. 2026;111(3):990-996. doi:10.3324/haematol.2024.286697. PMID:40994348.", "journal": "Haematologica", "year": 2026, "volume": "111", "issue": "3", "pages_or_article_id": "990-996", "doi": "10.3324/haematol.2024.286697", "pmid": "40994348", "publication_date": "2025-09-25", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:15.967613+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40995463", "original_article_title": "Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.", "authors": ["Thieblemont C", "Gomes Da Silva M", "Leppä S", "Lenz G", "Cottereau AS", "Fox C", "Lopez-Guillermo A", "Illidge T", "Jurczak W", "Eich H", "Aurer I", "Trneny M", "Rosenwald AA", "Davies A", "Zwezerijnen BG", "Bolanos N", "Marković M", "Jais JP", "Broussais F", "Dreyling M", "Vitolo U", "Tilly H", "Kersten MJ"], "authors_original": "Thieblemont C, Gomes Da Silva M, Leppä S, Lenz G, Cottereau AS, Fox C, Lopez-Guillermo A, Illidge T, Jurczak W, Eich H, Aurer I, Trneny M, Rosenwald AA, Davies A, Zwezerijnen BG, Bolanos N, Marković M, Jais JP, Broussais F, Dreyling M, Vitolo U, Tilly H, Kersten MJ.", "first_author": "Thieblemont C", "first_author_display": "Thieblemont C, et al.", "citation": "Thieblemont C, et al.. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2025;9(9):e70207. doi:10.1002/hem3.70207. PMID:40995463.", "journal": "HemaSphere", "year": 2025, "volume": "9", "issue": "9", "pages_or_article_id": "e70207", "doi": "10.1002/hem3.70207", "pmid": "40995463", "publication_date": "2025-09-23", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:19.891516+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41100801", "original_article_title": "Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.", "authors": ["Neelapu SS", "Chavez JC", "Sehgal AR", "Epperla N", "Ulrickson ML", "Bachy E", "Munshi PN", "Casulo C", "Maloney DG", "de Vos S", "Reshef R", "Leslie LA", "Oluwole OO", "Yakoub-Agha I", "Khanal R", "Rosenblatt JD", "Wulff J", "Shen RR", "Zhang W", "Poddar S", "Miao H", "Nikolajeva O", "Jacobson CA"], "authors_original": "Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA.", "first_author": "Neelapu SS", "first_author_display": "Neelapu SS, et al.", "citation": "Neelapu SS, et al.. Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43(33):3573-3577. doi:10.1200/jco-25-00668. PMID:41100801.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2025, "volume": "43", "issue": "33", "pages_or_article_id": "3573-3577", "doi": "10.1200/jco-25-00668", "pmid": "41100801", "publication_date": "2025-10-16", "publication_types": ["Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.229586+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41346230", "original_article_title": "Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.", "authors": ["Terpos E", "Gavriatopoulou M", "Ntanasis-Stathopoulos I", "Malandrakis P", "Fotiou D", "Kanellias N", "Migkou M", "Theodorakakou F", "Spiliopoulou V", "Solia E", "Eleutherakis-Papaiakovou E", "Psarros G", "Kastritis E", "Dimopoulos MA"], "authors_original": "Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M, Theodorakakou F, Spiliopoulou V, Solia E, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA.", "first_author": "Terpos E", "first_author_display": "Terpos E, et al.", "citation": "Terpos E, et al.. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood. 2026;147(14):1574-1583. doi:10.1182/blood.2025031629. PMID:41346230.", "journal": "Blood", "year": 2026, "volume": "147", "issue": "14", "pages_or_article_id": "1574-1583", "doi": "10.1182/blood.2025031629", "pmid": "41346230", "publication_date": "2026-04-01", "publication_types": ["Clinical Trial, Phase II", "research-article", "Multicenter Study", "Clinical Trial, Phase I", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:10.776056+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41358582", "original_article_title": "Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.", "authors": ["Kumar S", "Mateos MV", "Ye JC", "Atrash S", "Magen H", "Quach H", "Chu MP", "Trudel S", "Richter J", "Rodríguez-Otero P", "Chuah H", "Gatt M", "Medvedova E", "Raza S", "Yoon DH", "Ishida T", "Matous JV", "Rosiñol L", "Onodera K", "Scott E", "Heuck C", "Zhang J", "Henninger T", "O'Rourke L", "Thakkar P", "Festa M", "Huang L", "Zhou J", "Takamoto M", "Pei L", "Lu J", "Au N", "Krevvata M", "Usmani SZ", "Cohen YC", "RedirecTT-1 Investigators Study Group"], "authors_original": "Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodríguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosiñol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC, RedirecTT-1 Investigators Study Group.", "first_author": "Kumar S", "first_author_display": "Kumar S, et al.", "citation": "Kumar S, et al.. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. The New England journal of medicine. 2026;394(1):51-61. doi:10.1056/nejmoa2514752. PMID:41358582.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "1", "pages_or_article_id": "51-61", "doi": "10.1056/nejmoa2514752", "pmid": "41358582", "publication_date": "2025-12-07", "publication_types": ["Clinical Trial, Phase II", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:27.234321+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41358601", "original_article_title": "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.", "authors": ["Al-Sawaf O", "Stumpf J", "Zhang C", "Simon F", "Bosch F", "Feyzi E", "Ghia P", "Gregor M", "Kater AP", "Lindström V", "Mattsson M", "Niemann CU", "Staber PB", "Tadmor T", "Thornton P", "Wendtner CM", "Janssens A", "Noesslinger T", "Bohn JP", "da Cunha-Bang C", "Poulsen CB", "Ranti J", "Illmer T", "Schoettker B", "Böttcher S", "Gaska T", "Vandenberghe E", "Clifford R", "Benjamini O", "Frustaci AM", "Scarfò L", "Sportoletti P", "Schreurs J", "Levin MD", "van der Straaten H", "van der Klift M", "Tran H", "de la Serna J", "Loscertales J", "Lindblad O", "Bergendahl Sandstedt A", "Goede J", "Baumann M", "Fink AM", "Fischer K", "Ritgen M", "Kreuzer KA", "Schneider C", "Tausch E", "Stilgenbauer S", "Robrecht S", "Eichhorst B", "Hallek M", "CLL17 Trial Investigators"], "authors_original": "Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M, CLL17 Trial Investigators.", "first_author": "Al-Sawaf O", "first_author_display": "Al-Sawaf O, et al.", "citation": "Al-Sawaf O, et al.. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. The New England journal of medicine. 2026;394(11):1084-1096. doi:10.1056/nejmoa2515458. PMID:41358601.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "11", "pages_or_article_id": "1084-1096", "doi": "10.1056/nejmoa2515458", "pmid": "41358601", "publication_date": "2025-12-06", "publication_types": ["Clinical Trial, Phase III", "Equivalence Trial", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:30.894973+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41363801", "original_article_title": "Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.", "authors": ["Costa LJ", "Bahlis NJ", "Perrot A", "Nooka AK", "Lu J", "Pawlyn C", "Mina R", "Caeiro G", "Kentos A", "Hungria V", "Reece D", "Niu T", "Mylin AK", "Hansen CT", "Teipel R", "Besemer B", "Dimopoulos MA", "Zamagni E", "Yoshihara S", "Kim K", "Min CK", "Geerts P", "Van Leeuwen-Segarceanu E", "Tyczynska A", "Reguera JL", "Johansson M", "Hansson M", "Turgut M", "Grey M", "Sidana S", "Rodriguez-Otero P", "Martinez-Lopez J", "Hashmi H", "Carson R", "Kobos R", "Sun W", "Lantz K", "Seifert A", "Briseno-Toomey D", "O'Rourke L", "Rubin M", "Vieyra D", "Kang L", "Mateos MV", "MajesTEC-3 Trial Investigators"], "authors_original": "Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV, MajesTEC-3 Trial Investigators.", "first_author": "Costa LJ", "first_author_display": "Costa LJ, et al.", "citation": "Costa LJ, et al.. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine. 2026;394(8):739-752. doi:10.1056/nejmoa2514663. PMID:41363801.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "8", "pages_or_article_id": "739-752", "doi": "10.1056/nejmoa2514663", "pmid": "41363801", "publication_date": "2025-12-09", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:18.665107+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41370738", "original_article_title": "Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.", "authors": ["Popat R", "Beksac M", "Dimopoulos MA", "Gatt ME", "Gay F", "Jo JC", "Kapoor P", "Katodritou E", "Kortüm KM", "Ling S", "Nagarajan C", "Suzuki K", "Qiu L", "Onishi M", "Ku G", "Dail M", "Mukherjee N", "Ross JA", "Badawi MA", "Fusco MJ", "Dobkowska E", "Arriola E", "Bueno OF", "Bahlis NJ", "Iida S", "Moreau P", "Valent J", "Mateos MV"], "authors_original": "Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortüm KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV.", "first_author": "Popat R", "first_author_display": "Popat R, et al.", "citation": "Popat R, et al.. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(3):164-175. doi:10.1200/jco-25-00924. PMID:41370738.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2026, "volume": "44", "issue": "3", "pages_or_article_id": "164-175", "doi": "10.1200/jco-25-00924", "pmid": "41370738", "publication_date": "2025-12-10", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:46.895118+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41451861", "original_article_title": "Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.", "authors": ["Terao T", "Yoshida I", "Kobayashi H", "Urata T", "Fujii F", "Meguri Y", "Sugiura H", "Yoshioka T", "Saeki K", "Niiya D", "Asakura S", "Nishimori H", "Ikeda D", "Fujiwara H", "Ennishi D", "Maeda Y"], "authors_original": "Terao T, Yoshida I, Kobayashi H, Urata T, Fujii F, Meguri Y, Sugiura H, Yoshioka T, Saeki K, Niiya D, Asakura S, Nishimori H, Ikeda D, Fujiwara H, Ennishi D, Maeda Y.", "first_author": "Terao T", "first_author_display": "Terao T, et al.", "citation": "Terao T, et al.. Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study. British journal of haematology. 2026;208(2):554-563. doi:10.1111/bjh.70280. PMID:41451861.", "journal": "British journal of haematology", "year": 2026, "volume": "208", "issue": "2", "pages_or_article_id": "554-563", "doi": "10.1111/bjh.70280", "pmid": "41451861", "publication_date": "2025-12-26", "publication_types": ["Comparative Study", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.260287+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41498143", "original_article_title": "Unexplained Elevated Vitamin B12: Consider Macro-B12.", "authors": ["Hurkmans EGE", "Deneer R", "Nijziel MR", "Scharnhorst V"], "authors_original": "Hurkmans EGE, Deneer R, Nijziel MR, Scharnhorst V.", "first_author": "Hurkmans EGE", "first_author_display": "Hurkmans EGE, et al.", "citation": "Hurkmans EGE, et al.. Unexplained Elevated Vitamin B12: Consider Macro-B12. International journal of laboratory hematology. 2026;48(3):646-651. doi:10.1111/ijlh.70052. PMID:41498143.", "journal": "International journal of laboratory hematology", "year": 2026, "volume": "48", "issue": "3", "pages_or_article_id": "646-651", "doi": "10.1111/ijlh.70052", "pmid": "41498143", "publication_date": "2026-01-07", "publication_types": ["research-article", "Journal Article", "Case Reports"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:46.622461+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41538177", "original_article_title": "Incidentally Detected Splenomegaly and Risk of Hematologic Cancer and Liver Disease.", "authors": ["Juhl AR", "Glenthøj A", "Nordestgaard BG", "Petersen J", "Pham MHC", "Kofoed KF", "Kühl JT", "Fuchs A", "Sigvardsen PE", "Kristensen TS", "Bojesen SE", "Rønnemoes R", "Helby J"], "authors_original": "Juhl AR, Glenthøj A, Nordestgaard BG, Petersen J, Pham MHC, Kofoed KF, Kühl JT, Fuchs A, Sigvardsen PE, Kristensen TS, Bojesen SE, Rønnemoes R, Helby J.", "first_author": "Juhl AR", "first_author_display": "Juhl AR, et al.", "citation": "Juhl AR, et al.. Incidentally Detected Splenomegaly and Risk of Hematologic Cancer and Liver Disease. JAMA oncology. 2026;12(3):275-284. doi:10.1001/jamaoncol.2025.5934. PMID:41538177.", "journal": "JAMA oncology", "year": 2026, "volume": "12", "issue": "3", "pages_or_article_id": "275-284", "doi": "10.1001/jamaoncol.2025.5934", "pmid": "41538177", "publication_date": "2026-03-01", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.019231+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41557974", "original_article_title": "How I treat breakthrough thrombosis in patients with cancer.", "authors": ["Marx CE", "Carrier M"], "authors_original": "Marx CE, Carrier M.", "first_author": "Marx CE", "first_author_display": "Marx CE, et al.", "citation": "Marx CE, et al.. How I treat breakthrough thrombosis in patients with cancer. Blood. 2026;147(16):1804-1813. doi:10.1182/blood.2025030790. PMID:41557974.", "journal": "Blood", "year": 2026, "volume": "147", "issue": "16", "pages_or_article_id": "1804-1813", "doi": "10.1182/blood.2025030790", "pmid": "41557974", "publication_date": "2026-04-01", "publication_types": ["Review", "Journal Article", "Case Reports"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:14.825145+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41566054", "original_article_title": "Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.", "authors": ["Iori AP", "De Vivo A", "Di Bona E", "Caocci G", "Fioritoni F", "Ciceri F", "Beggiato E", "Rapezzi D", "Amendola A", "Figuera A", "Selleri C", "Longu F", "Fattizzo B", "Tucci A", "Cignetti A", "Amico V", "Sica S", "Metafuni E", "Raso S", "Urbano TA", "Marano L", "Di Renzo N", "Spedini P", "Rambaldi A", "Lanza F", "Clissa C", "Danesin C", "Greve MB", "Cabibbo S", "Ori A", "Cassanelli F", "Sottana F", "Campolo B", "Gasparri G", "Carini F", "Barcellini W"], "authors_original": "Iori AP, De Vivo A, Di Bona E, Caocci G, Fioritoni F, Ciceri F, Beggiato E, Rapezzi D, Amendola A, Figuera A, Selleri C, Longu F, Fattizzo B, Tucci A, Cignetti A, Amico V, Sica S, Metafuni E, Raso S, Urbano TA, Marano L, Di Renzo N, Spedini P, Rambaldi A, Lanza F, Clissa C, Danesin C, Greve MB, Cabibbo S, Ori A, Cassanelli F, Sottana F, Campolo B, Gasparri G, Carini F, Barcellini W.", "first_author": "Iori AP", "first_author_display": "Iori AP, et al.", "citation": "Iori AP, et al.. Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study. Annals of hematology. 2026;105(2):50. doi:10.1007/s00277-026-06792-w. PMID:41566054.", "journal": "Annals of hematology", "year": 2026, "volume": "105", "issue": "2", "pages_or_article_id": "50", "doi": "10.1007/s00277-026-06792-w", "pmid": "41566054", "publication_date": "2026-01-22", "publication_types": ["research-article", "Multicenter Study", "Journal Article", "Observational Study"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:42.338644+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41681868", "original_article_title": "Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.", "authors": ["Peñalver FJ", "Magnano L", "Alonso-Álvarez S", "Jiménez-Ubieto A", "López-Guillermo A", "Sancho JM"], "authors_original": "Peñalver FJ, Magnano L, Alonso-Álvarez S, Jiménez-Ubieto A, López-Guillermo A, Sancho JM.", "first_author": "Peñalver FJ", "first_author_display": "Peñalver FJ, et al.", "citation": "Peñalver FJ, et al.. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers. 2026;18(3):395. doi:10.3390/cancers18030395. PMID:41681868.", "journal": "Cancers", "year": 2026, "volume": "18", "issue": "3", "pages_or_article_id": "395", "doi": "10.3390/cancers18030395", "pmid": "41681868", "publication_date": "2026-01-27", "publication_types": ["other", "Guideline", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:18.855849+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41719502", "original_article_title": "Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.", "authors": ["Atrash S", "Symanowski J", "Robinson M", "Flynn C", "Norek S", "Cox R", "Plott M", "Bumgarner K", "Rhinehardt D", "Begic X", "Ndiaye A", "Robinson J", "Friend R", "Paul B", "Varga C", "Ferreri C", "Pineda-Roman M", "Foureau D", "Bhutani M", "Voorhees P"], "authors_original": "Atrash S, Symanowski J, Robinson M, Flynn C, Norek S, Cox R, Plott M, Bumgarner K, Rhinehardt D, Begic X, Ndiaye A, Robinson J, Friend R, Paul B, Varga C, Ferreri C, Pineda-Roman M, Foureau D, Bhutani M, Voorhees P.", "first_author": "Atrash S", "first_author_display": "Atrash S, et al.", "citation": "Atrash S, et al.. Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma. Blood advances. 2026;10(9):2925-2936. doi:10.1182/bloodadvances.2025019050. PMID:41719502.", "journal": "Blood advances", "year": 2026, "volume": "10", "issue": "9", "pages_or_article_id": "2925-2936", "doi": "10.1182/bloodadvances.2025019050", "pmid": "41719502", "publication_date": "2026-05-01", "publication_types": ["Clinical Trial, Phase II", "research-article", "Clinical Trial, Phase I", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:22.272101+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41723627", "original_article_title": "Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment.", "authors": ["Gertz MA"], "authors_original": "Gertz MA.", "first_author": "Gertz MA", "first_author_display": "Gertz MA", "citation": "Gertz MA. Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment. American journal of hematology. 2026;101(5):1056-1069. doi:10.1002/ajh.70246. PMID:41723627.", "journal": "American journal of hematology", "year": 2026, "volume": "101", "issue": "5", "pages_or_article_id": "1056-1069", "doi": "10.1002/ajh.70246", "pmid": "41723627", "publication_date": "2026-02-22", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:33.925438+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41727499", "original_article_title": "Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL.", "authors": ["Wang J", "Cui R", "Qi Y", "Mu J", "Li X", "Li Q", "Deng Q"], "authors_original": "Wang J, Cui R, Qi Y, Mu J, Li X, Li Q, Deng Q.", "first_author": "Wang J", "first_author_display": "Wang J, et al.", "citation": "Wang J, et al.. Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. Frontiers in immunology. 2026;17:1674235. doi:10.3389/fimmu.2026.1674235. PMID:41727499.", "journal": "Frontiers in immunology", "year": 2026, "volume": "17", "issue": null, "pages_or_article_id": "1674235", "doi": "10.3389/fimmu.2026.1674235", "pmid": "41727499", "publication_date": "2026-02-06", "publication_types": ["Clinical Trial", "research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:41.798713+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41774434", "original_article_title": "A new era for transplant-ineligible R/R LBCL patients: what's changing?", "authors": ["Tarantini G", "Miccolis RM", "Arcuti E", "Buquicchio C", "Carluccio V", "Ceccarelli R", "De Santis G", "Germano CR", "Gurgoglione L", "Leo M", "Loconte DC", "Mallano S", "Perfetto A", "Santeramo TM", "Strafella V", "Strippoli L", "Gini G"], "authors_original": "Tarantini G, Miccolis RM, Arcuti E, Buquicchio C, Carluccio V, Ceccarelli R, De Santis G, Germano CR, Gurgoglione L, Leo M, Loconte DC, Mallano S, Perfetto A, Santeramo TM, Strafella V, Strippoli L, Gini G.", "first_author": "Tarantini G", "first_author_display": "Tarantini G, et al.", "citation": "Tarantini G, et al.. A new era for transplant-ineligible R/R LBCL patients: what's changing?. Leukemia & lymphoma. 2026;67(5):997-1004. doi:10.1080/10428194.2026.2636979. PMID:41774434.", "journal": "Leukemia & lymphoma", "year": 2026, "volume": "67", "issue": "5", "pages_or_article_id": "997-1004", "doi": "10.1080/10428194.2026.2636979", "pmid": "41774434", "publication_date": "2026-03-03", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:20.480737+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41795103", "original_article_title": "Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.", "authors": ["Röth A", "Patriquin CJ", "Szer J", "Terriou L", "Patel AS", "Metzger J", "Gustovic P", "Nishimura JI", "Brodsky RA"], "authors_original": "Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, Gustovic P, Nishimura JI, Brodsky RA.", "first_author": "Röth A", "first_author_display": "Röth A, et al.", "citation": "Röth A, et al.. Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry. American journal of hematology. 2026;101(5):939-948. doi:10.1002/ajh.70268. PMID:41795103.", "journal": "American journal of hematology", "year": 2026, "volume": "101", "issue": "5", "pages_or_article_id": "939-948", "doi": "10.1002/ajh.70268", "pmid": "41795103", "publication_date": "2026-03-07", "publication_types": ["research-article", "Journal Article", "Observational Study"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:42.737055+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41809517", "original_article_title": "Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease.", "authors": ["Bienz M", "Oliver M", "Sperlich C", "Patriquin CJ"], "authors_original": "Bienz M, Oliver M, Sperlich C, Patriquin CJ.", "first_author": "Bienz M", "first_author_display": "Bienz M, et al.", "citation": "Bienz M, et al.. Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease. Journal of blood medicine. 2026;17:561117. doi:10.2147/jbm.s561117. PMID:41809517.", "journal": "Journal of blood medicine", "year": 2026, "volume": "17", "issue": null, "pages_or_article_id": "561117", "doi": "10.2147/jbm.s561117", "pmid": "41809517", "publication_date": "2026-03-03", "publication_types": ["article-commentary", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:39.694166+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41811525", "original_article_title": "Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment.", "authors": ["Zhou HY", "Deng Q", "Gao SQ", "Zhou JT", "Tian C", "Zhang CL"], "authors_original": "Zhou HY, Deng Q, Gao SQ, Zhou JT, Tian C, Zhang CL.", "first_author": "Zhou HY", "first_author_display": "Zhou HY, et al.", "citation": "Zhou HY, et al.. Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026;34(4):302. doi:10.1007/s00520-026-10549-6. PMID:41811525.", "journal": "Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer", "year": 2026, "volume": "34", "issue": "4", "pages_or_article_id": "302", "doi": "10.1007/s00520-026-10549-6", "pmid": "41811525", "publication_date": "2026-03-11", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:16.933101+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41867684", "original_article_title": "Evaluation of FGL1 as a hepatokine marker in iron deficiency.", "authors": ["Saboor M", "Abdul Rahim R", "Nabi Dad S", "Yusuf AM", "Nasser MM", "Mansoor HM", "Guella A", "Alkhayyal N"], "authors_original": "Saboor M, Abdul Rahim R, Nabi Dad S, Yusuf AM, Nasser MM, Mansoor HM, Guella A, Alkhayyal N.", "first_author": "Saboor M", "first_author_display": "Saboor M, et al.", "citation": "Saboor M, et al.. Evaluation of FGL1 as a hepatokine marker in iron deficiency. Frontiers in nutrition. 2026;13:1767385. doi:10.3389/fnut.2026.1767385. PMID:41867684.", "journal": "Frontiers in nutrition", "year": 2026, "volume": "13", "issue": null, "pages_or_article_id": "1767385", "doi": "10.3389/fnut.2026.1767385", "pmid": "41867684", "publication_date": "2026-03-06", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:13.610586+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41874671", "original_article_title": "Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy.", "authors": ["Yang F", "Liu R", "Fu Z", "Guo Y", "Ma L", "Cao M", "Deng B", "Wu H", "Chen C", "Ke X", "Hu K"], "authors_original": "Yang F, Liu R, Fu Z, Guo Y, Ma L, Cao M, Deng B, Wu H, Chen C, Ke X, Hu K.", "first_author": "Yang F", "first_author_display": "Yang F, et al.", "citation": "Yang F, et al.. Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy. Cancer immunology, immunotherapy : CII. 2026;75(4):120. doi:10.1007/s00262-026-04334-x. PMID:41874671.", "journal": "Cancer immunology, immunotherapy : CII", "year": 2026, "volume": "75", "issue": "4", "pages_or_article_id": "120", "doi": "10.1007/s00262-026-04334-x", "pmid": "41874671", "publication_date": "2026-03-24", "publication_types": ["Comparative Study", "research-article", "Journal Article", "Observational Study"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:40.045878+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41914434", "original_article_title": "Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.", "authors": ["Perrone S", "De Fazio L", "Monachetti S", "Molica M"], "authors_original": "Perrone S, De Fazio L, Monachetti S, Molica M.", "first_author": "Perrone S", "first_author_display": "Perrone S, et al.", "citation": "Perrone S, et al.. Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. Cancer. 2026;132(7):e70372. doi:10.1002/cncr.70372. PMID:41914434.", "journal": "Cancer", "year": 2026, "volume": "132", "issue": "7", "pages_or_article_id": "e70372", "doi": "10.1002/cncr.70372", "pmid": "41914434", "publication_date": "2026-04-01", "publication_types": ["Meta-Analysis", "research-article", "Systematic Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:33.346305+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41981151", "original_article_title": "A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.", "authors": ["Bewersdorf JP", "Mina A", "Stahl M", "Zeidan AM"], "authors_original": "Bewersdorf JP, Mina A, Stahl M, Zeidan AM.", "first_author": "Bewersdorf JP", "first_author_display": "Bewersdorf JP, et al.", "citation": "Bewersdorf JP, et al.. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. Nature reviews. Clinical oncology. 2026;23(7):481-500. doi:10.1038/s41571-026-01141-2. PMID:41981151.", "journal": "Nature reviews. Clinical oncology", "year": 2026, "volume": "23", "issue": "7", "pages_or_article_id": "481-500", "doi": "10.1038/s41571-026-01141-2", "pmid": "41981151", "publication_date": "2026-04-14", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:20.228197+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_41985134", "original_article_title": "Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk.", "authors": ["Skeith L", "Bates SM"], "authors_original": "Skeith L, Bates SM.", "first_author": "Skeith L", "first_author_display": "Skeith L, et al.", "citation": "Skeith L, et al.. Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk. The New England journal of medicine. 2026;394(15):1514-1528. doi:10.1056/nejmra2202438. PMID:41985134.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "15", "pages_or_article_id": "1514-1528", "doi": "10.1056/nejmra2202438", "pmid": "41985134", "publication_date": "2026-04-01", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:17.956244+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42037756", "original_article_title": "Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis.", "authors": ["Javaid H", "Qadri M", "Ali H", "Chilaka CF", "Syed W", "Habib E", "Zahin F", "Musani A", "Khan SA", "Rizwan D", "Saddique MN", "Hajj F"], "authors_original": "Javaid H, Qadri M, Ali H, Chilaka CF, Syed W, Habib E, Zahin F, Musani A, Khan SA, Rizwan D, Saddique MN, Hajj F.", "first_author": "Javaid H", "first_author_display": "Javaid H, et al.", "citation": "Javaid H, et al.. Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis. EJHaem. 2026;7:e70294. doi:10.1002/jha2.70294. PMID:42037756.", "journal": "EJHaem", "year": 2026, "volume": "7", "issue": null, "pages_or_article_id": "e70294", "doi": "10.1002/jha2.70294", "pmid": "42037756", "publication_date": "2026-04-24", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:28.259873+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42097206", "original_article_title": "A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation.", "authors": ["Bentolila G", "Desai N", "Holtan S", "Bonifazi F", "Broers AEC", "Mattsson J", "Rolon JM", "Schroeder T", "Kröger N", "Gagelmann N"], "authors_original": "Bentolila G, Desai N, Holtan S, Bonifazi F, Broers AEC, Mattsson J, Rolon JM, Schroeder T, Kröger N, Gagelmann N.", "first_author": "Bentolila G", "first_author_display": "Bentolila G, et al.", "citation": "Bentolila G, et al.. A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation. Transplantation and cellular therapy. 2026;32(8):1028.e1-1028.e13. doi:10.1016/j.jtct.2026.05.004. PMID:42097206.", "journal": "Transplantation and cellular therapy", "year": 2026, "volume": "32", "issue": "8", "pages_or_article_id": "1028.e1-1028.e13", "doi": "10.1016/j.jtct.2026.05.004", "pmid": "42097206", "publication_date": "2026-05-05", "publication_types": ["Systematic Review", "Network Meta-Analysis", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:20.413420+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42118692", "original_article_title": "How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.", "authors": ["Rejeski K", "Banerjee R", "Hill JA"], "authors_original": "Rejeski K, Banerjee R, Hill JA.", "first_author": "Rejeski K", "first_author_display": "Rejeski K, et al.", "citation": "Rejeski K, et al.. How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies. Blood. 2026;148(8):927-938. doi:10.1182/blood.2025032298. PMID:42118692.", "journal": "Blood", "year": 2026, "volume": "148", "issue": "8", "pages_or_article_id": "927-938", "doi": "10.1182/blood.2025032298", "pmid": "42118692", "publication_date": "2026-08-01", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:32.807548+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42170496", "original_article_title": "Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.", "authors": ["Davis M"], "authors_original": "Davis M.", "first_author": "Davis M", "first_author_display": "Davis M", "citation": "Davis M. Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma. Journal of the advanced practitioner in oncology. 2026:1-8. doi:10.6004/jadpro.2026.17.7.14. PMID:42170496.", "journal": "Journal of the advanced practitioner in oncology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": "1-8", "doi": "10.6004/jadpro.2026.17.7.14", "pmid": "42170496", "publication_date": "2026-05-06", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:45.868303+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42212933", "original_article_title": "Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.", "authors": ["Touzeau C", "Mina R", "Quach H", "Hungria V", "Bhutani D", "Chen W", "Kumar S", "Chaulagain C", "Dimopoulos MA", "Bahlis NJ", "Maral S", "van de Donk NWCJ", "Schmidt Filho J", "Saja K", "Teipel R", "Ando M", "Roeloffzen W", "Annibali O", "Augustson B", "Botta C", "Delforge M", "Bourgeois E", "Buda G", "Hus M", "Perrot A", "Preis M", "Beksac M", "Pour L", "Farmer S", "Nunes M", "Oriol A", "Melchardt T", "Hu Y", "Flogegård M", "Wang D", "Pei L", "Wroblewski S", "Ariës IM", "Quijano Cardé NA", "Perova T", "de Jager T", "Yeh TM", "Vanquickelberghe V", "Shah P", "Chastain K", "Kobos R", "Carson R", "Landgren O", "MajesTEC-9 Trial Investigators"], "authors_original": "Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegård M, Wang D, Pei L, Wroblewski S, Ariës IM, Quijano Cardé NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O, MajesTEC-9 Trial Investigators.", "first_author": "Touzeau C", "first_author_display": "Touzeau C, et al.", "citation": "Touzeau C, et al.. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine. 2026;395(5):440-453. doi:10.1056/nejmoa2603870. PMID:42212933.", "journal": "The New England journal of medicine", "year": 2026, "volume": "395", "issue": "5", "pages_or_article_id": "440-453", "doi": "10.1056/nejmoa2603870", "pmid": "42212933", "publication_date": "2026-05-29", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:18.482544+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42235013", "original_article_title": "All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.", "authors": ["Roboz GJ", "Zeidan AM", "Mannis GN", "Montesinos P", "Arnan M", "Savona MR", "Odenike O", "McCloskey JK", "Amin HV", "Fathi AT", "Bernal Del Castillo T", "Rodríguez-Macías G", "Liesveld JL", "Im AP", "Cerny J", "Gentile TC", "Oganesian A", "Chan D", "Wan Y", "Dijkstra M", "Keer HN", "Griffiths EA", "DiNardo CD"], "authors_original": "Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal Del Castillo T, Rodríguez-Macías G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD.", "first_author": "Roboz GJ", "first_author_display": "Roboz GJ, et al.", "citation": "Roboz GJ, et al.. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. The New England journal of medicine. 2026;394(21):2107-2116. doi:10.1056/nejmoa2510223. PMID:42235013.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "21", "pages_or_article_id": "2107-2116", "doi": "10.1056/nejmoa2510223", "pmid": "42235013", "publication_date": "2026-06-01", "publication_types": ["Clinical Trial, Phase II", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:09.493048+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42255947", "original_article_title": "Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.", "authors": ["Kulasekararaj A", "de Fontbrune FS", "Gaya A", "Weitz I", "Kuter DJ", "Patel BJ", "Araten DJ", "Singh A", "Jang JH", "Kelly RJ", "Di Bona E", "Loschi M", "Pullarkat V", "Schubert J", "Notaro R", "Yenerel MN", "Beckman J", "Blin N", "Murakhovskaya I", "Panse J", "Roman E", "Röth A", "Schrezenmeier H", "Tantravahi S", "de Latour RP", "Mahajan N", "Monaco L", "Ding T", "Lawniczek T", "Ferber P", "Dahlke M", "Risitano AM"], "authors_original": "Kulasekararaj A, de Fontbrune FS, Gaya A, Weitz I, Kuter DJ, Patel BJ, Araten DJ, Singh A, Jang JH, Kelly RJ, Di Bona E, Loschi M, Pullarkat V, Schubert J, Notaro R, Yenerel MN, Beckman J, Blin N, Murakhovskaya I, Panse J, Roman E, Röth A, Schrezenmeier H, Tantravahi S, de Latour RP, Mahajan N, Monaco L, Ding T, Lawniczek T, Ferber P, Dahlke M, Risitano AM.", "first_author": "Kulasekararaj A", "first_author_display": "Kulasekararaj A, et al.", "citation": "Kulasekararaj A, et al.. Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy. HemaSphere. 2026;10(6):e70384. doi:10.1002/hem3.70384. PMID:42255947.", "journal": "HemaSphere", "year": 2026, "volume": "10", "issue": "6", "pages_or_article_id": "e70384", "doi": "10.1002/hem3.70384", "pmid": "42255947", "publication_date": "2026-05-29", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.771455+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42267805", "original_article_title": "Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery.", "authors": ["Houston BL", "McIsaac DI", "Breau RH", "Kanji S", "Greenstreet P", "Andrews M", "Avramescu S", "Bagry HS", "Balshaw R", "Daya J", "Duncan K", "Harle CC", "Jacobsohn E", "Kerelska T", "Pitz M", "Komenda P", "McIsaac S", "Ramsay T", "Saha T", "Tinmouth A", "Recio A", "Szoke D", "Tenenbein M", "Slagerman S", "Solvason D", "Talarico R", "Fergusson DA", "Zarychanski R"], "authors_original": "Houston BL, McIsaac DI, Breau RH, Kanji S, Greenstreet P, Andrews M, Avramescu S, Bagry HS, Balshaw R, Daya J, Duncan K, Harle CC, Jacobsohn E, Kerelska T, Pitz M, Komenda P, McIsaac S, Ramsay T, Saha T, Tinmouth A, Recio A, Szoke D, Tenenbein M, Slagerman S, Solvason D, Talarico R, Fergusson DA, Zarychanski R.", "first_author": "Houston BL", "first_author_display": "Houston BL, et al.", "citation": "Houston BL, et al.. Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery. The New England journal of medicine. 2026;394(24):2419-2428. doi:10.1056/nejmoa2515820. PMID:42267805.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "24", "pages_or_article_id": "2419-2428", "doi": "10.1056/nejmoa2515820", "pmid": "42267805", "publication_date": "2026-06-10", "publication_types": ["Equivalence Trial", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Clinical Trial, Phase IV"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:32.766868+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42274647", "original_article_title": "High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.", "authors": ["Wilson MR", "Lewis KL", "Kirkwood AA", "Cwynarski K", "Cheah CY", "El-Galaly TC", "Villa D", "Savage KJ", "Ghione P", "Bobillo S", "Smedby KE", "Harrysson S", "Trneny M", "Klanova M", "Puckrin R", "Fox CP", "Bishton M", "Thanarajasingam G", "Wong Doo N", "Hapgood G", "Soussain C", "Choquet S", "Dickinson M", "Talaulikar D", "de Mel S", "Preston G", "Ahearne M", "Hawkes EA", "Schorb E", "Clavert A", "Ku M", "Guidetti A", "Narkhede M", "Calimeri T", "Durot E", "Smith J", "Renaud L", "McKay P", "Eyre TA"], "authors_original": "Wilson MR, Lewis KL, Kirkwood AA, Cwynarski K, Cheah CY, El-Galaly TC, Villa D, Savage KJ, Ghione P, Bobillo S, Smedby KE, Harrysson S, Trneny M, Klanova M, Puckrin R, Fox CP, Bishton M, Thanarajasingam G, Wong Doo N, Hapgood G, Soussain C, Choquet S, Dickinson M, Talaulikar D, de Mel S, Preston G, Ahearne M, Hawkes EA, Schorb E, Clavert A, Ku M, Guidetti A, Narkhede M, Calimeri T, Durot E, Smith J, Renaud L, McKay P, Eyre TA.", "first_author": "Wilson MR", "first_author_display": "Wilson MR, et al.", "citation": "Wilson MR, et al.. High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(24):2290-2302. doi:10.1200/jco-26-00947. PMID:42274647.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2026, "volume": "44", "issue": "24", "pages_or_article_id": "2290-2302", "doi": "10.1200/jco-26-00947", "pmid": "42274647", "publication_date": "2026-06-11", "publication_types": ["research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:31.959309+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42274870", "original_article_title": "Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.", "authors": ["Lee E", "Lee JH", "Kim HR", "Huh SJ", "Lee S", "Oh SY", "Kim SH", "Lee H"], "authors_original": "Lee E, Lee JH, Kim HR, Huh SJ, Lee S, Oh SY, Kim SH, Lee H.", "first_author": "Lee E", "first_author_display": "Lee E, et al.", "citation": "Lee E, et al.. Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention. Blood research. 2026;61(1):30. doi:10.1007/s44313-026-00145-2. PMID:42274870.", "journal": "Blood research", "year": 2026, "volume": "61", "issue": "1", "pages_or_article_id": "30", "doi": "10.1007/s44313-026-00145-2", "pmid": "42274870", "publication_date": "2026-06-11", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.142447+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42275618", "original_article_title": "Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.", "authors": ["Biltibo E", "Chakraborty R", "Bishop MR"], "authors_original": "Biltibo E, Chakraborty R, Bishop MR.", "first_author": "Biltibo E", "first_author_display": "Biltibo E, et al.", "citation": "Biltibo E, et al.. Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2026;46(3):e517460. doi:10.1200/edbk-26-517460. PMID:42275618.", "journal": "American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting", "year": 2026, "volume": "46", "issue": "3", "pages_or_article_id": "e517460", "doi": "10.1200/edbk-26-517460", "pmid": "42275618", "publication_date": "2026-06-11", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:16.328022+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42284699", "original_article_title": "High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.", "authors": ["Kauer J", "Krämer I", "Derigs P", "Blank MF", "Dietrich S", "Meissner J", "Kehl N", "Friedrich MJ", "Schubert ML", "Ho AD", "Schmitt A", "Kobbe G", "Müller-Tidow C", "Schmitt M", "Dreger P"], "authors_original": "Kauer J, Krämer I, Derigs P, Blank MF, Dietrich S, Meissner J, Kehl N, Friedrich MJ, Schubert ML, Ho AD, Schmitt A, Kobbe G, Müller-Tidow C, Schmitt M, Dreger P.", "first_author": "Kauer J", "first_author_display": "Kauer J, et al.", "citation": "Kauer J, et al.. High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT. Blood advances. 2026;10(16):5698-5705. doi:10.1182/bloodadvances.2026020219. PMID:42284699.", "journal": "Blood advances", "year": 2026, "volume": "10", "issue": "16", "pages_or_article_id": "5698-5705", "doi": "10.1182/bloodadvances.2026020219", "pmid": "42284699", "publication_date": "2026-08-01", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:32.223484+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42286378", "original_article_title": "Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.", "authors": ["Miyazaki K"], "authors_original": "Miyazaki K.", "first_author": "Miyazaki K", "first_author_display": "Miyazaki K", "citation": "Miyazaki K. Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma. International journal of clinical oncology. 2026;31(7):1137-1150. doi:10.1007/s10147-026-03062-7. PMID:42286378.", "journal": "International journal of clinical oncology", "year": 2026, "volume": "31", "issue": "7", "pages_or_article_id": "1137-1150", "doi": "10.1007/s10147-026-03062-7", "pmid": "42286378", "publication_date": "2026-06-12", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:13.377422+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42293463", "original_article_title": "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.", "authors": ["Eichhorst B", "Ghia P", "Bosch F", "Clifford R", "Gregor M", "Guieze R", "Kater AP", "Niemann CU", "Pospisilova S", "Robak T", "Schuh A", "Stamatopoulos K", "Tadmor T", "York N"], "authors_original": "Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.", "first_author": "Eichhorst B", "first_author_display": "Eichhorst B, et al.", "citation": "Eichhorst B, et al.. EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. HemaSphere. 2026;10(6):e70403. doi:10.1002/hem3.70403. PMID:42293463.", "journal": "HemaSphere", "year": 2026, "volume": "10", "issue": "6", "pages_or_article_id": "e70403", "doi": "10.1002/hem3.70403", "pmid": "42293463", "publication_date": "2026-06-10", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:12.922527+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42294841", "original_article_title": "Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.", "authors": ["Mina R", "Beksac M", "Rodríguez-Otero P", "Chen W", "Mateos MV", "Li J", "Moreau P", "Cohen YC", "Min CK", "Jelinek T", "Ye JC", "Magen H", "Rubinstein SM", "Fu W", "Hungria V", "Cengiz Seval G", "Farias JS", "Radocha J", "Maral S", "Turgut M", "Koh Y", "O'Leary D", "Schmidt Filho J", "Thertulien R", "An G", "Huang SY", "Grosicki S", "Tyczyńska A", "Banerjee R", "Pianko MJ", "Martínez-López J", "Steckiewicz P", "Maruyama D", "Fukushima K", "Oriol A", "Lopez Pardo J", "Goldschmidt H", "Pawlyn C", "Perrot A", "Zamagni E", "Dimopoulos MA", "Rasche L", "Tolbert J", "Terry W", "Courtoux C", "Liu X", "Vasey SY", "Connors K", "Festa M", "Heuck C", "Langlois A", "O'Rourke L", "Zhou J", "Qin X", "Lu J", "Gong J", "Vieyra D", "Voorhees PM", "MonumenTAL-3 Investigators"], "authors_original": "Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczyńska A, Banerjee R, Pianko MJ, Martínez-López J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM, MonumenTAL-3 Investigators.", "first_author": "Mina R", "first_author_display": "Mina R, et al.", "citation": "Mina R, et al.. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine. 2026;395(7):671-683. doi:10.1056/nejmoa2604657. PMID:42294841.", "journal": "The New England journal of medicine", "year": 2026, "volume": "395", "issue": "7", "pages_or_article_id": "671-683", "doi": "10.1056/nejmoa2604657", "pmid": "42294841", "publication_date": "2026-06-13", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:18.316865+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42341302", "original_article_title": "Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.", "authors": ["Ruella M", "Paruzzo L", "Chong ER", "Chong EA", "Landsburg DJ", "Nasta SD", "Devi P", "Michener P", "Stella F", "Carturan A", "Napier EB", "Van Deerlin VM", "Porazzi P", "Levine BL", "Frey N", "Porter DL", "Fraietta JA", "Svoboda J", "June CH", "Schuster SJ"], "authors_original": "Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ.", "first_author": "Ruella M", "first_author_display": "Ruella M, et al.", "citation": "Ruella M, et al.. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. The New England journal of medicine. 2026;394(24):2440-2448. doi:10.1056/nejmoa2518035. PMID:42341302.", "journal": "The New England journal of medicine", "year": 2026, "volume": "394", "issue": "24", "pages_or_article_id": "2440-2448", "doi": "10.1056/nejmoa2518035", "pmid": "42341302", "publication_date": "2026-06-01", "publication_types": ["Clinical Trial, Phase II", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:18.731298+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42345030", "original_article_title": "Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.", "authors": ["Eichenauer DA", "André M", "Borchmann P", "Collins GP", "Doherty I", "Eich HT", "Federico M", "Fossa A", "Hartmann S", "Hutchings M", "Illidge T", "Kobe C", "Plattel WJ", "Specht L", "Sureda A", "Zaucha JM", "Zijlstra JM", "Aurer I"], "authors_original": "Eichenauer DA, André M, Borchmann P, Collins GP, Doherty I, Eich HT, Federico M, Fossa A, Hartmann S, Hutchings M, Illidge T, Kobe C, Plattel WJ, Specht L, Sureda A, Zaucha JM, Zijlstra JM, Aurer I.", "first_author": "Eichenauer DA", "first_author_display": "Eichenauer DA, et al.", "citation": "Eichenauer DA, et al.. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2026;10(6):e70422. doi:10.1002/hem3.70422. PMID:42345030.", "journal": "HemaSphere", "year": 2026, "volume": "10", "issue": "6", "pages_or_article_id": "e70422", "doi": "10.1002/hem3.70422", "pmid": "42345030", "publication_date": "2026-06-23", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:14.625801+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42391582", "original_article_title": "Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.", "authors": ["Lachowiez CA", "Zeidner JF", "Othman J", "Kaempf A", "Yun S", "Heiblig M", "Heuser M", "Shahswar R", "Madero Marroquin R", "Cannova JM", "Žučenka A", "Marvin-Peek J", "Senapati J", "Abaza Y", "Swaroop A", "Zacheo I", "Monaco F", "Belhabri A", "Tauveron-Jalenques U", "Tavernier E", "Carré M", "Aspas Requena G", "Cook RJ", "Traer E", "Saultz JN", "O'Nions J", "Basheer F", "Laurie J", "Handa S", "Stein EM", "Baer MR", "Olin R", "Blum W", "Schiller G", "Lin T", "Curran E", "Yocum A", "Madarang E", "Daver N", "Kadia TM", "Marconi G", "Madanat Y", "Dillon R", "DiNardo CD", "Swords R", "Arango Ossa JE", "Watts J", "Loghavi S", "Pollyea DA", "Bernard E", "PRISM-AML Investigators"], "authors_original": "Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E, PRISM-AML Investigators.", "first_author": "Lachowiez CA", "first_author_display": "Lachowiez CA, et al.", "citation": "Lachowiez CA, et al.. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(25):2422-2434. doi:10.1200/jco-26-00347. PMID:42391582.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2026, "volume": "44", "issue": "25", "pages_or_article_id": "2422-2434", "doi": "10.1200/jco-26-00347", "pmid": "42391582", "publication_date": "2026-07-02", "publication_types": ["research-article", "Multicenter Study", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:43.001935+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42401567", "original_article_title": "Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.", "authors": ["Jabbour E", "Kantarjian H"], "authors_original": "Jabbour E, Kantarjian H.", "first_author": "Jabbour E", "first_author_display": "Jabbour E, et al.", "citation": "Jabbour E, et al.. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. Blood cancer journal. 2026;16(1):162. doi:10.1038/s41408-026-01566-z. PMID:42401567.", "journal": "Blood cancer journal", "year": 2026, "volume": "16", "issue": "1", "pages_or_article_id": "162", "doi": "10.1038/s41408-026-01566-z", "pmid": "42401567", "publication_date": "2026-07-04", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:09.491819+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42441431", "original_article_title": "Platelet-Activating Anti-Platelet Factor 4 Disorders.", "authors": ["Warkentin TE", "Greinacher A"], "authors_original": "Warkentin TE, Greinacher A.", "first_author": "Warkentin TE", "first_author_display": "Warkentin TE, et al.", "citation": "Warkentin TE, et al.. Platelet-Activating Anti-Platelet Factor 4 Disorders. The New England journal of medicine. 2026;395(5):478-491. doi:10.1056/nejmra2502459. PMID:42441431.", "journal": "The New England journal of medicine", "year": 2026, "volume": "395", "issue": "5", "pages_or_article_id": "478-491", "doi": "10.1056/nejmra2502459", "pmid": "42441431", "publication_date": "2026-07-13", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:41.266925+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42442416", "original_article_title": "Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.", "authors": ["Wang Y", "Xiao R", "Huang X", "Xiao Y"], "authors_original": "Wang Y, Xiao R, Huang X, Xiao Y.", "first_author": "Wang Y", "first_author_display": "Wang Y, et al.", "citation": "Wang Y, et al.. Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. European journal of haematology. 2026. doi:10.1111/ejh.70264. PMID:42442416.", "journal": "European journal of haematology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1111/ejh.70264", "pmid": "42442416", "publication_date": "2026-07-13", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:29.870089+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42447409", "original_article_title": "Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.", "authors": ["Ladetto M", "Gutmair K", "Tavarozzi R", "Pawlikowski A", "Schomaker M", "Doorduijn J", "Giné E", "Jerkeman M", "Walewski J", "Hutchings M", "Mey U", "Riise J", "Trneny M", "Vergote VKJ", "Horowitz NA", "Gomes da Silva M", "Leppä S", "Jiang L", "Stilgenbauer S", "Kerkhoff A", "Jachimowicz RD", "Heß G", "van Meerten T", "Wirths S", "Herhaus P", "Novak U", "Dierlamm J", "Hänel M", "Hanoun C", "Sonnevi K", "Visco C", "Castellino C", "Lemoli RM", "Zilioli VR", "Boccomini C", "Pott C", "Klapper W", "Schmidt C", "Dreyling M", "Hoster E", "European MCL Network"], "authors_original": "Ladetto M, Gutmair K, Tavarozzi R, Pawlikowski A, Schomaker M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Horowitz NA, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Heß G, van Meerten T, Wirths S, Herhaus P, Novak U, Dierlamm J, Hänel M, Hanoun C, Sonnevi K, Visco C, Castellino C, Lemoli RM, Zilioli VR, Boccomini C, Pott C, Klapper W, Schmidt C, Dreyling M, Hoster E, European MCL Network.", "first_author": "Ladetto M", "first_author_display": "Ladetto M, et al.", "citation": "Ladetto M, et al.. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(27):2582-2589. doi:10.1200/jco-26-00705. PMID:42447409.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2026, "volume": "44", "issue": "27", "pages_or_article_id": "2582-2589", "doi": "10.1200/jco-26-00705", "pmid": "42447409", "publication_date": "2026-07-14", "publication_types": ["research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:43.107667+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42453533", "original_article_title": "Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.", "authors": ["Griffin M", "Fattizzo B", "Lee JW", "Kelly RJ", "Trikha R", "Ueda Y", "Nishimura JI", "Patriquin CJ", "Röth A", "Muus P", "Panse J", "Álvarez MG", "Pike A", "Munir T", "Gandhi S", "Kulasekararaj A"], "authors_original": "Griffin M, Fattizzo B, Lee JW, Kelly RJ, Trikha R, Ueda Y, Nishimura JI, Patriquin CJ, Röth A, Muus P, Panse J, Álvarez MG, Pike A, Munir T, Gandhi S, Kulasekararaj A.", "first_author": "Griffin M", "first_author_display": "Griffin M, et al.", "citation": "Griffin M, et al.. Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety. HemaSphere. 2026;10(7):e70427. doi:10.1002/hem3.70427. PMID:42453533.", "journal": "HemaSphere", "year": 2026, "volume": "10", "issue": "7", "pages_or_article_id": "e70427", "doi": "10.1002/hem3.70427", "pmid": "42453533", "publication_date": "2026-07-14", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:44.246251+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42485589", "original_article_title": "International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.", "authors": ["Kastritis E", "Kumar SK", "Rajkumar VS", "Chng WJ", "Costa L", "Engelhardt M", "Gonsalves W", "Hungria V", "Hillengass J", "Jevremovic D", "Katodritou E", "Kristinsson SY", "Lonial S", "Ludwig H", "McCarthy P", "Mai E", "Manier S", "Martin T", "Mateos MV", "Mian H", "Mikhael J", "Moreau P", "Munshi NC", "Paiva B", "Pawlyn C", "Rasche L", "Richter J", "San Miguel J", "Sborov DW", "Usmani SZ", "Dimopoulos MA", "Zamagni E"], "authors_original": "Kastritis E, Kumar SK, Rajkumar VS, Chng WJ, Costa L, Engelhardt M, Gonsalves W, Hungria V, Hillengass J, Jevremovic D, Katodritou E, Kristinsson SY, Lonial S, Ludwig H, McCarthy P, Mai E, Manier S, Martin T, Mateos MV, Mian H, Mikhael J, Moreau P, Munshi NC, Paiva B, Pawlyn C, Rasche L, Richter J, San Miguel J, Sborov DW, Usmani SZ, Dimopoulos MA, Zamagni E.", "first_author": "Kastritis E", "first_author_display": "Kastritis E, et al.", "citation": "Kastritis E, et al.. International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(25):2447-2459. doi:10.1200/jco-26-00410. PMID:42485589.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "year": 2026, "volume": "44", "issue": "25", "pages_or_article_id": "2447-2459", "doi": "10.1200/jco-26-00410", "pmid": "42485589", "publication_date": "2026-07-22", "publication_types": ["research-article", "Practice Guideline", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:34.733294+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42489071", "original_article_title": "Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma.", "authors": ["Wang W", "Liu D", "Wei H", "Wang H", "Li P", "Ma J", "He Q", "Xie L", "Lu K", "Zhang W", "Xing L", "Li Z"], "authors_original": "Wang W, Liu D, Wei H, Wang H, Li P, Ma J, He Q, Xie L, Lu K, Zhang W, Xing L, Li Z.", "first_author": "Wang W", "first_author_display": "Wang W, et al.", "citation": "Wang W, et al.. Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma. Haematologica. 2026. doi:10.3324/haematol.2026.301018. PMID:42489071.", "journal": "Haematologica", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.3324/haematol.2026.301018", "pmid": "42489071", "publication_date": "2026-07-23", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:25.761735+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42520193", "original_article_title": "OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.", "authors": ["Borate UM", "Huang Y", "Lin TL", "Handa S", "Swords R", "Lachowiez CA", "Traer E", "Stock W", "Odenike O", "Patel AA", "Baer MR", "Duong VH", "Stein EM", "Blum W", "Vale CA", "Curran E", "Madanat YF", "Olin RL", "Schiller GJ", "Nichols AD", "Williams L", "Heerema NA", "Johnson MF", "Chen TL", "Marcus S", "Martycz M", "Stefanos M", "Rosenberg L", "DeGennaro LJ", "Gruenbaum L", "Burd A", "Byrd JC", "Druker BJ", "Levine RL", "Yocum AO", "Mims AS", "Zeidner JF"], "authors_original": "Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF.", "first_author": "Borate UM", "first_author_display": "Borate UM, et al.", "citation": "Borate UM, et al.. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026:blood.2026034611. doi:10.1182/blood.2026034611. PMID:42520193.", "journal": "Blood", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": "blood.2026034611", "doi": "10.1182/blood.2026034611", "pmid": "42520193", "publication_date": "2026-07-28", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:38.906523+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42540434", "original_article_title": "Risks of anticoagulation discontinuation after first venous thromboembolism in inherited thrombophilia: a long-term cohort study.", "authors": ["Kim SA", "Park SY", "Lee JY", "Hong J", "Na SH", "Lee JO", "Bang SM"], "authors_original": "Kim SA, Park SY, Lee JY, Hong J, Na SH, Lee JO, Bang SM.", "first_author": "Kim SA", "first_author_display": "Kim SA, et al.", "citation": "Kim SA, et al.. Risks of anticoagulation discontinuation after first venous thromboembolism in inherited thrombophilia: a long-term cohort study. Research and practice in thrombosis and haemostasis. 2026;10(5):106788. doi:10.1016/j.rpth.2026.106788. PMID:42540434.", "journal": "Research and practice in thrombosis and haemostasis", "year": 2026, "volume": "10", "issue": "5", "pages_or_article_id": "106788", "doi": "10.1016/j.rpth.2026.106788", "pmid": "42540434", "publication_date": "2026-06-12", "publication_types": ["research-article", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:43.011890+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42568509", "original_article_title": "CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.", "authors": ["Wang C", "Zhu J", "Qiao J", "Wang H", "Liang X"], "authors_original": "Wang C, Zhu J, Qiao J, Wang H, Liang X.", "first_author": "Wang C", "first_author_display": "Wang C, et al.", "citation": "Wang C, et al.. CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies. Frontiers in immunology. 2026;17:1903457. doi:10.3389/fimmu.2026.1903457. PMID:42568509.", "journal": "Frontiers in immunology", "year": 2026, "volume": "17", "issue": null, "pages_or_article_id": "1903457", "doi": "10.3389/fimmu.2026.1903457", "pmid": "42568509", "publication_date": "2026-07-24", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:23.854954+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42581608", "original_article_title": "Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.", "authors": ["Gundesen MT", "Vangsted AJ", "Helleberg C", "Haukås E", "Silkjær T", "Madsen JS", "Asmussen JT", "Teodorescu EM", "Jensen BA", "Slørdahl TS", "Nielsen AA", "Olsen DA", "Søe K", "Nahi H", "Waage A", "Abildgaard N", "Schjesvold F", "Lund T"], "authors_original": "Gundesen MT, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Madsen JS, Asmussen JT, Teodorescu EM, Jensen BA, Slørdahl TS, Nielsen AA, Olsen DA, Søe K, Nahi H, Waage A, Abildgaard N, Schjesvold F, Lund T.", "first_author": "Gundesen MT", "first_author_display": "Gundesen MT, et al.", "citation": "Gundesen MT, et al.. Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers. British journal of haematology. 2026;209(3):1076-1084. doi:10.1111/bjh.70612. PMID:42581608.", "journal": "British journal of haematology", "year": 2026, "volume": "209", "issue": "3", "pages_or_article_id": "1076-1084", "doi": "10.1111/bjh.70612", "pmid": "42581608", "publication_date": "2026-08-11", "publication_types": ["research-article", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:23.225246+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42587741", "original_article_title": "Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling.", "authors": ["Kikuchi J", "Yasui H"], "authors_original": "Kikuchi J, Yasui H.", "first_author": "Kikuchi J", "first_author_display": "Kikuchi J, et al.", "citation": "Kikuchi J, et al.. Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling. Cells. 2026;15(15):1331. doi:10.3390/cells15151331. PMID:42587741.", "journal": "Cells", "year": 2026, "volume": "15", "issue": "15", "pages_or_article_id": "1331", "doi": "10.3390/cells15151331", "pmid": "42587741", "publication_date": "2026-07-24", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:38.008485+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42588728", "original_article_title": "The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.", "authors": ["Martino M", "Marafioti V", "Pitea M", "Porto G", "Policastro G", "Canale FA", "Naso V", "Alati C"], "authors_original": "Martino M, Marafioti V, Pitea M, Porto G, Policastro G, Canale FA, Naso V, Alati C.", "first_author": "Martino M", "first_author_display": "Martino M, et al.", "citation": "Martino M, et al.. The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. Cancers. 2026;18(15):2513. doi:10.3390/cancers18152513. PMID:42588728.", "journal": "Cancers", "year": 2026, "volume": "18", "issue": "15", "pages_or_article_id": "2513", "doi": "10.3390/cancers18152513", "pmid": "42588728", "publication_date": "2026-08-05", "publication_types": ["review-article", "Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:45.363134+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42617115", "original_article_title": "Myeloproliferative Neoplasms.", "authors": ["Plo I", "Vainchenker W"], "authors_original": "Plo I, Vainchenker W.", "first_author": "Plo I", "first_author_display": "Plo I, et al.", "citation": "Plo I, et al.. Myeloproliferative Neoplasms. The New England journal of medicine. 2026;395(8):788-802. doi:10.1056/nejmra2507867. PMID:42617115.", "journal": "The New England journal of medicine", "year": 2026, "volume": "395", "issue": "8", "pages_or_article_id": "788-802", "doi": "10.1056/nejmra2507867", "pmid": "42617115", "publication_date": "2026-08-01", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED)", "retrieved_at": null, "provenance": "preserved approved migration manifest; verified bibliography and documentary association; not automatic clinical placement approval"}, {"reference_id": "PMID_42637879", "original_article_title": "Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.", "authors": ["Facon T", "Kumar SK", "Orlowski RZ", "Bahlis N", "Moreau P", "Goldschmidt H", "Basu S", "Hulin C", "Zweegman S", "Weisel K", "Perrot A", "Jacquet C", "Raje N", "Manier S", "Chari A", "Hansson M", "Mohty M", "Delforge M", "Plesner T", "Cook G", "Leleu X", "Quach H", "Venner CP", "Tiab M", "Macro M", "Frenzel L", "Wang G", "Pei H", "Bolyard K", "Carson R", "Borgsten F", "Usmani SZ"], "authors_original": "Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ.", "first_author": "Facon T", "first_author_display": "Facon T, et al.", "citation": "Facon T, et al.. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026. doi:10.1038/s41375-026-03097-9. PMID:42637879.", "journal": "Leukemia", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1038/s41375-026-03097-9", "pmid": "42637879", "publication_date": "2026-08-24", "publication_types": ["Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:26.708627+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42639825", "original_article_title": "Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.", "authors": ["Bhatt M", "Rajkumar SV", "Kumar S"], "authors_original": "Bhatt M, Rajkumar SV, Kumar S.", "first_author": "Bhatt M", "first_author_display": "Bhatt M, et al.", "citation": "Bhatt M, et al.. Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma. European journal of haematology. 2026. doi:10.1111/ejh.70301. PMID:42639825.", "journal": "European journal of haematology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1111/ejh.70301", "pmid": "42639825", "publication_date": "2026-08-25", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:15:10.797362+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42698151", "original_article_title": "Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.", "authors": ["Vachhani P", "Repp J", "Hamer-Maansson JE", "Braunstein E", "Bhatt V", "Al-Ali HK"], "authors_original": "Vachhani P, Repp J, Hamer-Maansson JE, Braunstein E, Bhatt V, Al-Ali HK.", "first_author": "Vachhani P", "first_author_display": "Vachhani P, et al.", "citation": "Vachhani P, et al.. Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. Hematology (Amsterdam, Netherlands). 2026;31(1):2725339. doi:10.1080/16078454.2026.2725339. PMID:42698151.", "journal": "Hematology (Amsterdam, Netherlands)", "year": 2026, "volume": "31", "issue": "1", "pages_or_article_id": "2725339", "doi": "10.1080/16078454.2026.2725339", "pmid": "42698151", "publication_date": "2026-09-04", "publication_types": ["Clinical Trial, Phase III", "Randomized Controlled Trial", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:40.333638+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_42715563", "original_article_title": "Treatment Decisions in Multiple Myeloma.", "authors": ["Mouhieddine TH", "Anderson KC"], "authors_original": "Mouhieddine TH, Anderson KC.", "first_author": "Mouhieddine TH", "first_author_display": "Mouhieddine TH, et al.", "citation": "Mouhieddine TH, et al.. Treatment Decisions in Multiple Myeloma. The New England journal of medicine. 2026;395(10):992-1008. doi:10.1056/nejmra2605253. PMID:42715563.", "journal": "The New England journal of medicine", "year": 2026, "volume": "395", "issue": "10", "pages_or_article_id": "992-1008", "doi": "10.1056/nejmra2605253", "pmid": "42715563", "publication_date": "2026-09-01", "publication_types": ["Review", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED)", "retrieved_at": null, "provenance": "preserved approved migration manifest; verified bibliography and documentary association; not automatic clinical placement approval"}, {"reference_id": "PMID_791473", "original_article_title": "Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.", "authors": ["McKelvey EM", "Gottlieb JA", "Wilson HE", "Haut A", "Talley RW", "Stephens R", "Lane M", "Gamble JF", "Jones SE", "Grozea PN", "Gutterman J", "Coltman C", "Moon TE"], "authors_original": "McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE.", "first_author": "McKelvey EM", "first_author_display": "McKelvey EM, et al.", "citation": "McKelvey EM, et al.. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484-1493. doi:10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i. PMID:791473.", "journal": "Cancer", "year": 1976, "volume": "38", "issue": "4", "pages_or_article_id": "1484-1493", "doi": "10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i", "pmid": "791473", "publication_date": "1976-10-01", "publication_types": ["Research Support, U.S. Gov't, P.H.S.", "Journal Article"], "metadata_status": "verified_bibliographic_record", "provider": "Europe PMC (MED records from PubMed)", "retrieved_at": "2026-10-13T02:12:33.158460+00:00", "provenance": "preserved PR337 references.csv; verified bibliographic identity, not automatic clinical approval"}, {"reference_id": "PMID_40044960", "original_article_title": "Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations", "authors": [], "authors_original": "Millot F et al.", "first_author": null, "first_author_display": null, "citation": "Millot F et al. Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations Leukemia 2025", "journal": "Leukemia", "year": 2025, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1038/s41375-025-02543-4", "pmid": "40044960", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_42634099", "original_article_title": "The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline", "authors": [], "authors_original": "Osborne W et al.", "first_author": null, "first_author_display": null, "citation": "Osborne W et al. The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline British Journal of Haematology 2026", "journal": "British Journal of Haematology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1111/bjh.70768", "pmid": "42634099", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_31489694", "original_article_title": "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", "authors": [], "authors_original": "Deshayes S et al.", "first_author": null, "first_author_display": null, "citation": "Deshayes S et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia American Journal of Hematology 2019", "journal": "American Journal of Hematology", "year": 2019, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1002/ajh.25632", "pmid": "31489694", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_41494138", "original_article_title": "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline", "authors": [], "authors_original": "Hicks LK et al.", "first_author": null, "first_author_display": null, "citation": "Hicks LK et al. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2026", "journal": "Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1200/JCO-25-02587", "pmid": "41494138", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_39871707", "original_article_title": "A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1", "authors": [], "authors_original": "Hallek M et al.", "first_author": null, "first_author_display": null, "citation": "Hallek M et al. A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus Tracking no: BGH-2026-000448R1 American Journal of Hematology 2025", "journal": "American Journal of Hematology", "year": 2025, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1002/AJH.27546", "pmid": "39871707", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_42613778", "original_article_title": "Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management", "authors": [], "authors_original": "Rajkumar SV et al.", "first_author": null, "first_author_display": null, "citation": "Rajkumar SV et al. Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management American Journal of Hematology 2026", "journal": "American Journal of Hematology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1002/ajh.70475", "pmid": "42613778", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_42545803", "original_article_title": "Classic Hodgkin Lymphoma A Review", "authors": [], "authors_original": "Patel KK et al.", "first_author": null, "first_author_display": null, "citation": "Patel KK et al. Classic Hodgkin Lymphoma A Review Jama 2026", "journal": "Jama", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1001/jama.2026.13402", "pmid": "42545803", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_42566728", "original_article_title": "Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia", "authors": [], "authors_original": "Castonguay M et al.", "first_author": null, "first_author_display": null, "citation": "Castonguay M et al. Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2026", "journal": "Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1200/JCO-26-00428", "pmid": "42566728", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "W2_SOURCE_009", "original_article_title": "Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2", "authors": [], "authors_original": "Zent C. et al.", "first_author": null, "first_author_display": null, "citation": "Zent C. et al. Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant Tracking no: BLD-2025-032757R2 Journal (via DOI) 2026", "journal": "Journal (via DOI)", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1182/blood.2025032757/2514009/blood.2025032757.pdf", "pmid": null, "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_40818987", "original_article_title": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms", "authors": [], "authors_original": "Gangat N et al.", "first_author": null, "first_author_display": null, "citation": "Gangat N et al. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms Blood Cancer Journal 2025", "journal": "Blood Cancer Journal", "year": 2025, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1038/s41408-025-01346-1", "pmid": "40818987", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_42471330", "original_article_title": "Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms", "authors": [], "authors_original": "Gangat N et al.", "first_author": null, "first_author_display": null, "citation": "Gangat N et al. Newly Diagnosed Acute Myeloid leukemia in Fit Patients: 2026 Treatment Algorithms Blood Cancer Journal 2026", "journal": "Blood Cancer Journal", "year": 2026, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1038/s41408-026-01578-9", "pmid": "42471330", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_41132246", "original_article_title": "EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma", "authors": [], "authors_original": "Jerkeman M et al.", "first_author": null, "first_author_display": null, "citation": "Jerkeman M et al. EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma Hemasphere 2025", "journal": "Hemasphere", "year": 2025, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1002/hem3.70233", "pmid": "41132246", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}, {"reference_id": "PMID_40095219", "original_article_title": "Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management", "authors": [], "authors_original": "Gertz MA et al.", "first_author": null, "first_author_display": null, "citation": "Gertz MA et al. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management American Journal of Hematology 2025", "journal": "American Journal of Hematology", "year": 2025, "volume": null, "issue": null, "pages_or_article_id": null, "doi": "10.1002/ajh.27666", "pmid": "40095219", "publication_date": null, "publication_types": [], "metadata_status": "source_metadata_unverified", "provider": "preserved_PaperBot_Drive_metadata", "retrieved_at": null, "provenance": "Previously audited metadata.json; bibliographic and clinical review not asserted"}], "browse_areas": ["Lymphoid Neoplasms", "Plasma Cell & Myeloma", "Myeloid Neoplasms", "Cellular Therapy & Immunotherapy", "Transplantation", "Non-Malignant Hematology", "Supportive Care & Complications"], "entity_labels": {"CALC_BMI": "Body Mass Index", "CALC_CAR_HEMATOTOX": "CAR-HEMATOTOX", "CALC_CNS_IPI": "CNS-IPI", "CALC_FLIPI": "FLIPI", "CALC_IPI": "IPI", "CALC_KHORANA": "Khorana", "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_EARLY_RELAPSE_SECOND_LINE": "Primary refractory / early relapse second-line therapy", "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_FRONTLINE": "Frontline DLBCL", "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_HIGH_GRADE_DOUBLE_HIT": "High-grade / double-hit context", "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_LIMITED_STAGE": "Limited-stage / favorable disease", "DEC_AGGRESSIVE_B_CELL_LYMPHOMA_RELAPSED_MODERN": "Relapsed/refractory modern combinations and bispecifics", "DEC_ALL_CAR_T": "CAR-T", "DEC_ALL_MRD_DIRECTED": "MRD-directed therapy", "DEC_ALL_PH_NEGATIVE_FRONTLINE": "Ph-negative frontline", "DEC_ALL_RELAPSED_IMMUNOTHERAPY": "Relapsed immunotherapy", "DEC_AML_NON_INTENSIVE_FRONTLINE": "Frontline patients ineligible for intensive induction", "DEC_CLL_FRONTLINE_FIXED_VS_CONTINUOUS": "Frontline fixed-duration vs continuous targeted therapy", "DEC_CLL_RELAPSED_FIXED_DURATION": "Relapsed fixed-duration venetoclax", "DEC_CML_ASCIMINIB": "Asciminib", "DEC_CML_FRONTLINE_TKI": "Frontline TKI choice", "DEC_CML_PONATINIB": "Ponatinib / T315I", "DEC_CML_TFR": "Treatment-free remission", "DEC_FOLLICULAR_LYMPHOMA_CAR_T": "CAR-T", "DEC_FOLLICULAR_LYMPHOMA_FRONTLINE": "Frontline treatment requiring therapy", "DEC_FOLLICULAR_LYMPHOMA_LOW_TUMOR_BURDEN": "Low tumor burden / observation", "DEC_FOLLICULAR_LYMPHOMA_RELAPSED_CHEMO_FREE": "Relapsed chemo-free / targeted therapy", "DEC_HODGKIN_LYMPHOMA_ADVANCED_FRONTLINE": "Advanced-stage frontline / PET adaptation", "DEC_HODGKIN_LYMPHOMA_EARLY_STAGE_PET_RT": "Early-stage PET-adapted treatment / radiotherapy", "DEC_HODGKIN_LYMPHOMA_RELAPSED_TRANSPLANT": "Relapsed/refractory and transplant pathway", "DEC_HSCT_CELLULAR_AUTO_HSCT_PLATFORM": "Autologous HSCT platform decisions", "DEC_MANTLE_CELL_LYMPHOMA_CAR_T": "CAR-T", "DEC_MANTLE_CELL_LYMPHOMA_OLDER_FRONTLINE": "Older/transplant-ineligible frontline", "DEC_MDS_LOWER_RISK_ANEMIA": "Lower-risk anemia", "DEC_MPN_MYELOFIBROSIS_MF_ANEMIA": "MF anemia-directed choices", "DEC_MULTIPLE_MYELOMA_BELANTAMAB_COMBINATIONS": "Belantamab mafodotin combinations", "DEC_MULTIPLE_MYELOMA_BISPECIFICS": "Bispecific antibodies in earlier relapse", "DEC_MULTIPLE_MYELOMA_EARLY_RELAPSE_CART": "Earlier-line CAR-T", "DEC_MULTIPLE_MYELOMA_TRANSPLANT_ELIGIBLE_FRONTLINE": "Transplant-eligible / transplant-intended frontline", "DIS_AGGRESSIVE_B_CELL_LYMPHOMA": "Aggressive B-cell lymphoma", "DIS_ALL": "Acute lymphoblastic leukemia", "DIS_AL_AMYLOIDOSIS": "AL amyloidosis", "DIS_AML": "Acute myeloid leukemia", "DIS_APL": "Acute promyelocytic leukemia", "DIS_B_ALL_LBL": "B-lymphoblastic leukemia/lymphoma", "DIS_CLL": "Chronic lymphocytic leukemia", "DIS_CML": "Chronic myeloid leukemia", "DIS_COLD_AGGLUTININ_DISEASE": "Cold agglutinin disease", "DIS_ESSENTIAL_THROMBOCYTHEMIA": "Essential thrombocythemia", "DIS_EXTRAMEDULLARY_PLASMACYTOMA": "Extramedullary plasmacytoma", "DIS_FOLLICULAR_LYMPHOMA": "Follicular lymphoma", "DIS_HEMOPHILIA_B": "Hemophilia B", "DIS_HIT": "Heparin-induced thrombocytopenia", "DIS_HODGKIN_CHL": "Classical Hodgkin lymphoma", "DIS_IRON_DEFICIENCY_ANEMIA": "Iron deficiency anemia", "DIS_ITP": "Immune thrombocytopenia", "DIS_MANTLE_CELL_LYMPHOMA": "Mantle cell lymphoma", "DIS_MDS": "Myelodysplastic neoplasm", "DIS_MPN_MYELOFIBROSIS": "Myelofibrosis and myeloproliferative neoplasms", "DIS_MULTIPLE_MYELOMA": "Multiple myeloma", "DIS_PMBCL": "Primary mediastinal large B-cell lymphoma", "DIS_PNH": "Paroxysmal nocturnal hemoglobinuria", "DIS_POLYCYTHEMIA_VERA": "Polycythemia vera", "DIS_PRIMARY_CNS_LYMPHOMA": "Primary CNS lymphoma", "DIS_PRIMARY_MYELOFIBROSIS": "Primary myelofibrosis", "DIS_SICKLE_CELL_DISEASE": "Sickle cell disease", "DIS_SOLITARY_BONE_PLASMACYTOMA": "Solitary bone plasmacytoma", "DIS_TRANSPLANT_CELLULAR_THERAPY": "HSCT and cellular therapy cross-cutting", "DIS_WALDENSTROM_MACROGLOBULINEMIA": "Waldenstrom macroglobulinemia", "DRUG_ACALABRUTINIB": "acalabrutinib", "DRUG_ASCIMINIB": "asciminib", "DRUG_AXICABTAGENE_CILOLEUCEL": "axicabtagene ciloleucel", "DRUG_AZACITIDINE": "azacitidine", "DRUG_BELANTAMAB_MAFODOTIN": "belantamab mafodotin", "DRUG_BENDAMUSTINE": "bendamustine", "DRUG_BLINATUMOMAB": "blinatumomab", "DRUG_BORTEZOMIB": "bortezomib", "DRUG_BOSUTINIB": "bosutinib", "DRUG_BRENTUXIMAB_VEDOTIN": "brentuximab vedotin", "DRUG_CARBOPLATIN": "carboplatin", "DRUG_CARFILZOMIB": "carfilzomib", "DRUG_CARMUSTINE": "carmustine", "DRUG_CILTACABTAGENE_AUTOLEUCEL": "ciltacabtagene autoleucel", "DRUG_CYCLOPHOSPHAMIDE": "cyclophosphamide", "DRUG_CYTARABINE": "cytarabine", "DRUG_DARATUMUMAB": "daratumumab", "DRUG_DASATINIB": "dasatinib", "DRUG_DAUNORUBICIN": "daunorubicin", "DRUG_DECITABINE": "decitabine", "DRUG_DEXAMETHASONE": "dexamethasone", "DRUG_DOXORUBICIN": "doxorubicin", "DRUG_ELRANATAMAB": "elranatamab", "DRUG_EPCORITAMAB": "epcoritamab", "DRUG_ETOPOSIDE": "etoposide", "DRUG_FLUDARABINE": "fludarabine", "DRUG_GEMCITABINE": "gemcitabine", "DRUG_GLOFITAMAB": "glofitamab", "DRUG_IBRUTINIB": "ibrutinib", "DRUG_IDARUBICIN": "idarubicin", "DRUG_IDECABTAGENE_VICLEUCEL": "idecabtagene vicleucel", "DRUG_IFOSFAMIDE": "ifosfamide", "DRUG_IMATINIB": "imatinib", "DRUG_INOTUZUMAB_OZOGAMICIN": "inotuzumab ozogamicin", "DRUG_ISATUXIMAB": "isatuximab", "DRUG_LENALIDOMIDE": "lenalidomide", "DRUG_LISOCABTAGENE_MARALEUCEL": "lisocabtagene maraleucel", "DRUG_LONCASTUXIMAB_TESIRINE": "loncastuximab tesirine", "DRUG_MELPHALAN": "melphalan", "DRUG_MITOXANTRONE": "mitoxantrone", "DRUG_MOSUNETUZUMAB": "mosunetuzumab", "DRUG_NILOTINIB": "nilotinib", "DRUG_NIVOLUMAB": "nivolumab", "DRUG_OBINUTUZUMAB": "obinutuzumab", "DRUG_OXALIPLATIN": "oxaliplatin", "DRUG_POLATUZUMAB_VEDOTIN": "polatuzumab vedotin", "DRUG_POMALIDOMIDE": "pomalidomide", "DRUG_PONATINIB": "ponatinib", "DRUG_RITUXIMAB": "rituximab", "DRUG_TAFASITAMAB": "tafasitamab", "DRUG_TALQUETAMAB": "talquetamab", "DRUG_TECLISTAMAB": "teclistamab", "DRUG_THALIDOMIDE": "thalidomide", "DRUG_TISAGENLECLEUCEL": "tisagenlecleucel", "DRUG_VENETOCLAX": "venetoclax", "DRUG_VINBLASTINE": "vinblastine", "DRUG_ZANUBRUTINIB": "zanubrutinib", "EV_PMID_21176949": "PRIMA", "EV_PMID_25796459": "AETHERA", "EV_PMID_25901426": "RAPID", "EV_PMID_28249141": "TOWER", "EV_PMID_28273028": "IRIS long-term", "EV_PMID_28379796": "IFM 2009", "EV_PMID_29061295": "GHSG HD18", "EV_PMID_29735299": "EURO-SKI", "EV_PMID_30658992": "CALGB 10403", "EV_PMID_30939090": "Alliance/CALGB 50303", "EV_PMID_31914241": "MEDALIST", "EV_PMID_33414482": "ENESTnd 10-year", "EV_PMID_33539742": "GHSG HD17", "EV_PMID_33827139": "Brentuximab vedotin + nivolumab salvage", "EV_PMID_34407543": "OPTIC", "EV_PMID_34891224": "ZUMA-7", "EV_PMID_35660812": "DETERMINATION", "EV_PMID_35830649": "ECHELON-1 mature OS", "EV_PMID_36709073": "MOMENTUM", "EV_PMID_36762851": "KarMMa-3", "EV_PMID_37272512": "CARTITUDE-4", "EV_PMID_37708911": "GRIFFIN final", "EV_PMID_37967311": "H10 long-term update", "EV_PMID_38084760": "PERSEUS", "EV_PMID_38343151": "Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia", "EV_PMID_38820078": "ASC4FIRST", "EV_PMID_38828933": "DREAMM-7", "EV_PMID_38971175": "HD21", "EV_PMID_39047240": "E1910", "EV_PMID_39082668": "Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study", "EV_PMID_39413375": "S1826", "EV_PMID_39976417": "Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia", "EV_PMID_40108332": "ZUMA-3 three-year follow-up", "EV_PMID_40334072": "ASCEMBL nearly 4-year", "EV_PMID_40521799": "FLAIR ibrutinib-venetoclax", "EV_PMID_40652943": "HD21 fertility", "EV_PMID_40706052": "Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML", "EV_PMID_41100801": "ZUMA-5 5-year", "EV_PMID_41358601": "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia", "EV_PMID_41915772": "RELEVANCE 10-year", "EV_PMID_41986580": "DREAMM-7 Japan expansion", "EV_PMID_41990300": "AUGMENT 5-year follow-up", "EV_PMID_42212933": "MajesTEC-9", "EV_PMID_42294841": "MonumenTAL-3", "PHASE_CML_TREATMENT_FREE_REMISSION": "Chronic myeloid leukemia — treatment-free remission", "PROT_ALL_BLINA_001": "Blinatumomab", "PROT_ALL_HYPERCVAD_001": "Hyper-CVAD", "PROT_ALL_INO_001": "Inotuzumab Ozogamicin", "PROT_ALL_MINIHCV_INO_BLINA_001": "Mini-Hyper-CVD + fractionated Inotuzumab → Blinatumomab (MD Anderson post-2017 amendment)", "PROT_AML_AZAVEN_001": "Azacitidine + Venetoclax", "PROT_AML_DEC10VEN_001": "DEC10-VEN", "PROT_AML_DEC5VEN_001": "DEC5-VEN", "PROT_CART_BREXUCEL_001": "Brexucabtagene autoleucel", "PROT_CART_IDECEL_001": "Idecabtagene vicleucel", "PROT_HL_ABVD_001": "ABVD", "PROT_HL_BRECADD_001": "BrECADD", "PROT_HL_NIVOAVD_001": "Nivolumab + AVD", "PROT_LYM_BR_001": "Bendamustine + Rituximab", "PROT_LYM_POLARCHP_001": "Pola-R-CHP", "PROT_LYM_RCHOP21_001": "R-CHOP-21", "PROT_MM_BVD_001": "Belantamab Mafodotin + Vd", "PROT_MM_CILTACEL_001": "Ciltacabtagene autoleucel", "PROT_MM_DARAVRD_001": "Dara-VRd (PERSEUS, transplant eligible)", "PROT_MM_TECDARA_001": "Teclistamab + Daratumumab (MajesTEC-3)", "TX_ALL_BLINA": "Blinatumomab", "TX_ALL_HYPERCVAD": "Hyper-CVAD", "TX_ALL_INO": "Inotuzumab Ozogamicin", "TX_CART_AXICEL": "Axicabtagene ciloleucel", "TX_CART_IDECEL": "Idecabtagene vicleucel", "TX_CART_LISOCEL": "Lisocabtagene maraleucel", "TX_CART_TISACEL": "Tisagenlecleucel", "TX_CLL_ACALABRUTINIB": "Acalabrutinib", "TX_CLL_ZANUBRUTINIB": "Zanubrutinib", "TX_CML_ASCIMINIB": "Asciminib", "TX_CML_BOSUTINIB": "Bosutinib", "TX_CML_DASATINIB": "Dasatinib", "TX_CML_IMATINIB": "Imatinib", "TX_CML_NILOTINIB": "Nilotinib", "TX_CML_PONATINIB": "Ponatinib", "TX_HL_ABVD": "ABVD", "TX_HL_BRECADD": "BrECADD", "TX_HL_EBEACOPP": "Escalated BEACOPP", "TX_HL_NIVOAVD": "Nivolumab + AVD", "TX_HSCT_BEAM": "BEAM", "TX_LYM_BR": "Bendamustine + Rituximab", "TX_LYM_DAEPOCHR": "DA-EPOCH-R", "TX_LYM_DHAOX": "DHAOx ± Rituximab", "TX_LYM_EPCORITAMAB_FL": "Epcoritamab", "TX_LYM_GLOFITAMAB": "Glofitamab", "TX_LYM_LONCASTUXIMAB": "Loncastuximab Tesirine", "TX_LYM_MOSUNETUZUMAB": "Mosunetuzumab (IV)", "TX_LYM_POLARCHP": "Pola-R-CHP", "TX_LYM_R2": "Lenalidomide + Rituximab (R²)", "TX_LYM_RCHOP21": "R-CHOP-21", "TX_LYM_RDHAP": "DHAP ± Rituximab", "TX_LYM_RGEMOX": "GemOx ± Rituximab", "TX_LYM_RICE": "ICE ± Rituximab", "TX_MM_BPD": "Belantamab Mafodotin + Pd", "TX_MM_BVD": "Belantamab Mafodotin + Vd", "TX_MM_CILTACEL": "Ciltacabtagene autoleucel", "TX_MM_DARAVRD": "Dara-VRd (PERSEUS, transplant eligible)", "TX_MM_ELRA": "Elranatamab", "TX_MM_ISAKD": "Isa-Kd (IKEMA)", "TX_MM_ISAVRD_TI": "Isa-VRd TI (IMROZ)", "TX_MM_KRD": "KRd (ASPIRE)", "TX_MM_TALQUE": "Talquetamab", "TX_MM_TEC": "Teclistamab", "TX_MM_VRD": "VRd", "TX_MM_VTD": "VTd"}}
